Investigations of age- and plaque-related learning deficits in PDAPP mice and evaluations of anti-amyloidosis strategies on amyloid precursor protein transgenic mice by Chen, Guiquan
Investigations of Age- and Plaque-related
Learning Deficits in PDAPP Mice and
Evaluations of Anti-amyloidosis Strategies on
Amyloid Precursor Protein Transgenic Mice.
Guiquan Chen
PhD Thesis
Submitted in satisfaction of the requirements for the degree of
PhD in the University of Edinburgh, 2004.
Declaration
In accordance with the University of Edinburgh postgraduate regulation 3.8.7, I
declare that the work described in this thesis is my own, except where otherwise




First of all, I thank my wife, Xiaoyan Zou for her invaluable emotional
support of my PhD study during the past five year.
I would like to thank my supervisor, Professor Richard Morris, for giving me the
opportunity to work on the PDAPP projects in his lab and for his constant advice
throughout. I thank our collaborators, Dr. Stephen Freedman, Dr. Karen Chen at Elan
Pharmaceuticals for supplying the PDAPP mice, AN-1792 and ELN44989; and Dione
Kobayashi at Elan Pharmaceuticals for doing the ELISAs for ELN44989 study. I also
thank our collaborators, Dr. Jie Shen and Dr. Carlos Saura at Harvard University for
supplying the PSlcKO;APP mice.
I am indebted to Jane Knox for conducting the 3D6 immunohistology; Richard
Watson and Larraine Wells for doing the dosing for ELN44989. Thanks also to
Andrew Bernard and Ann Paterson for technical help, Patrick Spooner for helping
with his superior EPS program of electrophysiology. Finally, I would thank other
members of the lab - Drs. Jennifer Inglis, Stephen Martin, Urania Coumis and Colin
O'Carroll for their constant advice, encouragement and technical help.
Finally, my thanks also go to the Medical Research Council (MRC, UK) for
supporting all studies described in this thesis, and to Elan Pharmaceuticals for paying





List of figures and tables vii
List of abbreviations x
Abstract 1
Chapter 1: Introduction.
1.1. The background of Alzheimer's disease.
1.1.1. Dementia and the prevalence of Alzheimer's disease 3
1.1.2. Clinical diagnostic methods for Alzheimer's disease 4
1.1.3. Neuropathological features of Alzheimer's disease 5
1.2. Aetiology of Alzheimer's disease.
1.2.1. The cholinergic hypothesis 7
1.2.2. The tau hypothesis 8
1.2.3. The amyloid cascade hypothesis 9
1.3. Molecular basis of Alzheimer's disease.
1.3.1. APP mutations and early onset of AD 11
1.3.2. Presenilins and early onset of AD 15
1.3.3. Apolipoprotein E and late onset of AD 18
1.3.4. Tau and AD 20
1.4. Modelling Alzheimer's disease.
1.4.1. Primate models of AD 22
1.4.2. Mouse models of AD 23
1.4.3. Bear models of AD 23
1.4.4. Canine models of AD 23
1.4.5. Aluminium injection model of AD 23
1.4.6. Lesion models of AD 23
1.4.7. Cholesterol-fed rat model of AD 24
1.4.8. Ap infusion models of AD 24
1.5. APP transgenic mouse models for Alzheimer's disease.
1.5.1. The APP751 (SciosNova) mouse 26
1.5.2. The PDAPP mouse 27
1.5.3. The Tg2576 mouse 28
iv
1.5.4. The Scripps, H6 and J9 mice 31
1.5.5. The C-terminus (C104) APP Tg mouse 32
1.5.6. The TgAPP22 and 23 mice 34
1.5.7. The TgCRND8 mouse 36
1.5.8. The TgAPP/Ld, APP/Sw and APP/Wt mice 36
1.5.9. The Tg2576/PSl mouse 37
1.6. Tau transgenic mouse models of Alzheimer's disease.
1.6.1. The ALZ7 mouse 39
1.6.2. The Tg23 mouse 39
1.6.3. The Tau 7, 27 and 43 mice 39
1.6.4. TheTau40-l and -5 mice 40
1.6.5. The ALZ17 mouse 40
1.6.6. The Tau P301L JNPL3 mouse 40
1.6.7. The Tau40 P301L (pR5-183) mouse 40
1.6.8. The Tau40 V337M (Tg214) mouse 41
1.6.9. The Tau40 R406W mouse 41
1.7. Plaque/Tangle transgenic mouse models for Alzheimer's disease.
1.7.1. The TAPP mouse 42
1.7.2. The triple Tg mouse model for AD (3xTg-AD) 43
1.8. The treatment of Alzheimer's disease.
1.8.1. Current treatment strategies for AD 44
1.8.2. Potential treatment strategies for AD 46
1.9. Aims of this thesis 54
Chapter 2: Materials and Methods.
2.1. Behavioural tests in the watermaze 55
2.2. Spontaneous object recognition test 61
2.3. Electrophysiology 64
2.4. Immunohistology and ELISA 73
Chapter 3: A cross-sectional investigation of age- and plaque-related






Chapter 4: A longitudinal investigation of age-dependent learning





Chapter 5: Investigation of the effects Ap vaccines on spatial learning and











Chapter 7: Investigation of the effects of y-secretase inhibitor treatment





Chapter 8: Conclusions and general discussion 172
References 179
Appendix (published work) 210
VI
List of figures and tables.
Figure 1. The Amyloid Cascade Hypothesis 9
Figure 2.1.1 Watermaze Apparatus 56
Figure 2.1.2 Watermaze Setup 56
Figure 2.1.3 The Delayed-match-to-place (DMP) Task 58
Figure 2.1.4 Trials-to-criterion Task 59
Figure 2.1.5 Learning Capacity Task 61
Figure 2.2.1 The Arena 62
Figure 2.2.2 Five Sets of Objects 62
Figure 2.2.3 Sample Phase 63
Figure 2.2.4 Choice Phase 63
Figure 2.3.1 Hippocampal Slice, Brain and Hippocampus 64
Figure 2.3.2 In vitro Technique in Transverse Hippocampal Slice 65
Figure 2.3.3 Design of the Interface Recording Chamber 67
Figure 2.3.4 Incubation of Hippocampal Slices 69
Figure 3.2.1 Experimental Design 82
Figure 3.2.2 Two Sets of Five Different Problems 83
Figure 3.2.3 Two Sets of Ten Different Problems for Learning Capacity Task 84
Figure 3.3.1 Cuetask Performance in PDAPP and non-Tg Mice 85
Figure 3.3.2 Normal Object Recognition Memory in PDAPP Mice 85
Figure 3.3.3 Early Deficits in Spatial Learning of PDAPP Mice Getting Progressively Worse.
87
Figure 3.3.4 Age-related Learning Deficit in PDAPP Mice 87
Figure 3.3.5 Age-related Learning Deficits in PDAPP Mice 89
Figure 3.3.6 Relationship between Amyloid Plaque Deposition and Behavioural Performance.
91
vii
Figure 3.3.7 Analysis of Performance on Platform Location 1 93
Table 4.1 The Number of the Mice Completing the Study 102
Figure 4.2.1 Experimental Design 102
Figure 4.2.2 Two Sets of Ten Different Platform Locations 103
Figure 4.3.1 Cuetask Performance in PDAPP and non-Tg Mice 106
Figure 4.3.2 Normal Object Recognition Memory in PDAPP Mice 106
Figure 4.3.3 Age-related Deficits in Spatial Learning of PDAPP Mice 107
Figure 4.3.4 Representative Swim Paths 109
Figure 4.3.5 Age-related Learning Deficits in PDAPP Mice 109
Figure 4.3.6 Impaired Basal Synaptic Transmission in PDAPP Mice Ill
Figure 4.3.7 Normal Synaptic Plasticity in PDAPP Mice Ill
Figure 4.3.8 Amyloid Plaques in the Brain of PDAPP Mice 113
Figure 4.3.9 Significant Correlation between Basal Synaptic Transmission and Behavioural
Performance 113
Figure 5.2.1 Experimental Design 124
Figure 5.2.2 Platform Location Design 125
Figure 5.3.1 Effects of Ap Vaccines on Cuetask Performance of PDAPP Mice 127
Figure 5.3.2 Effects of Ap Vaccines on Trials to Criterion of PDAPP Mice 127
Figure 5.3.3 Effects of Ap Vaccines on Learning Capacity of PDAPP Mice 129
Figure 5.3.4 Effects of Ap Vaccines on Basal Synaptic Transmission of PDAPP Mice.
131
Figure 5.3.5 Significant Correlation between Basal Synaptic Transmission and Behavioural
Performance 131
Table 5.1 Reduction of Ap42 in AP-vaccinated PDAPP Mice 132
Figure 6.2.1 Experimental Design 139
Figure 6.2.2 Platform Locations for Spatial Learning 139
Figure 6.3.1 Cuetask Performance of the Mice 141
viii
Figure 6.3.2 Performance of Young Mice in Spatial Learning 143
Figure 6.3.3 Performance of Old Mice in Spatial Learning 145
Figure 6.3.4 Object Recognition in the Mice 147
Figure 6.3.5 Impaired Basal Synaptic Transmission in APP Mice 147
Figure 6.3.6 Significant Correlations between the Basal Synaptic Transmission and Behavioural
Performance 149
Figure 7.2.1 Longitudinal Experimental Design 159
Figure 7.2.2 Design of Platform Locations for Trials to Criterion and Learning Capacity Task
before ELN44989 Treatment (age: 7-8 months) 159
Figure 7.2.3 Design of Platform Locations for Spatial Learning after 4-month ELN44989
Treatment (age: 11-12 months) 159
Figure 7.3.1 Side Effects Observed in the ELN44989-treated Mice 161
Figure 7.3.2 Cuetask Performance 163
Figure 7.3.3 Performance on the Trials to Criterion Task 165
Figure 7.3.4 Performance on the Learning Capacity Task 165
Figure 7.3.5 Impaired Basal Synaptic Transmission in PDAPP Mice 167
Figure 7.3.6 Total AP Levels in the Brain 167
ix
List of abbreviations:





ACSF artificial cerebrospinal fluid
AD Alzheimer's disease
ADAM a disintegrin and metalloprotease
ADAS-Cog Alzheimer disease assessment scale-cognitive
AICD amyloid intracellular domain
AIDS acquired immune deficiency syndrome
AMPA a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ANOVA analysis of variance
AP5 2-amino-5-phosphopentanoate
APLP amyloid precursor-like proteins
ApoE apolipoprotein E
APP amyloid precursor protein
Arg (R) arginine
Asn (N) asparagine
BACE beta-site APP cleaving enzyme
BEHAVE-AD behavioural pathology in Alzheimer's disease rating scale
BSA bovine serum albumin
CAATase chloramphenicol acetyltransferase
CaMKII Ca2+/calmodulin-dependent protein kinase II
cAMP cyclic adenosine monoposphate
CANTAB Cambridge neuropsychological test automated battery
CAT choline acetyltransferase
CDT clock draw test
CERAD consortium to establish a registry for Alzheimer's disease









Egb extract of Ginkgo biloba
ELISA enzyme linked immunosorbent assay
FAD familial Alzheimer's disease
fEPSPs field excitatory postsynaptic potentials
FTDP-17 frontotemporal dementia with Parkinsonism linked to chromosome 17
GFAP glial fibrillary acidic protein
Gin (Q) glutamine
Glu (E) glutamic acid
Gly (G) glycine
HDL high density lipoproteins
HE hydroxyethylene
HIV human immunodeficiency virus
HMG-CR 3-hydroxy-methyl-glutaryl CoA reductase
HPLC high performance liquid chromatography






KPI Kunitz-type protease inhibitor











MMSE mini mental state exam









NSAIDs nonsteroidal anti-inflammatory drugs
NTF N-terminal fragment
OA okadaic acid
PBS phosphate buffered saline
PDGF platelet-derived growth factor
Pg pico-gram
Phe (F) phenylalanine
PHFs paired helical filaments
PI preference index
PIP2 phosphatidylinositol bisphosphate





PSlcKO presenilinl conditional knockout
PTp post-tetanic potentiation
SAD sporadic Alzheimer's disease
SAMP senescence-accelerated- prone
SDS sodium dodecyl sulphate
Ser (S) serine
SMON subacute myelo-optico-neuropathy
SREBPs sterol regulatory element binding proteins





TNF tumor necrosis factor
Val (V) valine





Alzheimer's disease (AD) is a neurodegenerative disease, characterised by the
presence of amyloid plaques and neurofibrillary tangles, and is associated with a
progressive memory loss. It has been hypothesized that beta-amyloid (A(3)
accumulation and deposition play the central role in the pathogenesis of AD.
However, recent evidence suggests that the contribution of AP plaques to cognitive
impairment of AD is very controversial. Genetic studies showed that mutations of
amyloid precursor protein (APP), presenilins (PS1 and PS2) and apolipoprotein s4
(apoE4) genes in familial forms of autosomal AD (FAD) resulted in increased
amyloid plaques in the brain. PDAPP and other APP transgenic mice have previously
been shown to exhibit age-related deposition of amyloid plaques, other AD-like
neuropathology and age-independent learning deficits prior to any plaque deposition.
A cross-sectional and a longitudinal design were employed to address whether
PDAPP mice exhibit any plaque-related learning deficit. First, the cross-sectional
study indicated that PDAPP mice simultaneously displayed an early (plaque-
independent) and age-related learning impairment. Further analysis showed that the
age-related learning deficit was highly correlated with plaque burden in the
hippocampus of aged PDAPP mice, suggesting that amyloid plaques play a very
important role in memory loss of AD. Second, the longitudinal study showed that the
same PDAPP mice exhibited significant age-related learning deficits in trials to
criterion and learning capacity tasks when they aged. Interestingly, cued navigation
and object recognition in both cross-sectional and longitudinal studies were
unaffected, indicating normal sensorimotor function and recognition memory of
PDAPP mice. The longitudinal study further showed that the age-related learning
impairment was significantly correlated with significantly reduced size of field
potentials, suggesting important roles of amyloid plaques in disturbing synaptic
transmission and cognitive function.
Preclinical data indicated that A(3 immunotherapy is very effective to improve both
AD-like neuropathology and cognitive impairment in APP transgenic mice. Using
active A(3 immunisation, long-term (9 months: prevention study) and short-term (5
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months: treatment study) effects of AP vaccines (AN-1792) on synaptic transmission
and spatial learning of PDAPP mice were investigated. Although neither of the two
studies showed that Ap vaccines had significant improvement on either synaptic
transmission or spatial learning of PDAPP mice, both long-term and short-term Ap
vaccinations effectively reduced the levels of total Ap. Thus, these two studies
indicated that active Ap immunotherapy might be very effective to improve AD-like
pathology, but ineffective to rescue the learning impairment in APP mice.
The y- and P-secretases have become the prime targets for pharmaceutical
intervention of AD. In this thesis, it was investigated, using a genetic and a
pharmacological method, whether inhibition of the y-secretase has any effects on
synaptic transmission and spatial learning of APP transgenic mice. First, using
genetically modified APP mice, PSlcKO;APP mice, in which the PS1 gene is
conditionally inactivated in the forebrain, their spatial learning was studied.
Interestingly, young PSlcKO;APP mice exhibited normal spatial learning in the trials
to criterion and learning capacity tasks, whereas young APP transgenic mice were
impaired, suggesting a significant rescue effect of PS1 inactivation on spatial learning
at young age. However, although old PSlcKO;APP mice displayed normal learning in
the trials to criterion task, they exhibited significant impairment on a cuetask and a
learning capacity task, suggesting that long-term PS1 inactivation may only partially
rescue impaired learning in old APP animals. Thus, these findings raise the possibility
that massive accumulation of APP CTFs can cause learning deficits. Secondly, a
potent functional y-secretase inhibitor, ELN 44989 was administered to PDAPP mice
to investigate its chronic in vivo effects on AD-like pathology and spatial learning.
This study showed that ELN 44989 had no significant effect on Ap levels in the brain
and also showed no effect on impaired spatial learning of PDAPP mice. Future work
needs to examine whether more potent and selective y-secretase inhibitor will show
any effect on improvement of neuropathology and memory loss in APP mice.
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Chapter 1: General Introduction.
The main purposes of this chapter are to present a general overview of the
background, molecular mechanisms and animal models for Alzheimer's disease (AD).
As the contribution of transgenic animal models to the research of the pathogenesis of
AD is so huge, a big effort has been made to review transgenic mouse models of AD.
AD remains one of the biggest challenges to modern medicine, so current and
potential novel treatment strategies of AD are also reviewed. The aims of the present
experiments of this thesis are briefly described in the last section. Following this
introduction chapter, a more specific and/or detailed introduction to the issue
addressed will be presented in each subsequent chapter.
1.1 The background ofAlzheimer's disease.
1.1.1 Dementia and the prevalence ofAlzheimer's disease.
Dementia is defined as memory loss accompanied by one or more of the following
symptoms: aphasia, apraxia, agnosia and impaired executive functioning (American
Psychiatric Association, 1994). Dementia is present in up to 50% of elderly people
aged 85 years or over (Evans et al., 1989). There are various subtypes, including
Alzheimer's disease (AD), vascular dementia, Lewy body dementia, ffontotemporal
dementia, Parkinson's disease dementia, Pick's disease dementia, HIV infection and
AIDS dementia, etc. (Delacourte et al., 1998). Among these subtypes, AD and
vascular dementia are the most common causes, as AD accounts for more than 55% of
all dementia cases and vascular dementia accounts for about 15% (Dugu et al., 2003).
The first AD case of a 51 years old woman, Auguste D., was reported by Alois
Alzheimer in an abstract in which no morphology of the disease was presented
(Alzheimer, 1907). The detailed pathological data of amyloid plaques of AD were
later reported by Alzheimer and were actually from his second patient named Johann
F. (Alzheimer, 1911). The disease was named after him by Emil Kraeplin in 1910
(Moller and Graeber, 1998). Very interestingly, it has recently been argued that the
dementia of Auguste D is not caused by AD but by arteriosclerosis of the brain
(O'Brien, 1996).
3
Chapter 1: General Introduction.
As the most common cause of dementia, AD is an irreversible neurodegenerative
disorder. In addition to progressive memory loss, AD patients have developed other
typical symptoms, such as depression, anxiety, irritability, sleep disorder, hyper-
vulnerability to stress, delusions, hallucinations and hyperactivity. While the majority
of AD is sporadic Alzheimer's disease (SAD), being 90-95% of all cases, the
remaining (5-10%) is autosomal familial Alzheimer's disease (FAD) (Harman, 2002).
The prevalence of AD rises exponentially as the worldwide population ages.
Approximately 7% of the population older than 65 years has AD, but this figure
doubles every 5 years, so the prevalence of AD is more than 40% at age 85 or above
(Small et ah, 1997). It is estimated that there are more than 15 million AD patients
worldwide. In the USA, there were 4.5 million in 2000 and this number will increase
to 13.2 million by 2050 (Hebert et al., 2003; Helmuth, 2003). There are currently
400,000 AD people in the UK and the occurrence of AD is 4.4% of people over 65 in
Europe (Lobo et al., 2000). As the country with the largest population in the world,
China had about 4-5 million AD cases in 1999 and will have more than 15 million by
2050 (Chen, 1999; Zhang, 2003). One recent study has shown that annual costs for
all AD individuals are about 100 billion dollars in the USA (Ernst and Hay, 1994). As
the total number of AD people will reach more than 30 million worldwide in 2050, it
may bring a tremendous economic burden and an even larger public health problem if
we do not have an effective treatment for this devastating disease by that time.
1.1.2 Clinical diagnostic methods for Alzheimer's disease.
It is believed that AD can be definitively confirmed at autopsy by examining amyloid
plaques and neurofibrillary tangles from the brain of AD patients. The current clinical
diagnosis of AD is made by some informant interviews and several
neuropsychological tests, and it can reach an accuracy of up to 90 percent (Rasmusson
et al., 1996; Pearl, 1997). The neuropsychological tests used in the diagnosis of AD
include the Blessed Test (Blessed et al., 1968), Mini Mental State Exam (MMSE)
(Folstein et al., 1975), Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog)
(Rosen et al., 1984), Behavioural Pathology in Alzheimer's Disease Rating Scale
(BEHAVE-AD) (Reisberg et al., 1987), the Consortium to Establish a Registry for
Alzheimer's Disease (CERAD) (Morris et al., 1988), the Clock Draw Test (CDT)
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(Sunderland et al., 1989) and Cambridge Neuropsychological Test Automated Battery
(CANTAB) (Robbins et al., 1994).
The MMSE is most commonly used for medical diagnosis of cognitive status
(Folstein et al., 1975). ADAS-Cog is widely accepted for assessment of language and
memory of AD patients, and has been called a golden method for the diagnosis of AD
(Rosen et al., 1984). The CERAD includes Verbal Fluency Test, Boston Naming Test,
MMSE, ten-item word recall and delayed recall of praxis items (Morris et al., 1988;
Morris et al., 1989), and it is very effective in diagnosing cognitive decline in AD.
CDT has been proposed as a useful neuropsychological screening instrument for
dementia of Alzheimer type (DAT). As dementia may arise from more than one
disease, a brain autopsy is recommended to confirm a diagnosis of AD (The National
Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the
Neuropathological Assessment of Alzheimer's, 1997).
1.1.3 Neuropathological features ofAlzheimer's disease.
Although progressive cognitive impairment is the main clinical symptom of AD,
amyloid plaques, neurofibrillary tangles (NFTs) and neuronal loss are the major
pathological hallmarks of AD (Wilkins and Brody, 1969).
Amyloid plaques, the major lesion in AD, are extracellular deposits in the brain.
Amyloid plaques are composed of (3-amyloid peptides, which are 39-43 amino acids
in length and are derived from a larger integral membrane protein called amyloid
precursor protein (APP) (Kang et al., 1987). There are two major A(3 peptides found
in amyloid plaques, A(340 and A(342 (Masters et al., 1985). Amyloid plaques observed
in the brain of AD can be divided into two different types: neuritic plaques, the
minority of (3-amyloid deposits, and diffuse plaques, the majority (Allsop et al., 1989;
Ikeda et al., 1989b). A typical neuritic plaque consists of a central spherical core of
radiating amyloid fibrils surrounded by microglia, astrocytes as well as dystrophic
neuritis (Mann et al., 1989). These amyloid fibrils are straight, 6-10 nm in diameter,
and are of Congo red birefringence (Hardy and Allsop, 1991). The astrocytes and
microglia surrounding the neuritic plaques are highly activated (Wisniewski and
Wegiel, 1994). Both dystrophic and degenerating neurites are also observed in
5
Chapter 1: General Introduction.
neuritic plaques (Hardy and Allsop, 1991). The dystrophic and degenerating neuritis
contain degenerating mitochondria, electron-dense bodies, neurofilaments and paired
helical filaments (PHFs). Like neuritic plaques, diffuse plaques are spherical but are
less dense (Ikeda et al., 1989a), however, diffuse plaques do not contain dystrophic
neurites and are not associated with astrocytosis and microgliosis.
As the second major pathological hallmark of AD, neurofibrillary tangles (NFTs) are
abundant in the brain of AD. Interestingly, large amount of NFTs are also observed in
other neurodegenerative diseases such as Pick's disease and frontotemporal dementia
with Parkinsonism linked to chromosome 17 (FTDP-17) (Hutton et al., 1998).
Electron microscopy reveals that the main constituents of NFTs are pairs of twisted
filaments arranged in a helix (PHFs), 25nm across at its widest point and constricting
every 80nm (Kidd, 1963; Terry, 1963). Nukina et al first demonstrated that the actual
component of PHFs is microtubule associated protein tau (Nukina and Ihara, 1985,
1986). As monoclonal antibody against tau protein completely recognizes the de-
phosphorylated PHF of NFTs in vitro, this suggests that tau in NFTs is abnormally
phosphorylated (Grundke-Iqbal et al., 1986). The hyper-phosphorylated tau binds
poorly to microtubules, so it disturbs the stability of microtubule and other
cytoskeletal constituents, and affects intracellular transport (Lee et al., 2001).
Other neuropathological features of AD have also been widely documented. Davies
and Maloney first observed that there is a selective loss of cholinergic neurons in AD
(Davies and Maloney, 1976). AD patients display substantial neuronal loss
particularly in the nucleus basalis of Meynert (Whitehouse et al., 1981). The loss of
hippocampal neurons has also been found in AD with CA1 area displaying the most
prominent loss (West and Gundersen, 1990). An extensive synaptic loss (50% of
decrease) in the density of the granular neuropil immunoreaction in the parietal,
temporal and midfrontal cortex has been found in AD (Masliah et al., 1989). Dekosky
et al reported that the number of synapses in lamina III of Brodmann's area 9 is
significantly decreased (DeKosky and Scheff, 1990). Interestingly, synapse loss in
AD has been shown to be the major correlate of cognitive impairment (Terry et al.,
1991). Impaired neurotransmitter deficits have also been observed in AD patients.
Noradrenaline (NA), dopamine (DA) and serotonin (5-HT) are significantly reduced
in most sub-regions of the brain of AD patients (Cross et al., 1983; Arai et al., 1984).
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Glutamatergic neurotransmission abnormalities are found in AD (Cowburn et al.,
1990). Choline acetyltransferase activity is markedly decreased in the specimens of
AD (Arendt, 2001). The frontal cortex of AD patients display highly active astrocytic
reaction, suggesting an astrocytosis in AD (Jorgensen et al., 1990). Overall, synaptic
loss, deficits in the cholinergic system and other neurotransmitters, as well as
microgliosis and astrocytosis constitute the other neuropathological features of AD.
1.2 Aetiology of Alzheimer's disease.
The causes and mechanisms of AD are not clear. For the past two decades, many
hypotheses have been proposed to explain the pathogenesis of AD. This section
reviews three major theories which have made significant impacts in this field. These
include the cholinergic hypothesis, the tau hypothesis and the amyloid cascade
hypothesis.
1.2.1 The cholinergic hypothesis.
The cholinergic system is one of the most important neurotransmitter systems in the
brain and is believed to control activities underlying conscious awareness (Perry and
Perry, 1995). Evidence from human study suggests that the cholinergic pathways of
the basal forebrain play important roles in conscious awareness, attention and several
mnemonic processes (Perry et al., 1999). It is established that there is a profound
impairment in the cholinergic system of AD. For example, Bowen et al provided the
first evidence showing a markedly reduced activity of choline acetyltransferase (CAT)
in the cerebral cortex of AD patients (Bowen et al., 1976). A selective loss of central
cholinergic neurons is observed in AD (Davies and Maloney, 1976). The
acetylcholine synthesis in AD is less than that in controls (Powen et al., 1981).
The cholinergic hypothesis was first suggested by Davis and Berger when they were
investigating the cholinergic dysfunctions in Huntington's disease (HD) and
schizophrenia (Davis and Berger, 1978). In one of their early studies, choline chloride
and physostigmine, an acetylcholinesterase (AChE) inhibitor, were found to improve
the symptoms of HD (Davis and Berger, 1978). Physostigmine can also significantly
improve the recognition memory of AD subjects (Davis et al., 1978; Davis et al.,
1979). Interestingly, it is Bartus who has systematically proposed the cholinergic
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hypothesis, asserting that the loss of cholinergic function in the central nervous
system contributes significantly to the cognitive decline in the elderly (Bartus et al.,
1982).
Since the time of its inception (Davis and Berger, 1978; Bartus et al., 1982), this
hypothesis has stimulated widespread research interests and debates (Fibiger, 1991).
More importantly, ever since the first attempt to use physostigmine in clinical trials
for the treatment of AD (Davis et al., 1978), this hypothesis has become one of the
main rationales for the treatment strategy and drug development for AD. Thai and
colleagues were the first to investigate the clinical effects of physostigmine in AD.
They observed that physostigmine improves memory in AD patients. However, they
also found that progressive dementia ensues despite physostigmine therapy (Thai et
al., 1986). Long-term effects of physostigmine on patients with probable AD were
examined by a second group, who reported that memory test scores of AD patients are
significantly better during the drug-treatment period (Stern et al., 1988). More
recently, four AChE inhibitors, including tacrine, donepezil, galantamine and
rivastigmine, have been developed for the treatment of AD (Bartus, 2000).
1.2.2 The tau hypothesis.
NFTs are one of the major neuropathological features of AD. NFTs are intraneuronal
aggregations of highly phosphorylated microtubule-associated tau proteins. The tau
hypothesis, initially suggested by Braak and Braak, is also called the neuronal
cytoskeletal degeneration hypothesis, which emphasizes the central role of tau and
associated neurofibrillary tangles in neurodegeneration and dementia of AD (Braak
and Braak, 1991; Braak et al., 1994). In addition to emphasizing the most important
role of NFTs in the pathogenesis of AD, this hypothesis further implies that, although
deposition of extracellular Ap is almost an invariant event in AD, it is not the central
cause of dementia, but a by-product during neurodegeneration.
Early evidence that led to this theory came from a quantitative study by Wilcock and
Esiri who found a highly significant correlation between the severity of dementia and
the number of NFTs in the cerebral cortex (Wilcock and Esiri, 1982). Hyman and his
colleagues also demonstrated that NFTs but not amyloid plaques parallel the severity
of AD (Arriagada et al., 1992), and that the degree of dementia is better correlated
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with the density of cerebral NFTs (Hyman and Tanzi, 1992). Gomez-Isla and
colleagues have found that both NFTs and neuronal loss increase in parallel with the
severity of AD, and that plaques are not related to the duration of disease (Gomez-Isla
et al„ 1997).
1.2.3 The amyloid cascade hypothesis.
Missence mutations in the APP, PS1 and PS2 in FAD and
inheritance of apoE4 or failure of clearance of A(B in SAD.
I
Accumulation and oligomerization of A342.
I
Subtle effects of A342 oligomers on synaptic function.
I





Synaptic dysfunction and neuronal loss.
I
Symptoms of dementia.
Figurel. The Amyloid Cascade Hypothesis. Adopted from Selkoe (2002).
During the last decade, the amyloid cascade hypothesis has become the most popular
hypothesis for the aetiology of AD. This theory basically states that the
neurodegenerative process of AD is a series of events triggered by the abnormal
processing of APP and amyloid deposition (Hardy and Allsop, 1991; Hardy and
Higgins, 1992; Selkoe, 1994). As shown in Figure 1, it has been proposed that
accumulation of the 42-residue form of A(3 triggers synaptic dysfunction, causes
microgliosis and astrocytosis and finally leads to dementia in AD (Selkoe, 2002).
Despite several arguments, a large body of quantitative studies support this theory.
Earliest evidence has shown the correlation between quantitative measures of amyloid
plaques and dementia in the cerebral grey matter of AD patients (Roth et al., 1966;
Blessed et al., 1968). Wilcock and Esiri also demonstrated a significant correlation
between the severity of dementia and amyloid plaques (Wilcock and Esiri, 1982).
Cummings et al found that the strongest predictor of premortem cognitive impairment
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is the relative area of entorhinal cortex occupied by amyloid deposition (Cummings
and Cotman, 1995; Cummings et al., 1996a). It has been demonstrated that the mean
A|3 plaque burden in the hippocampus correlates with severity and psychological test
scores of AD (Bartoo et ah, 1997). Naslund et al also reported that the levels of AP40
and A|342 are elevated early in dementia and are strongly correlated with cognitive
decline (Naslund et al., 2000). Furthermore, in the frontal cortex, Ap is elevated
before the occurrence of significant tau pathology (Naslund et al., 2000).
Interestingly, some AD cases are a plaque-only disease and do not develop neocortical
NFTs at all (Terry et al., 1987; Graeber et al., 1997; Moller and Graeber, 1998). By
contrast, there are fewer studies showing the positive correlation between the level of
cognitive impairment and NFTs in AD, so the amyloid cascade hypothesis has gained
more evidence than the tau hypothesis.
Another line of strong support for the amyloid cascade hypothesis comes from genetic
studies. It has been long found that mutations on APP, presenilin-1 (PS1) and
presenilin-2 (PS2) are closely linked with the inherited FAD, and that apolipoprotein
E s4 (APOE4) is a risk factor for late-onset SAD (Price and Sisodia, 1998). All
mutations on APP (Citron and Oltersdorf T, 1992; Cai et al., 1993; Citron et al., 1994;
Haass et ah, 1994; Suzuki et al., 1994), PS1 and PS2 (Duff et al., 1996; Scheuner et
ah, 1996; Thinakaran et ah, 1996; Citron et ah, 1997) produce increased Ap levels or
Ap deposition. The APOE4 gene dose increases Ap deposition as well (Schmechel et
ah, 1993; Greenberg et ah, 1995). Studies on Down's syndrome have also shown that
patients who develop AD pathology before the age of 50 produce huge amount of Ap
from birth, often beginning to display amyloid plaques as early as 20 years old, long
before they develop NFTs (Querfurth et ah, 1995; Lemere et ah, 1996).
1.3 Molecular basis of Alzheimer's disease.
Genes, age and environmental factors can influence the development of AD. Age is
one of the main risk factors for AD while gene mutations account for all early-onset
autosomal FAD. Until now, more than 100 mutations on APP, PS1 and PS2, have
been identified, and they are linked with FAD. In late-onset SAD, mutations on these
three genes are quite rare, instead, a polymorphic variant of the APOE gene on
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chromosome 19 has been found to be a risk factor for SAD. The genes involved in
FAD and SAD are reviewed in the following sections.
1.3.1 APP mutations and early onset ofAD.
Glenner and Wong first isolated and purified Ap peptide, the major constituent of
amyloid, from the blood vessels of AD patients (Glenner and Wong, 1984). Using the
amino acid information of Ap by Glenner and Wong, several different groups
successfully cloned the APP gene (Goldgaber et al., 1987; Kang et al., 1987; Robakis
et ah, 1987). The APP gene is mapped to chromosome 21 (St George-Hyslop et ah,
1987). Levy and colleagues were the first to report a mutation on the APP gene, the
Dutch mutation, which is a missense substitution (Glu for Gin) at codon 693 of
APP770 (Levy et ah, 1990). The London mutation at residue 717 (lie for Val) was
discovered by Goate and colleagues (Goate et ah, 1991). Murrell et al reported the
Indiana mutation at 717 (Phe for Val) (Murrell et ah, 1991). Mullan and colleagues
identified the Swedish double mutations in two large early-onset AD families from
Sweden, and these mutations at codons 670 and 671 result in the substitution of Lys-
Met by Asn-Leu (Mullan et ah, 1992). There are several other AD-linked APP
mutations (Chartier-Harlin et ah, 1991; Hendriks et ah, 1992; Mullan et ah, 1992).
Interestingly, APP gene mutations account for a very small portion of FAD (Tanzi et
ah, 1992).
1.3.1.1 The structure of APP.
The APP gene is a -400 kb DNA, contains 18 exons, and encodes several
alternatively spliced APP mRNAs. APP is a big transmembrane protein including an
N-terminal signal peptide, a large ectodomain with sites for N-glycosylation, a
Kunitz-type protease inhibitor (KPI) domain, an Ap region, a single transmembrane
helix and a short cytoplasmic domain for endocytic signalling pathways (Hardy, 1997;
Price and Sisodia, 1998). Due to alternative mRNA splicing, three different isoforms
of APP, APP695, APP751 and APP770 are produced in neurons. APP695 is the
dominant isoform in both central and peripheral neurons (Sisodia et ah, 1993).
APP695 differs from APP751 and APP770 in that it does not contain the KPI domain
located near the N-terminus of the protein (Tanzi et ah, 1988). APP belongs to a
larger gene family including amyloid precursor-like proteins (APLP), APLP1 and
APLP2 (Wasco et ah, 1992; von Koch et ah, 1995). APLP1 and APLP2 share much
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sequence homology with APP, except that APLPs lack the Ap domain (Wasco et ah,
1992).
1.3.1.2 Processing of APP.
APP is cleaved by three different proteases, designated the a-, P- and y-secretases
(Price and Sisodia, 1998). In the CNS, APP is processed by two different cleavage
pathways, non-amyloidogenic and amyloidogenic pathway.
In the non-amyloidogenic pathway, the a-secretase first cleaves the site between
amino acid 612 and 613 and produces a soluble N-terminal ectodomain of APP called
sAPPa and an 83-residue C-terminal fragment called C83 (Esch et ah, 1990). The C83
is further processed by the y-secretase to release a 3-kDa peptide called p3 and C57-
59 fragment called amyloid intracellular domain (AICD). The physiological functions
of the AICD and p3 are unknown, but the sAPPa can promote neurite outgrowth in
PC 12 cells and is neuroprotective in cultured neurons from excitotoxic stimulations
(Mattson et ah, 1993).
In the amyloidogenic pathway, the P-secretase first cleaves between amino acid 596
and 597 of APP. A soluble N-terminal APP fragment called sAPPP and a 99-residue
C-terminal fragment, C99, are produced after the P-secretase cleavage. The C99
remains membrane-bound but is a substrate of the y-secretase. As the y-secretase
makes proteolyses the C99 within neuron membrane, the C99 is cut to release a 4-kDa
peptide called Ap and C57-59 (Haass et al., 1993). Cleavage of the C99 by the y-
secretase is heterogeneous: most of the full-length Ap species produced comprise 40-
residue peptide (AP40), whereas a small proportion comprise 42-residue fragment
(Ap42). AP42 is more hydrophobic and is much more prone to form fibril than AP40
(Jarrett et ah, 1993). AP42 is the major Ap species in amyloid plaques.
1.3.1.3 Proteases for APP cleavage.
1) a-Secretase.
The a-secretase cleaves APP at the a-site to release the C83 and sAPPa. This enzyme
displays characteristics of metalloproteases (Esch et al., 1990). It has been reported
that trans-Golgi might be the sites for the a-cleavage (Kuentzel et al., 1993). Three
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members from a disintegrin and metalloprotease (ADAM) family, tumor necrosis
factor-a (TNF-a)-converting enzyme (TACE or ADAM-17), ADAM-10 and ADAM-
9, are candidates for the a-secretase.
TACE cleaves pro-TNFa, releasing the extracellular domain (TNF-a) in a manner
similar to that of APP. TACE processes a spectrum of type 1 membrane
glycoproteins, including TNF-a, the p75 TNF receptor, L-selectin adhesion molecule
and TGF-a. TACE also processes Notch receptors. Gene knockout of TACE in cell
culture reduces the release of the sAPPa, but still produces a residual a-secretase
activity (Buxbaum et ah, 1998). ADAM-10 also processes APP (Lopez-Perez et al.,
1999). Overexpression of ADAM-10 increases the a-secretase activity in a phorbol
ester-inducible manner. A dominant-negative form of ADAM-10 with a point
mutation in the zinc-binding site has been found to inhibit the constitutive and PKC-
regulated a-secretase activity, but it does not totally abolish the sAPPa production
(Lammich et al., 1999). As a member of the ADAM family, ADAM9 (MDC9 or
meltrin-y) plays important roles in cell-cell fusion, intracellular signaling and other
cellular functions (Hotoda et al., 2002). ADAM9 also displays an a-secretase activity
which is activated by phorbol ester (Koike et al., 1999).
2) fl-Secretase.
Using genetic screening or direct enzyme purification, several different labs have
identified the P-secretase (beta-site APP cleaving enzyme, or BACE) (Hussain et al.,
1999; Sinha et al., 1999; Vassar et al., 1999). This enzyme is also called Asp2 or
memapsin 2 (Yan et al., 1999; Lin et al., 2000). The P-secretase RNA is highly
expressed in the brain and in a variety of human tissues. The P-secretase belongs to
aspartyl proteases of the pepsin family and is an integral membrane protein. In
addition to its transmembrane domain near the C-terminus, the P-secretase also
contains a cytosolic domain, a connecting strand and a protease domain at the N-
terminus.
There are two homologues for the P-secretase: BACE (or BACE1) and BACE2
(Bennett et al., 2000). BACE mRNA is highly expressed in the brain and is the
dominant form of the P-secretase (Vassar et al., 1999). By contrast, BACE2 mRNA is
highly expressed in peripheral tissues, such as heart, kidney, pancreas, placenta,
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prostate, stomach and trachea (Bennett et ah, 2000). The intracellular localization of
the P-secretase is primarily in the Golgi and endosomes (Vassar et al., 1999). The
BACE gene is located on chromosome 11, and no AD-causing mutation on this gene
has been found. BACE2 gene is mapped on chromosome 21, and this raises a
possibility that BACE2 contributes to Down's syndrome (Saunders et ah, 1999).
There is a third candidate for the P-secretase, which has been identified as a novel
protease belonging to the carboxypeptidase B (CPB) family. In contrast to BACE and
BACE2, this enzyme lacks a transmembrane domain and is a soluble enzyme
(Matsumoto et ah, 2000).
3) y-Secretase.
The y-secretase was first recognized because of its role in the production of Ap
(Selkoe, 2001). However, APP is not the only substrate for the y-secretase and the
other substrates include Notch, ErbB-4 (Ni et ah, 2001), sterol regulatory element
binding proteins (SREBPs) (Brown et ah, 2000) and numerous type I transmembrane
receptors.
It has been suspected that presenilins (PSs) are the long-sought y-secretase (Nunan
and Small, 2000). PSs can be cleaved into two heterodimers, N-Lerminal and C-
terminal fragments (NTF andCTF), which remain associated. These heterodimers are
the biologically active form of the protein (Thinakaran et ah, 1996). Each piece of the
two heterodimers contains one of the two aspartate residues important for y-secretase
activity. Presenilins do not act alone to carry out the proteolysis of the CTF of APP.
The levels of PS heterodimers are regulated by other limiting cellular factors
(Thinakaran et ah, 1997). Nicastrin (Net) is one of the factors. Recent evidence
suggests that maturation of Net depends on PS (Edbauer et ah, 2002) and is directly
associated with the y-secretase (Esler et ah, 2002). Other limiting factors are Aphl
and Pen2. Aphl is a transmembrane protein and displays similar functions to PS in C.
elegans (Levitan et ah, 2001). Both Aphl and Pen2 are required for PS
endoproteolysis in C. elegans (Francis et ah, 2002). Kimberly et al have found that
Aphl and Pen2 proteins are also the integral components of the y-secretase complex
(Kimberly et ah, 2003). Overall, the y-secretase is a large multimeric transmembrane
protein complex which is composed of PSs, Net, Aphl and Pen2.
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1.3.1.4 Neurotrophic and neurotoxic properties of Ap.
Ap is normally generated by healthy cells and circulates in extracellular fluids in
humans throughout life, so both AP40 and AP42 are normal metabolic products of
intracellular APP processing. However, the normal physiological role of Ap is still
unknown. It has been very controversial whether Ap is neurotrophic, neurotoxic, or
without effects on neurons.
It has been shown that Api-28 enhances survival of cultured hippocampal neurons
(Whitson et al., 1989). Synthetic Ap42 increases cell survival (Whitson et al., 1990).
AP at low concentrations is also neurotrophic to undifferentiated hippocampal
neurons (Yankner et al., 1990). By contrast, a high level of Ap is neurotoxic. A
considerable neuronal loss in the hippocampus has been found after SDS-isolated
amyloid cores were injected into the cortex and hippocampus of the rats (Frautschy et
al., 1991). Injections of AP40 peptides into rat or monkey cerebral cortex can induce
localized neuronal loss and gliosis (Kowall et al., 1992). Controversially, there is
much evidence showing no effects of Ap either in vivo or in vitro. Games et al
reported that a number of synthetic Ap peptides (AP40, AP38, and AP25-35) over a
wide range of concentrations were injected into the hippocampus and cortex of adult
rats, and that no significant morphological changes were produced (Games et al.,
1992). Clemens et al also observed that AP40 and AP42 injected into the brain of 3-
month-old and 18-month-old rats failed to induce pathological characteristic of AD
(Clemens and Stephenson, 1992).
To explain the discrepancy stated above, it has been suggested that the aggregation
properties of Ap are critical to its neurotoxicity in vitro and in vivo (Pike et al., 1993).
In general, large amounts of Ap can readily generate neurotoxicity in vitro and in
vivo, but a small amount of Ap injection does not induce neurotoxicity.
1.3.2 Presenilins and early onset ofAD.
The PS1 gene, mapped on chromosome 14 (St George-Hyslop et al., 1992; Van
Broeckhoven et al., 1992), was identified by a positional cloning strategy (Sherrington
et al., 1995). The PS2 gene, mapped to chromosome 1, was isolated and identified by
two different groups (Levy-Lahad et al., 1995a; Rogaev et al., 1995). Mutations on
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PS1 are responsible for 25-30% of all FAD cases (Schellenberg, 1995), while PS2
mutations in AD are very rare (Sherrington et al., 1996).
The PS1 gene spans more than 50 to 75 kb and contains 12 exons (Alzheimer's
disease collaborative group, 1995). The longest open reading frame, from exons 3 to
12, encodes a 463-amino acid protein. The localization of PS1 mRNAs is found very
similar in healthy and SAD brains (Nishiyama et al., 1996). More than 70 missense
mutations have been identified (Hardy, 1997) and some of them can cause AD before
the age of 30 (Campion et al., 1996). The number of mutations identified on the PS1
gene is still increasing. The gene structure of PS2 is very similar to that of PS1, with
12 exons corresponding to a 24-kb genomic region. Exons 3 to 12 give rise to an open
reading frame encoding a 448-amino acid protein (Levy-Lahad et al., 1996). 6
mutations on PS2 have been characterized (Hardy and Gwinn-Hardy, 1998).
1.3.2.1 The biology of presenilins.
PS1 and PS2 are highly homologous proteins and share 67% amino acid identity.
They are 463 and 448 amino acids in length, respectively. PS1 contains seven
transmembrane domains, including a hydrophilic acidic loop encompassing amino
acids 263-407, in which most of the missense mutations have occurred (Sherrington et
al., 1995). Topology studies show that the N-terminus, loop, and C-terminus of PS1
are cytoplasmic (Doan et al., 1996). PS1 immunoreactivity is mainly found in
perikarya and dendrites, but very weakly in axons (Elder et al., 1996). PS2 differs
from PS1 mainly in the N-terminus and the large hydrophilic loop between TM6 and
TM7 (Levy-Lahad et al., 1995b). Although PS2 is co-localized with PS1 in the brain,
PS2 immunoreactivity is mainly present in the cell body of neurons (Blanchard et al.,
1997). Several studies have shown that the subcellular localization of PS1 and PS2 is
in the endoplasmic reticulum (ER), Golgi apparatus (Cook et al., 1996; Kovacs et al.,
1996), plasma and nuclear membranes (Takashima et al., 1996; Li et al., 1997).
The metabolism of PS1 has been investigated in cell cultures and in vivo. PS1 is
synthesized as a -43 kDa polypeptide and is cleaved within a region encompassing
amino acids 260-407. Interestingly, PS 1-related species which accumulate in cell
culture, in animal or human brains are a 27 kDa N-terminal fragment (NTF) and a 17
kDa C-terminal fragment (CTF). The ratio of NTF to CTF is about 1:1 (Lee et al.,
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1996). The NTF of PS1 could be co-precipitated along with the CTF after the
detergent solubilization, and thus form a larger complex of -100 kDa in cell cultures.
There is little information on the identity of the enzyme for PS1/PS2 cleavage.
1.3.2.2 The physiological roles of presenilins.
As PSs are the active site of the y-secretase, one of the main functions of PS is to
cleave APP. Several studies indicate that elevated Ap and Ap42 levels are found in
the secreted medium of fibroblasts derived from patients bearing FAD-linked PS1 and
PS2 mutations (Scheuner et al., 1996). Overexpression of mutant human form of PS
leads to overproduction of AP42 in either stably transfected cells (Ancolio et al.,
1997) or APP/PS1 Tg mice (Duff et al., 1996). The mechanism by which mutant PS
regulates APP processing is possibly through reducing the activity of the y-secretase,
meanwhile increasing that of the p-secretase.
PS1 has very important role in somitic development. Wong et al reported that
embryos of PS1 knockout mice exhibit abnormal patterning of the axial skeleton and
spinal ganglia, suggesting defects in somitic segmentation and differentiation (Wong
et al., 1997). Shen and colleagues found that PS1 homozyous knockouts die shortly
after birth and the skeleton of the homozygote is grossly deformed. Haemorrhages
occur in the CNS of PS1 knockouts with varying location and severity (Shen et al.,
1997). Interestingly, PS1-/- mice can be rescued for viability by both wild-type and
FAD-linked PS1 (Davis et al., 1998; Qian et al., 1998), suggesting a very important
role of PS during development.
The involvement of PS1 in learning and memory has recently been reported (Yu et al.,
2001). Using the newly developed conditional gene knockout techniques, PS1
conditional knockout mice (PSlcKO), in which PS1 inactivation is restricted to the
postnatal forebrain, were generated. Interestingly, these mice display normal
hippocampal basal synaptic transmission, long-term potentiation (LTP) and long-term
depression (LTD), but exhibit long-term spatial memory deficit in a watermaze
reference memory task, suggesting a potential role of PS1 in long-term learning and
memory (Yu et al., 2001).
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1.3.3 Apolipoprotein E and late onset ofAD.
The genetic association between apolipoprotein E (APOE) s4 and the risk of AD was
first reported in 1993 (Saunders et ah, 1993; Strittmatter et ah, 1993a). These findings
mark a major breakthrough in understanding the etiology of AD. Subsequent studies
have established APOE gene as the most important genetic determinant of
susceptibility to SAD and late-onset FAD (Corder et ah, 1993; Mayeux et ah, 1993;
Poirier et ah, 1993). It appears that APOE4 accounts for -50% of the genetic risk for
AD.
APOE genotyping is considered a prototype of genetic risk factor assessment for
common and late-onset AD. APOE4 genotyping is not used as a predictive test for
AD and it is not recommended by the US National Institute on Aging/Alzheimer's
Association Working Group, as the usefulness of APOE4 genotyping for predicting
risk of AD in asymptomatic individuals has not been established in longitudinal
population studies. However, APOE genotyping has been proposed as a possible
adjunctive diagnostic test for AD, because it can improve specificity of the diagnosis
(Mayeux et ah, 1998).
1.3.3.1 The biology of apolipoprotein E.
The APOE4 allele is a common polymorphism in -25-33% of the population (Corder
et ah, 1993). The APOE gene is mapped on chromosome 19 and has three allelic
forms, APOE-s2, APOE-s3 and APOE-s4. APOE-s3 is the most common allele,
while the APOE-s4 allele only has a frequency of 15% in general population. The
APOE-s4 allele is about three times more frequent among AD patients than age-
matched controls, while APOE-s2 is lowly expressed in AD (Price et ah, 1998).
ApoE (protein) exists mainly in plasma and is also produced in astrocytes of the brain.
Antibodies to apoE are immunoreactive in plaques and NFTs in the brain sections of
AD patients (Strittmatter et ah, 1993b). Patients with homozygous APOE-e4 show
larger and denser A(3 immunoreactivity in the brain than those with homozygous
APOE-s3 (Schmechel et ah, 1993). ApoE contains 299 amino acids in a single
polypeptide chain (Strittmatter et ah, 1994). Three isoforms of apoE differ from each
other by cysteine-arginine interchanges at positions 112 and 158. At these
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polymorphic sites, apoE3 contains cysteine and arginine, apoE4 contains arginine and
apoE2 contains cysteine at both sites (Weisgraber et ah, 1981).
Structural analysis indicates that apoE contains two independent domains: an N-
terminal domain and a C-terminal domain. The N-terminal domain has five a-helices
and contains the region that binds to lipoprotein receptors. The C-terminus contains
the major lipid binding elements of apoE. ApoE3 and apoE4 show high affinity to the
low density lipoprotein (LDL) receptor, but apoE2 has low affinity (Dong et ah,
1994). Due to the cysteine-arginine difference at position 112 at the N-terminus,
apoE4 preferentially associates with large, triglyceride-rich very low density
lipoproteins (VLDL) and apoE3 with small, cholesterol-rich high density lipoproteins
(HDL).
1.3.3.2 The interaction between apoE and Ap.
It has been suggested that apoE isoforms differentially affect amyloid deposition,
NFTs formation, neuronal plasticity, cholinergic function and other pathophysiology
of AD (Horsburgh et ah, 2000). ApoE can bind to AP peptide, and the residues 244-
272 in the C-terminal domain are required for the interaction (Strittmatter et al.,
1993b). It has been shown that long-term incubation of both apoE3 and apoE4 with
AP peptide forms aggregates that precipitate from solution and further forms
monofibrillar structures, but apoE4 is more effective (Wisniewski et al., 1995).
1.3.3.3 The interaction between apoE and tau.
ApoE3 could form a sodium dodecyl sulphate (SDS)-stable complex with normal tau,
not the phosphorylated tau. It is suggested that the interaction between the apoE3 and
tau has protective role (Strittmatter et al., 1994). The binding site between the apoE3
and tau is in the vicinity of the polymorphic site at position 112, and
cysteine/arginine-112 or arginine-61 may be the key residues for the interaction. The
binding of the apoE3 to tau stabilizes microtubules and cytoskeleton, and thus helps
maintain the structure of neurons. This binding might also inhibit the phosphorylation
of tau and therefore prevent the PHF formation in NFTs. However, apoE4 does not
display any protection like that by apoE3.
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1.3.3.4 Brain injury and apoE.
ApoE plays important roles in the response to acute brain injury, neuronal protection
and repair. It has recently been found that the cortical levels of apoE do not change 30
minutes after the haematoma induction but are significantly elevated 4 hours after
(Horsburgh et ah, 1997). However, apoE isoforms may have different effects on
neuronal repair within the CNS, as impaired neuronal plasticity has been observed in
apoE4 transgenic (Tg) mice but not in apoE3 transgenics (White et al., 2001).
1.3.4 Tau and AD.
Tau proteins are one of the microtubule-associated proteins (MAPs) and are abundant
in the CNS. The mutations in the tau gene have been reported to cause
neurodegeneration, AD and dementia (Hutton et ah, 1998; Poorkaj et al., 1998;
Spillantini et al., 1998).
1.3.4.1 Microtubules and tau.
Cytoskeletal microtubules (MTs), along with actin and intermediate filaments,
establish the overall architecture of the cytoplasm. As the primary component of the
mitotic spindle, microtubules are mainly consisted of heterodimers of MAPs, a- and
(3-tubulin. It is believed that the oriented microtubule arrays in axons serve as the
tracks for vesicles and cell organelles to be translocated from the center part to the
distal end and back again by several different proteins such as members from the
kinesin and dynein families (Allen et al., 1985; Nangaku et al., 1994; Trinczek et al.,
1999). About 80% of microtubule components are tubulins, while the remaining 20%
are MAPs, including MAPI (>250 kDa), MAP2 (-200 kDa) and tau proteins (50-70
kDa). MAP2 and tau, the two major MAPs in neurons, are localized to different
subcellular compartments. The MAP2 is largely expressed in dendrites, but the tau is
mainly in axons. Astrocytes and oligodendrocytes also express low levels of tau.
The TAU gene contains 16 exons and major tau protein isoforms in the CNS are
encoded by 11 exons (Andreadis et al., 1992). By alternative mRNA splicing of exons
E2, E3, and E10, six tau isoforms named 4R2N, 4R1N, 4R0N, 3R2N, 3R1N, and
3R0N are expressed in adult human brain (Lee et al., 2001). Interestingly, only three
isoforms including the 4R0N, 4R1N and 4R2N are expressed in rodents (Goedert and
Jakes, 1990). They differ by the presence of one or two short fragments or absence of
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any fragment in the N-terminus (IN, 2N and ON), and by the presence of either three
or four microtubule-binding repeat motives in the C-terminus (3R and 4R).
1.3.4.2 Physiological functions of MAPs and tau.
One major physiological function of MAPs and tau is to promote microtubule (MT)
polymerization, bind to and stabilize microtubules (MTs) (Cleveland et al., 1977; Lee
and Rook, 1992). The polymerization of tubulin into MTs is regulated by the state of
phosphorylation of tau proteins. Hypophosphorylated tau induces tubulin
polymerization and microtubule stabilization. The MT binding domains of the tau are
localized to the C-terminus of the molecule within the four MT binding motives.
These motives are composed of highly conserved 18-amino-acid-long binding
elements separated by flexible, but less conserved, inter-repeat sequences that are 13-
14-amino-acid-long (Himmler et al., 1989; Lee et al., 1989). Among the 80 Ser/Thr
residues on the tau, at least 30 phosphorylation sites have been described, most of
which occur on Ser-Pro and Thr-Pro motives. In fact, phosphorylation of Ser262,
located in the first MT-binding domain, dramatically reduces the affinity of tau for
MTs in vitro (Buee et al., 2000).
The normal physiological function of tau has been investigated. Harada et al reported
that the nervous system of tau knockout mice appears to be normal and that axonal
elongation is not affected. However, MT stability is decreased and MT organization is
significantly changed in the tau knockouts, suggesting that tau is crucial in the
stabilization and organization of MTs in certain types of axon (Harada et al., 1994).
Tau also acts as a phosphatidylinositol bisphosphate (PIP2) binding protein and
regulates activities of several actin binding proteins (Flanagan et al., 1997).
1.3.4.3 Tau mutations and dementia.
All tau mutations identified so far are in the carboxyl-terminal side of the tau protein.
Hutton et al first reported three missense mutations in exons 9, 10, and 13 (G272V,
P301L and R406W) (Hutton et al., 1998). A V279M mutation was identified from
FTDP-17 family (Poorkaj et al., 1998). The G to A mutation in the intron following
the exon 10 of tau was found in a familial multiple system tauopathy with presenile
dementia (MSTD) (Spillantini et al., 1998). Mutations in exon 9 (K257T and G272V),
exon 12 (V337M and E342V) and exon 13 (G389R and R406W) affect all six tau
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isoforms, however, mutations in exon 10 (N279K, AK280, AN296, P301L, P301S and
S305N) only affect tau isoforms with the 4R (Clark et al., 1998; Goedert et ah, 1999;
Pastor et ah, 2001; Ferrer et ah, 2003). Tau mutations can cause changes in MT
binding, MT polymerization, rapid axonal transport and the abnormal aggregation of
tau in various neurodegenerative diseases (Jicha et ah, 1999). Missense mutations of
tau have also been found to affect the integrity of the MT system and to initiate the
formation of tau inclusions in FTDP-17 (DeTure et ah, 2000).
1.4 Modelling Alzheimer's disease.
The lack of good animal model of AD has been a big problem for the pathological
study of AD and to the development of novel therapeutics for AD. Animal models
displaying neuronal degeneration, plaque formation and neurofibrillary lesions are
certainly very powerful to facilitate understanding the mechanisms of the disease.
Generally, an ideal animal model should develop most or all aspects of a disease in a
reproducible way. Animal models of AD are dramatically advancing with lesions in
large animals such as primates and canines and the development of transgenic
animals.
Researchers in the field of AD have spent several decades trying to discover better
animal models. Flistorically, the development of AD animal models can be divided
into two phases: non-transgenic era, in which traditional lesion techniques have been
utilised to create non-transgenic models, and transgenic era, in which the modern
molecular biology technology has been used to produce transgenic (Tg) animals. Due
to great efforts devoted to the generation of Tg animal model of AD, during the past
decade, numerous Tg models have been published. This section (section 1.4) will only
focus on reviewing non-transgenic animal models of AD and discussing their
setbacks. The next three sections will review the APP (section 1.5), tau (section 1.6)
and plaque/tangle (section 1.7) Tg mouse models, separately.
1.4.1 Primate models ofAD.
Aged monkeys develop plaques, manifest behavioural impairments (Wisniewski et
al., 1973) and display neurotransmitter deficits (Goldman-Rakic and Brown, 1981).
Plaque loads are highest in the prefrontal and temporal cortices and lowest in the
22
Guiqaan Chen's PhD Thesis.
occipital cortex of aged macaques (Struble et al., 1984; Struble et al., 1985).
Nonhuman primates seem to be a feasible model for the study of human AD.
1.4.2 Mouse models ofAD.
It was generally believed that normal aged rodents do not develop any human AD
pathology, however, this view has been changed since the senescence-accelerated-
prone (SAMP) mouse was reported in early 1970s (Takeda et al., 1981). It has been
reported that the SAMP8 line exhibits an age-dependent plaque formation in the
hippocampus (Morley et al., 2000) and displays age-related learning impairments in
several behavioural tasks (Miyamoto et al., 1986; Flood and E. Morley, 1997; Ohta et
al., 2001). The SAMP mouse is a useful animal model of senescence and AD.
1.4.3 Bear models ofAD.
Plaques, cytoskeletal abnormalities and NFTs have been identified in aged bears
(Cork et al., 1988), so aged bears could be used as an animal model of AD.
1.4.4 Canine models ofAD.
Aged beagles have been found to develop diffuse plaques (Cummings et al., 1993).
Aged dogs also display behavioural deficits on discrimination, reversal and spatial
learning. It has been reported that behavioural deficits in dogs are significantly
correlated with the increased Ap deposition (Cummings et al., 1996b).
1.4.5 Aluminium injection model ofAD.
Injection of aluminium chloride into the CNS of rabbits has been found to produce
neurofibrillary changes and learning impairment (Wisniewski et al., 1980). However,
the structure of the neurofibrillary changes induced by aluminum is different from the
NFTs seen in AD.
1.4.6 Lesion models ofAD.
Monkeys, injected with cholinergic receptor blocker (scopolamine), display striking
memory impairments (Bartus et al., 1982). Chronic infusion of okadaic acid (OA), a
specific inhibitor of the serine/threonine protein phosphatases 1 and 2A, into rat brain
ventricles has been found to produce a severe memory impairment, a PHF-like
phosphorylation of tau protein and the formation of plaque-like structures in grey and
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white matter areas (Arendt et al., 1995). Another specific inhibitor of PP1 and PP2A,
calyculin A, can also induce tau hyperphosphorylation and a deficit in spatial learning
in rats (Sun et ah, 2003). Collectively, the OA- or calyculinA-induced
neurodegeneration may be a useful model for AD.
1.4.7 Cholesterol-fed rat model ofAD.
It has been suggested that cholesterol is involved in the pathophysiology of AD
(Wolozin et ah, 2000). A cholesterol diet was used to feed rats for 4-6 months and
immunohistochemical staining reveals amyloid plaques in the hippocampus and
cortex of the rats. Impaired hippocampal LTP is also observed (Koudinov and
Koudinova, 2001). No NFTs have been produced in the cholesterol-fed rats.
1.4.8 Afi infusion models ofAD.
In vitro studies have shown that aggregated synthetic Ap42 induces toxicity in
neurons (Pike et ah, 1991). Kowall and colleagues also found that infusion of Ap into
rats induces focal plaque deposition and profound neurodegeneration in the cortex
(Kowall et ah, 1991). Hippocampal LTP is impaired in AP-infused rats (Itoh et ah,
1999). One recent study has shown that rats injected with AP40 and Ap43 display
both impaired hippocampal LTP and working memory (Stephan et ah, 2001). Ap
infusion models are very useful to investigate the mechanisms of AD.
1.4.9 Summary for non-transgenie animal models ofAD.
Nonhuman primate, dog, bear and SAMP mouse have been useful models for the
research on AD. However, there are many drawbacks to these models. First, the
availability of some of these models is restricted. Monkeys, bears and dog live 20
years or longer, so the process of developing diffuse plaques is very time-consuming.
Second, only very limited AD-like pathology, such as diffuse plaques, has been
observed in those models, but no NFTs, no neuronal or synaptic loss, no microgliosis
and no astrocytosis. Obviously, the big animal models like monkey and bear are not
applicable to any general laboratory. Third, OA lesion or Ap infusion models seem
more promising than nonhuman primates, because they produce more AD-like
pathology both acutely and focally. However, one big problem about lesion or
infusion models is that AD is not an acute disease and its pathology develops
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progressively and chronically throughout the whole nervous system. Another problem
is that lesions or AP infusions can be quite variable and it is difficult to reproduce the
same results across different laboratories (Greenberg et al., 1996). Fourth, the SAMP8
mouse displays diffuse plaques and learning deficits at old ages, but they should be
viewed as a model for aging brain rather than AD.
The various weaknesses of the non-transgenic animal models have prevented them
from being used more widely. Although they have been in use for about four decades
in the research of AD, our understanding of AD remains very poor. Transgenic
technology has brought a new optimism, as it represents a unique and powerful tool
for in vitro and in vivo study of the pathophysiology of a gene of interest. As genetic
mutations on APP and tau in FAD and FTDP-17 have been identified, using
transgenic approaches, one can directly examine whether the overexpression of
human mutant APP or tau genes in the brain of animals leads to AD-like pathology
and thus provide extremely important information on the molecular mechanisms of
the disease. For the past decade, a very large number of research groups have been
attempting to generate rodent models of AD using both cDNA- and genomic-based
approaches. While the failure of early attempts to generate Tg AD models had been
very discouraging to the field, the advent of mouse models generated by
overexpression of human mutant APP (Games et al., 1995) and tau (Lewis et al.,
2000) has marked great breakthroughs and has been proven extremely important to
this field.
1.5 APP transgenic mouse models for Alzheimer's disease.
The overall goal of APP transgenic efforts is to get high levels of mutant APP
expression in the nervous system in order to produce partial or complete AD-like
pathology in animals. Ideally, the AD-like neuropathology should be developed in an
age-dependent manner in the animal so that it, at least partially, mimics the disease
progression in human AD. Interestingly, early efforts to generate plaque-producing Tg
mice using either full-length or fragment of wildtype APP were unsuccessful (Quon et
al., 1991; Yamaguchi et al., 1991). Since the mutated human APP gene was first
introduced into the mouse in 1995, numerous APP Tg mouse models have been
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created by a large number of different laboratories so far. This section will review the
representatives of APP Tg mouse models.
1.5.1 The APP751 (SciosNova) mouse.
The APP751 mice express the full-length wildtype human 751-amino acid isoform of
APP cDNA under the control of a rat neuron-specific enolase promoter (Quon et al.,
1991; Higgins et al., 1994; Higgins and Cordell, 1995). The APP751 mice display
more abundant transgene mRNA than endogeous APP mRNA, elevated AP and full-
length APP in the brain. Immunostaining with antibodies to AP and to the C-terminus
of AP42 reveals diffuse AP deposits. Histology was examined in mice at 2 and 22
months of age. At 2 months, 27% of brain sections of the APP751 mouse have at least
one deposit. At 22 months, 42% of sections have deposits. Increased tau protein
immunoreactivity is also found in the hippocampus, cortex and amygdala at old age
(Higgins et al., 1994; Higgins and Cordell, 1995). But there is no evidence showing
neuritic plaques, synaptic and neuronal loss.
Two cohorts of these mice, one at 5-6 months and the other at 9-12 months of age,
were first tested with several general sensorimotor tasks such as string test, rotarod,
general activity, elevated plus-maze and behavioural despair test (Moran et al., 1995).
The Tg mice do not differ from non-Tg controls at either 6 or 12 months in muscle
strength, motor coordination, level of anxiety or behavioural despair (Moran et al.,
1995). Tgs and non-Tgs display similar circadian activity at both ages. Cognitive
behaviour was then evaluated in a Y-maze for spontaneous alternation and in a water
maze for spatial reference memory and cued learning. Although the Tg mice do not
differ from the non-Tg in the spontaneous alternation at 6 months, they show lower
alternation rates than non-Tg littermates at 12 moths. During the watermaze reference
memory testing, The Tg mice display significantly longer average escape latency than
that by the controls at both 6 and 12 months. Interestingly, the Tg mice also
constantly display longer latencies in the cued learning. In three probe tests, the 12-
month Tg mice display significant impairment in searching for the target quadrant in
which platform was previously present during the acquisition training (Moran et al.,
1995).
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As the APP751 mouse is the first mouse model to overexpress the full-length
wildtype human APP gene, it might be a good model for Down's syndrome.
However, the weakness of this model is that it only develops diffuse plaques.
1.5.2 The PDAPP mouse.
The PDAPP mouse, overexpressing a mutated human APP gene harbouring the
Indiana mutation under the control of a P-chain promoter of platelet-derived growth
factor (PDGF), was first described by neuroscientists at Athena Neurosciences
(Games et ah, 1995). The introns 6-8 of APP gene are included in the construct which
allows alternative splicing of exon 7 and 8, leading to very high expression of all three
human APP isoforms in the brain. Probably the PDGF promoter and use of the introns
from the APP gene in the construct result in the expression of high level of both APP
and AP (Duff and Hardy, 1995). Levels of human APP mRNA and APP proteins are
approximately 4-5 times higher than that of endogenous APP (Games et al., 1995).
The PDAPP mouse displays an age-dependent AD-like pathology. At young age (<6
months), no diffuse AP deposits can be detected (Games et al., 1995). Between 6-9
months, the Tg mice start to display AP deposits and mature plaques in the
hippocampus and cerebral cortex. The deposition of AP becomes more abundant as
the animals get older (Johnson-Wood et al., 1997). At 18 months, the level of AP
deposits is higher than that in human AD brain (Irizarry et al., 1997). At >22 months,
the whole hippocampus and cortex are covered by huge amount of AP plaques. The
nature of the plaques in PDAPP mice is very similar to that in human AD (Masliah et
al., 1996). Besides diffuse and neuritic plaques, in which the amyloid core is
sumounded by massive clusters of dystrophic neuritis, PDAPP mice also display an
age-dependent astrocytosis and microgliosis similar to that in human AD brain; no
activated astrocytes are found at less than 6 months but begin to be apparent at 10
months. Astrocytosis lags the formation of AP plaque formation by about 2 months.
Microgliosis is also found at about 8 months and increases with aging.
Although there is no overt neuronal loss in PDAPP mice at even 24 months, about
20% of synaptic loss has been found in young Tg mice (Hyman et al., 1997). Dodart
et al also reported a hippocampal dystrophy at 3 months (Dodart et al., 2000). The
PDAPP mouse develops early neurofibrillary pathology, for example, Masliah et al
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(2001) observed phosphorylated neurofilament-immunoreactive dystrophic neurites in
plaques at 10- 12 months, phosphorylated tau-immunoreactive dystrophic neurites
after 14 months, but no paired helical filaments at even 20 months.
A clear weakness of this model is that the expression of APP and A(3 is much higher
than that in human AD. High levels of APP751 and APP770, which are believed to be
non-neuronal APP isoforms, have been found in the brain as well. It is reasonable to
argue that PDAPP mice may represent a model for the AP plaques of human AD
rather than a complete model. Nevertheless, as A(3 accumulation and deposition plays
the central role in the pathogenesis of AD (Hardy and Allsop, 1991), these mice have
been very helpful in understanding the mechanisms of Ap accumulation and in testing
agents that may reduce or remove AP plaque formation. Because PDAPP mice have
been the main subjects for my whole PhD study, the behavioural studies on this model
will be reviewed and discussed in two subsequent chapters (Chapters 3 and 4). Two
pharmacological studies using PDAPP mice, Ap vaccines and y-secretase inhibitors
are discussed in Chapters 5 and 7.
1.5.3 The Tg2576 mouse.
Two lines of APP transgenic mouse expressing both human wildtype and mutated
forms of APP695 have been generated by Karen Hsiao (Hsiao et al., 1995; Hsiao et
al., 1996). The first line, which express human APP695 driven by a prion promoter
(PrP) in the FVB strain background, display neophobia and seizures, die before 6
months of age and display no amyloid plaques (Hsiao et al., 1995). The second line,
named as the Tg2576 mouse, overexpress a mutant human APP695 gene with the
Swedish double mutations under the same prion promoter in the C57B6/SJL strain
background. Tg2576 mice express 3-5 times the level of endogenous APP in human
brain and display age-dependent Ap accumulation and deposition in the amygdala,
hippocampus and cortex (Hsiao et al., 1996). Tg2576 mice produce a 4-5 times
increase in the concentration of AP40 and a 14-fold increase of AP42 between 2-13
months of age. Tg2576 mice also display astrocytosis and microgliosis surrounding
the plaques (Hsiao, 1996).
In the initial paper by Hsiao et al, two behavioural tests have been performed in
Tg2576 mice aged from 3 to 14 months (Hsiao, 1996). First, two cohorts of Tg2576
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mice at 3 and 10 months were tested in Y-maze alternation; second, three groups of
mice at 3, 6 and 9 months, were evaluated by cuetask and reference memory task in a
watermaze. In the Y-maze task, 3-month Tg mice do not show any difference from
controls, however, 10-month Tg mice display much less alternations, suggesting an
age-dependent alternation in Tg2576 mice. In the reference memory task, 2-month Tg
mice are not different from the controls in terms of escape latency to the hidden
platform, 6-month Tg mice are also relatively unimpaired compared to the controls,
however, 9-10 months Tg2576 mice display significant impairment. A probe test, in
which 60s was given to allow animals to search for the hidden platform which was
previously available but not present during this trial, was conducted at the end of
training. In the probe trial, the percentage time spent in the target quadrant and the
total crossings of the previous platform were analysed. Young groups (3- and 6-
month) do not differ from the aged-matched controls and only old Tg mice show
much less time spent in the target quadrant and much less crossings of the platform
than that by the controls. The above results were interpreted as plaque-related
memory deficits (Hsiao et al., 1996), however, this claim was strongly criticized
(Routtenberg et al., 1997). First, the data presented in the initial paper (i.e. the graphs
for spatial learning in the water maze) clearly indicate that old Tg2576 mice display a
striking impairment in the visible cuetask (Hsiao et al., 1996), so these results at least
suggest an impairment related to locomotor component in Tg animals. Second, there
seems no evidence showing that three cohorts of Tg mice (2-, 6- and 9-10-month)
display any plaque-related impairment of memory, as the performance of the three
groups of Tg mice seems quite comparable. By contrast, the three cohorts of control
mice might display an age-related memory improvement, for example, the old non-Tg
mice (47% of target quadrant time) show much better performance than the young
ones (38% and 35% at 3- and 6-month, respectively) (Hsiao et al., 1996). Indeed, the
initial claim by Hsiao et al (1996), in which the deficit in spatial learning and memory
of Tg2576 mice is age- and plaque-related, is even weakened by a later study from
King and colleagues (King et al., 1999).
Using a comprehensive behavioural test battery, King et al re-examined sensorimotor
and cognitive performance of Tg2576 mice. Mice at 3 and 9 months of age were
tested with open-field, beam crossing, forepaw grip, Y-maze alternation, cuetask,
reference memory, Barnes maze, and passive and active avoidance tasks. In contrast
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to the findings by Hsiao et al (1996), King and colleagues found that Tg2576 mice do
not differ from the controls at both 3- and 9-month in the Y-maze alternation and
acquisition of reference memory in the water maze. However, Tg2576 mice display
significant impairment in a visible cuetask in the water maze, and this impairment is
progressively worsening with age. More interestingly, very old Tg2576 (14- and 19-
month) mice also exhibit no impairment in the reference memory in the water maze
but only show impairment in the visible cuetask (King and Arendash, 2002). It seems
very difficult to explain the difference between the findings by these two laboratories
(Hsiao et al., 1996; King et al., 1999). Procedural differences, such as animals being
singly housed during the experiment or animals being tested using a battery of
behavioural tests (King et al., 1999), may partially explain this discrepancy. It has
been suggested that different genetic background of mouse strains may yield different
results, but it is unclear whether these two laboratories bred or backcrossed their
Tg2576 mice to different strain, such as C57B/6.
Chapman et al (1999) later employed a different behavioural paradigm, a forced
choice T-maze alternation task to test Tg2576 mice. Analysis of the performance in
the T-maze between 2- and 10-month Tg mice and the controls indicated that, 2- and
10-month non-Tg mice perform this task comparably, but the 10-month Tg2576 mice
display a significantly lower rate of learning during training. Electrophysiological
studies on the same mice have shown that both young and aged Tg2576 mice exhibit
normal basal synaptic transmission and short term synaptic plasticity such as paired-
pulse facilitation (PPF), but only old Tg2576 mice display severely impaired in vitro
and in vivo LTP in both the CA1 and dentate gyrus regions of the hippocampus
(Chapman et al., 1999). The correlation study further demonstrated that LTP deficits
are significantly correlated with the impaired T-maze performance in old Tg mice
(Chapman et al., 1999).
In contrast to the electrophysiological findings from Chapman et al (1999), another
group of neuroscientists in the University of Bristol reported different results using
Tg2576 mice. In the study by Fitzjohn et al (2001), synaptic transmission, short- and
long-term synaptic plasticity in the hippocampus of Tg2576 mice were investigated.
Interestingly, an age-related deficit in basal synaptic transmission but no impairment
of LTP in the hippocampus was observed. Hippocampal slices from 12-month
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Tg2576 mice display reduced levels of synaptic transmission in the CA1 region
compared with the controls. The application of an ionotropic glutamate receptor
antagonist, kynurenate during the preparation of brain slices abolished this deficit. At
18 months, a selective deficit in basal synaptic transmission was again observed in the
CA1 region of the hippocampus with or without treatment of kynurenate during the
slice preparation. However, hippocampal LTP is normal in Tg2576 mice at both 12
and 18 months.
In conclusion, Tg2576 mice develop both diffuse and neuritic plaques, astrocytosis
and microgliosis in an age-dependent manner. Tg2576 mice also display age-related
cognitive impairment. As Tg2576 mice do not develop NFTs and neuronal loss, they
could serve as a good mouse model for the amyloidosis of AD. Although they are not
the first plaque-producing mouse model, Tg2576 mice have been much more widely
used by different laboratories throughout the world due to its unlimited commercial
distribution than PDAPP mice, the first plaque-producing model, which are not
commercially available.
1.5.4 The Scripps, H6 and J9 mice.
Scripps mice express wildtype or Indiana mutated form of APP695 and APP751
(Mucke et al., 1994). The promoter is the rat neuron-specific enolase promoter plus
the SV40 polyA signal. It has been reported that levels of human APP in Tg mice are
30-50% higher than these of endogenous murine APP. Interestingly, a synaptotrophic
effect in the cortex has been observed. No evidence indicates that Scripps mice
develop plaques or other AD-like pathology at age up to 24 months (Mucke et al.,
1994).
Although the Scripps mouse was unsuccessful in developing AD-like pathology,
Mucke's group subsequently generated other two lines, H6 and J9, both of which
display several aspects of AD-like neuropathology (Rockenstein et al., 1995; Wyss-
Coray et al., 1997; Hsia et al., 1999). The H6 line overexpresses the Indiana form of
mutated APP gene (V717F) under the control of a PDGF promoter. The J9 line
overexpresses both the Swedish (K670N, M671L) and Indiana (V717F) mutated
forms of APP gene, driven by the same PDGF promoter. The expression level of APP
in the brain of H6 mice is similar to that of PDAPP mice, but much higher than that of
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the J9 (Mucke et al., 2000). There is a widespread expression of human APP in the
brain of both H6 and J9 mice with maximal levels found in the neocortex and
hippocampus. Interestingly, hippocampal levels of human APP and A(3 increase in an
age-dependent manner and the deposition of Ap plaques is age-dependent. Amyloid
plaques have been found in H6 and J9 mice at 8-10 months, but the J9 exhibit more
plaques than the H6 at this age. J9 mice display plaques at 5-7 months, but no plaques
have been found at 2-5 months in both lines. J9 mice also display much higher levels
of total A|3 and A[342 in the hippocampus than H6 (Mucke et al., 2000). The densities
of synaptophysin-immunoreactive presynaptic terminals and MAP2-positive neurons
in the CA1 region are significantly lower in 2-3-month H6 and J9 mice than in the
controls. More interestingly, neuronal loss was observed in the CA3 region of old H6
animals (Hsia et al., 1999).
Using extracellular slice recording techniques, Hsia et al (1999) investigated synaptic
transmission and plasticity in H6 and J9 mice. Basal synaptic transmission in the
Schaeffer-collateral pathway was examined by recording field EPSPs. In 1-4-month
H6 mice, a -40% decrease in the slope of input-output curves was observed,
suggesting a significant deficit in hippocampal synaptic transmission. At 8-10 months,
a >80% impairment in basal synaptic transmission was again observed in H6 mice,
suggesting a progressive decline of the strength of synaptic transmission. The deficit
in hippocampal synaptic transmission in J9 mice is almost twice as large as that in the
H6. This might be due to the J9 expressing much higher level of A(3 and A(342 than
the H6. Moreover, no amyloid plaques were detected in H6 and J9 mice at 2-4
months, indicating that the deficits in basal synaptic transmission in the H6 and J9 are
not related to extracellular deposition of A(3 and thus are plaque-independent (Hsia et
al., 1999). Finally, hippocampal LTP in the CA1 region of the two lines is not
impaired (Hsia et al., 1999). No behavioural study was conducted on the same mice
examined electrophysiologically.
1.5.5 The C-terminus (C-104) APP Tg mouse.
The C-104 model was reported in 1997. It is a line of Tg mice containing APP cDNA
encoding residues 591-695 (C104 APP) being cloned into the first exon of the human
neurofilament NF-L gene and under transcriptional control of its regulatory elements
(Nalbantoglu et al., 1997). With aging, C-104 mice exhibit more prevalent
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extracellular A(3 immunoreactivity, which is present as dense structures in the cortex
and hippocampus but absent in control animals which are transgenic for
chloramphenicol acetyltransferase (CAATase) under the control of the same NF-L
sequences. This immunoreactivity is accompanied by a generalised gliosis which
increases with aging. Glial fibrillary acidic protein (GFAP)-positive reactive
astrocytes were found as early as 4-5 months in C-104 mice, but not in controls.
Apparent microgliosis was also observed. Interestingly, analysis in hippocampal CA1
cell counting in old C-104 animals reveals a decrease in both cell number (about 10%)
and density (about 20%) (Nalbantoglu et al., 1997).
Spatial memory of 8-month-old CI04 mice was studied using a water maze task
(Nalbantoglu et al., 1997). The mice were first trained for 8 trials per day for 7 days.
After this, the platform was moved to the opposite quadrant and all animals were
trained 8 trials per day for 7 days again. Probably at the end of this stage, or the next
day, a probe test was given (the methods are unclear). Following this, a visible
cuetask was conducted for the next 7 days. A final 7-day training of hidden platform,
8 trials per day, was performed. The main behavioural finding of this study is that the
C104 mice take longer to find the platform than the CAATase Tg mice on all 3 phases
of hidden platform testing. In the visible cuetask, the overall performance of both
groups is comparable. The reversal transfer test reveals a strong spatial memory of
the new platform position in the CAATase Tg mice but not in the C104 group.
Interestingly, analysis of swim speed reveals that the C104 mice swam faster and over
longer distances than the controls. No thigmotaxis data on these animals at three
different phases of testing are presented, but it is likely that C104 mice are more
thigmotaxic than the controls.
The C104 mouse was the first APP Tg model to be analyzed electrophysiologically
(Nalbantoglu et al., 1997). Hippocampal CA1 LTP was induced by theta-burst
stimulation (TBS) and recorded for at least 60 min after the tetanus. Although there is
no difference in post-tetanic potentiation (PTP), C104 mice exhibit significantly
impaired hippocampal LTP as compared to the control group. Both PPF and LTD
were also studied, but there is no difference. After the electrophysiology, a binding
study was conducted to test whether the impairment of hippocampal LTP in C104
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mice might be due to deficits in NMDA receptor function. The amount of binding of
lOOnM JH-glutamate was assayed in several different regions of the brain, but no
differences were found. Second, in the presence of a low Mg2+ concentration and
DNQX (the AMPA antagonist), the NMDA response was further studied and it is
normal in C104 mice. So the impairment of LTP is due to other mechanism rather
than the NMDA receptor function (Nalbantoglu et al., 1997).
Overall, the C104 Tg mice display several aspects of AD-like neuropathology in the
brain, and they also display neuronal and synaptic loss (Nalbantoglu et al., 1997).
More interestingly, C104 mice show striking impairment in both spatial learning and
hippocampal synaptic plasticity. Worthy of mention, unlike previous studies in which
non-Tg (or wildtype) mice always served as the control group (Games et al., 1995;
Hsiao et al., 1996), Nalbantoglu et al first employed a control transgene, i.e. the
CAATase gene, driven by the same promoter used in the C104 mice. This CAATase
Tg line may be a better control group than the wildtype controls in previous studies.
For example, the deficits in spatial learning and synaptic plasticity shown in the C104
mice can be concluded to be specifically due to the expression of the C-terminus of
APP in the brain, but not any other protein or promoter effects.
1.5.6 The TgAPP22 and TgAPP23 mice.
TgAPP22 and TgAPP23 mice were reported by neuroscientists in Novartis Pharma,
Inc. (Sturchler-Pierrat et al., 1997). Transgenic constructs used contain murine Thy-1
expression cassettes and human mutant APP751 cDNAs. TgAPP22 mice overexpress
an APP transgene harbouring the Swedish (K670N, M671L) and London (V717I)
mutations, while the TgAPP23 only have the Swedish mutations.
Different patterns for plaque development were found in these two lines. TgAPP22
mice show a 2-fold overexpression of APP over endogenous human APP and display
Ap deposits in the cortex and hippocampus at 18 months of age. However, TgAPP23
mice exhibit a 7-fold overexpression of APP and display A[3 plaques as early as 6
months. TgAPP22 and TgAPP23 mice develop different types of plaques in the brain.
The major form of amyloid deposits found in TgAPP22 mice is the diffuse plaque, but
almost all amyloid deposits in TgAPP23 mice are the neuritic ones which are Congo
red-positive. Vascular amyloid is also present and occurs most frequently in the
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meningeal, neocortical and thalamic vessels (Calhoun et ah, 1998). Using unbiased
stereological methods of cell counting, Calhoun et al demonstrated that, in
hippocampal CA1 area of 14-18-month TgAPP23 mice, neuronal loss is 14% and
much higher in mice with high A[3 load, but no neuronal loss was found in the
neocortex (Calhoun et ah, 1998).
Although the overt AD-like neuropathology in TgAPP23 mice was reported several
years ago, until very recently, the behavioural testing of this Tg line has been
conducted by two different groups. First, using a passive avoidance and a water maze
protocols, Kelly et al (2003) completed a cross-sectional study using three cohorts of
APP23 mice aged at 3, 18 and 25 months. In the passive avoidance task, although no
main genotype effects were observed, the 25-month group shows an impaired
retention compared to age-matched non-Tgs, suggesting an age-related deficit (Kelly
et al., 2003). These mice were further evaluated in two water mazes with different
sizes, one being 60 cm in diameter and the other 133 cm. Results from the smaller
water maze indicate significant main genotype and age effects, suggesting an age- and
plaque-related impairment in spatial learning (Kelly et al., 2003). However, in the
bigger pool, it was found that APP23 mice at all ages are impaired in acquisition
training, suggesting an age-independent learning deficit. As 18-month APP23 and
controls display identical performance in a visible cuetask, the spatial learning deficit
in APP23 mice is therefore not due to sensorimotor problem. The interesting finding
from the two studies is that, using two different sizes of water maze, both age-
dependent and age-independent deficits in spatial learning are observed and can be
dissociated in APP23 mice (Kelly et al., 2003). This conclusion is similar to that from
a PDAPP study by us (Chen et ah, 2000). Second, Van Dam and colleagues (2003)
focused on exploring activity, learning and cognition only in young heterozygous
APP23 mice aged at 6-8 weeks, 3 and 6 months. The pool used in this study is 150 cm
in diameter. Consistent with the finding by Kelly et al (2003) from their large pool,
Van Dam et al (2003) also observed a learning deficit in APP23 mice as early as 6-8
weeks. More interestingly, APP23 mice further display an age-dependent decline
(Van Dam et ah, 2003). Performance in the probe trial was found to be negatively
correlated with soluble A(3 level in 3-month APP23 mutants, suggesting that the
learning deficit in young APP23 mice is due to soluble A[3, but not amyloid burden
(Van Dam et ah, 2003).
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1.5.7 The TgCRND8 Mouse.
TgCRND8 mice were reported by Janus et al (2000) in a vaccine study. TgCRND8
mice encode a double mutant form of APP695, including the Swedish (K670N,
M671L) and Indiana mutation (V717F), under the control of a PrP promoter. Both
human AP40 and AP42 are present in the brain of TgCRND8 mice and their levels
increase with age. AP40 keeps stable between 4 and 10 weeks, but AP42 increases
slowly between 4 and 8 weeks and shows a sharp increase at 10 weeks (Chishti et al.,
2001). Amyloid plaques increase with age and spread to more regions of the brain at
65-90 days of age. 11-35 and 22-43 plaques are present in the cortex at 90 and
150 days, but there are 127-416 and 528-1024 at 240 and 350 days. In the
hippocampus, 1-5 and 11-12 plaques are found at 90 and 150 days, but 39-65 and
123-147 plaques at 240 and 360 days. By 243 days, the cerebellum and brain stem are
also fully filled by plaques (Chishti et al., 2001).
Spatial learning of these mice was assessed (Janus et al., 2000). In a visible cuetask of
water maze, 10.5-week TgCRND8 mice use equivalent time to learn it to the control.
However, TgCRND8 mice display a significant impairment in both acquisition and
retention training of water maze, taking significantly longer latencies to find the
hidden platform and spending markedly less time in the target quadrant during the
probe test than the control (Janus et al., 2000; Chishti et al., 2001). This finding
suggests a plaque-independent deficit in spatial learning of TgCRND8 mice.
1.5.8 The TgAPP/Ld, APP/Sw and APP/Wt mice.
Moechars et al reported two lines of mice expressing the London mutation (V717I),
TgAPP/Ld/-2 and -6, two lines expressing the Swedish mutation (K670N, M671L),
TgAPP/Sw-1 and -3, and two lines expressing wildtype human APP, TgAPP/Wt-2
and -4 (Moechars et al., 1999). In a behaviour study, TgAPP/Ld/2 and TgAPP/Wt/4,
were chosen to undergo spatial memory testing in a water maze at 3 to 6 months. Both
of them display much longer escape latencies to find the hidden platform than control
animals. The performance of TgAPP/Ld/2 and TgAPP/Wt/4 mice is equivalent. In the
probe trial (24 h after training), control mice show preferential search of the target
quadrant, however, the two APP lines only display a chance performance (25%
searching time). While they display early-onset learning impairment, the two APP
lines also show a decreased hippocampal LTP (Moechars et al., 1999). These results
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indicate that the overexpression of human mutant or wildtype APP gene in the mice
disrupt spatial learning and memory either long before the formation of amyloid
plaques, which start to be apparent at 13-18 months in TgAPP/Ld/2 mice, or in the
absence of amyloid deposits in APP/Wt mice (Moechars et al., 1999).
1.5.9 The Tg2576/PSl mice.
Presenilins are integral components of the y-secretase complex (Kimberly et al.,
2003). Using a PDGF promoter, Duff et al (1996) generated transgenic mice
expressing human wildtype PS1 and mutant PS1 (M146L or M146V). Expression of
mutant or wildtype PS1 has no effect on brain AJ340, but expression of mutant but not
wildtype PS1 increases brain Ap42 (Duff et al., 1996). PS1 Tg lines do not display
any AD-like pathology by two years of age (Duff et al., 1996; Citron et al., 1997). The
advent of APP and PS1 Tg mice has prompted a number of studies on mice
expressing both the human presenilins and APP. Doubly transgenic line, Tg2576/PSl,
from a cross between Tg2576 mice and TgPSl mice has been reported by Mayo
Clinics (Holcomb et al., 1998). The double mutant Tg2576/PSl model displays
accelerated AD-type phenotype relatively to the Tg2576 animals. Tg2576/PSl mice
develop detectable amyloid deposits in hippocampus and cerebral cortex at an earlier
age than their single Tg2576 littermates (Holcomb et al., 1998). Tg2576/PSl double
Tg mice also display a selective increase in Ap42 in the brain, and exhibit massive
amyloid deposits in the hippocampus and cortex by 6 months of age (McGowan et al.,
1999).
The Tg2576/PSl mice were tested in a Y-maze spontaneous alternation task at 3
months of age. Both Tg2576/PSl and Tg2576 mice show significantly lower
spontaneous alternation than control groups (Holcomb et al., 1998). In a follow-up
study by the same investigators, 6- and 9-month Tg2576/PSl, Tg2576, TgPSl and
non-Tg littermate mice were tested using a Y-maze alternation and a water maze
reference memory task. At 6 months, both Tg2576/PSl and Tg2576 mice show
significantly lower alternation rate compared to TgPSl and non-Tgs. At 9 months,
only Tg2576/PSl mice are significantly impaired compared to non-Tg mice. At 6
months, no differences have been found in acquisition training of the water maze
between four genotypes. The performance during the probe trial is comparable
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between four different genotypes. Similarly, no significant genotype effect was found
during the acquisition training at 9 months. The probe test also reveals a comparable
performance between four genotypes (Holcomb et al., 1999). This study seems to
indicate that plenty of amyloid plaques are not sufficient to produce cognitive
impairment in a triple genetic background that includes Swiss Webster, C57BL/6//SJL
and DBA/2 strains.
Recently, Arendash et al (2001) have re-investigated Tg2576/PSl mice using a
behavioural testing battery including a Y-maze alternation, a water maze reference
memory and a radial-arm watermaze task. Progressive cognitive impairment was
found in Tg2576/PSl mice in the water maze acquisition and radial arm water maze
working memory (Arendash et al., 2001). However, Tg2576/PSl mice do not display
impairments in the Y-maze alternation, water maze retention or visible cuetask at 5-7
and 15-17 months of age (Arendash et al., 2001). In summary, the Tg2576/PSl
mouse is an ideal transgenic model to develop therapeutics for the treatment and
prevention of Alzheimer's disease.
1.5.10 Concluding remarks
The main purpose of using transgenic animals is to examine the function of genes
implicated in AD in vivo. It is generally believed that a valid animal model for AD
should exhibit progressive AD-like neuropathology and ideally, age- and/or plaque-
related cognitive deficits. All APP Tg models reviewed above display most AD-like
pathology, age-related and/or plaque-independent learning deficits. Because none of
them recapitulates all AD features, the APP Tg mouse should be viewed as a partial
model for AD. However, APP transgenics are indeed good rodent models for the
amyloidosis of AD. Despite some limitations, they have greatly helped us not only to
understand the molecular and cellular mechanisms of the pathophysiology of human
AD since the advent of the first APP Tg mouse in 1991, but also to answer questions
for therapeutic intervention of AD, such as whether the pathology and the progression
can be reversed or prevented.
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1.6 Tau transgenic mouse models of Alzheimer's disease.
Although all APP Tg models replicate most AD-like neuropathology, their major
drawback is that they do not produce any neurofibrillary tangles (NFTs). Great efforts
have been made by neuroscientists during the last decade in order to create the NFTs-
producing mouse model. Using wildtype human tau gene, one group led by Gotz
(1995) tried their first attempt to make NFTs-producing mice. However, this tau
model fails to display any pretangles or NFTs in the brain (Goedert et al., 1995; Gotz
et al., 1995). Shortly after the FTDP-17 tau mutation was discovered (Hutton et al.,
1998), the first NFTs-producing mouse (JNPL3) has eventually been generated at
Mayo Clinic (Lewis et al., 2000). Several different groups have later published other
NFTs-producing mice (Gotz et al., 2001a; Higuchi et al., 2002). As tau models are not
the main focus of this thesis, this section will briefly review several tau Tg mice
available to the field.
1.6.1 The ALZ7 mouse.
The ALZ7 mouse, the first tau model of AD, expresses the longest human four-repeat
(4R) tau isoform, htau40, under the control of a human Thyl promoter in the B6D2F1
background. This line expresses human tau at 10% of endogenous murine tau level
and no NFTs were observed (Gotz et al., 1995).
1.6.2 The Tg23 mouse.
The Tg23 tau mice express the shortest human tau, htau44, using a murine 3-hydroxy-
methyl-glutaryl CoA reductase (HMG-CR) promoter. The human tau protein is
widely produced in the CNS, but no NFTs were found (Brion et al., 1999).
1.6.3 The Tau 7,27 and 43 mice.
A murine PrP promoter was used to drive the expression of a htau44 in three lines, 7,
27 and 43. About 20% of axon degeneration was observed in the brain and spinal cord
(Ishihara et al., 1999). Very old mice (18-24 months) display NFTs in the
hippocampus, entorhinal cortex, amygdala and neocortex (Ishihara et al., 2001).
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1.6.4 The Tau40-1 and -5 mice.
In tau40-l and -5 mice, a murine Thy1.2 promoter was used to express a htau40 in the
FVB genetic background. The expression level of human tau protein in transgenic
mice is 1.5-fold and 4-fold, respectively, higher than that of endogenous tau in the
brain. Both lines do not show any NFTs (Spittaels et al., 1999).
1.6.5 The ALZ17 mouse.
Using a murine Thy 1.2 promoter and a htau40 in the B6D2F1 background, Gotz's
group generated the ALZ17 mouse. The level of human tau in ALZ17 mice is much
higher than that of endogenous tau. However, the ALZ17 mouse shows no evidence
of NFTs up to 17- to 20-month of age (Probst et al., 2000).
1.6.6 The Tau P301L (JNPL3) mouse.
The JNPL3 mouse is the first tau mouse model to display true NFTs. A human 4R tau
isoform lacking the two N-terminus inserts, htau43 with a mutation of P301L, is
expressed under the control of a mouse PrP promoter (Lewis et al., 2000).
Heterozygous JNPL3 mice express the mutant human tau at levels equivalent to that
of endogenous tau. In the brain, the tau-positive NFTs, including flame- and globe-
shaped NFTs, are similar to those found in FTDP-17. Neurons with NFTs in the
brainstem and spinal cord have filamentous aggregates in the perikarya and proximal
dendrites. Most filaments are straight and about 10-30 nm in diameter, but others
have a twisted ribbon appearance. Reactive astrocytes with abundant glial filaments,
but not tau inclusions, are found to be around NFTs (Lewis et al., 2000).
1.6.7 The Tau40 P301L (pR5-183) mouse.
In the tau40 P301L mouse, a mutant htau40 with a P301L mutation is expressed in the
pR5 background under the control of a neuron-specific mouse Thy 1.2 promoter. NFTs
are detectable in the spinal cord, brain stem, and cortical layers 5 and 6 by thioflavin-S
and Gallyas silver staining. The activated astrocytes can be found in the amygdala
and cortical areas. Astrocytosis is positively correlated with the number of tau
expressing neurons, but there is no astrocytosis in the hippocampus. No neuronal loss
was observed (Gotz et al., 2001b).
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1.6.8 The Tau40 V337M (Tg214) mouse.
A mouse PDGF-[3 promoter was used to drive a htau40 with a mutation of V337M
(Val-Met) in Tg214 mice. Mutant tau is observed in the hippocampus at 11 months.
The irregularly shaped NFT-bearing neurons are also observed. No deficits were
found in a spatial learning task in the water maze, suggesting a normal spatial learning
in Tg214 mice (Tanemura et ah, 2001).
1.6.9 The Tau40 R406W mouse.
A htau40 gene with a mutation of R406W, driven by an alpha-calcium-calmodulin-
dependent kinase-II (aCaMKII) promoter is used to generate the tau40 R406W
mouse. Aged mice (>18 months) display a selective expression of mutant tau in the
brain. The irregularly shaped NFT-bearing neurons are detectable. Behavioural
studies have shown no significant differences between tau R406W Tg mice and non-
Tg controls regarding to sensorimotor reflexes, motor coordination and locomotor
activity. However, tau40 R406W mice display significant impairment in both
contextual and cued fear conditioning, suggesting an impaired associative learning
(Tatebayashi et ah, 2002).
1.6.10 Summary.
In early attempt to create tau Tg mice, Gotz and colleagues used wildtype human tau
and generated two lines, Alz7 and Alzl7 mice, which display some changes
associated with NFTs but fail to develop any NFTs-like neuropathology. In later
efforts to develop tau mice, several other groups have realized that similar strategies
to those adopted in the generation of APP mice, i.e. stronger promoters and mutant
human tau isoforms, might be needed in order to successfully generate NFTs-
producing models. Overall, the most recent NFTs-producing Tg mice, such as the
JNPL3 and tau40 P301L, have marked a further breakthrough in modelling AD to
APP Tg models.
1.7 Plaque/Tangle transgenic mouse models for Alzheimer's disease.
All tau Tg models reviewed in section 1.6 develop neither amyloid plaque nor
massive neuronal loss, although the JNPL3 mouse displays motor neuron loss in the
spinal cord (Lewis et ah, 2000). Plaques, tangles and neurodegeneration may be
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reproduced by combining transgenic strains that express different disease-associated
genes in brain. By inter-crossing the current tau Tg mice with APP transgenics, it will
allow us to examine the relationship between AP production and neurofibrillary
tangles. In this section, two latest transgenic mouse models displaying both amyloid
plaques and neurofibrillary tangles are reviewed.
1.7.1 The TAPP mouse.
The TAPP mouse is made by Lewis and colleagues (2001) who crossed the JNPL3
line with the Tg2576 mouse. The brain and spinal cord of TAPP mice aged at 2.5-
3.5 months, 6-7 months and 8.5-15 months were examined. Plaques can be detected as
early as 6 months of age and become numerous in the olfactory cortex, cingulate
gyrus, amygdala, entorhinal cortex and hippocampus of 8.5-15-month TAPP and
Tg2576 mice. NFTs become numerous in 8.5-15-month TAPP and JNPL3 mice. All
NFTs are positive for Gallyas silver stain and immunoreactive with tau antibodies.
Ultrastructurally, NFTs, composed of straight filaments, 17 to 22 nm in diameter, in
TAPP mice are similar to those in JNPL3 mice (Lewis et al., 2001).
Interestingly, 9-11 month female TAPP mice display a marked increase in NFTs in
limbic areas, such as the olfactory cortex, entorhinal cortex and amygdala, compared
to JNPL3 mice. The density of NFTs in these regions is much greater in 9-11 month
female TAPP mice than age-matched female JNPL3 mice. The increase of NFTs
occurs as early as 6 months in TAPP mice. NFTs are also found in the subiculum,
hippocampus and isocortex of TAPP mice, but have never been found in the same
areas of JNPL3 mice. By contrast, no increase in the density of NFTs is found in the
diencephalon, hindbrain and spinal cord of TAPP mice. Increased astrocytosis is also
found in limbic areas of TAPP mice, but gliosis is equally severe in the ventral
diencephalon, hindbrain and spinal cord of both lines. Interestingly, the distribution
and density of amyloid plaques is similar in TAPP and Tg2576 mice (Lewis et ah,
2001). In addition to increased NFTs, granulovacuolar degeneration was observed in
neurons in the amygdala, entorhinal cortex and subiculum of female TAPP mice. By
contrast, JNPL3 mice show rare granulovacuolar degeneration in the amygdala.
TAPP mice develop similar motor disturbances to those in JNPL3 mice, showing
progressive hindlimb weakness, hunched posture, eye irritations, reduced vocalization
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and decreased grooming. It was found that the motor phenotype is associated with
spinal and neuromuscular pathology in both TAPP and JNPL3 mice (Lewis et ah,
2001).
1.7.2 The triple Tg mouse model for AD (3xTg-AD).
Instead of crossing independent Tg lines, two independent transgenes, encoding
human APP with the Swedish mutation and human tau (P301L) under the control of
mouse Thy 1.2 regulatory element, were co-microinjected into single-cell embryos
from homozygous mutant PS1(M146V) knockin (KI) mice (Oddo et ah, 2003). Six
founder lines were identified, five of which harbour all three transgenes. Southern
blotting analysis indicated that tau and APP transgenes are integrated at the same
locus in the majority of founder lines.
As the mouse Thy 1.2 promoter drives transgene expression predominantly in the
CNS, tau and APP are exclusively found there. The hippocampus and cerebral cortex
show the highest levels of human tau and APP. A progressive increase in A|3
formation can be observed in 3xTg-AD mice as they get older. Intracellular A(3
immunoreactivity is present in the neocortex of 3xTg-AD mice at 3-4 months, and in
CA1 region of the hippocampus by 6 months. Extracellular A|3 deposits first appear
in the frontal cortex at 6 months and become evident in other cortical regions,
including the hippocampus by 12 months, suggesting that A(3 deposition develops first
in the neocortex and progresses to the hippocampus. Although extracellular Ap
deposits are first seen in the cortex by 6 months of age, no tau alterations are observed
at this age. It has been found that, at about 12 months, extensive human tau
immunoreactivity is first evident in CA1 neurons of the hippocampus, and later
progresses to other cortical areas. These findings indicate that Ap pathology develops
much earlier than tau pathology in 3xTg-AD mice, consistent with the amyloid
cascade hypothesis.
Two cohorts of mice at 1- and 6-month were used to investigate synaptic transmission
and synaptic plasticity in the hippocampus of 3xTg-AD mice. The I-O curves of 1-
month PS1-KI and 3xTg-AD mice are not different from those of non-Tg mice. By
contrast, both 6-month PS1-KI and 3xTg-AD mice exhibit significantly smaller
fEPSP slopes and amplitudes than non-Tg mice. These results suggest an age-related
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impairment of basal synaptic transmission in both PS1-KI and 3xTg-AD mice.
Although 3xTg-AD mice do not show any impairment in PPF compared to non-Tg
mice, an age-related impairment of hippocampal LTP was observed. As there are no
Ap deposits in the hippocampus of 3xTg-AD mice at 6-month, synaptic dysfunction
might be due to intraneuronal accumulation of Ap (Oddo et al., 2003).
1.8 The treatment of Alzheimer's disease.
Although much has been learned about AD since last century, there is still not a cure.
Five drugs have recently been approved by the FDA of the USA for the treatment of
AD, but they provide only symptomatic effects. Several novel treatment strategies
have been in the process of development. This section reviews the currently available
and potentially novel treatment strategies for AD.
1.8.1 Current treatment strategies for AD.
The cholinergic hypothesis has historically shown its massive impacts on the field of
AD (Bartus et al., 1982). From early 1980s to late 1990s, many acetylcholinesterase
inhibitors (AChEIs), which can pharmacologically enhance cholinergic
neurotransmission and maintain ACh levels in the brain, have been tested and found
to improve learning and memory. The FDA first approved tacrine for the treatment of
AD in 1993. Since then, donepezil, galantamine and rivastigmine have also been
approved. These four drugs are the well-known AChEIs. However, memantine, the
fifth drug approved by the FDA, is an N-methyl-D-aspartate (NMDA) receptor
antagonist.
1.8.1.1 Tacrine (Cognex).
Tacrine can inhibit AChE reversibly in a noncompetitive manner (Hardegg and
Heilbronn, 1961). Recently, a 30-week randomized controlled trial of tacrine (40-160
mg/day) has been conducted in patients with AD. Tacrine produces significant
improvements on objective performance-based tests, clinician- and caregiver-rated
global evaluations, and measures of quality of life. However, tacrine-treated patients
frequently show hepatotoxicity, such as highly elevated alanine aminotransferase
level, nausea, vomiting, diarrhea, anorexia, dyspepsia and abdominal pain (Knapp et
al., 1994). These side effects have limited its clinical use.
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1.8.1.2 Donepezil (Aricept).
Donepezil, approved by the FDA in 1999, is a piperidine-based reversible inhibitor of
AChE and has a long plasma half-life of approximately 70 h (Snape et al., 1999).
Unlike tacrine, donepezil does not induce hepatotoxicity. In a short-term, double-
blind, placebo-controlled clinical study, mild-to-moderate AD patients were randomly
assigned to daily receive a single dose of placebo or 5 or 10 mg donepezil
hydrochloride for 24 weeks and the cognitive ability is significantly improved by
donepezil (Rogers et al., 1998). The side effects by donepezil are much less than those
by tacrine and can be controlled.
1.8.1.3 Galantamine (Reminyl).
Galantamine is a selective competitive AChEI and has a serum half-life of 4-6 h. In a
clinical study, galantamine (8, 16, or 24 mg/day) or placebo was given to 978 patients
for 5 months. The cognitive ability of the galantamine group is significantly improved
at dose levels of 16 or 24 mg/day compared to the placebo group (Tariot et al., 2000).
The long-term (2 years) effects of galantamine on cognition of AD patients were also
reported (Doody, 2003). ADAS-cog scores for the galantamine group are about 4
points below their initial baseline after 2 years of treatment, but are 12-14 points
below the original baseline for the placebo group (Doody, 2003). The major side
effects of galantamine are nausea, vomiting, diarrhea and headache, but there is no
evidence of hepatotoxicity.
1.8.1.4 Rivastigmine (Exelon).
Rivastigmine tartrate is a reversible AchE inhibitor and has been approved in more
than 40 countries. It can be well-absorbed and has a plasma half-life of 2 h (Spencer
and Noble, 1998). In a randomised, double blind, placebo controlled, 26-week trial,
725 patients with mild-to-moderate AD in Europe and America received placebo, 1-4
mg/day (lower dose) or 6-12 mg/day (higher dose) rivastigmine. At the end of the
study, the placebo group show deteriorated cognitive function, however, and the
higher dose rivastigmine group display significant improvement in cognition as
compared to the placebo group (Rosier et al., 1999).
In conclusion, tacrine , donepezil, galantamine and rivastigmine show positive effects
on the treatment of AD and they are effective for mild-to-moderate AD. Limitations
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of the AChEIs are related to their modest effects on baseline and their side effects.
The modest improvements do not sustain indefinitely, as the disease still progresses
while patients are receiving their treatment. Moreover, the adverse effects such as
vomiting and weight loss sometimes make patients discontinue the treatment.
1.8.1.5 Memantine.
As clinical studies indicated deficits of glutamatergic function in AD, the
glutamatergic neurotransmitter pathway has been hypothesized as a target for
therapeutic intervention of AD. Memantine is a low affinity, uncompetitive NMDA
receptor antagonist. Memantine can rapidly cross the blood-brain barrier and exhibits
a long half-life of 60-80 hours. In a recent randomised, double blind, placebo
controlled clinical study, 252 patients from 32 US AD centres have participated.
Patients receiving memantine showed a better outcome than those receiving placebo
(Reisberg et al., 2003). Importantly, memantine is not associated with a significant
frequency of adverse events (Reisberg et al., 2003). Memantine has been approved
for the treatment of moderately severe to severe AD in the European Union and
Australia, but it was not approved by the FDA in the US until late last year.
1.8.2 Potential treatment strategies for AD.
At the present time, cholinergic-based therapy is still the most important clinical
approach for improving cognitive deficits in AD. However, several novel treatment
strategies have also been in the process of development.
1.8.2.1 Agents that increase neuroprotective sAPPa.
APPa, the soluble N-terminus fragment of APP, is derived from the a-secretase
cleavage pathway. The sAPPa protects neurons from ischemic injury or enhances
recovery from ischemic injury in rats (Bowes et al., 1994). Many acetylcholine
receptor agonists such as acetylcholine, nicotine and carbacol were found to increase
the release of the sAPPa and reduce the accumulation of toxic Ap (Mattson et al.,
1993). Evidence suggested that stimulation of the nicotinic receptor improves
amyloidosis in animal models of AD (Nordberg et al., 2002). In a double-blind study,
three doses (6, 12, and 23 mg) of a novel selective nicotinic agonist, ABT-418 were
acutely administered over 6 h in AD patients. Subjects receiving ABT-418 displayed
significant improvements in total recall, spatial learning and memory, and repeated
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acquisition (Potter et al., 1999). However, long-term clinical effects of nicotinic
agonists need to be assessed in a larger population.
1.8.2.2 Metal chelators inhibiting aggregation of plaques.
It is long believed that some bio-metals such as aluminium, iron, zinc and copper
promote Ap aggregation and neurotoxicity in the brain of AD (Suh and Checler,
2002). Clioquinol is a metal chelator for copper and zinc and can solubilize Ap from
postmortem AD brain (Cherny et al., 1999). In a recent animal study, a significant
decrease in Ap deposits but a highly elevated level of soluble AP were found in the
brain of Tg2576 mice treated with clioquinol for 9 weeks (Cherny et al., 2001).
However, it remains unclear whether clioquinol also improves cognitive deficits in the
same APP mice.
Clioquinol causes severe adverse effects, such as vitamin B-12 deficiency and
subacute myelo-optico-neuropathy (SMON), in human or dogs, so the use of
clioquinol was banned in Japan (Tabira et al., 2001). In the US, a randomized pilot
clinical study has recently been conducted. Patients with moderately severe AD were
assigned to receive either clioquinol or placebo. The clioquinol group show minimal
deterioration in cognitive tests, but the placebo group show a substantial worsening of
scores, suggesting that clioquinol might slow down the progression of AD (Ritchie et
al., 2003). Further study on clioquinol with a much larger size of samples is needed to
test its potential use in the treatment of AD.
1.8.2.3 Antioxidants.
Ginkgo biloba, an antioxidant, has been used in traditional Chinese medicine for
thousand years. Ginkgo biloba extract can protect neurons from hydrogen peroxide-
induced oxidative stress (Oyama et al., 1996). A double-blind, randomized, placebo-
controlled, one-year clinical study of Egb761, an extract of Ginkgo biloba (Egb) was
conducted. 236 AD patients were assigned randomly to receive Egb (120 mg/d) or
placebo. Interestingly, the Egb group show no significant change in the ADAS-Cog
test before and after treatment. However, the placebo group show a significant worse
effect in the ADAS-Cog (Le Bars et al., 1997).
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Studies on animal models have shown that cognitive impairments can be attenuated
by treatment of either vitamin E or idebenone, an antioxidant and free-radical
scavenger (Behl et ah, 1992; Yamada et al., 1999). Idebenone was examined in
450 mild-to-moderate AD patients in a 2-year randomized, double-blind clinical
study. During the first year of treatment, idebenone produces significant dose-
dependent improvement on ADAS cognitive test. A further improvement was also
found in the second year (Gutzmann and Hadler, 1998). A follow-up clinical study
indicated that patients who received idebenone show a better benefit than those with
tacrine (Gutzmann et al., 2002). In conclusion, antioxidants have beneficial effects on
the prevention and treatment of AD, but the improvement observed in clinical studies
is small or only marginal (Thai et al., 2003). More studies are needed to draw a
conclusion on the efficacy of antioxidants.
1.8.2.4 Anti-inflammatory drugs.
Much clinical evidence has shown that the sustained use of nonsteroidal anti¬
inflammatory drugs (NSAIDs) delays the progression of AD (McGeer et al., 1990;
Rich et al., 1995; Stewart et al., 1997). Several clinical trials on the effects of NSAIDs
on the treatment of AD have recently been reported. In two double-blind, placebo-
controlled, randomized, 26-week trials, concurrent use of anti-inflammatory agents
and estrogen in AD patients produced superior cognitive performance (Doraiswamy et
al., 1997). Another study showed that the risk of AD is significantly lower in those
with long-term use of NSAIDs than those with short-term or intermediate-term use (in
't Veld et al., 2001; Landi et al., 2003). Interestingly, chronic treatment of Tg2576
mice with 375 ppm ibuprofen from 10 months of age for 6 months significantly
reduces astrogliosis, microgliosis and amyloid deposits (Lim et al., 2000; Yan et al.,
2003).
1.8.2.5 Estrogen.
Estrogen, one member of a family of sex hormones, is closely associated with AD
(Tang et al., 1996). It is suggested that the risk of AD is lower in women receiving
estrogen-replacement therapy (ERT) during the postmenopausal period, and that
estrogen replacement improves cognitive performance (Tang et al., 1996). Estrogen
may serve as an antioxidant or stimulate a-secretase activities (Behl et al., 1994; Jaffe
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et al., 1994). Estrogen can also enhance synaptic transmission and synaptic plasticity
(Foy et al., 1999).
1.8.2.6 A(3 vaccines.
The vaccine concept for the treatment of AD first appeared after a novel Ap
vaccination study on PDAPP mice (Schenk et al., 1999). Schenk and colleagues
injected synthetic AP42 (AN-1792) into PDAPP mice for several months either prior
to (prevention study) or after (treatment study) plaque formation. Plaques are
completely prevented in PDAPP mice in the prevention study, and are significantly
reduced in the treatment study. These results raise a hope that Ap vaccine is possibly a
novel therapy for AD (Schenk et al., 1999).
Weiner et al (2000) extended the initial finding by the Schenk group. They orally or
nasally administered Ap peptide to immunize the PDAPP mouse and have found a
50 to 60% reduction of plaque burden in the brain of mice, which were immunized
intranasally by a high dose of Ap (25 fig) (Weiner et al., 2000). There are no
significant effects in mice immunized intranasally by a lower dose (5 fig) or in mice
immunized orally. Lower Ap load is associated with decreased local microglial and
astrocytic activation. These results suggest a novel mucosal immunological approach
for the treatment or prevention of AD (Weiner et al., 2000). In another study, a
soluble nonamyloidogenic, nontoxic AP homologous peptide was used to immunize
Tg2576 mice for 7 months. Immunisation has reduced cortical and hippocampal brain
amyloid burden by 89% and 81%, respectively. The brain levels of soluble AP42 are
reduced by 57% (Sigurdsson et al., 2001).
Two separate behavioural studies using Ap vaccine were conducted and reported by
two different research groups. In one of them, a reference memory task in the water
maze was used. Ap vaccination on 3-4-month CRND8 Tg mice significantly improves
learning deficits in acquisition training, although the vaccinated CRND8 mice are still
significantly worse than the controls (Janus et al., 2000). A significant reduction of
Ap deposits is also observed in the vaccinated CRND8 mice. The other one used
Tg2576/PSl Tg mice and a radial-arm water maze to test the effects of Ap vaccines
on spatial learning (Morgan et al., 2000). Vaccinated Tg2576/PSl mice perform
significantly better than non-immunized Tg mice, but worse than non-Tg controls.
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However, Ap vaccines do not produce a significant decrease in plaque burden
(Morgan et al., 2000).
The above two preclinical behavioural studies provided strong evidence to support a
novel AP immunotherapy. However, as Janus et al (2000) tested only very young
mice, it remains unknown whether Ap vaccines can also rescue learning deficit of old
APP mice. Secondly, as the novel radial-arm water maze used by Morgan et al (2000)
is not sensitive to reveal any soluble AP-dependent learning deficit in PS1/APP mice,
it is difficult to explain why Ap vaccines fail to reduce plaque burden but only reverse
learning impairment. In the same time that Janus et al and Morgan et al published
their findings, our own AP vaccine study was in the progress. These findings are
described in Chapter 5.
1.8.2.7 P-secretase inhibitors.
Because Ap and its accumulation seem to play a central role in the pathogenesis of
AD, two proteases, directly responsible for the production of Ap, have become the
most interesting targets for therapeutic intervention of AD. As BACE (p-secretase) is
the dominant form of P-secretase in the brain (Sinha et al., 1999; Vassar et al., 1999;
Yan et al., 1999), blockage of this enzyme will certainly reduce the production of Ap.
As a homolog to BACE, BACE-2 is the main P-secretase in peripheral organs of
human and rodents (Hussain et al., 1999). As several reports have shown that BACE
homozygous knockout mice do not produce any detectable Ap in the brain and are
healthy and viable, inhibition of BACE may not produce severe side effects (Cai et
al., 2001; Luo et al., 2001; Roberds et al., 2001).
Recently, several different structure-based BACE inhibitors have been published. The
first P-secretase inhibitor is substrate-based analogue and contains a critical statine
residue and has an IC50 of about 30 nM (Sinha et al., 1999). Based on the P-secretase
cleavage site (VNL-DA) of the Swedish mutant APP, Abbenante et al developed a
series of p-secretase inhibitors, which display very low potency (IC50 = 700 nM)
(Abbenante et al., 2000).
The structural analysis of memapsin 2 (BACE), co-crystallized with an active-site-
directed BACE inhibitor indicated that BACE is more open and less hydrophobic than
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other human aspartic proteases (Hong et al., 2000). Due to its resemblance to other
aspartic proteases such as Renin and HIV-1 protease, the structure-based design has
been used to search for more potent and selective BACE inhibitors. Using this design,
a group led by Tang in Oklahoma generated two inhibitors for BACE, OM99-1 and
OM99-2, displaying very potent inhibitory activity against recombinant BACE
(Ghosh et al., 2000). Later, the same group generated a third BACE inhibitor, OM00-
3, which is the most potent inhibitor for memapsin 2 (K[ = 0.3 nM), about three times
more potent than OM99-2 (Turner et al., 2001). The molecular size of OM00-3 is only
722 Da, but it can not freely penetrate the blood brain barrier. Moreover, OM00-3
equally inhibits both BACE and memapsin 1 (BACE2) (Hong et al., 2002).
Since publishing the first BACE inhibitor, Elan has recently reported two potent cell-
permeable BACE inhibitors, Compound 38 (John et al., 2003) and Compound 20
(Horn et al., 2004). Compound 38 selectively inhibits A(3 secretion in human
embryonic kidney cells (John et al., 2003). Compound 20 is a hydroxyethylene (HE)
transition state isostere-based BACE inhibitor. Compound 20 is very potent
(IC50=30nM) and has an enhanced cell penetration (Horn et al., 2004). The inhibitory
specificity of either Compound 38 or Compound 20 is unclear. As BACE1/BACE2
double knockout mice display no gross phenotypic defects (Harper et al., 2003), itself
a puzzling observation given the importance of APP processing in normal brain
function, the specificity of either OM00-3 or BACE inhibitor 20 may not be a big
problem for in vivo study. Recently, scientists at LG Life Science have reported three
peptidomimetic BACE inhibitors, LB83190, LB83192 and LB83202. Using a cell-
based assay, LB83190, LB83192 but not LB83202 were found to effectively inhibit
BACE activity in a dose-dependent manner (Oh et al., 2003).
In 2001, Takeda disclosed the first non-peptide BACE inhibitor, aminoethyl-
substituted tetralin inhibitor 7, identified as the most potent inhibitor of BACE with an
IC50 of 0.35 (John et al., 2003). However, in vivo data have not been reported for
this low molecular weight BACE inhibitor. Neurologic has disclosed piperazine-
substituted phosphinyl- and phosphorylmethyl succinic acid derivatives as inhibitors
of BACE, showing a dose-dependent release on sAPPa (John et al., 2003).
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In summary, as recent genetic and behavioural studies on BACE knockouts are
extremely encouraging (Cai et ah, 2001; Luo et ah, 2001; Ohno et ah, 2004), P~
secretase inhibitors are believed to be very promising as a potential candidate for the
treatment of AD. However, caution also needs to be taken. A recent study has
indicated that homozygous BACE1 KO mice display learning deficits in a novel
training to criterion task in the water maze at all ages tested (3, 13 and 18 months).
Furthermore, BACE1(-/-)APP mice are also impaired in learning this task at all ages
tested (Kobayashi et ah, 2003). Thus, this study has raised a possibility that BACE1
inhibition may not be effective in rescuing memory loss in AD patients.
1.8.2.8 y-secretase inhibitors.
Gamma-secretase is an important enzyme for processing both APP and Notch. Due to
being a complex of integral membrane proteins including presenilin, nicastrin, Aph-1,
and Pen-2, the y-secretase is more complex than the P-secretase (Kimberly et ah,
2003). However, searching for cell-permeable y-secretase inhibitors seems much
easier than for the P-secretase ones. Great progress has been made in developing y-
secretase inhibitors. The currently available y-secretase inhibitors can be classified as
peptidic and non-peptidic.
The peptidic y-secretase inhibitors are structure-based and many of them have been
synthesized. MDL28170 (Z-VF-CHO) is the first published y-secretase inhibitor, and
also is a calpain proteinase inhibitor. MDL28170 (>50 /xM) significantly inhibits the
production of Ap40, but not AP42 in CHO cultures stably transfected with APP695
(Higaki et al., 1995; Citron et ah, 1996). MG132 (Z-LLL) reduces the production of
Ap40, but not AP42 production (Klafki et ah, 1996; Skovronsky and Lee, 2000).
Difluoroketone peptidomimetic 1 (MW167), a selective y-secretase inhibitor
(IC5o=13 jtxM), inhibits both AP40 and AP42 production in human APP-transfected
CHO cells, reduces the NICD production as well (IC50=10-30 /xM) (Wolfe et ah,
1998; De Strooper et ah, 1999). 2-Naphthoyl-VF-CHO and Z-LF-CHO are cell-
permeable and inhibit the release of AP40 and AP42 in HEK293 cells transfected with
the Swedish mutant APP (Sinha and Lieberburg, 1999). Compound t-3,5-DMC-IL-
CHO, a potent cell-permeable and reversible y-secretase inhibitor, mainly inhibits the
secretion of AP40 in CHO cells stably transfected with the cDNA encoding APP695
(Higaki et ah, 1999). Z-LL-CHO and Z-VL-CHO are cell-permeable and reversible y-
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secretase inhibitors which inhibit the secretion of both Ap40 and AP42 in APP-
transfected cell cultures (Figueiredo-Pereira et al., 1999). Boc-GVV-CHO can
preferentially inhibit AP40 production in HEK293 cells transiently transfected with
APP695NL, but has no effect on AP42 (Murphy et al., 2000).
The nonpeptidic y-secretase inhibitors are normally the transition-state analogues. The
first nonpeptidic y-secretase inhibitor is Compound L-685,458 (Shearman et al.,
2000). L-685,458 dose-dependently inhibits Ap production in both Neuro2A and
CHO cell lines overexpressing human APP695. L-685,458 reduces both AP40 and
AP42 production in these cells and is not neurotoxic at concentrations up to 10/xM
(Shearman et al., 2000). As a potent transition-state analogue y-secretase inhibitor,
WPE-III-31C inhibits the cleavage of both APP and Notch (Esler et al., 2000). The
third one is called as DAPT (A-[A-(3,5-difluorophenacetyl)-L-alanyl]-S-phenglycine
/-butyl ester), which is very potent. The DAPT reduces the production of AP40 and
AP42 in HEK293 cells overexpressing human APP751 and in human primary
neuronal cultures. It was reported that oral administration of DAPT to PDAPP mice
reduces levels of Ap in the brain within 3 h (Dovey et al., 2001). LY411575, which is
100 times more potent than DAPT, was used to treat PDAPP mice (6.5-7 months) for
90 days and this chronic treatment resulted in 70-90% reduction of brain Ap levels
(May et al., 2001).
It remains very interesting whether inhibition of y-secretase rescues learning and
memory impairment in APP Tg mice. An answer for this question is pivotal to clinical
use of y-secretase inhibitors as a novel treatment strategy of AD. To address this
question, a genetic and a pharmacological study have been designed and conducted in
this thesis. First, using PSlcKO;APP mice, I have investigated whether selective
inactivation of PS1 in the forebrain has any effects on spatial learning and memory.
Second, using ELN44989, a potent compound like LY411575 (May et al., 2001), I
have examined its in vivo efficacy and its effects on spatial learning and memory of
PDAPP mice. These two studies are described in Chapters 6 and 7.
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1.9 Aims of this thesis.
1) The first aim of this thesis was to use a cross-sectional design, in which three
different cohorts of nai've PDAPP mice were utilised, and a behavioural test
battery to investigate whether PDAPP mice display an age- and plaque-related
learning deficit;
2) The second purpose of this thesis was to use a longitudinal design, in which
the same PDAPP mice were tested repeatedly at three different ages, and a
behavioural test battery to investigate whether the same PDAPP mice also
display an age- and plaque-related learning deficit;
3) The third objective of this thesis was to use aged PDAPP mice behaviourally
tested to investigate whether they display altered synaptic transmission, and
whether there is any relationship between altered synaptic transmission and
impaired spatial learning in the same mice;
4) The fourth aim of this thesis was to use our novel serial spatial learning task to
investigate whether A|3 immunisation has any effects on altered synaptic
transmission and impaired spatial learning in PDAPP mice;
5) As the y-secretase in one of the prime targets for novel therapeutics for AD,
the fifth aim of this thesis was to use a genetically modified PSlcKO;APP
mouse and the serial spatial learning task to investigate whether inactivation of
PS1 in APP mice could improve the impaired synaptic transmission and
spatial learning;
6) The sixth aim of this thesis was to use a functional y-secretase inhibitor,
ELN44989, and the serial spatial learning task to test the amyloid cascade
hypothesis and to examine whether ELN44989 can rescue the impaired spatial
learning in PDAPP mice.
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Chapter 2: Materials and Methods.
2.1 Behavioural tests in the watermaze.
The watermaze was first developed to investigate spatial learning and memory in rats
and to test its dependence on the hippocampus (Morris, 1981; Morris et ah, 1982).
Since then, the watermaze has become a powerful and widely used tool in behavioural
neuroscience for the examination of learning and memory in rodents. It has been
estimated that the watermaze has been utilized in more than 2000 original research
publications between 1989 and 2001 (D'Hooge and De Deyn, 2001).
The watermaze is an open-field navigation task that is very sensitive to lesions of the
hippocampus in rats (Morris et ah, 1982). In practice, a variety of different tasks can
be scheduled such that it is valuable to distinguish between the watermaze as an
'apparatus'and the watermaze as a set of 'protocols'. The hidden platform task of the
watermaze is most commonly used to train the rodent to swim through the open-field
and search for the platform. As there are no local cues for the hidden platform, the
animal has to learn the extra-maze cues and needs to figure out the relation between
the cues and the platform location.
2.1.1 The watermaze apparatus.
The watermaze (Fig.2.1.1) is 2m (in diameter) and 60cm (in height). It is made of
fibreglass with the interior wall being painted white. It is about 60cm above the floor
of the testing room enriched with extra-maze cues such as posters, black curtains,
metal racks and doors. The water level is about 40cm above the bottom of the maze.
Escape platform is 20cm in diameter and is about 1.5 cm below the water surface. The
water is made opaque by adding 800 ml of cempolatex liquid (Cementone-Beaver
Ltd., UK), so the escape platform is not visible to a swimming mouse. The swimming
path of a mouse is monitored by a video camera sitting far right above the pool (on the
ceiling of the room) and the video signal is recorded by a video recorder (Fig.2.1.2).
This signal is fed to an image analyser (HVS VP112). The co-ordinates of the mouse
are sampled at 10Hz by an Acom computer running the Watermaze software (Roger
Spooner) or a PC running the PC version of Watermaze program (Actimetrics). The
software calculates several measures such as the escape latency taken on a training
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Figure 2.1.1 Watermaze Apparatus.
Video Recorder
Figure 2.1.2 Watermaze Setup. (See texts for description)
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trial, the swim path length, the swim speed, the percentage time spent near the side-
walls (thigomataxis) and the percentage time spent in each quadrant of the pool during
probe tests.
2.1.2 The general protocol.
Each training trial consists of the following sequence of events. The mouse is placed
and released into the water by hand facing the wall at one of the four pre-planned start
positions (North, South, East and West). The mouse swims until it finds the platform.
If it fails to find the platform after 90 sec has elapsed, the mouse is guided to it by
hand. Once on the platform, which is a metal cylinder (20cm in diameter) with its top
surface 1.5 cm below the water, the mouse is allowed to remain on it for 30 s to look
around the extra maze cues and so learn the platform position. After 30 s, the mouse is
taken away from the platform using a small paint roller and placed back into a drying
cage. This cage is placed under an infra-red heat lamp in a small animal room next to
the watermaze room. The mouse is given about 10 min before the next trial starts, as
this interval can allow the animal to dry itself and avoid hypothermia. Each animal
receives 3 to 8 trials per day in different tasks (see below).
2.1.3 The cuetask.
In this task, curtains are drawn round the pool to occlude the extra-maze cues. The
platform, submerged below the water, is made visible by putting a 15 cm high bronze
cylinder on it that can be easily seen. The purpose of this task is to habituate the
animals to the watermaze, to ensure that they can see, swim and climb onto the
platform normally, and to establish that they are motivated to escape. Animals with
serious sensorimotor abnormalities would display a deficit in this task. There were 4
trials per day for 5 days and the platform position was changed across trials. The
water during testing was kept at 25±1°C.
2.1.4 The reference memory task.
In this task, the hidden platform remains fixed throughout training in the centre of one
of four quadrants (North East, South West, North West or South East). This task
consisted of 4-day acquisition training and two probe trials (or transfer tests). There
were 4 trials per day. The inter-trial interval (ITI) was 10 min, the same as in the
cuetask. At the end of training, or one week after the acquisition training, the mice
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were given two probe trials. In the probe trial, the platform was removed from the
maze and the mouse was allowed to swim in the pool for 60 s and was removed by the
painter roller after 60 s has elapsed. By analyzing the swim paths, the time spent in
different quadrants of the maze by each mouse could be further analyzed. These two
probe tests can determine either the short-term (1 day after training) or long-term (7
days) memory for the location of the platform within the maze for each animal.
2.1.5 The delayed-match-to-place (DMP) task.
Tl T2 T3 T4
OlOmin jT^\ 10min 10min /~\—Q—Q—Qj
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Figure 2.1.3 The Delayed-match-to-place (DMP) Task. Animals are
given 4 trials/day. The platform location is changed between days.
Although this task was never used in the experiments of this thesis, the novel spatial
learning task described in the next two sections is a modified version of the DMP
task. The method is introduced here in order that readers can compare and better
understand the other two modified versions of the DMP task. The DMP task
(Fig.2.1.3) in watermaze was initially developed by Steele & Morris (Steele and
Morris, 1999). The platform position is changed randomly from day to day and the
animal receives 4 trials per day to learn its position. In other words, the platform
position remains in the same position within each day, but is different between days.
So, on the first trial (Tl) of any day (Day n), the mouse has no information about
where the platform is present, but in subsequent trials (T2-T4), the location of the
platform remains the same as that on Tl of that day. On the next day (Day n+1), the
platform moves on Tl, and remains fixed in that position for the remaining trials. On
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T1 of any day, the mouse does not know the platform location, but on T2 to T4, it can
'match to place'.
2.1.6 The trials-to-criterion version ofDMP.
In this task, the platform is always hidden under water and is not marked by any local
cues within the pool. All animals are trained on 5 consecutive different problems (i.e.
platform locations). The platform location was changed only after a mouse reached a
strict performance criterion for any particular location, so each mouse needed to reach
the performance criterion five times in order to complete this task (Fig.2.1.4). The
performance criterion for learning each problem was an average escape latency for
three trials in a row being less than 20 s. On each day, all mice received up to 8 trials,
and this depended on the performance by individual animal. Overall, the total number
of trials on each day (after day 1) for each mouse could vary from 1 to 8, because a
mouse was stopped swimming and taken back to its original home cage in the animal
house on any given day once it reached the performance criterion. So, on the first trial
of the next day, this mouse started searching for a new platform location and
continuously learned the same new position in the subsequent trials of that day until it
reached the criterion. After all animals finished this task, the number of trials taken by
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Figure 2.1.4 Trials-to-criterion Task. See details from the texts.
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The learning rate of this novel watermaze task by each animal reflects the speed with
which it acquires new information in successive problems and how fast it forgets old
information for previous locations. Accordingly, this task requires animals to change
their memory representation in order to solve all the problems. As the learning rate is
different in each animal, it is possible to calculate a mean and a variance for a group
of mice learning this task. Sometimes, learning failed. Accordingly, an additional
criterion was that if a mouse could not reach the criterion for any problem by 32 trials
(4 days), it was stopped by Trial 32 on this problem and started learning a new
location the next day. In this case, 32 trials would be used as the number of trials to
reach criterion for this problem in calculating the mean.
2.1.7 The learning capacity version ofDMP.
The form 'learning capacity' is used to capture a measure of how much the mice
could learn in a given time. Strictly speaking, it is not a measure of absolute capacity
but only of capacity per unit of time. The design for this task is slightly different from
the trials-to-criterion, in which all 5 consecutive problems had to be learned by all
animals, no matter how many days to be taken. In this task, the mice were given 10
days to learn as many platforms as they could, so the duration of this task was 10 days
(Fig.2.1.5). Procedurally, the task is identical with respect to what happens in the
watermaze. The platform location was changed only after a mouse reached the
performance criterion (average escape latency for three trials in a row being less than
20 s). The maximum number of trials of every day for each mouse was again 8, and
this number also varied from 1 to 8 from mouse to mouse. The maximum number of
trials for any mouse to learn any problem was 32. The ITI was always 10 min. At the
end of day 10, the number of problems learned by each animal was calculated as
learning capacity. As there were a maximum of 10 different problems (locations) to
be learned in this task, the total number of problems learned by each mouse varied as
a function of the individual learning ability of such mouse.
The trials-to-criterion and learning capacity versions of DMP are not totally
independent tasks, and they should be viewed as part of the serial spatial learning
task. However, as they have been conducted separately in Chapters 3 and 4, the names
of the trials to criterion task (for the trials to criterion version of DMP) and learning
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Figure 2.1.5 Learning Capacity Task. 10 different platform locations
are set. The animals use 10 days to learn as many locations as they can.
2.2 Spontaneous object recognition test.
2.2.1 The object recognition arena.
The object recognition task was first introduced by Enaceur et al in 1988 (Ennaceur
and Delacour, 1988; Ennaceur et al., 1989). Due to its simple methodology, it has
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been widely accepted since its first introduction (Tang et ah, 1999; Chen et ah, 2000;
Malleret et ah, 2001; Dodart et ah, 2002). It is sometimes called spontaneous object
recognition as no training is involved.
The object recognition arena with sloping walls is 50 cm long, 50 cm in wide and 40
cm high. The floor of the arena is covered by 1 cm of sawdust. It is made of plywood
and painted white. The arena is placed 60cm above the floor of the laboratory room
and is enclosed with white curtains. Exploratory behaviour is monitored via a video
camera 1.5 m above the arena with the video signal recorded by a video recorder.
Exploration time for each object is calculated using a Labview-based program for
timing (written by Patrick Spooner on a PC). This PC timer software can calculate
time spent in each object by a mouse and the preference index (PI = time spent in
exploring the novel object/total exploration time* 100).
2.2.2 The habituation in the arena.
The object recognition task consists of habituation and two test phases. For
habituation, each mouse was placed in the empty arena (Fig. 2.2.1) for 5 min/day for 5
days, or 10 min/session, two sessions/day for 2 days. For the latter case, the inter-
session interval was 3 hours. The bedding of sawdust was changed every day.
Figure 2.2.1 The Arena Figure 2.2.2 Five Sets of Objects
2.2.3 The sample phase of the task.
After 1 week or 2 days of habituation (used in different procedures), all mice received
object recognition tests for five days. Five different retention intervals were chosen to
test immediate, short-term and long-term object recognition memory. There were five
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sets of different objects available for this task (Fig.2.2.2). On every testing day, the
object recognition test consisted of a sample phase and a choice phase. In the sample
phase (Fig.2.2.3), two identical objects, 10-15 cm in height were first placed into the
arena at two fixed locations, about 10 cm away from the corner of the arena. A mouse
was then released facing the opposite wall of the objects and allowed to explore these
two objects until it had accumulated 30 s of total exploration time. The exploration
was scored only when the mouse was within 1 cm of the object and was sniffing,
licking, touching, pushing or even biting the objects. Staying or sitting on the objects
without moving was not considered as active exploration. Once the 30 sec of
exploration time was reached, the mouse and the objects were removed from the arena
immediately. The objects were then cleaned with 90% alcohol.
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Figure 2.2.3 Sample Phase Figure 2.2.4 Choice Phase
2.2.4 The choice phase in the arena.
After any one of 5 different intervals (10s, lmin, lOmin, lh or 4h) from sample phase,
a third copy of the earlier familiar objects (the TRACTOR as shown by black arrow in
Fig.2.2.4) used in sample phase was placed into the arena at one location and a novel
object, which did not appear in the sample phase, like the SNAIL as shown by red
arrow in Fig.2.2.4, at the other position. Once the interval elapsed, the mouse was
then taken back to the arena from its home cage and released again facing the opposite
wall. The choice phase was stopped once 30s of exploration time had again
accumulated. After the choice phase was completed, the objects and the animal were
taken away from the arena and the objects were cleaned with 90% alcohol. Finally, a
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preference index (PI) was calculated using the formula PI = 100 x (Novel Object
Exploration Time)/30.
2.3 Electrophysiology.
2.3.1 The in vitro hippocampal slice.
The brain slice in vitro electrophysiology has become a standard tool to investigate
the physiological or pharmacological features of neurons as well as neuronal circuits
since it was first developed in 1966 (Yamamoto and Mcllwain, 1966; Yamamoto and
Kawai, 1967; Bliss and Richards, 1971). The in vitro slice electrophysiology
technique provides several attractive advantages: first, the recording environment,
such as the incubating solution and temperature, is very easy to control; second, even
with low-power microscope, the anatomical structures of hippocampal slices are
visibly clear to experimenters; third, one single animal can provide many slices to the
experimenters, and so on. Within the hippocampus (Fig.2.3.1 & Fig.2.3.2), there are
several distinct cellular areas, such as CA1, CA2, CA3 and dentate gyrus (DG). The
entorhinal cortex provides the DG with input via the perforant pathway. The DG
sends its projections by mossy fibres to pyramidal cells in the CA3 area. CA3
pyramidal cells project the CA1 pyramidal cells via the Schaffer collaterals pathway
in the hippocampus.
CAT
Figure 2.3.1 Hippocampal Slice, Brain and Hippocampus.
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Figure 2.3.2 In vitro Technique in Transverse Hippocampal Slice.
2.3.2 Preparation ofslices.
For all the electrophysiological experiments, transverse hippocampal slices were
prepared by a vibrotome slicer (Campden Instruments, Loughborough, UK) from APP
Tg or non-Tg mice at different ages. All animals were singly housed, and were
maintained on a 12:12h light: dark cycle, with lights on at 0800 hours. Food and water
was supplied ad libitum. Most had participated in behavioural experiments. The
artificial cerebrospinal fluid (ACSF) was made up using distilled water filtered (10-18
MO/Cm) by the Millipore Milli-Q filter system (Millipore; Molsheim, France). The
standard ACSF comprised (in mM): NaCl, 124; KC1, 3; NaHC03, 26; NaH2P04, 1.25;
CaCl2, 2; MgS04, 1; D-glucose, 10; and was bubbled with 95% 02/5% C02 (BOC
Medical Gasses, UK) to maintain a pH of 7.4—7.5. All chemicals were ordered from
BDH Chemicals Ltd., Poole, UK. The xlO stock medium, from which the fresh ACSF
was made, was stored in the fridge, which did not contain either NaHCCf or D-
Glucose, both of which were freshly prepared before experiments. Stock solutions
were made every 2 weeks.
The mice were killed by cervical dislocation followed by decapitation in accordance
with UK Home Office guidelines (Schedule 1). The brain was rapidly taken out with a
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spatula and immediately put into ice cold (0-4°C) ACSF bubbled with 95% 02/5%
C02 for at least 10 minutes. In order to keep the temperature of the ACSF in a 400 ml
Petri beaker at 0-4°C throughout the dissection process, an aluminium cooling block,
which had been kept in the freezer at -20°C for at least several hours, was placed
beneath the Petri beaker. After removal of the cerebellum on one piece of filter paper
which was placed in a small Petri dish and moistened by the addition of cold ACSF, a
big cut was carefully made in the sagittal plane of the brain without the cerebellum,
along the midline, to separate the two hemispheres. The right hemisphere of the brain
was immediately placed back in ice cold ACSF bubbled with 95% 02/5% C02 for
further immunohistological analysis. Using superglue, the left hemisphere was then
fixed to a polypropylene block for the subsequent sectioning of 400 /xm thick
transverse coronal slices by a vibroslicer. The position of the blade in the slicer was
adjusted before dissection so that the longitudinal axis of the hippocampus was
oriented at 20-30° to the blade. The blade was always submerged in the cold ACSF
during dissection. Slices were cut by either manual or automatic regulation of the
movement and the position of the blade. Approximately 5-6 transverse slices were cut
from the ventral brain. Throughout the whole process of dissection, the chamber,
which contained the brain and slices, was fulfilled with ice cold ACSF, so that the
slices were always maintained cold and oxygenated. After dissection, the first 2-3
slices were discarded, and the others, from which the cortical and midbrain parts were
cut away, were transferred to incubation wells in a plastic beaker containing cold, and
oxgenated ACSF at room temperature (18-24 °C).
2.3.3 The recording chambers.
Fig. 2.3.3 shows the set-up for recording chamber. Two different types of recording
chambers have been widely used for LTP experiments in different laboratories, the
submerged and the interface chamber. They have constituted the standard recording
methods for in vitro electrophysiology. The main difference between the submerged
and interface chamber was that nylon mesh was taken out from the central
compartment for the submerged recording (Fig. 2.3.3). Without the nylon mesh, slice
was sitting at the bottom of the recording chamber and was held by two silver grids,
so it was completely covered by the oxygenated ACSF, which flowed at lml/min.
There are several advantages in submerged recording. For example, the ACSF flows
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completely through the slice and can allow pharmacological molecules to enter the
slice thoroughly and therefore interact with their targets very fast and easily. As the
temperature for this chamber is easier to control and can be maintained constantly, this
makes the recording more stable, especially for the recording of late-phase LTP (>3hr)
or late LTP (>6hr). The condensation problem, which happens very often in the
interface recording, does not occur in this case, as the recording electrode is already
deeply in the ACSF medium. However, the major problem found for the submerged
recording was that the size of the evoked fEPSP was very small for either PDAPP or
non-Tg mice (PhD thesis by Urania Coumis, the University of Edinburgh). The
possible reason is that the surrounding solution of the recording electrode shunted the
current and also magnified stimulus artefacts. It was also found that, the surface of the







Figure 2.3.3 Design of The Interface Recording Chamber.
Schematic representations of the recording chamber as viewed
from above (A) and from the side (B).
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Due to these problems, the submerged chamber was modified to the interface one
(Spencer et al., 1976). In this case, the nylon mesh was fixed tightly in the small
recording chamber, so the slices sat on the mesh. The top surface of the ACSF
medium in the recording chamber was just slightly above the level of the mesh, so the
ACSF (lml/min) can only flow slowly through the slices, which were maintained at
the interface between a layer of slow flowing ACSF and a layer of humidified 95% O2
/ 5% C02 gas. This type of chamber was found to be very advantageous especially in
conducting electrophysiology in Tg animals. For example, the surface of the slice was
very visible under the low-resolution microscope when placing electrodes. More
importantly, this design produced much bigger responses after delivering stimuli.
Although the condensation was observed during the recording, it did not become a
disaster as no long-term experiments were performed.
The whole recording system, supplied by Scientific Systems Design Inc., UK,
consisted of an outer water bath with two tightly fixed thick platforms on which the
tri-compartmental recording chamber was securely mounted (Fig.2.3.3 and Fig.2.3.4).
The outer water bath was normally about 70% filled with distilled water. Using a
peristaltic pump (Watson-Marlow, England), the oxygenated ACSF was pumped into
the first compartment (or well) of the recording chamber at a constant flow rate of 2
ml/min. The ACSF then flowed around the circumference of this well and slowly
entered the recording chamber through a small hole between these two compartments.
In this compartment, the ACSF flowed underneath the nylon mesh and also through
the slices, finally entering the third well through another hole between the second and
the third compartments. In the last well, there was hypodermic suction needle which
was connected to pump which finally removed the ACSF from the recording chamber.
The peristaltic pump from Watson-Marlow has multi channels. One channel of this
pump served as the inflow to drive the ACSF into the recording chamber and another
one or two were used as outflow channels to remove the ACSF from the recording
chamber. By changing the magnitude of the outlet suction (for example, two outflow
channels of the pump could be connected suction tubing), the level of ACSF in the
recording chamber could be in balance such that it paralleled with the mesh but would
not fully cover the slices later. Using the artists brush, two slices were then
transferred from the incubation chamber to the interface recording chamber, where
they needed to be maintained for lh at 32°C. As these two slices were already
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incubated for about 30 min in the incubation chamber at room temperature after
dissection, the total incubation time was approximately 90 min. The remaining slices
kept in the plastic incubation chamber were still viable for at least several hours. If
either of the first two slices got damaged by the brush or the quality of recordings
from either of them looked bad, it could be replaced at a later time. As the perfusion
ACSF was bubbled by 95% 02 / 5% C02 gas, the slices could get the oxygen supply
from the solution. But, as ACSF is a poor carrier of dissolved oxygen, the slices
needed to obtain extra oxygen from the environment within the recording chamber.
This was achieved through the following mechanism. In the base of the outer water
bath filled with water, there was a ceramic bubbler which passed the 95% O2/ 5% CO2
gas into water. By carefully adjusting the height of the covering lid of the outer bath,
it could allow an oxygenated and humidified atmosphere to fulfill the entire recording
chamber.
Figure 2.3.4 Incubation of Hippocampal Slices
(two hippocampal slices are incubated in the recording chamber)
2.3.4 Recording in hippocampal slices.
In hippocampal slices, field potentials can be elicited and recorded postsynaptically
when a stimulus is applied to presynaptic fibres. The responses come from a
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population of neurons within the area recorded. Normally, the recording position is
within the dendritic regions of CA1 pyramidal neurons, i.e. stratum radiatum, with
stimulations applied to the Schaffer-collateral pathway. The responses from the
dendritic region are called the field excitatory postsynaptic potential (fEPSP).
Sometimes, action potentials can also be found and recorded from the dendritic areas.
The action potentials, also called population spikes, are recorded simultaneously and
are superimposed each other. From the stratum radiatum of CA1 neurons, the fEPSP
is always negative, when a stimulus is applied to the Schaffer-collateral pathway,
suggesting an inward current associated with dendritic synaptic activity.
All electrodes were mounted on mechanical manipulators (MB-K, Narishige, Japan)
which allowed three-dimensional movement in the x, y and z axes. For the recording
electrode, an additional hydraulic manipulator (MB-K, Narishige, Japan), which can
do fine movement, was used to allow increased sensitivity when moving the electrode
into slice. In order to make fine placement of electrodes into the slice, an overhead
dissecting angle microscope (M3C, Leica, England) and a cold light source which was
projected from above onto the slices were used to view the slice. All the recording
and stimulating electrodes were placed, at about a 45° to the vertical, in stratum
radiatum (CA1 pyramidal cell apical dendritic layer) of the hippocampal slice.
The Schaffer collateral-commissural fiber input to CA1 pyramidal neurons were
orthodromically stimulated using bipolar stimulating electrodes which were placed on
the surface of the slice in stratum radiatum. The stimulating electrodes consisted of
two 50 /xm diameter Formvar insulated nickel-chromium (80%:20%) wires (Advent
Research Materials Ltd., England) twisted together and cut at the end to provide a
focal stimulation. Stimuli were produced by constant voltage isolated stimulator
boxes (DS2A, Digitimer, England) (for the longitudinal and vaccination studies
described in this thesis) and constant current isolated stimulator boxes (NL800,
Digitimer, England) (for the PS1 and y-secretase studies described in this thesis). The
timing and duration of test stimuli (biphasic square-wave pulse, pulse half-width 0.1
ms, ranging from 0-100V for DS2A or 0-100jUA for NL800) were controlled by
Neurolog. The stimuli were delivered homosynaptically at a fixed intensity every 30
sec.
70
Guiquan Chen's PhD Thesis.
For the longitudinal and vaccination studies, recording electrodes were made from
thick walled (internal diameter: 0.69 mm; outer diameter: 1.2 mm) borosillicate glass
capillaries with an inner filament (120F-10, Clark Electromedical Instruments,
England), by a horizontal Flaming-Brown P-97 micropipette puller (Sutter
Instruments Co., USA). The recording electrode was filled with 3M sodium chloride
(NaCI) with resistance ranging from 1 to 5 M£2. Before recording, this electrode was
mounted into electrode holder (Clark Electrochemical Instruments, England) in which
a silver chloride coated silver wire made a tight contact with the NaCI solution within
the recording electrode. This holder was then inserted into the head stage (current
gain x 0.1 or x 1.0: Axon Instruments, CA, USA) and connected to an Axoclamp-2B
amplifier through the microelectrode 1 (ME1) port for use in "bridge balance" mode.
The reference electrode, a silver wire, submerged in the recording chamber, was also
connected to the head stage and grounded through the Axoclamp amplifier. Synaptic
potentials recorded through the ME1 port on the Axoclamp-2B amplifier were
amplified 10 fold by an in-built gain. In DCC mode the amplifier set the sample rate
(3-5 kHz switching frequency). Signals above 1-3 kHz were filtered, using a low-
pass filter, which did not noticeably affect the waveform of the synaptic potentials.
Secondary amplification of synaptic responses was provided by variable gain DC
amplifiers (Neurolog, Digitimer, England). The output signals were then digitally
filtered through a Digidata 1200 interface (Axon Instruments Ltd.) connected to a PC
(Dell, Texas, USA) (Fig. 2.3). In LTP experiments, a program called LTP (Version
1.14J) was used to record and analyze data (written by William Anderson, University
of Bristol, http://www.ltp-program.com/Ltpl 14j).
For the PSlcKO;APP and ELN44989 studies, due to an upgrade of the recording
system in the lab, the old recording system was replaced by a new AM recording
system. The old LTP recording software, LTP114J, was based on a DOS interface, so
it was also upgraded by new labview-based LTP software. After upgrade, field EPSPs
*
were recorded with a monopolar stainless steel electrode with a 250 tip diameter,
tapered at 12°, with a resistance of 5MG (AM Systems Inc. USA). The reference
electrode in the recording chamber was connected to the ground wire. Field EPSPs
were amplified, filtered at 5k Hz (1700, AM Systems), sampled at 10k Hz, and then
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stored onto a PC computer. The waveform and amplitude of the fEPSP (mV) was
monitored by labview-based LTP software written by Patrick Spooner (Division of
Neuroscience, the University of Edinburgh). On-line or off-line analysis of the fEPSP
slope (mV/ms) was made by the same software. The slope of fEPSP was measured by
linear regression between the 10% and the 90% of the peak response of fEPSP curve.
Two stimulating electrodes were placed in the Schaffer-collateral pathway of the
stratum radiatum. Each stimulating electrode was approximately 200/xm distant from
the recording electrode, so they stimulate independent synaptic populations in
Schaffer-collateral pathway. The maximum fEPSP response was judged after
measuring the input/output curve (I/O curve). Single biphasic pulses (0.2 ms in width)
were applied to the slice by each stimulating electrode, once every 30 sec, at
intensities ranging from 10-100/xA (10/xA, 20/xA, 30/rA, 40/xA, 50/xA, 60/xA, 70/xA,
80/xA, 90/xA and 100/xA). The maximum response was induced by a pulse at an
intensity of 70-100/xA. In all the electrophysiology experiments, the intensity of test
stimulation was set to evoke a response, the amplitude of which was -50% of the
maximum response found from the I/O curves. Normally, the half size of the
maximum fEPSPs was between 0.8 and 1.5mV. To measure paired-pulse facilitation
(PPF), four different inter-pulse intervals (IPIs), such as 25ms, 50ms, 100ms, and
200ms, were used.
For long-term potentiation (LTP) experiments (the longitudinal study), stimuli were
delivered by alternating between 2 independent Schaeffer collateral-CAl pathways,
one being the test and the other being the control pathway. Each pathway received a
stimulus once every minute, so the stimulus interval between the two pathways was
30 s. During a baseline period (30 minutes duration), if the slope of the fEPSP for
both pathways increased or decreased by >20%, the recording was stopped and the
stimulus intensity was adjusted by either reducing or increasing the value of intensity
which elicited a half size of maximal response. In any experiment for LTP, if the time
taken to get a stable baseline of LTP exceeded 2 hours, the slice was discarded and,
another slice from the incubation chamber was used to get a new LTP recording. LTP
was induced in the testing pathway by theta-burst stimulation (TBS) of 3 trains (2min
intertrain interval), each consisting of 15 [200ms inter-stimulus interval (ISI)]x4
pulses (100 Hz). Data were collected by LTP114J and stored on a computer. The
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initial slope of field EPSP evoked by stimulation of the Schaeffer collateral-CAl
pathway was analyzed online. Responses in each experiment were normalized to
baseline, which was defined as the mean value obtained in at least 20-minute
responses before TBS. A 20-minute stable baseline comprised of successive field
EPSP slopes that differed no more than 15 %. At this point, TBS was delivered to the
slice and the recording of EPSPs was continued for 1^1 h depending on the LTP
induction protocol employed.
2.3.5 Analysis ofdata.
In the 1-0 curves, at each stimulus intensity, the synaptic responses were averaged
from three successive responses; In the LTP experiments, 6 fEPSPs were averaged in
a two-minute period. Averaging six responses could reduce noise (variance of
response). Pooled data were presented as means ± standard error of the mean (SEM.)
and statistical significance was assessed using Students Mest. P < 0.05 indicates
statistical significance.
2.4 Immunohistology and Enzyme Linked Immunosorbent Assay (ELISA).
2.4.1 Brain tissue preparation for quantitating APP and A/3.
After the brain was removed during hippocampal slice preparation, the first 6 brain
slices from one hemisphere were prepared for in vitro slice electrophysiology. The
remaining brain tissue from this hemisphere was used for immunohistochemical
analysis. In the mean time, from the other hemisphere of the same brain, three brain
areas, including the cerebellum, hippocampus and cortex, were dissected and used for
Ap ELISA measurements.
The procedures of tissue preparation consisted of: 1) the dissections for three brain
regions mentioned above were performed on a piece of filter paper (Whatman 3 mm)
dampened with ACSF placed on top of an ice-cold aluminum block (an upside-down
micro test tube stand from Micro-Metric Instrument Co., FL, USA); 2) each region
was placed into a pre-weighed homogenization tube (Kontes Microtubes, Fisher,
USA) and kept on ice; 3) the tubes were weighed with the tissue on a balance after
wiping off any excess moisture from the ice on the outside of the tube prior to
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weighing; 4) the volume of 5M guanidine buffer (5.97g guanidine; 7.5ml sterile
water; 0.625ml Tris; more sterile water was added to 12.5ml) to add to each tube was
determined by subtracting (tissue+tube) from (tube alone) and multiplying the tissue
weight (mg) by 10 to obtain the volume of guanidine buffer in microlitre (/x 1) to be
added to the tube; 5) 200 /x1 of guanidine buffer or less was added to each tube. If the
tissue weight was less than 20 mg, the appropriate volume of 5M guanidine buffer
was added to each tube for homogenization; 6) the tissue was completely
homogenized with a hand-held homogenizer (Kontes motorized pestle, Fisher, USA);
7) the remainder of 5M guanidine buffer was added to each tube. For the cortical
samples, it was always best to add another 200 /xl as cortical tissue is often heavier
than 20 mg, and the homogenization procedure repeated, and finally the remainder of
the 5M guanidine buffer was added; 8) once all the samples were processed, the tubes
were gently agitated on a Nutator (Adams Nutator, Fisher, USA) for 3-4 hrs at room
temperature and stored at -20 °C until assayed for APP and Ap levels.
2.4.2 3D6 immunohistology.
The tissue was prepared during slice dissection for electrophysiology. One
hemisphere of the brain for each mouse was dropped into 4% formaldehyde and post-
fixed for about one week. After 1-week fixation, the following immunohistological
procedures were all carried out by Ms. Jane Knox. The tissue was mounted coronally
and cut at 30fxm sections using a vibratome. Every fifth section from the posterior
cortex through the hippocampus was collected in multiwells filled with antifreeze
solution (30% glycerol/30% ethylene glycol in 40 mM NaP04) and stored at -20°C in
freezer before immunostaining. On day 1 for staining, 1) wash sections for twice, 10
minutes each, using phosphate buffer saline (PBS); 2) put sections in 4.5 ml PBS with
30%H2O2 and 50 jtxl Triton-X-100 for 20 minutes; 3) wash sections in PBS for twice,
10 minutes/each; 4) make up 1% horse serum in PBS; 5) add primary antibody 3D6 at
1:500; 6) incubate sections in fridge overnight. On day 2, 1) make up AB kit
(horseradish peroxidase-avidin-biotin complex (Vector Laboratories)) with two drops
of A + 5 ml TBS + two drops of B. This was done 30 minutes before use; 2) wash
sections for twice, 10 minutes/each, in PBS; 3) incubate sections for 30 minutes with
AB at room temperature; 4) wash sections in PBS for twice, 10 minutes/each; 5) make
up diaminobenzidine (DAB) kit using 5 ml distilled water. 6) develop the sections in
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DAB for 40 seconds; 7) wash sections in distilled water; 8) mount sections on
Superfrost charged slides; 8) dry, dehydrate, clear and mount sections with
Fluoromount.
2.4.3 A/3 load quantification.
This part of work was conducted by Dr. Jennifer Inglis and Ms. Jane Knox. Amyloid
deposition was quantified automatically using a Leica Q-Win image analysis system.
Video images of the brain were captured, and the area of the hippocampus was
outlined and a threshold optical density was obtained that discriminated staining from
background. The amyloid 'plaque burden' was defined as the average percentage of
hippocampal area covered by amyloid depositions over six sections.
2.4.4 ELISA measurements for A/3.
The ELISAs were carried out by our collaborators, Karen Chen and Dione Kobiyashi,
in Elan Pharmaceuticals, but the methods are described as follows. The brain
homogenates were further diluted 1:10 with ice-cold casein buffer (0.25%
casein/0.05% sodium azide/20 jUg/ml aprotinin/5 mM EDTA, pH 8.0/10 /xg/ml
leupeptin in PBS) before centrifugation (16,000 x g for 20 min at 4°C). The A(3
standards (40 or 42) were prepared such that the final composition included 0.5 M
guanidine in the presence of 0.1% bovine serum albumin (BSA).
The total A[3 sandwich ELISA consisted of the capture antibody 266, which was
specific to amino acids 13-28 of Ap, and the biotinylated reporter antibody 3D6,
which was specific to amino acids 1-5 of A(3. The 3D6 antibody did not recognize
secreted APP or APP-FL but detected only Ap species with amino-terminal aspartic
acid. The assay had a lower limit of sensitivity of -50 pg/ml (11 pM) and showed no
crossreactivity to the endogenous murine AP peptide at concentrations up to 1 ng/ml.
The Ap42-specific sandwich ELISA used the capture antibody mAb 21F12 (AP33.42).
Biotinylated 3D6 was the reporter antibody in this assay, which had a lower limit of
sensitivity of -125 pg/ml (28 pM). An Apv.42 sandwich ELISA, using 266 as the
capture antibody and biotinylated 21F12 as the reporter antibody, was used on a subset
of brain homogenates. The low end sensitivity of this assay is -250 pg/ml (56 pM).
The 266 and 21F12 mAbs were coated at 10 ^g/ml into 96-well immunoassay plates
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(Costar) overnight at room temperature. The plates were then aspirated and blocked
with 0.25% human serum albumin in PBS buffer for at least 1 hr at room temperature,
then stored dessicated at 4°C until use. The plates were rehydrated with wash buffer
(0.05% Tween 20 in tris-buffered saline) before use. The samples and standards were
added to the plates and incubated at room temperature for 1 hr. The plates were
washed three or more times with wash buffer between each step of the assay.
The biotinylated 3D6, diluted to 0.5 pig/ml in casein assay buffer (0.25% casein/
0.05% Tween 20, pH 7.4, in PBS), was incubated in the wells for 1 hr at room
temperature. Avidin-horseradish peroxidase (Vector Laboratories), diluted 1:4000 in
casein assay buffer, was added to the wells for 1 hr at room temperature. The
colorimetric substrate, SlowTMB-ELISA (Pierce), was added and allowed to react for
15 min, after which the enzymatic reaction was stopped with addition of 1 M H2S04.
Reaction product was quantified using a Molecular Devices Vmax spectrophotometer
measuring the difference in absorbance at 450 nm and 650 nm.
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Chapter 3: A Cross-sectional Investigation of Age- and Plaque-
related Learning Deficits in PDAPP Mice.
3.1 Introduction.
The purpose of this first experiment was to use three cohorts of naive PDAPP mice at
three different ages to investigate plaque- and age-related cognitive impairment.
3.1.1. Early studies on APP Tg mice failed to reveal plaque-related learning deficit.
The APP751 (or SciosNova) mouse was the first APP Tg model of AD (Quon et al.,
1991). Created in 1991, immunohistological and behavioural analysis was not
conducted until 1995, revealing the age-related formation of diffuse plaques, but not
neuritic plaques (Higgins et al., 1995), and an age-related behavioural deficit in
spontaneous Y-maze alternation and an age-independent deficit in spatial learning
(Moran et al., 1995). These findings indicated that overexpression of wildtype (WT)
human APP could impair learning.
Historically, a learning deficit in APP Tg mice was first reported as early as 1991.
This was found using the so-called Cambridge mouse, in which a mouse
metallothionein II promoter was used to overexpress human WT APP695 (Yamaguchi
et al., 1991). Although no mRNA and protein expression data were published, a
cohort of animals aged 8-20 weeks were tested in the watermaze. Only a subtle deficit
in the initial performance of Tg mice was observed, but no difference from non-Tg
mice during the later days of reference memory training. No pathological changes,
such as amyloid deposition, were reported in the same mice used for the behavioural
test. It is difficult to know what to make of these findings, but a possible link between
overexpression of WT human APP and a subtle impairment of spatial learning in APP
Tg mice was hinted.
Between 1991 and 1995, several different APP Tg mouse lines, all of which
overexpress either full-length or C-terminus of APP using different promoters, were
reported. They all expressed WT human APP at a level equivalent to the endogenous
mouse APP but did not develop any neuritic plaques in the brain (Kawabata et al.,
1991; Kammesheidt et al., 1992; Kawabata et al., 1992; Fukuchi et al., 1993; Lamb et
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al., 1993; Fukuchi et al., 1994; Greenberg et al., 1996). Behavioural studies indicated
that most of these Tg lines display early learning deficits prior to plaque deposition,
suggesting that APP metabolites, such as APP CTF and Ap, may be responsible
(Nalbantoglu et al., 1997; Sato et al., 1997; Berger-Sweeney et al., 1999).
3.1.2. A standard reference memory task in the watermaze may not be sufficiently
sensitive to reveal plaque-related learning deficit in APP Tg mice.
Using a P-chain promoter of PDGF and a human APP gene containing the Indiana
mutation, Games et al reported the first plaque-producing Tg rodent, the PDAPP
mouse (Games et al., 1995). Importantly, the PDAPP mouse displays AD-like
pathology such as Ap accumulation, diffuse and neuritic plaques, microgliosis and
astrocytosis in an age-dependent manner (Games et al., 1995; Irizarry et al., 1997;
Johnson-Wood et al., 1997). Preliminary behavioural characterization of PDAPP mice
was conducted by Justice et al (former Athena Neuroscience) and Ramsay (MSc
thesis, Edinburgh University). Using a standard reference memory task in the
watermaze, Justice et al observed an age-independent learning deficit, unrelated to
plaque deposition (Justice and Motter, 1997). Ramsay et al employed a DMP task in
the watermaze (Steele and Morris, 1999) to test PDAPP mice using a longitudinal
design. This longitudinal study also revealed an age-independent learning deficit in
PDAPP mice (Ramsay and Morris, 1998). Both findings were surprising and raised
issues of task sensitivity.
Shortly after Games et al (1995) reported the PDAPP mouse, a second group
successfully generated a plaque-producing Tg mouse line, the Tg2576 mouse, which
overexpresses a mutant human APP695 gene with the double Swedish mutations
under the control of a prion promoter (Hsiao et al., 1996). The Tg2576 mouse starts
the formation of neuritic plaques from 8-10 months of age. It has been reported that
Tg2576 mice display both age- and plaque-related learning deficits in a Y-maze
alternation and a watermaze reference memory task. In the watermaze, two young
groups (2- and 6-month) of Tg2576 mice were found to be unimpaired in acquisition
training and the probe test of reference memory. However, older Tg2576 mice (9-10-
month) were impaired (Hsiao et al., 1996). The claim of an age- or plaque-related
memory deficit in Tg2576 mice has been criticised (Routtenberg et al., 1997), as
inspection of the data indicates that the age-related memory deficit was primarily due
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to improved spatial memory in old non-Tg mice. Indeed, using Tg2576 mice and a
watermaze reference memory protocol, a second group have failed to observe any
deficit in spatial learning and memory even at very old ages (14- and 19-month) (King
and Arendash, 2002). Recently, Hsiao's group have re-investigated learning and
memory of Tg2576 mice and reported a detergent insoluble A(3-related learning
deficit in Tg2576 mice (Westerman et ah, 2002). However, due to performance
incompetence, about 16-32% of Tg2576 mice were excluded from their final data
analysis. The fact that so many mice were excluded in a behavioural study raises
questions about the adequacy of the behavioural protocol.
3.1.3. Novel behavioural task to investigate plaque-related learning deficits in APP
Tg mice.
The studies discussed above imply that the standard reference memory task in the
watermaze might not be sensitive enough to detect a plaque-related learning deficit in
APP Tg animals. Chapman et al were the first to report a different behavioural
paradigm, a forced choice T-maze alternation task to test the plaque-related learning
deficit in Tg2576 mice (Chapman et al., 1999). 2- and 10-month mice were tested in
this study. Only the 10-month Tg2576 mice displayed a significantly lower rate of
performance than age-matched non-Tgs. This finding suggests that novel behavioural
paradigms may be able to dissociate age-related and age-independent learning deficits
in Tg animal models of AD.
Dodart et al (1999) tested three different cohorts of PDAPP mice on C57BL/6, DBA/2
and Swiss Webster genetic background at 3, 6, and 9-10 months of age (Dodart et al.,
1999). The testing protocols included an object-recognition task, an eight-arm radial-
maze spatial discrimination task and a bar-press learning task. In the radial maze task,
PDAPP mice displayed a robust age-independent memory deficit. They also showed
age-independent deficit in the barpress learning task. However, in the object
recognition task, PDAPP mice showed an age-dependent decrease in performance,
which was more severe at the age at which amyloid deposition started (Dodart et al.,
1999). The same investigators also analyzed neuroanatomical abnormalities in the
same mice behaviourally tested (Dodart et al., 2000). An unexpected observation was
a 20^10% of hippocampal atrophy in PDAPP mice as young as 3 months. A
correlation analysis indicated that the deficit in object recognition was significantly
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correlated with the number of plaques in the cingulate cortex, and in CA1, CA3, and
dentate gyrus of the hippocampus. However, the deficits in radial-maze spatial
learning were unrelated to plaque deposition, but did correlate with the marked
atrophy of the hippocampal formation. These results further suggest that novel
behavioural tasks may reveal different components of learning deficits in APP Tg
mice.
It is believed that brain areas, which are affected at the early stage of AD, are the
entorhinal cortex and hippocampus. Studies on the function of the hippocampus have
suggested that the hippocampus is implicated in learning and memory (Squire, 1992),
or the hippocampus mediates a neuronal representation of space or a cognitive map
(O'Keefe and Nadel, 1978). Two seminal studies demonstrated that watermaze spatial
training is a task very sensitive to hippocampal lesions in rats (Morris et al., 1982;
Moms et al., 1986). More evidence further indicated that hippocampus-lesioned rats
are severely impaired when learning new place problems, i.e. reversal locations in
watermaze (Morris et al., 1986; Whishaw and Tomie, 1997; Steele and Morris, 1999).
A novel delayed matching-to-place (DMP) protocol in the watermaze was first
introduced by Morris in 1983 and has been developed later (Steele and Morris, 1999).
In the DMP task, there are 4 trials each day at a 10-min ITI. On each trial, once the
mice find the escape platform, they are allowed to stay there for 30 s before being
taken away from the pool to have a 10 min rest. Normally, the mice exhibit a striking
reduction in escape latency between trial 1 of the day and subsequent trials. Once the
mice have learned the general strategy of this task, new spatial problems can be tested
repeatedly.
In the present study, I modified the general DMP protocol by introducing a
performance criterion. Two novel behavioural protocols in the watermaze, 'trials to
criterion' and 'learning capacity' were developed. Generally speaking, once the mice
were escaping quickly onto the hidden platform at one location and had reliably
learned this location by reaching the performance criterion, the platform was moved
to a new location. Five successive platform locations were learned by the mice in the
trials to criterion task. In the learning capacity task, but only the total number of
problems learned by the mice in a 10-day period is counted as a measure of learning
capacity. In these two modified DMP protocols, the learning of earlier platform
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locations is encoded into long-term memory, which can potentially cause interference
with the learning of later problems. In order to perform this task reliably, memory
retrieval must be restricted to the most recently encoded information, i.e. the new
location. This property of these tasks gives them the character of being "episodic".
Interestingly, the PDAPP mouse first forms the highest density of plaques in the outer
molecular layer of the dentate gyrus and other regions of the hippocampus. So, like
AD in humans, the hippocampus is possibly the first brain area to be affected by
amyloid plaques in PDAPP mice. As human AD subjects develop impairment in
episodic memory, the "episodic memory-like" character of the DMP tasks may be
particularly suitable for revealing plaque-related cognitive impairment.
3.2 Methods.
3.2.1. The subjects.
All PDAPP mice used in this study were non-white heterozygous males, on a
DBA/C57BL/6 double strain background. They were shipped from the former Athena
Neurosciences, USA. Three different ages of mice were tested. Young, middle-aged
and old groups were 6-9 months (n=50, PDAPP=25, non-Tg=25), 13-15 months
(n=29, PDAPP=15, non-Tg=14), and 18-21 months (n=20, PDAPP=9, non-Tg=ll) of
age. The mice were group-housed (2-4 mice each cage) and had different ear marks so
that the experimenter could recognize any individual without problem. The mice were
given acl libitum access to food and water. The animal room was kept at a temperature
of 25 °C and on a 12:12 light dark cycle.
3.2.2. The watermaze.
The watermaze used is 2 m in diameter. The temperature was kept at 25 ± 1°C. The
escape platform is 20 cm in diameter and its top surface is 1.5 cm below the water
surface. In all testing trials, the animals were placed into the pool by hand but
removed by them climbing onto a small paint roller from the platform. During the ITI,
the animals were singly housed in an experimental cage with dry paper. The running
sequence was organized by Dr. Stephen Martin, so the experimenter was blind to the
genotype of the mice throughout the whole duration of the study. The mice were run
in squads of 6 mice (3 non-Tg and 3 Tg per squad).
81
Guiquan Chen's PhD Thesis.
3.2.3. Experimental design.
Figure 3.2.1 Experimental Design.
The experimental design is shown in Fig. 3.2.1. PDAPP and control mice were tested
on a battery of 4 different behavioural tasks, consisting of (1) cuetask for 5 days, (2)
trials to criterion task for 1 to 4 weeks, depending on performance of individual
animal, (3) object recognition task for 10 days, and (4) learning capacity task for 10
days. After the behavioural testing was completed, the mice were
immunohistologically analyzed for Ap plaques.
3.2.4. Visible cuetask.
There were 4 trials per day for 5 days and platform location was changed across trials.
If any individual mouse failed to learn the cuetask, it was excluded from the study.
3.2.5. Trials to criterion task.
The trials to criterion task consisted of learning 5 successive different hidden platform
locations to the strict performance criterion. Once this criterion was met, the mouse
was stopped on that day and only started to learn the next platform location on the
following day. The mice were trained for up to 8 trials per day and trained for as
many days as necessary to learn all 5 different problems. As several animals failed to
reach the criterion when learning some of the five locations, the maximum trial
number was set to 40 for problem 1 and 32 for problems 2 to 5. For counterbalancing
reasons, two different sets of platform locations were arrayed. In these, Problem 1 in
82
Chapter 3: Age-related and Age-independent Learning Deficits in PDAPP Mice.
Set A was close to the centre of the pool, but Problem 1 in Set B was close to the wall,
and so on. Half of the mice were assigned to receive training using platform locations
in Set A and the other half using locations in Set B. Fig. 3.2.2 shows the 2 sets of 5
consecutive platform locations used in this task.
Prob. 1 Prob. 2 Prob. 3 Prob. 4 Prob. 5
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Figure 3.2.2 Two Sets of Five Different Problems. All mice at three different
ages were divided into two groups. One group were trained by the platform
locations shown on Set A, and the other group were tested by Set B.
3.2.6. Object recognition.
The floor of the object recognition arena was covered by 1 cm of sawdust.
Habituation consisted of 5-min period for 5 days in the arena without any object
presented. Following 5 days habituation, object recognition test consisting of a
sample phase, a retention interval, and a choice phase was given to the mice. In order
to examine short- and long-term object recognition memory in the mice, five different
retention intervals were used, 10 s, 1 min, 10 min, lh and 4h. During the interval, the
animal stayed in its home cage, and the objects were cleaned with 95% alcohol.
3.2.7. Learning capacity task.
For counterbalancing reasons, two different sets of 10 platform locations were used in
the learning capacity task. All mice at 3 different ages were assigned into 2 different
groups by Dr. Stephen Martin, so one group received the Set C platform locations and
the other one received the Set D. For any individual mouse, the platform position was
changed only after the performance criterion was met. Each mouse was trained for up
to 8 trials per day. At the end of 10-day training, each mouse was regarded as having
a "learning capacity" defined as the total number ofplatform locations learned.
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Figure 3.2.3 Two Sets of Ten Different
Problems for Learning Capacity Task.
All mice at three different ages were
divided into two groups. One group were
trained by the 10 platform locations
shown on Set C, and the other one
by Set D.
3.2.8. Immunocytochemistry and plaque load quantification.
After all behavioural training was completed, all middle-aged and old mice, and a
subset of young mice (n=12, 6 Tg and 6 non-Tg) were sacrificed to examine the
extent of amyloid plaque deposition. The methods for immunocytochemistry and
plaque load quantification are given in Chapter 2. The immunocytochemistry was
conducted by Ms. Jane Knox and the quantification of plaque burden was done by Dr.
Jenniffer Inglis.
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3.3 Results.
1. Normal cuetask learning in PDAPP mice.
The results of cuetask training are shown in Fig. 3.3.1. Statistical analysis revealed no
significant genotype effect for all 3 different ages of mice (6-9, 13-15 and 18-21
months) (F=3.31, df1/93, p>0.07). Interestingly, in the old age group (18-21-month),
although no significant genotype effect was found (F<1), old PDAPP mice displayed
a significant impairment on day 1 (p<0.05, two-tailed student t-test) as compared to
non-Tg mice, suggesting a transient deficit. Overall, old PDAPP mice swam as well
as the controls from day 2 to day 5. The mean escape latency was less than 10 s in
both non-Tg and PDAPP mice for all 3 age groups after day 1, indicating that PDAPP
mice did not display any significant sensorimotor abnormalities.
2. Normal object recognition memory in PDAPP mice.
It has previously been reported that PDAPP mice can display a plaque-related deficit
in long-term object recognition memory (Dodart et ah, 1999). Flowever, Dodart et al
tested their PDAPP mice with a 4 h retention interval only, leaving the presence of
short-term object recognition deficits unknown. In this study, several different
memory retention intervals were used to investigate both short- and long-term object
recognition memory in PDAPP mice. As shown in Fig. 3.3.2, in contrast to the
findings by Dodart et al, it seems that PDAPP mice did not display any age-related or
age-independent deficits in this task at any memory retention delay. Both PDAPP and
non-Tg mice were found to explore the novel object preferentially (Fig. 3.3.2). The
analysis of variance revealed gradual forgetting over 4 h (F=20.8, df4/352, p<0.001)
but no difference between PDAPP and non-Tg mice at any age (Fig. 3.3.2: F<1).
Memory for novel objects in both genotypes decayed normally over time (Fig. 3.3.2).
The mean performance of both groups was significantly above chance at all retention
intervals (p<0.05, independent t-test), indicating that PDAPP mice displayed normal
short- and long-term object recognition memory.
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Figure 3.3.3 Early Deficits in Spatial Learning of PDAPP Mice Getting Progressively
Worse. Five different platform locations needed to be learned in trials to criterion task.
Performance of PDAPP and non-Tg mice at 6-9 months (A), 13-15 months (B), and
18-21 months (C).

























































Figure 3.3.4 Age-related Learning Deficit in PDAPP Mice. A. Performance on
trials to criterion task by PDAPP mice only. There was a highly significant aging effect.
B. There was no significant genotype effect observed in swim speed of PDAPP mice.
C. PDAPP mice displayed a significant aging effect as a function of mean performance
across five platform locations in trials to criterion task. D. PDAPP mice displayed a
significant aging effect in learning capacity task.
87
Guiquan Chen's PhD Thesis.
3. Early impairment of spatial learning in PDAPP mice getting worse with age.
Figure 3.3.3 shows the performance of both PDAPP and non-Tg mice at 6-9, 13-15
and 18-21 months of age on trials to criterion task. Analysis of variance (Fig. 3.3.3A)
showed that young PDAPP mice displayed a significant learning deficit in the trials to
criterion task (F=26.28, dfl/48, pcO.OOl), although they could have only developed
few plaques in the brain at this age point (Johnson-Wood et al., 1997). Interestingly,
the other two groups of older PDAPP mice also displayed severe deficits (Fig. 3.3.3B:
F=10.25, dfl/27, p<0.01, at 13-15-month; Fig. 3.3.3C: F=10.97, dfl/18, p<0.01, at
18-21-month). The observation of early spatial learning deficit in young PDAPP mice
was further confirmed when measuring the mean trials to criterion across the five
successive platform locations, which represents an overall performance of the mice in
this task (Fig. 3.3.4C: pcO.OOl, at 6-9-month). Very consistently, an early learning
deficit was also observed in the learning capacity task in young PDAPP mice (Figure
3.3.4D: F=7.88, dfl/48, p<0.01), further indicating that young PDAPP mice had
already displayed early deficit in spatial learning. Older PDAPP mice also showed
significant impairment in the learning capacity (Figure 3.3.4D: F=9.27, dfl/27,
p<0.01, at 13-15-month; F=14.36, dfl/18, p<0.002, at 18-21-month).
However, the analysis above is somewhat deceptive because the overall statistical
analysis of variance for the trials to criterion not only revealed a significant genotype
(F=45.61, df1/93, p<0.001) and age (F=12.20, df2/93, p<0.001) effect, but also a
significant genotype x age interaction (F=5.26, df2/93, p<0.01), which allowed a
further separate analysis of the performance by PDAPP and non-Tg mice. Across all 5
successive spatial problems, PDAPP mice displayed a significant aging effect on their
performance (Figure 3.3.4A+C: F=8.32, df2/46, p<0.002); the controls did also
although, in absolute terms, the aging effect in controls is much more modest (Figure
3.3.4C: F=7.24, df2/47, p<0.005). Figure 3.3.4A clearly shows that young PDAPP
mice performed significantly better than both middle-aged and old PDAPP mice.
Consistently, in terms of the mean trials to criterion, PDAPP mice again displayed
significant aging effects (Fig. 3.3.4C).
Similarly, the learning deficit of PDAPP mice in the learning capacity progressively
got worse with age (Fig. 3.3.4D). Statistical analysis of the learning capacity showed a
significant genotype effect (F=37.36, df1/93, pcO.OOl), an age effect (F=11.92,
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Figure 3.3.5 Age-related Learning Deficits in PDAPP Mice.
A. Age-related learning deficit of PDAPP mice in learning platform locations 4 and 5.
B. Representative swim paths taken from 1 non-Tg and 1 PDAPP mouse at
6-9 (young), 13-15 (midde-aged) and 18-21 (old) months of age on problem 5.
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df2/93, p<0.001) and, importantly, a genotype x age interaction (F=4.04, df 2/93, p<
0.05). Separate analysis of each genotype group revealed a trend but not significant
age-related decline in non-Tg mice (F = 2.94, df 2/47, 0.10 >p> 0.05), however, a
highly significant performance decline in PDAPP mice (F = 8.84, df 2/46, p < 0.002),
further confirming that PDAPP mice displayed a deficit in spatial learning at young
age, but this deficit progressively got worse with age. It seems that this age-related
deficit may be specific to spatial learning in my test battery. First, a swim speed
analysis revealed no difference between PDAPP and non-Tg mice on the first three
trials of training (Fig. 3.3.4B, p>0.05), although the swim speed of both groups was
significantly reduced with age (F=27.46, df2/93, p<0.001). Second, as shown above,
there is no impairment in object recognition memory
Very interestingly, ANOVA of the trials to criterion further revealed a significant
location x age interaction (F=2.275, df7.03/327.00, p<0.05; Greenhouse-Geisser
correction), suggesting an age-related deficit in learning individual platform locations
of this task. This further justified separate analysis of age-related and age-independent
learning deficits in PDAPP mice, and these findings are discussed in the following
two sections.
4. Age-dependent component of learning impairment in PDAPP mice.
Statistical analysis restricted to the PDAPP mice only revealed a significant locations
x age interaction (F=2.17, 6.59/151.7, p<0.05; Greenhouse-Geisser correction; Fig.
3.3.4A). Very interestingly, young PDAPP mice were indistinguishable from age-
matched controls on platforms 4 and 5 of this task, by contrast, middle-aged and old
PDAPP mice took much longer to learn these two platform locations than the controls
(Fig. 3.3.5A). This suggests that PDAPP mice display an age-dependent component
of their learning deficit. In contrast, all three non-Tg control groups learned the last
two platform locations at an equivalent rate (Fig. 3.3.5A). As shown in Fig. 3.3.5A.,
analysis of performance on platform locations 4 and 5 revealed not only significant
genotype and age effects, but also a genotype x age interaction (F=6.82, df2/93,
p<0.005). Separate analyses of these two locations averaged together indicated that
PDAPP mice performed progressively worse with age (F=11.3, df2/46, p<0.001),
whereas non-Tg mice displayed only a trend towards a significant age effect (F=2.58,
df2/47, 0.10>p>0.05) (Fig. 3.3.5A).
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It remains unknown why young PDAPP mice performed much better on the later
problems in a series of 5. However, analysis of swim paths of these mice may give us
some clues. Fig. 3.3.5B shows swim paths for all trials taken to learn platform
location 5 of trials to criterion task from a representative control and PDAPP mouse at
three ages (6-9-month; 13-15-month; 18-21-month). Interestingly, young PDAPP
mouse reached the performance criterion (the criterion trials being named as CI, C2
and C3) as quickly as its age-matched non-Tg animal did, as both of them took 4
trials. By contrast, middle-aged PDAPP mouse finished this problem with 13 trials
whereas the control did it with 4 trials, and old PDAPP mouse took 19 trials to leam
this problem whereas the control littermate made it with 6 trials (Fig. 3.3.5B). Fig.
3.3.5B also shows that the older PDAPP mice displayed more circuitous searching
behaviour than that of the young one, and it seems that they could not maintain
accurate swim paths constantly from trial to trial until they finally reached criterion.
This inconsistency may explain why older PDAPP mice could not improve their
performance on later problems.
5. Significant correlation between plaque burden and behavioural performance.
The immunocytochemical analyses (Jane Knox) confirmed an age-dependent
deposition of amyloid plaques in PDAPP mice. There were few plaques in the
hippocampus of PDAPP mice at 9 months (Fig. 3.3.6A). At 16 months, plaques
became much denser, particularly in the dentate gyrus, hippocampus and entorhinal
cortex (Fig. 3.3.6B). At 22 months, amyloid plaques showed the highest level of
density throughout the hippocampus and cortex (Fig. 3.3.6C). Quantification analysis
of plaque burdens in the hippocampus revealed these were 0.6%, 11.8% and 14.5%
across three ages.
In order to investigate possible relationship between plaque burden and behavioural
performance of PDAPP mice, two correlation studies between plaque burden and
performance on both tasks were conducted (Fig. 3.3.6D and E). As middle-aged and
old PDAPP mice developed statistically indistinguishable levels of amyloid plaques,
they were pooled together. First, an overall analysis of all PDAPP mice aged at 16-22
month revealed a significant positive correlation between trials to criterion on
locations 4 and 5 and plaque burden (r=0.57; p<0.01).
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Figure 3.3.7. Analysis of Performance on Platform Location 1.
A. Age-independent learning deficit of PDAPP mice on platform location 1 as
a function of age.
B. Escape latency on the first 3 trials of problem 1 (averaged all 3 age groups).
C. Thigmataxis of the mice. Percentage time spent within 15cm of the
watermaze walls over the first 3 trials on problem 1 (averaged all 3 age groups).
D. Backward learning curves show escape latency for three criterion trials
(C1-C3) plus the preceding trial immediately to the first criterion trial (C1) on
problem 1.
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(Fig. 3.3.6D). Second, a significant negative correlation between learning capacity
and plaque burden of PDAPP mice was also observed (r=-0.50, p<0.05) (Fig. 3.3.6E).
As the correlation between plaque burden and behavioural performance is significant,
it suggests that amyloid plaques play a very important role in disrupting spatial
learning of PDAPP mice.
6. Age-independent deficit in spatial learning of PDAPP mice.
Comparisons of the performance of PDAPP mice at all three ages on problem 1 (Fig.
3.3.3) showed that the spatial deficit in PDAPP mice was equivalent at all ages.
Performance of both PDAPP and non-Tg mice on location 1 is plotted and shown in
Fig. 3.3.7A. ANOVA of problem 1 revealed only a significant genotype effect
(F=15.2, df1/93, pcO.OOl), but neither an age effect (F<1) nor any interaction. It is
likely that learning problem 1 in the trials to criterion task is no different from
learning a standard spatial reference memory task in the watermaze, so this age-
independent learning impairment of PDAPP mice is consistent with previous findings
using a reference memory task (Justice and Motter, 1997).
The slower learning rate of PDAPP mice was also analysed in relation to escape
latency on platform location 1. As some mice, including both non-Tg and PDAPP,
only took three trials to learn the first location, the analysis had to focus on only the
first three trials to include all animals. Figure 3.3.7B shows that the escape latency for
the first three trials of PDAPP mice decreased more slowly than that of non-Tg mice.
Thus PDAPP mice have a slower learning rate on problem 1 compared to non-Tg
controls.
Increased thigmotaxis in PDAPP mice was observed on these same first three trials of
location 1, compared with non-Tg controls (Fig. 3.3.7C). This might contribute to or
be due to the impaired learning of PDAPP mice. It is not an impairment of swimming
ability, as there was no significant difference in swim speed between PDAPP and
non-Tg mice (Fig. 3.3.4C). Finally, the so-called backward learning curves, in which
the escape latency on all three criterion trials for all animals on platform location 1
plus one preceding trial immediately to the first criterion trial was averaged for both
genotype groups, are shown in Fig. 3.3.7D. Analysis of these learning curves revealed
no genotype difference (F=2.33, dfl/94, p>0.1) and no genotype x trials interaction
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(F=l. 18, df 2/188, p > 0.3), suggesting that, once PDAPP mice learned problem 1 by
using more trials than the controls, they showed no difficulty in finding the platform.
Thus they were not different from the controls after reaching the performance
criterion. Collectively, these findings indicated that PDAPP mice could eventually
learn (or encode) and remember the hidden platform location, although their learning
rate was relatively slow.
3.4 Discussion.
In early 1999, when this research project initially started, no evidence showing age-
related or more specifically, plaque-related learning deficit in the PDAPP mouse had
been reported. Although Hsiao et al's report (1996) had suggested an age- and plaque-
related memory deficit in Tg2576 mice using the standard watermaze reference
memory task, this claim was contested (Routtenberg et al., 1997). Indeed, early
studies on either plaque-free APP transgenics or PDAPP mice had failed to reveal any
plaque- or age-related learning deficits. I therefore claim that the findings of this study
are the first convincing demonstration of an age- and plaque-associated learning
deficit. They were published in Chen et al (2000).
Interestingly, since it was proposed in 1991, the amyloid cascade hypothesis, which
emphasizes the central role of plaque deposition in AD, has become the dominant one
in the field. Although much genetic evidence supports this hypothesis, there is much
less clinical or pre-clinical support. As human AD subjects display progressive
memory loss with age, it has been important to establish whether overexpression of
mutant really does play a central role in cognitive impairment of AD. The initial
purpose of this cross-sectional study was to investigate plaque- and age-related
learning deficits in APP Tg animals, and it seems to have succeeded in revealing
these.
Consistent with previous reports (Justice and Motter, 1997; Ramsay and Morris,
1998), a learning deficit in young PDAPP mice was also found using this novel DMP
task. However, the deficit in young PDAPP mice also got progressively worse with
age, suggesting that there is an additional spatial learning deficit that is age-
dependent. As significant correlation between plaque burden and behavioural
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performance on the trials to criterion and learning capacity tasks was observed in
PDAPP mice, the age-related learning deficit is plaque-related as well.
It is possible that the learning deficit in PDAPP mice is due to high levels of APP,
total Ap or APP CTFs. First, studies on human wildtype APP Tg mice have indicated
that overexpression of human APP disrupts spatial learning and memory in Tg mice
even in the absence of plaques (Yamaguchi et al., 1991; Moran et al., 1995). Second,
several other plaque-free APP Tg mice, who produce high levels of AP and APP
CTFs in the brain, also display severe deficit in spatial learning and memory
(Nalbantoglu et al., 1997; Berger-Sweeney et al., 1999), strongly suggesting that
abnormal accumulation of Ap, APP CTFs or both has significant deleterious effect on
spatial learning and memory. As PDAPP mice express very high levels of soluble and
insoluble Ap (40 and 42) but few plaques at 6-9 months of age (Johnson-Wood et al.,
1997), these might account for the impaired spatial learning of PDAPP mice at early
age. However, the cellular mechanisms by which they do so are unclear.
The claim of a separate age-related learning deficit of PDAPP mice rests on three
lines of evidence. First, the deficit in PDAPP mice got progressively worse with age;
second, young PDAPP mice improved their performance on later problems 4 and 5 of
a series of 5 in the trials to criterion task to a point where they were not different from
age-matched non-Tg controls, whereas two older groups displayed consistent severe
deficits on problems 4 and 5; third, correlation studies revealed an association with
plaque deposition which clearly can not be a factor in the deficit by young PDAPP
mice. These findings are consistent with the idea that deposition of plaques plays a
very important role in causing spatial learning or memory loss in PDAPP mice, but
one must also consider the possibility that plaques are a surrogate marker for some
other upstream events including elevated Ap levels.
The successful demonstration of a component of age-related learning deficit in
PDAPP mice in this study indicates that a behavioural task sensitive to the integrity of
the hippocampus, entorhinal, cingulate and cerebral cortex is sufficient and may even
be required to achieve this goal. A key factor seems to be the constantly changing
platform location requiring the animal to keep updating his memory representation. In
contrast, previous studies have indicated that the watermaze reference memory task is
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sufficiently sensitive to reveal plaque-independent impairment of spatial learning in
APP Tg mice (Justice and Motter, 1997; Moechars et al., 1999). But interestingly, this
task has consistently failed to reveal an age-independent learning deficit in Tg2576
mice (Hsiao et ah, 1996; King and Arendash, 2002; Westerman et ah, 2002).
However, plaque-independent learning deficits have been commonly observed in all
other APP Tg lines, PDAPP, WT human APP transgenics, APP104 and CRND8 Tg
mice (Yamaguchi et ah, 1991; Moran et ah, 1995; Justice and Motter, 1997;
Nalbantoglu et ah, 1997; Moechars et ah, 1999; Janus et ah, 2000; Van Dam et ah,
2003).
In contrast to Dodart et al's (1999) finding of age-related deficit in object recognition
memory of PDAPP mice, unimpaired object recognition memory was observed here.
It is difficult to explain this discrepancy. Differences of methodology may partly
account for it. First, Dodart et al (1999) have only tested a 4h retention interval with
their cohort of PDAPP mice. In this study, PDAPP mice were repeatedly tested with 5
different intervals ranging from short-term (10 s) to long-term (4 h). It is possible that
repeated exposure to the range of objects used in this study might reduce exploration
initiatives and activities for novel objects, or simply produce a carry-over (practice)
effect in the mice. For example, the object memory index (-70%) at 10 s interval in
both PDAPP and non-Tg mice of this study was equivalent to that at 4 h delay in
Dodart et al's report (1999). Second, it is unclear whether using two identical objects
in the sample phase of this task and using 30 s of total active exploration time as the
duration of each phase affected the overall performance of the mice. Third, and
probably most importantly, the two studies used different genetic background of
PDAPP mice. Although the original PDAPP mouse was produced in a
DBA/C57BL6/Swiss Webster triple strain background, the colony of PDAPP mice
used by Dodart et al (1999) were the same as the original one, but the colony of
PDAPP mice used in this study was the DBA/C57BL6 double strain background
(personal discussion with Dione Kobayashi). Recently, Mathis' group in Strasbourg
have tested performance difference between WT C57/BL/6 and Swiss Webster mice.
What they have found was that Swiss Webster mice display above 70% memory
index of object recognition at 4 h interval, similar to that for the control group in their
original report, but very interestingly, C57BL/6 mice only display chance
performance (scientific communications with J.C Dodart and C. Mathis). It is
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observed that the color of the mice used for this cross-sectional and following
longitudinal study from the former Athena Neuroscience, was black, agouti or brown,
but many Dodart's mice were white (personal discussion with J.C. Dodart). This,
however, raises a problem about Dodart et al's methodology. Their use of only one
retention interval makes it very unlikely to distinguish between a perceptual and a
memory deficit. Albino mice are thought to have poorer vision and the PDAPP
phenotype may interact to influence perceptual abilities in the Lilly but not the Elan
(or Athena) line of mice. Finally, it is unclear whether gender differences between our
studies may also make difference in the results, as all mice in this study were male,
but Dodart et al used both genders (personal discussion with J.C. Dodart). To
summarise, it is inappropriate to draw a firm conclusion about the presence or absence
of recognition memory deficits in PDAPP mice.
In conclusion, PDAPP mice were found to display both age-related and age-
independent spatial learning deficits. These were significantly correlated with plaque
burden in old PDAPP mice. Furthermore, our line of PDAPP mice showed normal
swimming ability, normal learning in the visible cuetask, and normal object
recognition memory, suggesting that the age-related learning deficit of PDAPP mice
is not due to sensorimotor problems or motivation to learn.
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Chapter 4: A Longitudinal Investigation of Age-related Learning
Deficits in PDAPP Mice.
4.1 Introduction.
4.1.1. The advantages of a longitudinal design for the study of age-related changes in
cognition on APP mice.
Cross-sectional designs have most commonly been used in behavioural explorations
of age-related cognitive deficits in APP Tg mice. Most cross-sectional studies have
been carried out at limited selection of different age points (i.e. 2 to 3 different ages).
For example, Hsiao et al's (1996) study was on Tg2576 mice at 3, 6 and 9-10 months
of age using Y-maze alternation and watermaze reference memory. More recently,
Tg2576 mice were tested at 2 and 9-10 months using a forced choice T-maze task
(Chapman et ah, 1999). Likewise, object recognition, bar press and radial 8-arm maze
tasks were used to test PDAPP mice at 3, 6 and 9-10 months (Dodart et ah, 1999).
It seems that no longitudinal studies on APP Tg mice had been published before 1998.
Although the progression of severity of AD can be evaluated from several cross-
sectional studies of different groups of patients, cross-sectional methods are not the
usual way to study progressive disorders. Clinical trials to evaluate the therapeutic
efficacy of a prospective anti-AD drug are necessarily dependent on longitudinal
studies, as one major setback of the cross-sectional method is that the variance of
individual differences is sometimes huge. A longitudinal study on APP Tg mice could
allow us to test the same mice repeatedly at different stages of development, such that
individual differences have less impact than in a cross-sectional study. It should
provide more reliable information on changes of cognitive performance. Overall,
longitudinal studies on APP Tg mice are essential to the field to validate the transgene
effect on disease progression.
4.1.2. Longitudinal studies on APP Tg mice.
To our knowledge, our group was the first to apply longitudinal methodology to the
study of APP Tg mice (Ramsay and Morris, 1998). Using a longitudinal design,
Ramsay and Morris used a 4 trials/day DMP task in the watermaze to investigate
whether PDAPP mice display an age- or plaque-related learning deficit. PDAPP mice
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were initially tested using a visible cuetask at 4-5 months of age, and then repeatedly
tested by a DMP task at 6 different age points from 5-6 to 19-20 months. The
performance of PDAPP mice in the cuetask was normal. In the DMP task, 5-6-month
PDAPP mice displayed a significant deficit which persisted throughout the whole
testing period in the same mice (Ramsay and Moms, 1998). These findings indicated
that the early deficit seen in spatial learning of PDAPP mice did not progress with age
when the same mice performed the same task. So these findings are consistent with
those observed in PDAPP mice using a cross-sectional design (Justice and Motter,
1997). However, the study was conclusive as the PDAPP mice were severely
impaired. The lack of an age effect may have been due to a ceiling effect.
After our group's first attempts to longitudinally examine PDAPP mice, several
longitudinal studies have been reported on other APP Tg lines later. For example,
Janus et al have reported an age-independent early deficit in TgCRND8 mice using
the standard watermaze reference memory task in an Ap vaccine study (Janus et al.,
2000). In another Ap vaccine study, using a longitudinal design and a radial-arm
watermaze task, Morgan et al have reported that the same APP/PS1 doubly Tg mice
display normal spatial learning at 11 months of age but impaired learning at 15
months (Morgan et al., 2000). Paradoxically, it is possible that age-related learning
deficits of APP/PS1 mice in the radial-arm watermaze are not plaque-dependent, as
11-month mice, which are plaque-rich, are cognitively normal. Using a forced choice
T-maze alternation task, another longitudinal study has been reported on Tg2576 mice
(Barnes et ah, 2001). The same male Tg2576 mice were tested at three different ages.
At four months of age, Tg2576 mice exhibited normal acquisition of the forced-choice
alternation. At 8 months, the same animals displayed a deficit when performing the
same task. This deficit increased in severity at 12 months (Barnes et al., 2001).
Consistent with previous findings from the same group (Chapman et al., 1999), these
results established an age-dependent learning impairment in the Tg2576 mouse model
of AD. However, no data on amyloid plaques were reported.
4.1.3. Purposes of this longitudinal study on PDAPP mice.
As reported in Chapter 3 of this thesis, both age-related and age-independent learning
deficits were simultaneously observed in PDAPP mice in a cross-sectional study using
a modified DMP task. It seemed very interesting to us whether a longitudinal design
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would reveal a similar finding by using the same PDAPP mice. To answer this
question, PDAPP mice were first tested at 6-9 months using several different
behavioural paradigms including cuetask, trials to criterion, object recognition and
learning capacity task. 6-9 months was chosen as the earliest testing age, because it is
a crucial stage for PDAPP mice to first display the formation of amyloid plaques in
the dentate gyrus and hippocampus of the brain (Johnson-Wood et al., 1997). The
same mice were then repeatedly tested using the same behavioural protocols at 14-15
and 21-22 months. In order to avoid as much as the carry-over (practice) effect on the
same mice due to repeated testing, 7-8 months was used as the interval between
different testing phases. At the end stage of this study, synaptic transmission, synaptic
plasticity of the hippocampus and plaque burden of the brain were further examined.
Overall, a longitudinal design allows a direct comparison of performance among
young, middle-aged and old mice while the plaque pathology develops with age, and
also allows a direct correlation study to examine relationships between behavioural
performance, synaptic strength in the hippocampus and amyloid plaques.
4.2 Methods.
4.2.1. The subjects.
PDAPP and non-Tg control mice used in this study were the same 50 young animals
(6-9 months) used in the cross-sectional study of Chapter 3. Tg mice were
heterzygous on a DBA/C57BL/6 double strain background. The mice (PDAPP =25,
non-Tg=25) were first tested at 6-9 months, and later, repeatedly at 14-15 and 21-22
months. The mice were group-housed (2-4 mice each cage). The running sequence
was assigned by Dr. Stephen Martin.
During the long duration of this longitudinal testing (18 months), some animals died.
12 of them (PDAPP=6; non-Tg=6) were sacrificed at 9 months to examine the
pathology for the young groups of the cross-sectional study in Chapter 3. The
following table (Table 1) shows how many mice were alive at three different stages of
testing. Final data analyses were only carried out on 25 mice who completed the
whole behavioural and electrophysiological study (PDAPP =12, non-Tg=13) at 22
months. The mortality of PDAPP and non-Tg mice was 36.84% and 31.58%,
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respectively, during the 18-month testing period. Under the same experimental
conditions, there was no difference of mortality between PDAPP and non-Tg mice
(x2=0.117; df=l; p>0.5; chi-square test).
Age of the Mice Number of the PDAPP Mice Number of the non-Tg Mice
6—9 months 25 25
14—15 months 18 19
21 —22 months 12 13
Table 4.1 The Number of the Mice Completing the Study.
4.2.2. The experimental design.
Figure 4.2.1 Experimental Design.
The experimental design for this longitudinal study is shown in Fig. 4.2.1. PDAPP
and control mice were tested with a battery of 4 different behavioural tasks, including
cuetask, trials-to-criterion, object recognition and learning capacity task at 6-9
months. About six months later, the same mice were tested again with the same tasks,
but the trials to criterion task and learning capacity task were run concurrently, and
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continued for whichever took longer. Old mice were tested at 21-22 months and the
testing protocols were exactly the same as those used for 14-15 months of mice.
Finally, hippocampal synaptic transmission, synaptic plasticity and A(3 plaques of the
mice were investigated at 22-23 months.
4.2.3. The watermaze.
The same watermaze and associated equipment was used as described in Chapters 2
and 3.
4.2.4. Visible cuetask.
For young mice, there were 4 trials/day for 5 days. At two older ages, the duration of
the cuetask was reduced to two days.
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Figure 4.2.2 Two Sets of Ten
Different Platform Locations.
A. Two sets (E and F) for the
middle-aged groups.
B. Two sets (G and F) for the
old groups.
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For young groups, the trials to criterion and learning capacity tasks were run
separately (see Chapter 3). For two older ages, the trials to criterion and learning
capacity tasks were run concurrently. Fig. 4.2.2 shows four sets of 10 different
locations for middle-aged (Sets E and F) and old (Sets G and Fl) animals. At 14-15 or
21-22 months, the animals were required to leam as many problems as they could in
10 days. But if any of them had not learned the first five platform locations within 10
days, they were allowed to take as long as they needed to complete the first five,
which constituted the trials to criterion task. The learning capacity for the animals was
the total number of problems learned in 10 days. A maximum trial number of 32 was
allowed for each animal to learn any one of the first five problems.
4.2.6. Object recognition.
For young animals, five ITIs were used, as described in Chapter 3. For middle-aged
and old groups, only three ITIs were chosen to explore immediate (10 s), short-term
(10 min) and long-term (4 h) object recognition memory.
4.2.7. Slice preparation.
Briefly, 400 /xm thick standard transverse coronal slices were prepared using a
vibroslicer and collected into an incubation chamber (see Chapter 3). About 10
minutes later, two slices were then transferred to the recording chamber.
4.2.8. Electrophysiology.
Slices were allowed to recover in the recording chamber for 80 min. Recording was
performed at 32 ± 1°C. Field EPSPs of CA1 apical dendrites were recorded
extracellularly with a glass electrode filled with 3M NaCl. Two bipolar stimulating
electrodes were placed on either side of the recording electrode. Input-output (I-O)
curves were recorded using 11 different intensities of stimulation (0.2 V, 0.3 V, 0.4 V,
0.5 V, 0.6 V, 0.8 V, 1.0 V, 1.2 V, 1.4 V, 1.6 V and 1.8 V). At each stimulus intensity,
3 fEPSPs were elicited with the mean value of fEPSP slope used for final data
analysis. To measure paired-pulse facilitation (PPF), 4 different interpulse-intervals
(IPIs), 25ms, 50ms, 100ms and 200ms, were exploited. For long-term potentiation
(LTP) experiments, stimuli were delivered by alternating between 2 independent
Schaeffer collateral-CAl pathways, one being the tetanized and the other one being
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the control pathway, at a frequency of 0.067 Hz to each pathway. Stimulation was set
to induce a fEPSP with amplitude of -50% of maximum response. LTP was induced
in the testing pathway by theta-burst stimulation (TBS) of 3 trains (2min intertrain
interval), each consisting of 15 (200ms interstimulus interval (ISI))x4 pulses (100
Hz). Data were collected by software called LTP114J© and stored into a computer.
The initial slope of fEPSP evoked by stimulation of the Schaeffer collateral-CAl
pathway was analyzed online. Responses in each experiment were normalized to
baseline, which was defined as the mean value obtained in at least 20-minute
responses before TBS, and shown as mean±SEM.
4.2.9. Immunocytochemistry and plaque load quantification.
The right hemispheres of 25 mice were fixed in formalin for at least one week. Ms.
Jane Knox then did all immunohistology experiments.
4.3 Results.
4.3.1. PDAPP mice showed normal cuetask learning at all ages tested.
Results for the longitudinal cuetask testing are shown in Fig. 4.3.1. Statistical analysis
revealed no significant genotype or age effect for the same mice (F=0.27, dfl/23,
p>0.6). All PDAPP mice swam as well as the controls at different testing ages,
suggesting that they were normal in cuetask learning.
4.3.2. PDAPP mice displayed normal object recognition memory.
Similar to the findings of Chapter 3, Fig. 4.3.2 shows that both PDAPP and non-Tg
mice displayed comparable performance in this task at all ages tested (F<1). They
explored the novel objects preferentially. The ANOVA revealed gradual forgetting
over 4 h (F = 21.21, df 1.97/23.65, p < 0.001, Greenhouse-Geisser correction), but no
difference between PDAPP and non-Tg mice at any age (F<1). Overall, the mean
performance of both groups was significantly above chance at all retention intervals
(p<0.05, one sample t-test). This indicates that PDAPP mice displayed normal short-
and long-term object recognition memory.
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Figure 4.3.1 Cuetask Performance in PDAPP and non-Tg Mice. There was no
significant difference between the same PDAPP and non-Tg mice at 3 different
ages. A. 6-9 months. B. 14-15 months. C. 21-22 months.
A. 6-9 months. B. 14-15 months. C. 21-22 months.
10 s 10min 4h 10 s 10min 4h 10 s 10min 4h
Retention intervals Retention intervals Retention intervals
Figure 4.3.2 Normal Object Recognition Memory in PDAPP Mice. PDAPP
and non-Tg mice showed equivalent performance for three age groups (F < 1).
A. 6-9 months. B. 14-15 months. C. 21-22 months.
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4.3.3. PDAPP mice displayed age-related deficits in spatial learning.
I. Age-related learning deficit ofPDAPP mice in trials to criterion task.
Fig. 4.3.3 shows the performance by the same PDAPP and non-Tg mice at different
ages. Analysis of variance first revealed a significant main transgene effect in this
longitudinal study (F=10.36, df1/23, p<0.005), indicating that PDAPP mice were
impaired in this trials to criterion task. The ANOVA further revealed a significant
genotype x age effect (F=8.86, df1.48/34.01, p<0.003), reflecting the age-related
impairment of spatial learning in PDAPP mice. Moreover, separate analyses of
variance for both PDAPP and non-Tg mice showed significant age-related worsening
of performance in PDAPP groups (Fig. 4.3.3 D: F=20.02, dfl.39/15.3, p<0.001) and,
though smaller in non-Tgs as well (Fig. 4.3.3 D: F=5.59, dfl.73/20.72, p<0.05). In
contrast to the finding of a small but a detectable deficit in learning in young PDAPP
mice from my previous cross-sectional study (Chapter 3), the subset of 12 PDAPP
mice, who successfully survived and completed the longitudinal study of the original
25, were unimpaired at 6-9 months (Fig. 4.3.3A and Fig. 4.3.3D: F=1.53, df1/23,
p>0.2). However, these same PDAPP mice did significantly differ from the age-
matched non-Tgs at the two older age points (for 14-15 months: Figs. 4.3.3B and
4.3.3D: F=5.79, dfl/23, p<0.05; for 21-22 months: Figs. 4.3.3C and 4.3.3D: F=19.16,
df1/23, p<0.001, respectively).
In contrast with what I have observed in the middle-aged PDAPP mice of the cross-
sectional study (Fig. 3.3.3B, Chapter 3), Figure 4.3.3B shows that the middle-aged
PDAPP mice did not display deficit in learning the first platform location. The
longitudinal set of animals had been trained with 15 different locations in the
watermaze at 6-9 months of age and had learned the procedural aspects of the task.
The findings which they displayed deficit on platforms 2 to 5 at 14-15 months but not
on platform 1 suggest that changing a memory representation is particularly difficult
in middle-aged PDAPP mice.
108








Figure 4.3.4 Representative Swim Paths. Representative swim paths taken
from a non-Tg and PDAPP mouse at 6-9, 14-15 and 21-22 months of age on
problem 5 (the same mice). A. 6-9 months. B. 14-15 months. C. 21-22 months.
p< 0.002 □PDAPP
■ Non-Tg
Figure 4.3.5 Age-related Learning
Deficits in PDAPP Mice.
There was a significant age-related
impairment of iearning capacity in
PDAPP mice. The same PDAPP mice
learned equivalent number of platform
locations to that by the controls at
young age, but showed significant
impairment from the age-matched
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Figure 4.3.4 shows the swim paths taken by two representative animals (1 non-Tg, 1
Tg) in the longitudinal study on learning location 5 at all ages. The same PDAPP
mouse reached the performance criterion (the criterion trials were labelled CI to C3)
as quickly as the control (4 trials) at young age. As these two mice got older, the same
PDAPP mouse displayed more circuitous paths and took 12 and 19 trials to learn the
fifth problem at 14-15 and 21-22 months, but the same non-Tg mouse learned the
same problem using 4 and 6 trials at 14-15 and 21-22 months. Figure 4.3.4 also shows
that the PDAPP mouse occasionally displayed short paths (i.e. trials 4, 10 and 14), but
was unable to do a series of short paths easily. Interestingly, the swim paths taken by
this old PDAPP mouse were comparable to those by old PDAPP mice described in
Chapter 3 for the cross-sectional study.
II. Age-related learning deficit ofPDAPP mice in learning capacity task.
Although the learning capacity task is similar to the trials to criterion, it measures a
slightly different aspect of learning ability of the mice. An age-related learning deficit
in PDAPP mice was again observed using this task (Fig. 4.3.5). First, the ANOVA
revealed a significant main effect of genotype (F=8.84, df1/23, p<0.01). Second, it
also revealed a significant genptype x age interaction (F=6.83, df1.75/40.32, p<0.01;
Greenhouse-Geisser correction). This interaction allowed a separate analysis of two
different groups. In non-Tg groups, no significant age-related decline was observed
(Fig. 4.3.5: F=1.66, dfl.67/20.01, p>0.2), by contrast, in PDAPP groups, a significant
decline of learning capacity was found (Fig. 4.3.5: F=18.30, dfl.80/19.79, p<0.001).
The results on learning capacity strongly suggested that the decline of learning
capacity of PDAPP mice progressed significantly with age whereas that of non-Tg
mice showed only a trend.
Three further ANOVAs were conducted at the separate ages. At 6-9 months, no
significant difference of learning capacity between PDAPP and non-Tg mice was
found (Fig. 4.3.5: F<1). The same PDAPP mice did differ from the same non-Tgs at
14-15 months of age (Fig. 4.3.5: F=5.57, dfl/23, p<0.05). At the oldest age (21-22
months), a highly significant difference was found between PDAPP and control mice
(Fig. 4.3.5: F=13.94, dfl/23, p<0.002).
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Figure 4.3.6 Impaired Basal Synaptic Transmission in PDAPP Mice.
Input-output curves for aged PDAPP and non-Tg mice (22-23 months). There was
a significant main genotype effect (p<0.001). Inset: Two responses (waveforms)
from a PDAPP and Non-Tg hippocampal slice (about half maximum size of fEPSP
by 1.0 V stimulation intensity).
A. Traces for paired-pulse facilitation.

































Figure 4.3.7 Normal Synaptic Plasticity in 22-23 Months PDAPP Mice.
A. Waveforms of fEPSPs for paired-pulse facilitation (PPF) in PDAPP and
non-Tg mice. B. There was no difference on PPF between PDAPP and
non-Tg mice. C. Waveforms of fEPSPs before (light curves) and 2 h after
(solid curves) tetanization in PDAPP and non-Tg mice. D. Normal hippocampal
long-term potentiation (LTP) in PDAPP mice 1 or 2 h after tetanization.
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4.3.4. Old PDAPP mice exhibited an altered synaptic transmission.
Hippocampal slices were taken from the mice longitudinally tested to investigate
basal synaptic transmission and synaptic plasticity of the Schaeffer collateral CA1
area. First, the input-output curves were recorded using several different intensities of
stimuli. Aged PDAPP mice displayed much smaller field EPSPs in area CA1 than
non-Tg controls (Fig. 4.3.6: F=29.93, dfl/17, pcO.OOl).
Two different forms of synaptic plasticity, short- and long-term, were further
investigated in aged PDAPP mice. Paired-pulse facilitation (PPF) belongs to a short-
term form of synaptic plasticity. Using several different interstimulus intervals,
including 25, 50, 100 and 200 ms, PPFs were induced and shown in Figure 4.3.7. The
representative responses (fEPSPs) from non-Tg and PDAPP mice are shown in Figure
4.3.7A. No significant difference of PPF between non-Tg and PDAPP mice was found
(F<1; Fig. 4.3.7B). PPF at 50 ms ITI showed the biggest ratio among all tested ITIs in
both PDAPP and non-Tg groups (Fig. 4.3.7B).
Early- and mid-phase of hippocampal LTP was also investigated in slices from aged
PDAPP mice (Fig. 4.3.7C+D). Figure 4.3.7C shows representative traces from both
PDAPP and non-Tg mice. Interestingly, there was no significant difference of
hippocampal LTP between these two groups (Fig. 4.3.7D: ps > 0.8, student's T-test, at
1 h and 2 h post-tetanization).
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A. Control mouse.



























Figure 4.3.8 Amyloid Plaques in the Brain of PDAPP Mice.
A. 3D6 staining of a control mouse (age: 22 months).
B. 3D6 staining of a PDAPP mouse (age: 23 months).

























Figure 4.3.9 Significant Correlation between Basal Synaptic Transmission and
Behavioural Performance. A. Significant correlation between the medium size of
fEPSPs (stimulation intensity=1.0V) of the hippocampus and trials to criterion on
location 5 in 22-23 months PDAPP mice. B. Significant correlation between the
medium size of fEPSPs of the hippocampus and learning capacity in PDAPP mice.
r = -0.65
p < 0.05
Correlation between fEPSP slope and B. Correlation between fEPSP slope
trials to criterion on location 5. and learning capacity.
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4.3.5. Significant correlation between synaptic transmission and behavioural
performance.
In this longitudinal study, PDAPP mice displayed deficits on both basal synaptic
transmission and behavioural performance on the trials to criterion and learning
capacity task. This allowed an examination of possible relationships between the
reduced synaptic transmission and impaired learning in individual PDAPP mice. First,
a significant negative correlation was observed between the medium size of fEPSPs
and the number of trials to reach criterion on platform location 5 (r=-0.65, p<0.05;
Fig. 4.3.9A). Second, a significant positive correlation of the medium size of fEPSPs
to learning capacity (r=0.65, p<0.05; Fig.4.3.9B) was also observed. Analysis of
plaque burden in the hippocampus of PDAPP mice by Jane Knox indicated that about
52.69% area of the hippocampus was occupied by amyloid plaques (Fig.4.3.8).
Flowever, no significant correlation between plaque burden in the hippocampus and
behavioural performance was found in this longitudinal study (ps>0.1, for both trials
to criterion and learning capacity).
4.4 Discussion.
The purpose of this longitudinal study was to use a within-subjects design to test the
same mice repeatedly at different age points. One important advantage of this design
over the most commonly used cross-sectional study in behavioural neuroscience is
that it cuts down data noise. For example, the cross-sectional study showed that
individual differences in performance on the trials to criterion and learning capacity
was large, varying from 3 to 32 trials (trials to criterion) and 2 to 10 (learning
capacity) in individual mice. This huge individual difference brings considerable
noise into the results of between-subjects (cross-sectional) study. The main findings
of this longitudinal study were that a subset of PDAPP mice also display an age-
related learning deficit in the serial spatial learning task, but normal learning in the
visible cuetask and unimpaired object recognition memory.
The above results essentially replicate those of my previous cross-sectional study,
further validating the claim for an age-related learning deficit in PDAPP mice. These
may be strong evidence to support the amyloid cascade hypothesis which suggests the
central role of A(3 accumulation or deposition in the progression of AD (Hardy and
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Allsop, 1991). In some way, findings from this longitudinal study are analogous to
those of Barnes et al who have reported that Tg2576 mice display an age-related
deficit in a forced choice T-maze alternation, using a similar longitudinal design
(Barnes et al., 2001). The earliest age point in Barnes et al study was 4 months,
whereas in my study, it was 6-9 months. Interestingly, these two different longitudinal
studies indicated that young PDAPP mice and young Tg2576 mice can be normal in
the respective tasks, suggesting that overexpression of APP may not be as important
as the gradual accumulation of AP amyloid plaques in causing learning impairment of
APP Tg mice.
One major disadvantage of the longitudinal design was that, as the same animals were
tested repeatedly with the same behavioural tasks, their performance at later age
points may improve, possibly through a practice effect (Winer et al., 1991). Due to the
carry-over effect in the longitudinal design, the worsening in performance of the
PDAPP group in the trials to criterion and learning capacity may not be a foregone
conclusion, as any age-related decline of spatial learning may have been compensated
by practice effects carrying over from one testing period to another. It is perhaps
noteworthy that in non-Tg animals, a significant aging effect is apparent in the cross-
sectional experiments when they were tested for the first time at different ages.
Therefore, an aging effect in non-Tgs was less apparent in the longitudinal study
(Figs. 4.3.3 and 4.3.4). This might be due to practice effect overcoming a small aging
effect.
However, some differences were observed between the cross-sectional and
longitudinal studies. One was that learning deficits on the trials to criterion and
learning capacity were found in young PDAPP mice in the cross-sectional study, but
not in the longitudinal one. More specifically, the 25 young PDAPP mice (6-9
months) in the cross-sectional study were impaired (Chapter 3: Fig. 3.3.3 and Fig.
3.3.4), but the subset of 12 PDAPP who survived a 18-month testing period did not
differ from the age-matched non-Tg controls at 6-9 months. Statistical analysis
showed that the initial performance of these 12 PDAPP mice was significantly better
than that of the original 25 in the trials to criterion (F=7.55, df1/35, p<0.01), whereas
the performance of 13 non-Tg mice was not different from that of the original 25
(F<1, P > 0.9). It is possible that PDAPP mice with better learning ability can live
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longer, to put it another way, or demented mice with worse learning ability have
shorter life span. However, the PDAPP group did not show higher mortality during
the duration of this study than non-Tgs. Due to the death of several cognitively
impaired PDAPP mice before the end of the study, a sampling bias may have been
introduced that accounts for the entire effect.
Using in vitro slice electrophysiology techniques, aged PDAPP mice were found to
show impaired basal synaptic transmission but normal short- and long-term synaptic
plasticity (PPF and LTP) in the hippocampus. These findings are consistent with
previously published reports on either PDAPP or Tg2576 mice (Hsia et al., 1999;
Larson et al., 1999; Fitzjohn et al., 2001). However, Tg2576 mice were also reported
by Chapman et al. (1999) to be unimpaired in basal synaptic transmission in CA1 area
of the hippocampus. The reasons for the discrepancy are really unknown. One
possible reason for this is that Chapman et al (1999) used kynurenate during slicing
procedures. It has been suggested that hippocampal slices from APP Tg mice are
more susceptible to trauma, and that using kynurenate in the dissection ACSF can
improve slice viability (Fitzjohn et al., 2001). Indeed, Fitzjohn et al. (2001) have
reported that kynurenate rescues impaired basal synaptic transmission in 12-month-
old, but not 18-month-old TG2576 mice. As the mice used in this longitudinal study
were about 23 months old, kynurenate was not used in the dissection medium. But it
seems likely that the inclusion of kynurenate in the slice preparation may not be able
to improve the impaired synaptic responses in very old PDAPP animals (>23 months).
Nevertheless, my data here are very consistent with those by Hsia et al (1999) who
used the H6 line expressing the same APPind and by Larson et al (1999) who have
used the PDAPP mice. However, both Hsia et al (1999) and Larson et al (1999) have
demonstrated that, like very old mice, very young (2-4 months) H6 or PDAPP mice
also display significantly reduced synaptic responses. As there is no apparent plaque
deposition at this age (<6 months), elevated levels of soluble A(3 may be accounted
for the observed effects on basal synaptic transmission.
As behaviour, electrophysiology and histology studies were combined to examine the
same PDAPP mice, this allowed further correlation analyses to explore the
relationship between synaptic transmission, amyloid plaques and spatial learning.
Another main finding of this longitudinal study was the significant correlation
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between reduced hippocampal synaptic transmission and behavioural performance of
PDAPP mice. For example, significant correlations were observed between fEPSPs
and trials to criterion, and between fEPSPs and learning capacity. Although the
correlation coefficients were not very high (r=0.65 for fEPSPs and trials to criterion;
r=-0.65 for fEPSPs and learning capacity), they were significant. The significant
correlation between reduced fEPSPs and impaired behavioural performance suggested
a possible cellular mechanism to explain the impaired learning of PDAPP mice, that
is, overproduction of Ap plaques damages the circuits of several neuron systems in
the hippocampus and cortex, and therefore disrupted learning of these mice.
Unlike our previous cross-sectional study, learning deficits in aged PDAPP mice were
not correlated with plaques burden in this study. Plaque burden, quantified by Jane
Knox, was 52.69% ± 2.20% in the hippocampus. Compared to 14.46% ± 2.28% of
plaque burden for old PDAPP mice in the cross-sectional study, the difference was
highly significant (F=137.19, dfl/15, p<0.001). Very high amount of plaque burden in
aged PDAPP mice for the longitudinal study may preclude any potential correlation
analysis with behavioural performance. It remained unknown why these 12 PDAPP
mice (22-23 months) had developed so high levels of plaque burden in the brain.
Overtraining of the same PDAPP mice using a longitudinal design may accelerate the
deposition of A(3 plaques. It remains unclear whether this is true or not.
The practice effects are one type of carry-overs which are potential extraneous
variables to the present study. It has been suggested that the confounding carry-over
effects could be reduced by counterbalancing (Kinnear and Gray, 2000). Indeed, in
the trials to criterion and learning capacity task of this study, all platform locations
used for the different age groups were counterbalanced as much as I could. Although
the counterbalancing procedure might help to reduce the carry-over effects to a very
low level, it still exists in this study. For example, in the trials to criterion, after
comparing the performance for the two older age groups (middle-aged and old) from
the cross-sectional and longitudinal study, a significant difference between these two
designs was observed (F=4.26, df1/91, p=0.042), indicating that the overall
performance of all old PDAPP mice in the longitudinal study was better than that in
the cross-sectional one. However, analysis of learning capacity for the two old age
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groups in the longitudinal and cross-sectional study revealed no such carry-over effect
(F<1). This suggests that the trials to criterion task is more sensitive to show carry¬
over effects than the learning capacity.
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Chapter 5: Investigation of the Effects of Ap Vaccines on Spatial
Learning and Synaptic Transmission of PDAPP Mice.
5.1 Introduction.
5.1.1. The importance ofA/1 immunotherapy.
Most FDA-approved anti-AD drugs are cholinergic inhibitors that, while helpful for
attention and memory show modest or no effects on the progression of AD. As Ap
abnormal accumulation and plaque deposition are believed to play a central role in
neurodegeneration and dementia of AD, Ap has become the most important molecular
target for the treatment of AD. The results reported in the previous two chapters are
consistent with this emphasis given the correlations with plaque deposition observed.
Novel vaccine concept for the treatment of AD first appeared in 1999 from Schenk
and colleagues who reported that plaques in PDAPP mice can be completely removed
when Ap vaccines are administered at 2 months of age for 11 months; and
significantly reduced when AP vaccines are administered at 11 months of age for 7
months (Schenk et al 1999). This groundbreaking study raised the possibility that an
active Ap vaccine might be a novel therapeutic method for AD. It also suggested that
agents which can prevent AP production and accumulation, such as P-, y-secretase
inhibitors and Ap blockers (antibodies), might eventually have potential clinical
benefit for the treatment of AD.
AP immunotherapy has since received widespread attention. Using passive
immunisation and PDAPP mice, two independent groups at Elan and Lilly have
explored why Ap immunotherapy works in animals. One study from Elan suggests
that AB vaccines can stimulate the immune system to fight Ap and remove the pre¬
existing plaques. For example, Bard et al examined passive immunization of PDAPP
mice. They reported that Ap antibodies can cross the BBB, enter the CNS, bind to
plaques, activate microglial cells and finally clear plaques (Bard et al 2000). Another
hypothesis about a possible mechanism of Ap immunotherapy is called the peripheral
AP sink theory (DeMattos et al 2001). Using passive immunisation, DeMattos et al
have found that m266, an Ap monoclonal antibody, induces a rapid 1000-fold
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increase in plasma A(3 in PDAPP mice. This increase may be caused by a change in
A(3 equilibrium between the CNS and plasma, suggesting that m266 antibodies have
removed A(3 deposits from the brain by altering the equilibrium of AP between brain,
CSF and plasma.
After the first AP vaccine study on PDAPP mice was published in 1999, Elan started a
Phase 1 clinical trial of AN-1792 (the AP vaccine). Results from the Phase 1 clinical
trial looked promising in a small number of participants, as AN-1792 was apparently
safe and well tolerated by these people (Schenk 2002) (but see a case report (Nicoll et
al 2003)). After the success of the Phase 1 trial, AN-1792 has gone to Phase Ha
clinical trial, in which much more patients around the world have been involved.
However, a serious side effect of meningoencephalitis has recently been observed in a
very small proportion of the participants in the Phase Ha trial, so all study dosing was
halted in January 2002 (Schenk 2002). It remains unknown why this side effect
occurred.
5.1.2. Preclinical evidence for A/3 immunotherapy.
Early preclinical studies on the effects of Ap vaccines on learning and memory of
APP Tg mice were very positive.
In one study, TgCRND8 mice, which express a mutant human APP695 gene
harbouring both the Swedish and Indiana mutations, were immunized at 6, 8, 12, 16
and 20 weeks (Janus et al 2000). A longitudinal design was employed to repeatedly
test these mice at 11, 15, 19 and 23 weeks of age using the standard watermaze
reference memory task. The data were analyzed using a mixed model analysis of
variance, with immunogen (AP vs IAPP) and genotype (TgCRND8 vs non-Tg) as
between-subject factors, and age as a within-subject factor. The AP-vaccinated Tg
mice performed significantly better than IAPP-treated Tg mice in the acquisition
training, although AP-vaccinated TgCRND8 mice were still significantly worse than
non-Tg controls (Janus et al 2000). A significant reduction of AP deposits was also
observed in Ap-vaccinated Tg mice. Thus, an AP vaccine can produce a partial rescue
effect in TgCRND8 mice. However, the authors did not observe any main genotype or
immunisation effects in post-training probe tests, as the TgCRND8 Tg mice displayed
120
Guiguan Chen's PhD Thesis.
relatively normal reference memory. The impact of the vaccine seemed to be largely
restricted to performance effects during training.
The effects of active AP vaccination on learning of PS1/APP double transgenic mice
were investigated by a different group using a novel radial-arm watermaze (Morgan et
al 2000). It is suggested that this task is very sensitive to detect plaque-related
learning deficit and is more efficient in sample size requirements than the normal
watermaze task. A longitudinal design was used and untreated non-Tg, AP-vaccinated
or KLH (keyhole limpet haemocyanin, a control peptide)-vaccinated Tg mice were
tested first at 11.5 months of age. All three groups displayed good learning. After five
monthly inoculations of either Ap or KLH, the same animals were re-tested at 15.5
months. Interestingly, although KLH-vaccinated Tg mice now failed to learn this task,
non-Tg and Ap-vaccinated Tg mice learned it very well, suggesting a significant Ap
vaccination effect. Unexpectedly, there were no effects of the Ap vaccine on plaque
burden in the AP-vaccinated Tg mice, so the improved learning of AP-vaccinated
PS1/APP double Tg mice was explained in terms of reduced levels of soluble Ap in
the brain (Morgan et al 2000). This explanation can not be the whole story, as 11.5-
month-old PS1/APP Tg mice displayed high levels of soluble Ap and Ap plaques, and
showed normal spatial learning in the radial-arm water maze. A further puzzling
feature of this study was the very small group sizes (Morgan et al 2000).
Recently, effects of passive Ap immunisation on object recognition memory of
PDAPP mice was explored (Dodart et al 2002). In this study, m266, an Ap specific
monoclonal antibody, was first administered into 24-month-old PDAPP mice for six
weeks, once a week. The authors reported that the impaired object recognition
memory in PDAPP mice is reversed by the administration of m266. Furthermore,
m266 was also acutely injected into 11-month PDAPP mice, and the mice were then
tested 24 hours later. It was observed that m266-treated PDAPP mice displayed a
comparable level of object recognition memory to that of non-Tgs, although PBS-
treated PDAPP mice displayed chance performance. Plaque burden was unaffected by
the treatment of m266 in these two studies, however, and the level of plasma AP40
and AP42 was significantly increased as compared to PBS-treated PDAPP mice. It
was suggested that the rescued object recognition memory in m266-treated animals
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was associated with the cerebral clearance of AP40 and A|342, as increased plasma
concentrations were observed.
5.1.3. Purpose of this A/3 vaccine study.
The preclinical studies discussed above brought a huge optimism to AP
immunotherapy. On the other hand, the importance of amyloid plaques to dementia
and cognitive impairment of AD may have been challenged by studies from Morgan
et al and Dodart et al, as both of them clearly indicate that Ap immunotherapy can
significantly improve learning or memory of APP Tg mice without effect upon
amyloid plaques.
Although the preclinical findings discussed above are extremely exciting, they have
not answered several fundamental questions. First, in Janus et al's study, as only very
young (23 weeks of age) animals were tested, it is possible that an AP vaccine may
only partially rescue learning in APP Tg mice at early stage of life. In this study, the
biggest rescue effect of Ap vaccines can be seen as early as 11 weeks of age. As
TgCRND8 mice have not developed any plaques at this age (Figure 2b of Janus et al),
it clearly suggests that AP vaccines have effects on plaque-independent or soluble AP-
dependent processes. It is unknown whether the same animals would display any
significant rescue effects at much older age. It also remains unknown whether Ap
vaccines will show any effects on spatial learning when vaccinated at an older age, at
which many plaques have developed in the brain. Second, although Morgan et al
observed a rescue of the learning impairment in PS1/APP mice by active Ap
immunisation, plaque burden was unaffected at all. Paradoxically, the spatial learning
deficit of PS1/APP mice has been claimed to be plaque-related by these same authors
(Morgan et al 2000). If so, why should not we see any change in plaque burden in the
cognitively improved Tg mice induced by AP vaccines?
Three fundamental questions related to potential clinical treatment of AD with active
AP vaccination were addressed in this study: first, can Ap vaccination rescue the
plaque-related learning deficits in PDAPP mice using the trials to criterion and
learning capacity task? Second, can it improve the AP-independent learning deficit in
PDAPP mice? Third, can it have any impacts on plaque burden and soluble Ap
levels? Therefore, two separate AP vaccination experiments were designed. In
122
Guiauan Chen's PhD Thesis.
Experiment 1, Ap immunisation started in PDAPP mice at 11 months and lasted for 5
months. As Ap plaques were already seen in the brain at this age, this design is then
called the 'plaque treatment' study. In Experiment 2, PDAPP mice were immunised at
7 months for 9 months. As only few plaques can be detected in the brain at 7 months,
this design is called the 'plaque prevention' study. After treatments with AN-1792,
spatial learning was examined using the trials to criterion and learning capacity task.




All mice were non-white heterozygous males, on a Swiss Webster/DBA/C57BL6
triple strain background. In the treatment study, total 84 mice were tested (PDAPP
vaccinated, n=24; PDAPP vehicle, n=19; non-Tg vaccinated, n=22; non-Tg vehicle,
n=22). In the prevention study, total 73 mice were tested (PDAPP vaccinated, n=18;
PDAPP vehicle, n=20; non-Tg vaccinated, n=20; non-Tg vehicle, n=15). The mice
were group-housed (2-4 mice each cage). The experimenter was blind to both
genotype and vaccine status.
5.2.2. The watermaze.
The watermaze and escape platform were as used previously.
5.2.3. The experimental design.
Two studies, 'treatment' and 'prevention', were designed. The mice first received Ap
vaccinations for either 5 months (treatment study) or 9 months (prevention study).
Due to commercial reasons, the vaccination treatments for all mice were conducted in
Elan Pharmaceuticals at San Francisco. After the treatment, all mice were shipped to
Edinburgh. After one week of habituation in the lab, the mice first underwent a 5-day
cuetask, followed by the concurrent trials to criterion and learning capacity task,
which took 10-20 days (Fig. 5.2.1). Due to the large animal numbers in the two
studies, there was insufficient time to do the object recognition task. After the serial
spatial learning task was completed, all animals were subjected to in vitro slice
electrophysiology and ELISAs for Ap quantification.
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Figure 5.2.1 Experimental Design.
5.2.4. Ap vaccination of PDAPP mice.
Although AP immunisation procedures were conducted in Elan Pharmaceuticals by
our collaborators, they are described as follows. Ap peptide was freshly prepared from
lyophilized powder for each set of injections. For Ap immunisations, 2mg human
Ap42 (US Peptides) was added to 0.9 ml deionized water and the mixture was
vortexed to generate a relatively uniform suspension. A 100-ml aliquot of 10 x PBS
(where 1 x PBS is 0.15M NaCl, 0.01M sodium phosphate, pH 7.5) was added. The
suspension was vortexed again and incubated overnight at 37 °C for use the next day.
The control immunogen was MPL-AF, a common mixed adjuvant to help elicit the
immune response for B-cells in vaccinations. AP42 or MPF-AF peptides (lOOmg
antigen per injection) were emulsified 1:1 (v/v) with complete Freund's adjuvant for
the first immunisation, followed by a boost in incomplete Freund's adjuvant at 2
weeks, and monthly thereafter. AP42 or MPF-AF in PBS alone was injected from the
fifth immunisation onward. Titres were determined by serial dilutions of sera against
either aggregated AP42 or MPL-AF which had been coated onto microtitre wells.
Detection used goat antimouse immunoglobulin conjugated to horseradish peroxidase
and slow-TMB (3,30,5,59-tetramethyl benzidine; Pierce) substrate. Titres were
defined as the dilution yielding 50% of the maximal signal.
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5.2.5. Visible cuetask.
There were 5 days, 4 trials per day, and platform location was changed across trials.
5.2.6. Trials to criterion and learning capacity task.
Prob. 1 Prob. 2 Prob. 3 Prob. 4 Prob. 5 Prob. 6 Prob. 7 Prob. 8 Prob. 9 Prob.10
"'OOOOOOOOOO
-oooooooooo
Figure 5.2.2 Platform Location Design. For counterbalancing reason, two
sets of 10 platform locations were designed to test spatial learning of the mice.
Half of the animals were trained by Set A, and the other half by Set B.
The trials to criterion and learning capacity tasks were concurrently conducted in both
the treatment and prevention studies, whichever took longer. Figure 5.2.2 shows two
sets of 10 different locations.
5.2.7. Electrophysiology.
The standard transverse slice was made using the same procedure described in
Chapters 2 and 4. Input-output (1-0) curves were induced using 18 different
intensities of stimulation (0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6, 1.8, 2, 10, 20, 30, 40, 50,
60, 80 and 100 V). At any intensity of the stimuli, 2-3 fEPSPs were elicited. Due to
the limited time available, only hippocampal synaptic transmission of the mice was
examined, and LTP experiments for 180 mice could not be performed.
5.2.8. Tissue preparation and ELISA analysis of Ap.
Briefly, three brain areas, including the cerebellum, hippocampus and cortex, were
dissected and put into ice cold pre-weighed tubes. 5M guanidine buffer was added to
each tube and the tissue was completely homogenized with a hand-held homogenizer.
ELISA analysis of Ap on all samples was conducted in Elan Pharmaceuticals and the
methods for ELISA were described in Chapter 2.
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5.3 Results.
1. AP vaccination did not affect normal cuetask learning of PDAPP mice.
Statistical analysis revealed no significant vaccination effects in either the treatment
or prevention study (F<1; Fig.5.3.1). Interestingly, an early deficit of PDAPP mice on
day 1 was observed in both the treatment and prevention studies (For the former:
F=20.48, df 1/80, p<0.001; for the latter: F=8.47, df 1/69, p<0.01), indicating that
PDAPP mice took much longer to approach the platform on day 1. However, after day
1, as all AP42- or MPL-AF-treated PDAPP mice learned this task to a comparable
level to that of non-Tgs, PDAPP mice displayed no obvious deficit in sensorimotor
function.
2. Ap vaccinations did not improve learning deficits of PDAPP mice using the trials
to criterion task.
Figure 5.3.2A (performance on individual platforms) and 2B (mean trials to criterion
across five locations) show the performance of AP42- and MPL-AF-treated PDAPP
and non-Tg mice in learning five different platform locations of the trials to criterion
task for the treatment study. ANOVA revealed a main transgene effect (F=28.17,
df1/80, p<0.001), but no vaccine effect (F<1).
Similarly, Figure 5.3.2C and 2D show the trials to criterion in the prevention study.
Again, ANOVA revealed only a main transgene effect (F=8.87, df1/69, p<0.01) but
no vaccine effect (F<1). These data indicated that Ap immunisation of PDAPP mice
with AP vaccines for either 5 months or 9 months did not improve impaired spatial
learning.
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Figure 5.3.1 Effects of Aft Vaccines on Cuetask Performance of PDAPP Mice.
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Figure 5.3.2 Effects of Aft Vaccines on Trials to Criterion of PDAPP Mice.
A. There was a significant genotype effect but no vaccination effect on trials to
criterion in the treatment study. B. Mean trials to criterion in the treatment study.
C. There was a significant genotype effect but no vaccination effect on trials to
criterion in the prevention study. D. Mean trials to criterion in the prevention study.
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3. AP vaccinations did not rescue learning deficit of PDAPP mice in the learning
capacity task.
The effects of AP vaccines on spatial learning of PDAPP mice were further examined
using the learning capacity task. Figure 5.3.3 shows the results for both the treatment
and prevention study using AP vaccine or a control immunogen, MPL-AF. In terms of
total number of platform locations learned in 10 days, AP42- and MPL-AF-treated
PDAPP mice were significantly impaired as compared to non-Tg mice (Treatment
study: F=40.58, df 1/80, p<0.001; Prevention study: F=12.58, df 1/69, p<0.01).
However, no vaccination effects were found in two studies (Treatment study: F<1;
Prevention study: F<1). These results clearly indicated that, short-term (5 months) or
long-term (9 months) treatment of AP vaccines did not show any significant effects on
impaired learning capacity of PDAPP mice.
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Figure 5.3.3 Effects of All Vaccines on Learning Capacity of PDAPP Mice.
A. There was a significant genotype effect but no vaccination effect on learning
capacity in the treatment study.
B. There was a significant genotype effect but no vaccination effect on learning
capacity in the prevention study.
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4. AP vaccines did not improve deficit of synaptic transmission of PDAPP mice.
The effects of Ap vaccination on synaptic transmission of PDAPP mice were
investigated using the same animals behaviourally tested. Input-output curves were
recorded from hippocampal slices of all mice. Figure 5.3.4 shows the I-O curves for
the treatment and prevention study. In both studies, Ap42- and MPL-AF-treated
PDAPP mice exhibited significantly decreased fEPSP slope (Treatment study:
F=70.90, df 1/75, pcO.OOl; Prevention study: F=19.44, df 1/60, p<0.001), but no
vaccination effects were observed (F<1, for both the treatment and prevention
studies).
Finally, as significant correlations between synaptic transmission in the hippocampus
and behavioural performance have been reported in Chapter 4, a rank correlation
analysis was then conducted between the sizes of fEPSPs slope of hippocampal slices
and learning capacity of PDAPP mice. Significant correlations were again observed
(Figure 5.3.5). Figure 5.3.5A shows the significant correlation between maximum
fEPSP and learning capacity in PDAPP mice for the treatment study (r=0.379,
p<0.02). Figure 5.3.5B shows the correlation between maximum fEPSP and learning
capacity in PDAPP mice for the prevention study (r=0.367, p<0.03). When all
PDAPP mice from these two studies were combined together, the correlation between
maximum fEPSP and learning capacity was again highly significant (r=0.411,
pcO.OOl).
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Figure 5.3.4 Effects of Aft Vaccines on Basal Synaptic Transmission of
16-17 Months PDAPP Mice. A. Input-output curves for the treatment study. There
was only a significant genotype effect but no vaccination effect (F<1). B. Input-output
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Figure 5.3.5 Significant Correlation between Basal Synaptic Transmission and
Behavioural Performance. There was a significant correlation between the maximum
size of fEPSP of the hippocampus and learning capacity of PDAPP mice in the
treatment study (A), the prevention study (B) and the combined treatment and prevention
study (C).
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5.4 Discussion.
1. Afi immunisation failed to improve cognition and synaptic transmission, but
improved pathology ofPDAPP mice.
Using a short-term treatment (5 months) or a long-term prevention (9 months) design,
the effects of Ap immunisations on spatial learning of PDAPP mice were examined in
this study using the trials to criterion and learning capacity task. The treatment and
prevention studies indicated that AP-vaccinated PDAPP mice did not show any
improvement on learning a series of different platforms in the watermaze, no matter
when the AP immunisation started (either at 7 or 11 months), and no matter how long
the treatment lasted (either at 5 or 9 months). Furthermore, electrophysiology data
also showed no rescue effects on the reduced synaptic transmission of PDAPP mice in
both studies.
After behavioural and electrophysiology experiments were completed, brain tissues
were processed and ELISAs was conducted by our collaborators at Elan to examine
whether Ap vaccines reduced pathology of the same mice behaviourally tested.
Interestingly, Ap vaccines seemed reasonably effective in reducing total AP levels in
the brain. Table 1 has listed the AP42 levels in the brain of Ap- or MPL-AF-treated
PDAPP mice. ELISA results from Elan indicated that AP vaccines significantly
reducd AP42 levels in PDAPP mice (F=26.3, df 1/73, p<0.0005). As reported
previously, 9-month Ap immunisation of PDAPP mice in the prevention study
produced significantly lower levels of AP42 than 5-month immunisation in the
treatment study (F=8.0, df 1/73, p<0.01). Flowever, significant reductions of AP42 did
not show any benefit to PDAPP mice in performing the trials to criterion and learning
capacity task. These results thus suggest that Ap42 vaccines might only be effective to
improve AD-like pathology but not impaired cognition of APP Tg mice.
Units = ng/gm Non-vaccinated PDAPP Vaccinated PDAPP % of decrease
Treatment Ap42 = 6902 +/- 562 Ap42 = 3778 +/- 631 45.26%
Prevention Ap42 = 5219 +/- 771 Ap42 = 1927 +/- 387 63.08%
Table 5.1 Reduction of Ap42 in Ap-vaccinated PDAPP Mice. 5-month
treatment of AP vaccines produced 45.26% of Ap42 reduction in PDAPP mice; however, 9-
month treatment produced 63.08% of AP42 reduction.
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2. Task sensitivity.
The failure of AP vaccines to improve the impaired learning of PDAPP mice, using a
treatment and a prevention design, may also raise a question of the sensitivity of the
trials to criterion and learning capacity tasks, as our findings are inconsistent with
those of previously published reports (Dodart et al 2002, Janus et al 2000, Morgan et
al 2000). Compared to the standard acquisition training in the watermaze used by
Janus et al (2000), our serial spatial learning task is more sensitive to reveal both age-
related and age-independent learning deficits in PDAPP mice, as Janus et al have not
found any apparent age-related learning deficit in TgCRND8 mice using the
acquisition version of reference memory task (the youngest groups (11-week-old)
showed the worst performance) (Janus et al 2000). Moreover, as all TgCRND8 mice
performed comparably to age-matched non-Tgs in probe trials at four different testing
ages, this suggests that the reference memory task in the watermaze is not sensitive to
detect memory impairment in TgCRND8 mice.
In this study, as we were trying to address whether AP vaccines are effective to
improve plaque-related and age-independent learning deficits in PDAPP mice, we did
not design any experiments using even earlier AP immunisation (i.e. before 2 months
of age). However, as the prevention and treatment study did not show any significant
AP vaccination effects on cognition of PDAPP mice, it remains unknown whether
earlier AP42 immunisation can produce any significant effect on impaired learning of
PDAPP mice at young and old ages. Interestingly, analysis of the performance for
AP42-vaccinated animals in the treatment and prevention studies revealed a
significant treatment effect in PDAPP mice groups (Fig. 5.3.3: F=5.58, df 1/77,
p<0.02), but not in non-Tg groups (F<1), possibly suggesting that early treatment of
AP vaccines might improve the performance of PDAPP mice in spatial learning.
However, there was no overall vaccination effect for all PDAPP groups (F<1). It
seems possible that earlier Ap immunisation (before 2 months) might be effective to
prevent mild functional damage of the brain caused by abnormal accumulation of AP
or AP plaques in Tg animals, however, late AP immunisation (after 7 months) is not
effective to improve the pre-existing brain lesion caused by Ap and/or amyloid
plaques, and the pre-existing memory impairment.
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3. A/3 immunotherapy may be ineffective in the treatment ofcognitive loss ofAD.
From this study, on the one hand, an Ap vaccine was very effective to reduce AD-like
pathology in PDAPP mice. On the other hand, the vaccine did not produce any
improvement in spatial learning. These findings suggest that active Ap
immunotherapy is useful for the treatment of AD-like pathology, but might not be an
ideal treatment strategy for memory loss of AD. More recently, Morgan's group have
re-tested active AP immunotherapy using 16-month-old PS1/APP Tg mice. They used
4 immunisations of AP42 biweekly to the Tg mice. There was no improvement in the
impaired learning when tested at 18 months using the same radial-arm watermaze
protocols (Austin et al 2003). Together with findings from this Ap vaccine treatment
or prevention study, it strongly suggests that active Ap immunotherapy might not be
effective in the treatment of cognitive impairment in AD.
Due to side effects of AN-1792, the clinical study dosing has been halted recently.
However, clinical efficacy assessment such as MRI changes, cognitive decline and
safety is still continuing. After the suspension of AN-1792 dosing, Hock et al
continued to evaluate cognitive functions in a cohort of 30 patients with mild-to-
moderate AD, based at Zurich. They have recently reported that 20 AN-1792-treated
patients successfully produced antibodies against Ap and showed significantly slower
rates of decline in cognition and daily activities (Hock et al 2003). However, the
sample size (AD subjects=20) of Hock's study is still small. Before data on a large
proportion of the 376 patients on cognitive function and daily activities for the phase
IIA clinical study on AN-1792 are published, it will be difficult to draw firm
conclusions. Overall, much more work needs to be done to understand mechanisms of
the side effects caused by Ap vaccines before a new clinical trial is re-launched in the
future.
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Chapter 6: Investigations of Spatial Learning and Synaptic
Transmission in PSlcKO;APP Mice.
6.1 Introduction.
1. The importance ofPSl and y-secretase.
The significant importance of the presenilins in AD is recognized by genetic evidence
showing that mutations of presenilin-1 (PS1) account for most cases of early-onset of
FAD (25-50%), whereas the linkage of APP mutations to FAD is very small (-5%).
Since PS1 was first identified in 1995, its structure, metabolism and other biological
properties have been extensively studied (Levy-Lahad et ah, 1995; Rogaev et al.,
1995; Sherrington et al., 1995; Takashima et al., 1996; De Strooper et al., 1997).
Recently, the importance of PS1 in early development was discovered following
knockout experiments. Homozygous PS1-/- mice die prematurely, and their embryos
display abnormal patterning of the axial skeleton and spinal ganglia, suggesting an
important physiological role of PS1 in neuron development (Shen et al., 1997; Wong
et al., 1997).
One of the most important functions of PSs is as the active site of y-secretase, which
cleaves APP and Notch to produce A(3 and NICD. Studies using overexpression and
knockout techniques indicate that overexpression of mutant human form of PS leads
to overproduction of A(3 in transgenic mice (Borchelt et al., 1996; Duff et al., 1996)
and in stably transfected cells (Ancolio et al., 1997; Tomita et al., 1997). APP-Semliki
Forest virus (SFV)-infected cultured neurons from the hippocampus of PS1 knockout
mice produce significantly reduced levels of A(340 and AP42 (De Strooper et al.,
1998). Recent evidence indicates that PS1 is part of the y-secretase complex, which is
generally believed to be composed of PSs, Net, Aphl and Pen2 (Kimberly et al.,
2003).
2. Involvement ofPSl in spatial learning and memory.
Recent evidence has suggested that PS1 is involved in learning and memory. Using
the newly developed conditional gene knockout techniques, two different PS1
conditional knockout mice (PSlcKO), in which PS1 inactivation is restricted to the
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postnatal forebrain, were generated by two separate groups (Feng et al., 2001; Yu et
al., 2001). Yu and colleagues reported that, while PSlcKO mice exhibit normal basal
synaptic transmission, LTP and LTD of the hippocampus, they also display a
significant long-term deficit in spatial memory (Yu et al., 2001). Flowever, Feng et al
did not find any deficit in spatial learning using a second line of PSlcKO mice (Feng
et al., 2001). The discrepancy between these two groups may be due to different
training protocols. Indeed, the learning deficit of PSlcKO mice observed by Yu et al
(2001) is quite subtle.
3. Inhibition ofPSl or y-secretase for intervention ofAD.
As A|) is produced as a result of sequential proteolytic cleavages of APP by the [3- and
y-secretases, these two proteases have become the top targets for therapeutic
intervention of AD. During the past few years, important progress has been made in
searching for effective inhibitors for the P- and y-secretases. However, as genetic
inactivation of PS1 causes early perinatal lethality in homozygous PS1-/- animals,
PS1 inhibition may produce severe side effects on animals and humans. This suggests
that y-secretase may not be an ideal target for therapeutic development. By contrast,
BACE seems to be a more promising target than the y-secretase, as BACE1-/-
knockout animals (Cai et al., 2001; Luo et al., 2001) or BACE1/2 double knockouts
display no gross phenotype (such as embryonic lethality). However, as conditional
inactivation of neuronal PS1 in the forebrain reveals no gross abnormalities, partial or
selective inhibition of PS1 (or y-secretase) may still be possible for anti-AD therapy.
Modelling the amyloidosis of AD in rodents has been very successful for many years,
as most different lines of APP Tg mice display age-related Ap accumulation and
amyloid plaque deposition. They also exhibit learning deficits which are either age-
related or age-independent. Thus, inter-crossing of APP Tg and PSlcKO mice should
allow us to examine whether inactivation of PS1 in the forebrain has any effects on
both pathology and cognitive impairment of APP Tg mice.
4. The study ofPSlcKO;APP mice by Shen's group.
Shortly after Shen's group published PSlcKO mice in 2001, they crossed these mice
with an APP Tg line (J20) (Mucke et al., 2000), and generated PSlcKO;APP mice.
The APP line J20 is similar to line J9 (described in Chapter 1). Briefly, J20 APP mice
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overexpress mutant human APP with both the Indiana and Swedish mutations under
the control of a |3-chain PDGF promoter. J20 line mice display very high levels of A[3
production and start the formation of plaques in the brain as early as 5-6 months.
However, behavioural study of this line has never been reported. In early 2002,
Shen's lab did a thorough study of pathology, electrophysiology and behaviour on J20
mice while also testing PSlcKO;APP ones. What they have found on these mice is
briefly reviewed as follows.
4.1. The generation ofPSlcKO;APP mice by Shen's group.
J20 mice were first crossed with homozygous floxed PS1 (fPSl/fPSl) mice to get
fPSl/+;APP mice. The latter were then bred to fPSl/fPSl again to obtain
fPSl/fPSl;APP mice. Finally, fPSl/fPSl;APP mice were crossed to PSlcKO
(fPSl/fPSl;CaM-Cre) to get PSlcKO;APP (fPSl/fPSl;CaM-Cre;APP) mice.
4.2. PSlcKO;APP mice display a significant reduction ofAft.
Western analysis revealed that 2- and 6-month old APP and PSlcKO;APP mice
display comparable levels of full-length APP (mouse and human) in the cortex which
are 2-fold the endogenous level of mouse APP found in PSlcKO and control mice.
The level of APP CTFs in PSlcKO;APP mice increases in an age-dependent manner.
Quantitative ELISAs reveal an age-dependent accumulation of A(340 and A|342 in
APP mice, but highly significantly reduced A(340 and A(342 in PSlcKO;APP mice.
The levels of A[340 and A|342 are comparable between 2 and 6 months of age in
PSlcKO;APP mice.
4.3. PSlcKO;APP mice display no amyloid plaques and gliosis.
At 3 months of age, both APP and PSlcKO;APP mice display no plaques in the brain.
However, at 6 months, although APP mice exhibit plaques in the hippocampus and
cortex, PSlcKO;APP mice display no plaques in the same brain areas. While 6-month
APP mice develop much microgliosis and astrocytosis, PSlcKO;APP mice display
neither of them.
4.4. PSlcKO;APP mice display a learning deficit in the watermaze.
3- and 6-month APP, PSlcKO;APP, PSlcKO and control mice were tested in a
watermaze using the standard reference memory task. They were trained for 5 days (6
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trials per day, 2 trials per block, interblock interval=2 hr) with a hidden platform in
the watermaze. 60-s probe tests were given following the training of day 3 and day 5.
APP and PSlcKO;APP mice were found to perform this task significantly more
poorly than control and PS1 mice. Analysis of the two probe trials reveals that both
APP and PSlcKO;APP mice did not show any preference to the training quadrant, but
control and PS1 mice spent significant more time in the training quadrant. This is a
disappointing result but should not be taken as the last word on the prospects of
exploiting the y-secretase.
5. Purpose of this study on PSlcKO;APP mice.
These unpublished data suggest that, although inactivation of PS1 in the forebrain
effectively prevents the pathology of APP mice, it does not effectively restore the
impaired reference memory. The questions to raise about this deficit in spatial
learning in PSlcKO;APP mice are: can this deficit be seen in all watermaze tasks, or
is it task-dependent? If it is task-dependent, could we see any rescue effect in
PSlcKO;APP mice using the newly developed trials to criterion and learning capacity
paradigms in watermaze? If these novel protocols can reveal rescue effects on spatial
learning of PSlcKO;APP mice, will these effects be age-dependent or age-
independent?
Compared to the standard reference memory task, the trials to criterion and learning
capacity task is very sensitive to reveal A(3- and/or plaque-related learning deficit in
APP Tg mice, so we have tried these novel watermaze tasks to investigate spatial
learning of PSlcKO;APP mice.
6.2 Methods.
6.2.1. The subjects.
48 young (3-4-month-old) and 44 old (15-17-month-old) mice including control,
PSlcKO, PSlcKO;APP and APP four genotype groups were shipped from Boston,
Harvard University. The genders (male and female) were balanced in each genotype
group. The mice were group-housed before they arrived at Edinburgh. However, after
their arrival, they were singly housed. The experimenter was blind to the genotype of
all mice. The mice were given ad libitium access to food and water.
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6.2.2. The experimental design.
Figure 6.2.1 Experimental Design.
The watermaze was described in previous chapters. A cross-sectional design was
used. There were two different age groups, one being 3-4 months and the other 15-17
months. A battery of behavioural tasks including cuetask, trials to criterion, learning
capacity and object recognition task were used. After behaviour testing is completed,
all mice were subjected to electrophysiology study to examine basal synaptic
transmission and short-term synaptic plasticity.
6.2.3. Visible cuetask.
There were 5 days and 4 trials per day.
6.2.4. Concurrent trials to criterion and learning capacity task.
Prob. 1 Prob. 2 Prob. 3 Prob. 4 Prob. 5 Prob. 6 Prob. 7 Prob. 8 Prob. 9 Prob. 10
-OOOOQOQOOO
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Figure 6.2.2 Platform Locations for Spatial Learning. Two sets of 10
platform locations were used. All the mice were randomly and equally
assigned to two sub-groups to receive Set A or Set B training protocols.
The trials to criterion and learning capacity tasks were concurrently conducted,
whichever took longer (Figure 6.2.2).
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6.2.5. Object recognition task.
Several changes were made from previous studies: first, the session time for sample
and choice phases was changed to 10 min, as this protocol has been reported to be
more sensitive than ours (Dodart et al., 1999; Dewachter et al., 2002); second, in the
sample phase, only one object, rather than two, was placed in the middle position
between two side walls but 10 cm away from the back wall.
6.2.6. Electrophysiology.
Due to an upgrade of the recording system in the lab, a new automatic Hampden
vibroslicer replaced our previous model for slice dissection, and fEPSPs of CA1
apical dendrites were recorded extracellularly using a steel electrode with our new
recording AM system. After -80 min incubation of slices in the recording chamber,
input-output (I-O) curves were induced by 5 different intensities of stimulation (20,
40, 60, 80 and 100 juA) using a different current stimulation isolators (system
upgrade: NL800, Digitimer, England). Due to time limit, LTP experiments for 92
mice were not carried out. Data were collected by the upgraded recording system
based on Labview software written by Patrick Spooner, and stored into a Dell
Dimension computer. The slope of field EPSP evoked by stimulation of the Schaeffer
collateral-CAl pathway was analyzed off-line.
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Figure 6.3.1 Cuetask Performance of the Mice.
A. Cuetask performance for mice at 3-4 months. There was no significant
main genotype effect. B. Cuetask performance for mice at 15-17 months.
There was a significant main genotype effect. Both APP and PS1cKO;APP
mice performed worse than control and PSIcKO mice.
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6.3 Results.
1. Selective age-related changes in cuetask learning.
Figure 6.3.1A shows the performance for four genotypes at 3-4 months of age in
cuetask. Statistical analysis revealed that there was no significant genotype effect
(F<1). All groups learned this task with less than 10 s of escape latency after three
days of training, suggesting that, at this age, neither APP nor PSlcKO;APP mice had
developed any sensorimotor problem. The overall performance of all four groups in
cuetask at 15-17 months is shown in Figure 6.3.IB. Interestingly, a significant main
genotype effect was observed (F=5.84, df3/40, p<0.005). Pair-wise analysis of
variance showed that control mice were not different from PSlcKO group at this age
(F<1), but were significantly different from APP (F=12.72, df 1/21, p<0.005) and
PScKO;APP group (F=10.22, df 1/24, p<0.005), respectively.
It is unclear why old APP and PScKO;APP mice displayed a deficit in the cuetask.
All four old genotype groups took less than 10 s to approach the visible platform on
the last day of training. It seems that the basic learning ability of APP and
PScKO;APP mice was indeed normal, for example, during the 5-day cuetask training,
old APP group improved their performance from 32.7 s on day 1 to 9.9 s on day 5
(savings=22.7 s between day 1 and 5) and PSlcKO;APP group also showed 25.6 s
improvement in escape latency from day 1 to day 5, by contrast, control and PSlcKO
groups displayed 16.2 s and 16.7 s of savings between day 1 and 5, suggesting that
neither APP nor PSlcKO;APP mice developed any apparent swimming or learning
problem in this task. Old APP and PSlcKO;APP mice may have some subtle
sensorimotor abnormalities, for example, several of them were observed to stay still in
the water for a few seconds immediately after they were dropped from the start
position. Perhaps these mice needed to adjust body position in order to get balanced in
the water. This problem alone can explain their subtle deficit in this task. As old APP
and PSlcKO;APP mice had reached an averaged escape latency of less than 20 s after
4 trials of cuetask training on day 1, they should readily reach the 20 s performance
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2. Young PSlcKO;APP mice show a rescue of learning.
Performance on the trials to criterion task by young animals on the 5 individual
platform location is shown in Figure 6.3.2A. The mean trials to criterion across five
platform locations is plotted in Figure 6.3.2B. Analysis of variance revealed a
significant genotype effect (Fig. 6.3.2A and B: F=5.12, df3/43, p<0.005). Compared
to control mice, separate ANOVA revealed that young PSlcKO mice displayed a
subtle impairment in this task (Fig. 6.3.2A and B: F=4.89, dfl/22, p=0.038), and
young PSlcKO;APP mice performed this task very well and did not differ from
control animals (F=3.58, dfl/23, p>0.05). However, young APP mice were
significantly impaired (F=10.57, dfl/23, p<0.005). Very interestingly, compared to
PSlcKO;APP group, young APP mice were also significantly impaired in learning the
trials to criterion task (F=4.73, dfl/23, p<0.05), suggesting a significant rescue effect
of PS1 inactivation on spatial learning of young APP mice.
Results for the learning capacity task are quite similar to those for the trials to
criterion, as statistical analysis also revealed a significant main genotype effect (Fig.
6.3.2C: F=4.98, df3/43, p<0.005). Compared to the control, separate pair-wise
ANOVA showed that young PSlcKO mice were not impaired (F=1.30, dfl/22,
p>0.05), young PSlcKO;APP mice were not impaired (F=2.69, dfl/23, p>0.1),
however, young APP mice were again significantly impaired (F=10.47, dfl/23,
p<0.005). Interestingly, the difference between young PSlcKO;APP and APP mice
was a trend towards significant in this task (F=4.08, dfl/23, p=0.056). These results
further suggest a rescue effect of PS 1 inactivation on learning capacity of APP mice.
In summary, inactivation of PS1 successfully restored learning deficits of young (3-4
months) APP mice on both trials to criterion and learning capacity tasks. As young
J20 APP mice displayed early learning deficit, this confirms that early accumulation
of AP or other APP metabolites is sufficient to disrupt normal spatial learning of the
mice. However, prevention of early accumulation of Ap or other APP metabolites by
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3. Old PSlcKO;APP mice show only a partial rescue of learning.
Figure 6.3.3A shows the performance of old mice on the 5 individual platform
location of the trials to criterion task. Figure 6.3.3B shows the mean trials to criterion
across all five platform locations. Analysis of variance revealed a trend towards a
significant genotype effect (Fig. 6.3.3A and B: F=2.81, df3/40, p=0.051). Compared
to control mice, pair-wise comparisons showed that old PSlcKO mice were normal
(F=2.21, df1/17, p>0.1), old PSlcKO;APP mice were also not abnormal (F=3.38,
dfl/24, p>0.05), however, old APP mice were significantly impaired (F=10.18,
df1/21, p<0.005). Very interestingly, although old PSlcKO;APP mice were not
significantly different from control mice, they were also not different from old APP
mice (Fig. 6.3.3A and B: F=1.63, df1/23, p>0.2), suggesting only a partial rescue
effects of PS1 inactivation on trials to criterion of APP mice.
The effects of conditional inactivation of PS1 were further examined using the
learning capacity measure (Fig 6.3.3C). An overall ANOVA had revealed a
significant main genotype effect (Fig. 6.3.3C: F=4.19, df3/40, p<0.05). Pair-wise
ANOVAs revealed that the difference between old control and PSlcKO mice was a
trend towards significant (Fig. 6.3.3C: F=3.11, dfl/17, 0.05>p>0.1). However,
compared to control mice, old PSlcKO;APP mice were significantly impaired
(F=8.50, dfl/24, p<0.01), and old APP mice were impaired as well (F=14.61, df1/21,
p<0.001). Again, old PSlcKO;APP mice were not different from APP mice (Fig.
6.3.3C: F=1.61, dfl/23, p>0.2).
It seemed that old PSlcKO;APP mice displayed normal learning in trials to criterion
task, but impaired learning in learning capacity task. This may suggest that PS1
inactivation partially improves the impaired learning of old APP mice. However, as
old PSlcKO;APP mice were not different from APP mice in both tasks, the rescue
effects of PS1 inactivation are very limited on spatial learning.
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A. Young groups.
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Figure 6.3.4 Object Recognition in the Mice. A. Object recognition memory for young
mice. All mice showed above-chance performance. B. Object recognition memory
for old mice. There was no significant genotype effect.












































Figure 6.3.5 Impaired Basal Synaptic Transmission in APP Mice.
A. Input-output curves for young mice. There was no significant overall effect,
but the difference between the control and APP groups was significant.
B. Input-output curves for old mice. There was no significant overall effect,
but the difference between the control and APP groups was significant.
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4. Both young and old APP and PSlcKO;APP mice displayed unimpaired object
recognition memory.
In order to test whether APP and PSlcKO;APP mice displayed any impaired object
recognition memory, only a 4 h retention interval was used (Dewachter et ah, 2002;
Dodart et ah, 2002). Figure 6.3.4A shows the performance for young mice. All four
groups explored the novel object preferentially (p<0.05, one sample t-test), and
ANOVA revealed no main genotype effect (F<1), indicating that young APP and
PSlcKO;APP mice displayed normal object recognition. The performance of old mice
is shown in Figure 6.3.4B. No genotype effects were found (F = 2.06, df 3/39, p>0.1),
suggesting that old APP and PSlcKO;APP mice were also not impaired in object
recognition memory.
5. APP mice displayed deficit of synaptic transmission in the hippocampus.
Using similar protocols to those in my previous studies, input-output (I-O) curves
were recorded in both young and old mice. Figure 6.3.5 shows basal synaptic
transmission in young mice (Fig. 6.3.5A) and old mice (Fig. 6.3.5B). In Fig. 6.3.5A,
ANOVA revealed a trend towards a significant genotype effect (F=2.66, df3/42,
p=0.06). Compared to control animals, APP mice were impaired (F=8.55, dfl/20,
p<0.01) and PSlcKO;APP mice showed a trend towards significant difference
(F=3.49, df1/21, p=0.076). However, APP mice were not different from PSlcKO;APP
(F=1.69, df1/21, p>0.2) in hippocampal basal synaptic transmission, suggesting only a
subtle rescue effect of PS1 inactivation on synaptic transmission of young APP mice.
Analysis of input-output curves for old mice (Fig. 6.3.5B) showed that there was no
significant main genotype effect (F=1.47, df3/28, p>0.2). Compared to control
animals, old APP mice were impaired (F=5.0, df1/14, p<0.05) and PSlcKO;APP mice
were not (F=1.74, df1/16, p>0.2). However, old APP mice were not different from
PSlcKO;APP (F<1). The data further suggested only a partial rescue effect of PS1
inactivation on synaptic transmission.
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Figure 6.3.6 Significant Correlations between the Basal Synaptic Transmission and
Behavioural Performance. A. Significant correlation between the medium size of fEPSP
of the hippocampus and the mean trials to criterion for all mice tested in this study.
B. Significant correlation between the medium size of fEPSP of the hippocampus and the
mean trials to criterion only in APP mice. C. Significant correlation between the medium
size of fEPSP of the hippocampus and learning capacity for all mice. D. Significant
correlation between the medium size of fEPSP of the hippocampus and learning capacity
only in APP mice.
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6. Relationship between synaptic transmission of the hippocampus and behavioural
performance in trials to criterion and learning capacity task.
Several correlation studies were conducted to analyse the relationship between
synaptic transmission and behavioural performance in the same mice. First, there was
a significant correlation between the size of fEPSP and the mean trials to criterion for
all mice (Fig. 6.3.6A) and APP mice only (Fig. 6.3.6B). Although the correlation
coefficient, r=-0.31, in Fig. 6.3.6A (p<0.01, all mice) was smaller than that, r=-0.48,
in Fig. 6.3.6B (p<0.05, APP mice only), all the correlations were significant. Second,
Figure 6.3.6C and 6D shows the significant positive correlations between the size of
fEPSPs and learning capacity (Fig. 6.3.6C, for all mice: r=0.37, p<0.002; Fig. 6.3.6D,
for APP mice only: r=0.55, p<0.02; medium size of fEPSPs). The significant
correlations between behavioural performance on the trials to criterion and learning
capacity task and the size of fEPSPs suggest, unsurprisingly, that basal synaptic
activity is involved in spatial learning.
6.4 Discussion.
1. Conditional inactivation of PS1 in the forebrain ofAPP mice successfully restored
impaired spatial learning at young age.
In this study, four different genotypes of mice, control, PSlcKO, PSlcKO;APP and
J20 APP mice were first tested at 3-4 months of age, using a behavioural testing
battery. Like PDAPP mice, the J20 APP mice displayed learning deficit in the trials to
criterion and learning capacity tasks, but exhibited normal swimming ability and
normal object recognition memory. These findings are consistent with previous
observations on PDAPP mice. As the J20 mice do not start the formation of amyloid
plaques until 5-6 months, the impairment of spatial learning at 3-4 months is plaque-
independent, but presumably AP-dependent. When analyzed at both 2 and 6 months
using ELISA, these mice displayed very high levels of Ap40 and AP42 (personal
communications with Dr. Carlos Saura). Due to overexpression of mutant APP in the
brain, young APP mice have also developed a high amount of other APP derivatives,
such as APP CTFs. However, this learning deficit in young APP mice seems not to be
APP CTF-dependent, as both young PSlcKO and PSlcKO;APP mice also have high
levels of APP CTFs in the brain (because Ap production is inhibited), but they
showed relatively normal spatial learning. The results from young mice strongly
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suggest that learning deficit of APP mice can be fully rescued by inactivation of PS1
in the forebrain.
2. Conditional inactivation of PS1 in the forebrain of APP mice only partially
improved learning deficits in old animals.
Like other APP Tg animals, as J20 APP mice aged, they progressively developed AD-
like pathology, such as amyloid plaques, synaptic loss, gliosis and learning deficit.
Interestingly, data from Shen's group further indicated that postnatal inactivation of
PS1 in the forebrain prevented neuropathology very effectively at older ages, i.e >12
months (personal communications with Dr. Carlos Saura). In this study, four different
genotypes of old mice (15-17 months) were also tested using our behavioural test
battery. At this age, conditional inactivation of PS1 displayed only a subtle rescue
effect on the trials to criterion measure, but not learning capacity. Furthermore, as the
performance of old PSlcKO;APP mice in both tasks did not differ from that of age-
matched APP mice, this suggests that inactivation of PS1 in the forebrain is less
effective in old APP mice. Although the mechanisms are unknown, the findings that
the rescue effect on spatial learning by conditional inactivation of PS1 in APP mice is
age-related may suggest that there is an AP-independent component of cognitive
impairment in old APP and PSlcKO;APP mice.
Unpublished data on contextual fear (CF) conditioning by Shen's group indicated that
J20 APP mice displayed plaque-independent deficits at 3 and 6 months, however,
PSlcKO;APP mice showed normal fear responses at 3 months but were impaired at 6
months (personal communications with Dr. Carlos Saura). So these findings are
consistent with the results in this study.
3. Significant rescue effect at young age versus non-significant rescue effect at old
age in PSlcKO;APP mice.
The age-dependency of the rescue effect raises the possibility that abnormal
accumulation of APP CTFs in the brain may also cause disruption of learning and
memory in the mice. One example is that, in this study, young PSlcKO mice showed
significantly impaired spatial learning in trials to criterion task. Likewise, it has been
reported that PSlcKO mice also showed subtle impairment of spatial learning and
memory using the standard watermaze reference memory task (Yu et al., 2001).
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Interestingly, young PSlcKO mice were found to be normal in learning capacity in
this study. Do these findings suggest that inactivation of PS1 may affect several forms
of spatial learning but not all in the mice? To answer this question, a factorial
ANOVA (two-factor: agexgenotype) was used to assess the overall effects of PS1
inactivation on spatial learning of young and old PSlcKO mice. For trials to criterion
task, a significant main genotype effect was observed (F=5.99, df1/38, p<0.05).
Similar results were also found in learning capacity task (F=1.04, df1/38, p<0.05).
These analyses indicate that inactivation of PS1 in the forebrain of PSlcKO mice
indeed has caused impairment on spatial learning. This may help to explain why a full
rescue effect on learning in all PSlcKO;APP mice has not been seen. These findings
further suggest a possibility that elevated levels of endogenous or mutant APP CTFs
are deleterious to spatial learning of the mice.
In this study, the performance of old PSlcKO;APP mice on the trials to criterion and
learning capacity did not differ from that of age-matched APP mice. Pathological
differences between these two Tg lines are that, old APP mice have very high levels
of human mutant A^/plaques and relatively low human APP CTFs in the brain,
however, old PSlcKO;APP mice have no human A(3/plaques but a huge amount of
human APP CTFs in the brain. Although the pathology of old APP and PSlcKO;APP
mice seems totally different, they are not different in cognition in the tests used so far.
An explanation for this observation may be that either high levels of Ap/plaques or
APP CTFs in the brain damage normal cognitive functions of the mice. The
mechanisms seem to be unclear. However, as there is a significant correlation
between synaptic transmission and behavioural performance, it might suggest that
synaptic transmission in the hippocampus may serve as a cellular mechanism for
spatial learning in the mice or at least in APP animals.
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Chapter 7: Investigation of the Effects of y-Secretase Inhibitor
Treatment on Spatial Learning of PDAPP Mice.
7.1 Introduction,
7.1.1. The y- and /3-secretases as therapeutic targetsfor the treatment ofAD.
Currently, most FDA-approved drugs for AD treatment, such as tacrine, donepezil,
rivastigmine and galantamine, are the AChEIs. However, these drugs only provide
symptomatic treatment: they do not stop the progression of AD, but only stabilize
cognitive impairment for a limited time period and eventually they become
ineffective. It is very likely that a better treatment strategy would be targeting the
molecules responsible for the neurodegenerative pathogenesis of AD. The primary
enzymes for modulating APP processing are a-, P- and y-secretases, with the P- and y-
secretases being directly responsible for Ap production. Due to the central role of AP
accumulation in the pathogenesis of AD, the P- and y-secretases have recently become
prime candidates for therapeutic development for AD. As the a-secretase is not
directly involved in the production of Ap, it seems unlikely to be a very promising
therapeutic target.
The attempts to seek better agents such as the inhibitors for the p- and y-secretases
have been proven very successful during the past few years. In 1999, four groups
reported the identification and characterization of the p-secretase, using either
genomic-based approach or expression cloning (Hussain et al., 1999; Sinha et al.,
1999; Vassar et al., 1999; Yan et al., 1999). The development of p-secretase inhibitors
has been very challenging due to its pharmacological kinetics. Interestingly, since the
first peptidic BACE inhibitor was reported by Elan (Sinha et al., 1999), major
progress on the so-called structure-based approaches has been achieved. For
examples, a group based in Oklahoma have recently reported two very powerful
BACE inhibitors, OM99-2 and OMOO-3, both being eight-residue transition state
inhibitors (Ghosh et al., 2000; Turner et al., 2001). Very recently, Elan reported a
peptidic BACE inhibitor with very small molecular weight, Compound 38, which
inhibits 50% of Ap production in cell culture at 4 pM and is also cell permeable (John
et al., 2003).
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Like P-secretase, pharmacological evidence indicates that y-secretase belongs to
aspartyl protease family (Li et al., 2000). However, the y-secretase is much more
complex than the p- secretase and is composed of PSs, Net, Aphl and Pen2 (Kimberly
et ah, 2003). As the active site of y-secretase is hydrophobic, the inhibitors of y-
secretase are also hydrophobic and this property helps membrane permeability. Due to
this property, searching for the cell-permeable y-secretase inhibitors has been much
less challenging than for BACE inhibitors. Much progress has been made in
developing y-secretase inhibitors since 1995 (Higaki et al., 1995). Many peptidic and
nonpeptidic y-secretase inhibitors have been reported by pharmaceutical industry and
academic laboratories and are reviewed in Section 1.8.2.8 of Chapter 1. Moreover, at
least one of them is currently in clinical trial (Wolfe, 2002).
7.1.2. Development ofselective y-secretase inhibitors.
The first selective y-secretase inhibitor is called MW167, a difluoro ketone peptide
analogue (Wolfe et al., 1998). This drug is highly selective, but not a very potent
peptidic inhibitor for y-secretase (ICso=13 /rM) and it is reported to block the
production of both AP40 and AJ342 in human APP-transfected CHO cells (Wolfe et
al., 1998). It has also been reported that this compound inhibits y-secretase-mediated
cleavage of APP expressed in neurons using recombinant Semliki forest virus (SFV)
in a concentration-dependent manner, thus leading to the accumulation of C-terminal
fragment (CTF) of APP. MW167 inhibits neither the a- nor P-secretase activity, but
does inhibits NICD production (IC50=10-30 pM) (De Strooper et al., 1999). This
latter finding thus raises the concerns that inhibition of y-secretase activity for the
treatment of AD may cause serious toxicity by blocking the Notch signalling pathway.
Further, it has not been reported whether this compound can potently inhibit either Ap
production or plaque formation in APP Tg mice. Overall, MW167 and other peptidic
inhibitors like MDL28170 and MG132 only display weak potency for the inhibition
of y-secretase (Higaki et al., 1995; Klafki et al., 1996).
Although there is serious concern about the impact of y-secretase inhibitors on Notch
processing, searching for an effective y-secretase inhibitor has not been stopped.
Indeed, several attempts have proven successful. One typical example is L-685458, a
highly powerful transition-state analogue y-secretase inhibitor, which was first
reported by neuroscientists from Merck (Li et al., 2000; Shearman et al., 2000). L-
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685458 contains a hydroxyethylene isostere and its photoreactive derivatives can
specifically label PS1 and PS2 (Li, 2001). Unlike the difluoroketones y-secretase
inhibitors, L-685458 does not resemble the native peptide substrate. It was reported
that L-685 458 concentration-dependently inhibits A[3 production in both Neuro2A
and CHO cell lines overexpressing human APP695 and is not cytotoxic to cells. This
compound seems much more potent than other published y-secretase inhibitors, as its
IC50 is only 14 nM for Ap40 and 13 nM for AP42 using SH-SY5Y neuroblastoma
cells stably transfected with SPA4CT (Shearman et al., 2000; Beher et al., 2001). It is
reported that, while L-685458 inhibits the AP40 production in HEK293/APP695 cells
and cells transfected with BACE1 or BACE2, it does not inhibit the activities of
BACE1 and BACE2 (Shi et al., 2003). Scientists from Merck have disclosed several
newly developed benzodiazepine-containing y-secretase inhibitors which show even
higher inhibition potency than L-685 458. For example, compound 34 displays an
IC5o=0.06 nM (Churcher et al., 2003). It is unknown whether these highly potent
nonpeptidic y-secretase inhibitors display similar inhibition potency in vivo or are
already in clinical trials for the treatment of AD.
Since scientists from Elan and Lilly published the compound 7 (DAPT, N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-S-phenglycine r-butyl ester) in 2001, DAPT has
become the first potent y-secretase inhibitor to be tested in vivo. Early work has
shown that DAPT reduces the production of AP40 and AP42 in HEK293 cells
overexpressing human APP751 and in human primary neuronal cultures. Like L-
685458, the IC50 for DAPT is ~20nM. Very interestingly, it is reported that, after oral
administration of DAPT (100 mg/kg) to PDAPP Tg mice, peak DAPT levels are
found in the brain 3 hr after treatment and high levels of DAPT are maintaining
throughout the first 18 hr. The reduction of AP reaches 40% of inhibition 3 hr after
treatment. Further investigation shows that cortical total AP is reduced by 50% with 3
hr treatment of 100 mg/kg DAPT (Dovey et al., 2001). In a later chronic study of
PDAPP mice by the same investigators, the effects of LY411575 (benzocaprolactam,
or Compound 9) on AP accumulation and subsequent plaque pathology have been
examined (May et al., 2001; Wolfe, 2002). Beginning at 6.5-7 months of age, PDAPP
mice were administered with LY411575 (1 mg/kg) or com oil vehicle twice a day for
a period of 90 days. Excitingly, this chronic treatment results in 70-90% reduction of
brain AP levels. Moreover, these researchers further display that markers of neuritic
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pathology and glial inflammatory responses are also significantly attenuated (May et
al., 2001). These results indicate that chronic treatment with a y-secretase inhibitor
can alter pathology in an animal model of AD and thus strongly point to the
therapeutic potential of y-secretase inhibitors for the treatment of AD.
This progress offers great hope for therapeutic intervention in AD. However, the
inhibition of y-secretase interferes with Notch processes that are pivotal to
mammalian development. For example, one recent study has shown that application
of y-secretase inhibitors to fetal thymus organ cultures interferes with T cell
development in a manner consistent with the loss or reduction of Notch 1 function
(Hadland et al., 2001). Another study also shows that treatment of zebrafish with a y-
secretase inhibitor causes a severe neurogenic phenotype (Geling et al., 2002). It
seems very important that more specific inhibitors of APP relative to Notch are
needed. Interestingly, novel nonpeptidic y-secretase inhibitors such as the isocoumarin
JLK inhibitors have recently been reported (Petit et al., 2001). It is shown that JLK2
and JLK6 inhibit Ap production in a dose-dependent manner (IC50=80 jitM, for both
compounds) in HEK293 cells stably transfected with human wildtype or Swedish
mutant APP gene. Moreover, JLK inhibitor does not affect proteolytic cleavage of
endogenous PS1 (Petit et al., 2001). In vivo study of JLK inhibitors by the same group
has shown that JLK compounds do not affect Notch pathways, nor to cause cell death
or inhibition of BACE1, BACE2, a-secretase and other proteasome (Petit et al.,
2003). Obviously, the JLK inhibitors represent a new class of highly selective and
cell-permeable y-secretase inhibitors, but their potency is much less than other
transition-state based y-secretase inhibitors (Esler et al., 2002). Due to their high
selectivity for the APP pathway, the JLK compounds might be more promising than
other y-secretase inhibitors for developing the treatment of AD. But to gain this goal,
several important questions related to this novel y-secretase inhibitor need to be
answered. Firstly, can the JLK agents reduce amyloid plaques or other AD-related
pathology in vivo? Secondly, can the JLK agents reverse learning impairment in APP
Tg mice? Thirdly, should the weak potency of the JLK agents be improved for clinical
study on the treatment of AD? However, as I had no access to these compounds, I
have focused on the Elan compound, ELN44989, despite its lower selectivity.
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7.1.3. Purpose of this study: Evalulation of y-secretase inhibitors on learning ability
ofanimal models ofAD.
The in vivo study of L-411575 seems quite exciting, as it has demonstrated that long-
term treatment of a y-secretase inhibitor could effectively reduce Ap loads and other
AD-like neuropathology in APP Tg mice (May et ah, 2001). However, these
researchers did not report any apparent side effect of the chronic treatment of PDAPP
mice with L-411575. Perhaps, inhibition of Notch pathway with a y-secretase
inhibitor could be well tolerated in adult mice.
At the time of starting this study, no study had appeared reporting whether the
treatment of a y-secretase inhibitor can rescue cognitive deficits shown in APP Tg
mice. Evaluation of the effects of y-secretase inhibitor on learning ability of APP Tg
mice is very important, as it could be a key preclinical step to establish the this novel
effective treatment strategy for AD. As reported in a previous chapter of this thesis, a
vaccine of Ap has been found ineffective in improving the impaired spatial learning
of PDAPP mice, despite significantly reducing the levels of Ap and Ap42 in the
cortex and hippocampus. It would therefore be interesting to examine what effects a
y-secretase inhibitor treatment would have on both neuropathology and cognitive loss
in APP Tg mice.
Recently, Elan has developed a new y-secretase inhibitor compound, ELN44989.
Confidential data by Elan show that this compound is more potent than DAPT, but
with a half-life of 1.5 h (personal communication with D. Kobayashi at Elan). In a
previous longitudinal study of a cohort of 25 mice (12 PDAPP and 13 non-Tg mice),
as shown in Chapter 4, I have found that this cohort of PDAPP mice display normal
learning at young age (6-9 months), but impaired learning at older ages (14-15 or 21-
22 months). In this study, a similar longitudinal design was used, with the trials to
criterion task in the watermaze.
7.2 Methods.
7.2.1. Subjects.
A total of 82 male mice (44 non-Tg and 38 PDAPP) aged at 6-7 months were shipped
from Taconic (Elan Pharmaceuticals.). The mice were singly housed after they arrived
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at Edinburgh. The experimenter was blind to the genotype of mice. The mice were
given ad libitium access to food and water.
7.2.2. Watermaze.
The watermaze was used as previously.
7.2.3. Experimental design.
A within-subject (longitudinal) design was used, as shown in Fig 7.2.1. At 7-8 months
of age, all mice were first examined for sensorimotor function using the standard
visible cuetask. Due to previous findings showing that either PDAPP or APP J20 mice
have displayed normal object recognition memory, this was excluded from the test
battery. Only sensitive tasks such as trials to criterion and learning capacity over
several spatial locations were utilized to test drug effects. At 7-8 months, after cuetask
training was complete, all mice were subjected to the serial spatial task to test spatial
learning ability.
The treatment of ELN44989 started immediately after the first phase of testing. The
experiments were conducted double-blinded, that is, the experimenter who did the
behavioural testing and electrophysiological study was blind to both the genotype and
the drug status. A second person, who knew the genotype of the animals but not the
drug identity, did the assignment of the animals into two subgroups for drug treatment
according to their behavioural performance in Phase 1. To conduct this assignment,
both non-Tg and PDAPP mice were divided into two sub-groups, such as Group A
and Group B, which behavioural performance was equally matched each other. A
third party, who knew the drug (ELN44989 or corn oil=control) but not the genotype,
prepared the solution once a week. And a fourth group, the animal technicians who
did the drug delivery were also blind to both the genotype and drug.
In order to get maximal effect on AP reduction by y-secretase inhibitor in PDAPP
mice, the total treatment period was designed as 4 months. After the chronic treatment
of ELN44989, all the animals who survived for this period were first tested again with
2-day cuetask followed by the concurrent trials to criterion and leaning capacity. After
the behaviour testing was done, all mice were subjected to an electrophysiology study
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Phase 1: mice at 7-8 months.
Figure 7.2.1 Longitudinal Experiment Design.
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Figure 7.2.2 Design of Platform Locations for Trials to Criterion and Learning
Capacity Task before ELN44989 Treatment (age: 7-8 months).
For counterbalancing reason, two sets of 10 platform locations were designed.
All young mice were randomly assigned to two groups. Half of them were
trained Set A, and the other half were tested by Set B.
Prob. 1 Prob. 2 Prob. 3 Prob. 4 Prob. 5 Prob. 6 Prob. 7 Prob. 8 Prob. 9 Prob. 10
-*0000000000
Figure 7.2.3 Design of Platform Locations for Spatial Learning after 4-month
ELN44989 Treatment (age: 11-12 months). Two sets of 10 platform locations
were designed as above. The mice, who were previously trained by the Set A
of platform locations in Fig. 7.2.2, would now be tested with the Set A1 platform
positions, and similarly, the others, who were tested with the Set B, now
received the Set B1 platform locations.
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to examine basal synaptic transmission. Finally, the brain tissue samples were
analyzed by ELISA to evaluate the drug effects on AP reduction in all the animals.
7.2.4. Visible cuetask.
Before any drug treatment, there were 5 days, 4 trials/day, for cuetask training. After
4 months drug treatment, there were 2 days for cuetask training at 11-12 months.
7.2.5. Trials to criterion and learning capacity task.
Trials to criterion and learning capacity tasks were concurrently conducted again,
whichever took longer. The Figures 7.2.2 (7-8 months) and 7.2.3 (11-12 months)
showed two different sets of 10 consecutive platform locations for spatial testing.
7.2.6. Drug preparation and delivery.
ELN44989 was made in Elan. This compound was reported to us to be well tolerated
in the mouse (up to 3mg/kg), more efficacious than DAPT, and produce >80%
reduction of AP in plasma (personal discussion with D. Kobayashi). Due to the
agreement between Elan and Prof. Richard Morris, more detailed information about
the structure and efficacy of this compound was not disclosed. As the half-life is 1.5h,
twice oral administrations per day were given to PDAPP mice. Dosing needles (20G x
25mm, straight) were purchased from VetTech (Cheshire, UK). For this study, the
dosing concentration of the compound was lmg/kg. Corn oil was served as the control
vehicle. The drug was made up once a week by Jane Knox (who was only aware of
the drug but not the genotype of the mice). Two highly experienced technicians,
Richard Watson and Laraine Wells did the oral gavarage for all mice (twice a day,
8:00 AM and 17:00 PM).
7.2.7. Electrophysiology.
A new automatic Hampden vibroslicer was used for hippocampal slice dissection. The
fEPSPs of CA1 apical dendrites were recorded extracellularly using a steel electrode.
Input-output (I-O) curves were induced by 7 different intensities of stimulation (40,
50, 60, 70, 80, 90 and 100 /xA) using current stimulation isolators (NL800, Digitimer,
England). Data were collected by labview software written by Patrick Spooner and
stored into a Dell computer. The slope of field EPSP evoked by stimulation of the
Schaeffer collateral-CAl pathway was analyzed off-line.
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A. An ELN44989-treated mouse.
B. A corn oil-treated mouse.
Before treatment 1 month after 3 months after
C. High mortality in ELN44989-treated mice.
p < 0.001 (x2 =10.88, df=l)
Corn Oil ELN44989
Figure 7.3.1 Side Effects Observed in the ELN44989-treated Mice.
A. Coat color change in an ELN44989-treated mouse.
B. No coat color change was found in corn oil-treated mice.
C. A significantly higher mortality was found in ELN44989-treated
mice, compared to corn oil-treated animals (p<0.001).
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7.2.8. Tissue preparation for ELISA analysis of A[3.
The method for tissue preparation was described in Chapters 2 and 5. After
preparation, all the samples were stored at -20 °C for ELISA analysis.
7.3 Results.
1. Chronic treatment with ELN44989 caused severe side effects in the mice.
In contrast to previous findings by May et al (2001), several unexpected side effects
of ELN44989 on the mice were observed in this study (Fig. 7.3.1). First, a color
change on the fur of ELN44989-treated mice was observed approximately 3 to 4
weeks after the start of ELN44989 treatment (Fig. 7.3.IB). Approximately 3 months
after this y-secretase inhibitor treatment, the fur of all mice became totally discolored.
The second side effect of this y-secretase inhibitor was that it caused mortality,
leading us to allow a much higher discontinuation rate (Fig. 7.3.1C). For example,
nearly half the ELN44989-treated animals (42.86%) had to be discontinued in this
study, as they were found dead or had displayed at least 40% weight loss (25% is the
allowable severity level to maintain the study in terms of Professor Morris's Personal
Project License). By contrast, the corn oil-treated groups only showed 8.82%
mortality. Chi-square analysis revealed a highly significant discontinuation rate
difference between the ELN44989- and corn oil-treated mice (p < 0.001; x2=10.88,
df=l), but no difference between genotype groups (p > 0.5; x2=0.19, df=l). These
findings indicate that the treatment of mice with lmg/kg ELN44989 caused serious
"side effects" on animals. As lmg/kg was the only concentration used in this study,
it remains unclear whether lower concentrations could minimize the side effects.
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Figure 7.3.2 Cuetask Performance.
A. Cuetask performance of the mice before the treatment
of ELN44989. There was a significant main genotype effect.
B. Cuetask performance of the mice 4 months after the
treatment of ELN44989. There was a significant main
genotype effect, but no drug effect or genotype*drug interaction.
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2. APP mice displayed impaired basic learning in cuetask.
Cuetask training was conducted before and 4 months after the treatment of
ELN44989. Fig. 7.3.2A shows the cuetask performance for PDAPP and non-Tg mice
at 7-8 months, prior to ELN44989 treatment. Einexpectedly, statistical analysis
revealed a significant main genotype effect (F=23.26, df1/51, p<0.0001) and a day x
genotype interaction (F=6.65, df1/112.92, p<0.01), suggesting that this cohort of
PDAPP mice were impaired in their basic learning of cuetask. Although the PDAPP
mice reached 7.3 s performance on the last day of cuetask training, compared to 4.9 s
by the non-Tg mice, the difference between groups was again highly significant
(F= 19.29, dfl/74, p<0.0001). Compared with the findings reported in previous
chapters of this thesis, this study indicated a clear deficit in the sensorimotor function
of the newly bred PDAPP mice.
The basic learning ability of the same mice used in this study was further evaluated 4
months later after the treatment with ELN44989 (Figures 7.3.2B). Analysis of
variance for 55 mice, who survived after 4 months treatment of EFN44989, again
revealed a highly significant main genotype effect (F=12.34, df1/51, p<0.001) and a
significant genotype x day interaction (F=4.37, df1/51, p<0.05). No treatment effect
or genotype x treatment interaction was found (Fscl). Although Figs. 7.3.2B shows
that PDAPP mice improved their performance significantly on Day 2, compared to
Day 1, the separate ANOVA for Day 2 again revealed only a significant main
genotype effect (F=5.15, df1/51, p<0.05), but no significant treatment effect or
genotype x treatment interaction (Fs < 1). Overall, in the cuetask training, 7-8 months
old PDAPP mice were found to display either sensorimotor impairment or basic
learning deficit and the 4-month treatment of EFN44989 did not improve the impaired
performance of the same mice in this task.
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Figure 7.3.3 Performance on the Trials to Criterion Task.
A. Performance of trials to criterion in 7-8 months old mice across the five
platform locations before the treatment, and "n" represents the total number
of animals that survived during the study. B. After 4 months treatment
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Figure 7.3.4 Performance on the Learning Capacity Task.
A. Performance of 7-8 months old mice before the treatment of ELN44989.
B. After 4 months treatment of ELN44989, performance of 11-12 months old mice.
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3. PDAPP mice displayed impaired learning in serial spatial learning before and after
treatment of ELN44989.
As before, trials to criterion was used as a measure to examine the learning rate of the
animals on a series of 5 successive hidden platform locations in watermaze. Figure
7.3.3 shows the results for this task before and after the treatment of ELN44989. As
shown in Fig. 7.3.3A, PDAPP mice displayed significant learning deficit in this task,
as revealed by ANOVA (F=19.25, df1/51, pcO.OOl). After 4 months treatment of
ELN44989, analysis of variance again revealed a significant main genotype effect
(Fig. 7.3.3B: F=13.15, df1/51, p<0.001), but no significant treatment effect or
genotype x treatment interaction (Fs < 1) (Fig. 7.3.3B). The results here indicated that
the 4-month treatment of EFN44989 did not improve the performance of PDAPP
mice on trials to criterion task.
4. PDAPP mice displayed impaired learning in learning capacity task before and after
treatment of EFN44989.
To investigate whether there is any effect of EFN44989 on spatial learning of PDAPP
mice, learning capacity task was then used to test these mice. The results were shown
in Figure 7.3.4. Fig. 7.3.4A shows the performance of PDAPP mice before the
treatment. Analysis of variance revealed a significant genotype effect in this task
(F=23.07, df1/51, p<0.001), suggesting that PDAPP mice were impaired in learning
this task at young age (7-8 months) prior to plaque deposition. After 4 months
treatment of EFN44989, the same mice were tested again with a different set of 10
consecutive platform locations. Interestingly, ANOVA again revealed a significant
main genotype effect (Fig. 7.3.4B: F=11.86, df1/51, p<0.002), but no significant
treatment effect or genotype x treatment interaction (Fs < 1) (Fig. 7.3.4B). These data
again indicated that the 4-month treatment of PDAPP mice with EFN44989 did not
improve the performance in learning capacity task.
5. PDAPP mice displayed deficit of synaptic transmission in the hippocampus after
treatment of EFN44989.
The above behavioural study showed that EFN44989 had no effect on spatial learning
of PDAPP mice. As it is unknown whether the treatment of EFN44989 has any effect
on synaptic transmission of PDAPP mice, the hippocampal basal synaptic
transmission of the same mice, which were behaviourally tested, was further
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Figure 7.3.5 Impaired Basal Synaptic Transmission in PDAPP Mice.
Input-output curves for PDAPP and non-Tg mice. There was only a significant
main genotype effect (p<0.05). The treatment of ELN44989 did not significantly
affect the input-output curves of either non-Tg mice (F=2.18, df1/29, p>0.15)
or PDAPP mice (F<1). N is the total number of animals used in the experiments.








































Figure 7.3.6 Total AfJ Levels in the Brain.
A. Cortical total AR. level (Red bar represents the mean value). The treatment
of ELN44989 did not significantly reduce AR> level in the cortex of PDAPP
mice (p>0.25). B. Hippocampal total AR. level. The treatment of ELN44989 did
not significantly reduce AR> level in the hippocampus (p>0.6) as well.
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investigated. Using in vitro slice electrophysiology, the input-output curves were
recorded from hippocampal slices of the mice (Figure 7.3.5). A significant main
effect of genotype was found (F=4.66, df1/48, p<0.05), but there is no significant
treatment effect (F=1.81, df1/48, p=0.18) or genotype x treatment interaction (F < 1),
suggesting that the treatment of ELN44989 did not improve the reduced level of
synaptic transmission in PDAPP mice.
6. Four months treatment of ELN44989 did not significantly reduce AP levels in
PDAPP mice.
We did not observe any effects of ELN44989 on either spatial learning or synaptic
transmission of PDAPP mice. There are several possible reasons. First, ELN44989
might improve AD-like pathology but not learning and memory of the same mice.
Second, ELN44989 might not also affect AD-like pathology in the treated animals. To
investigate the second possibility, my colleague Dione Kobayashi at Elan completed
ELISAs of total Ap levels in all PDAPP mice used in my behavioural study. Fig. 7.3.6
shows the in vivo effects of chronic treatment of ELN44989 on total Ap levels in both
the cortex and hippocampus of PDAPP mice. Surprisingly, the 4 months treatment of
ELN44989 did not significantly reduce total AP levels in either the cortex (Fig.
7.3.6A: F=1.27, df1/21, p>0.25) or hippocampus (Fig. 7.3.6B: F<1), suggesting that
ELN44989, a y-secretase inhibitor did not effectively inhibit Ap production in PDAPP
mice. It is unclear why this drug did not work in this chronic in vivo study. As
ELN44989 did not show any effect on Ap reduction, it seems very reasonable that it
failed to improve the impaired spatial learning of PDAPP mice. However, due to the
failure of ELN44989 to reduce AP levels, it remains unknown whether more potent
secretase inhibitor that did cause high levels of Ap reduction could rescue the
impaired spatial learning in APP Tg mice.
7.4 Discussion.
1. Side effects ofELN44989, a y-secretase inhibitior.
Although previous reports do not describe side effects of acute or chronic treatment
with DAPT or LY411575, such as coat colour changes or mortality (Dovey et al.,
2001; May et al., 2001), side effects of ELN44989, a more potent y-secretase inhibitor
than DAPT, were observed in this study. Firstly, treatment of the mice with
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ELN44989 induced a significantly higher discontinuation rate than corn oil. Initially,
a total number of 42 mice (non-Tg=24, PDAPP=18) were treated with ELN44989
(lmg/kg). At the end of 4 months treatment, 18 mice had been discontinued. Among
these 18 mice, 9 were found dead in their home cages, the remainder were sacrificed
by named veterinary surgeons in this university due to dramatic weight loss (>40%).
With such a big weight loss (>40%), they would eventually die even if they had not
been sacrificed. The 42.86% discontinuation rate in the ELN44989-treated groups
(8.82% in corn oil-treated groups) suggested that ELN44989 induce a very high
mortality. It is unclear whether the death of animals caused by ELN44989 was
through Notch pathway or other reasons. At least, one possibility is that, ELN44989
had severe toxic gastric or intestinal effects on treated animals, as bleeding in the anus
in all ELN44989-treated mice was also observed. It has recently reported that doses of
10 and 20 mg/ml of Compound X (Seiffert et ah, 2000), a y-secretase inhibitor,
produced severe gastrointestinal toxicities in rats after four daily doses (Searfoss et
ah, 2003).
Secondly, color change (discoloured fur) was observed in all ELN44989-treated mice.
This side effect occurred as early as 4 weeks after ELN44989 treatment. Although not
reported previously (Dovey et ah, 2001; May et ah, 2001; Searfoss et ah, 2003), this
has been seen elsewhere (personal communication with Karen Chen at Elan). The
reason why this effect was not observed in a previous chronic study by May (2001)
was possibly that, white PDAPP mice (Swiss Webster background) were used, so the
color change of coat may not be easy to observe. It is unclear whether lower
concentrations of ELN44989 can prevent these two side effects.
2. ELN44989 had no effects on Aft levels and spatial learning ofPDAPP mice.
Major findings of this study were that chronic treatment with ELN44989 showed no
effects on either synaptic deficits or impaired learning of PDAPP mice, suggesting
that ELN44989 might not be a good compound for the treatment of AD. The ELISA
study by Dione Kobayashi further confirmed that chronic treatment of PDAPP with
ELN44989 produced only a 20% reduction of total A(3 in the cortex, and this
reduction was not significant. Although ELN44989 was found to be a better y-
secretase inhibitor to reduce Ap levels (>80% reduction) in vitro than DAPT, its in
vivo potency was not efficacious.
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In contrast to this study on ELN44989, a group from Wyeth have since reported an
acute effect of DAPT on cognition of Tg2576 mice (Comery et al., 2003). Contextual
fear conditioning was used with acute treatment of Tg2576 mice 3 h before contextual
fear conditioning training. 20-, 36-, 54- and 65-week old Tg2576 mice were treated
with DAPT (lOOmg/kg) and their performance on conditioning was found to be
significantly improved by this acute treatment. The efficacy of DAPT on A(3 levels in
the same Tg2576 mice was not reported, but the authors showed that there was a 55%
peak reduction of AP 4h after acute treatment with DAPT in another cohort of 12-14
weeks old Tg2576 mice (Comery et al., 2003). These results looked very interesting,
as one dose of DAPT seemed enough to rescue the impaired fear contextual
conditioning of Tg2576 mice. As a chronic disease, AD shows progressive memory
loss and other cognitive impairment. It seems very unlikely that one dose of DAPT
could cure the devastating AD, but acute as distinct from chronic effects should still
be considered.
In this study, the failure of ELN44989 to significantly reduce Ap levels and to rescue
impaired spatial learning of PDAPP might not necessarily suggest that y-secretase
inhibitors are ineffective for the treatment of AD. Indeed, compared to other studies
on DAPT, the concentration of ELN44989 used in this study was only 1% of the
DAPT by other groups. In order to produce significant reduction of Ap in vivo, a yet
higher concentration of ELN44989 may be needed. However, due to severe toxic
effects of this compound, it is impossible to further increase the concentration of
ELN44989 for in vivo study as it is not tolerated by the animals. The hope of y-
secretase inhibitor for the treatment of AD is not dead because more selective JLK
isocoumarin inhibitors than DAPT or ELN44989 have recently been developed (Petit
et al., 2001; Petit et al., 2002; Petit et al., 2003). Although these new compounds are
less potent and are reported to exert only an indirect inhibition of y-secretase, they do
act only on APP processing and not the Notch pathway (Esler et al., 2002). This raises
a possibility that these JLK isocoumarin inhibitors may be free of toxicity. To validate
that JLK isocoumarin inhibitors are promising candidates for the treatment of AD,
more in vivo studies are needed to evaluate their efficacy of reducing Ap levels in
APP Tg mice or tangle/plaque mice. Furthermore, behavioural studies are also needed
to assess the effects of JLK inhibitors on cognition of APP Tg mice.
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On the other hand, as at least one group have started clinical studies of y-secretase
inhibitor for a couple of years (Wolfe, 2002), we may not need to wait too long to
learn what the clinical trials will bring us on its potential use for the treatment of AD.
3. Sensorimotor abnormalities in young PDAPP mice.
As shown in Chapters 3 and 4, young PDAPP mice at 6-9 months of age performed as
well as the non-Tg littermates (Figs. 3.3.1 and 4.3.1) on all days of testing, although
old PDAPP mice (18-21 months) displayed a transient deficit in the cuetask on Day 1,
their performance level matched that of old non-Tg controls in subsequent days.
Unlike the mice used in the previous studies, the new cohort of PDAPP mice for this
study displayed significant sensorimotor abnormalities as revealed by cuetask
training. However, although statistically clear, the absolute magnitude of the
impairment (differences in escape latency) of PDAPP mice was very slight on the last
two days of training before the treatment of ELN44989. Similarly, only a very
moderate transgene effect was again observed after 4 months of drug treatment. As all
PDAPP mice could reach less than 10 s of escape latency on the last two days of the
cuetak training, this indicates that young PDAPP mice may not have severe
sensorimotor problem.
It is difficult to explain this difference between the present and previous studies. One
possibility is related to the genetic background of these mice. The background of
PDAPP mice used in my previous studies was mainly on DBA and C57/B6, whereas
that for the present study was a triple background (Swiss Webster, DBA and C57/B6).
We do not know why Elan changed the breeding lines of PDAPP mice to maintain
these mice. Maybe the Swiss Webster is a better mouse strain to develop AD-like
pathology, such as amyloid plaques and gliosis. At least, this seems to be true of the
JNPL3 Tau Tg mouse line, developed by Mayo Clinics. For example, the JNPL3 mice
on Swiss Webster background displayed NFTs as early as 6-9 months (Lewis et al.,
2000), but the C57B/6-background JNPL3 mice did not show any NFTs by 14-15
months of age (personal communication with Dr. Karen Horsburgh).
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Chapter 8: Conclusions and General Discussion.
8.1. Age-related and ase-indepenclent learning deficits in PDAPP mice: evidence for
the amyloid cascade hypothesis.
Although the amyloid cascade hypothesis has become the dominant theory for the
pathogenesis of AD for more than a decade (Hardy and Allsop, 1991), it is still very
puzzling whether amyloid plaques play the central role in dementia and cognitive
impairment in AD. For example, several clinical studies have indicated that senile
plaques are correlated very well with dementia and cognitive decline in AD (Blessed
et ah, 1968; Cummings and Cotman, 1995; Naslund et al., 2000; Roth et al., 1966).
By contrast, other clinical evidence showed that NFTs and/or neuronal loss, rather
than plaques, are highly correlated with dementia and cognitive impairment in AD
(Arriagada et al., 1992; Gomez-Isla et al., 1997; Guillozet et al., 2003; Hyman and
Tanzi, 1992; Wilcock andEsiri, 1982).
Most of recent studies on APP rodents seemed to suggest that soluble AP is more
important than amyloid plaques in causing learning and memory deficits. Firstly,
PDAPP mice consistently display a plaque-independent learning deficit (Chen et al.,
2000; Justice and Motter, 1997; Ramsay and Morris, 1998). Secondly, evidence from
the studies of other known APP Tg lines has indicated that there are indeed plaque-
independent synaptic deficit and learning impairment (Hsia et al., 1999; Janus et al.,
2000; Moechars et al., 1999; Moran et al., 1995; Nalbantoglu et al., 1997; Van Dam et
al., 2003).
In this thesis, a cross-sectional and a longitudinal design were used to investigate the
relationships between learning deficits and amyloid plaques in PDAPP mice. Firstly,
using three different cohorts of naive PDAPP mice, I have indicated that PDAPP mice
simultaneously display an age-independent and a plaque-related learning deficit. Very
interestingly, I have found that the age-related component of cognitive impairment in
old PDAPP mice is highly correlated with plaque burden in the hippocampus.
Secondly, in the longitudinal study, I have found that the same PDAPP mice display
significant age-related learning deficits. In other words, young PDAPP mice (6-9
months) display unimpaired spatial learning, but the same mice exhibit impaired
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learning when they get older (14-15 or 21-22 months). So, the longitudinal study also
suggests that amyloid plaques play a very important role in causing learning deficit.
As the sample size (non-Tg=13, PDAPP=12) for the longitudinal study is relatively
small, compared to that for the cross-sectional study, I did not observe any age-
independent learning impairment. If the sample size for PDAPP is larger, it is very
likely to observe the same age-independent learning impairment as that in the cross-
sectional study. It has also been shown that Tg2576 mice display plaque-related
memory deficits only (Chapman et al., 1999; Hsiao et al., 1996). Recent evidence
further indicated that injection of Ap42 and Ap40 into rat hippocampus induces focal
amyloid plaques, causes deficits in synaptic plasticity and disrupts spatial learning
(Stephan et al., 2001). Therefore, these data have provided strong evidence to support
the amyloid cascade hypothesis.
Although the original theory for the amyloid cascade apparently emphasizes amyloid
plaques being the most important in the pathogenesis of AD (Hardy and Allsop,
1991), recently, Selkoe (2002) has systematically proposed a sequential events for this
hypothesis, in which the important role of soluble Ap in causing early synaptic
function has been recognized (also see Chapter 1). Thus, the results from my
longitudinal and cross-sectional studies, plus many other behavioural and
electrophysiological ones support both accumulation of soluble Ap and amyloid
plaques playing the most important role in causing learning and memory deficits in
APP Tg mice (Hsia et al., 1999; Janus et al., 2000; Moechars et al., 1999; Moran et
al., 1995; Nalbantoglu et al., 1997; Van Dam et al., 2003). Therefore, the findings of
both plaque-independent and plaque-related learning impairment in APP Tg mice are
supportive to the amyloid cascade hypothesis.
8.2. Effects of active A3 immunisation on spatial learning of PDAPP mice and
potential AB immunotherapy) in the treatment ofAlzheimer's disease.
In this thesis, two active Ap immunisation studies have been conducted. However,
neither long-term prevention (prior to any apparent plaque formation in the brain of
PDAPP mice) nor short-term (after plaque deposition) treatment study shows
significant improvement effects on synaptic transmission and spatial learning of
PDAPP mice. Interestingly, the long-term and short-term AP vaccination effectively
reduces levels of AP42 to 60% and 40%, respectively. Thus, these two studies suggest
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that, on the one hand, active A(3 immunotherapy seems very effective in reducing AD-
like neuropathology, such as AP levels, microgliosis and astrocytosis, on the other
hand, active AP immunotherapy is relatively ineffective in improving the impaired
learning of PDAPP mice, possible due to the altered synaptic transmission being
unimproved after active AP immunotherapy.
By contrast, it has been shown that active AP immunisation rescues impaired learning
either in TgCRND8 (Janus et al., 2000) or Tg2576/PSl Tg mice (Morgan et al.,
2000). Recently, Dodart et al showed that one dose of passive AP immunisation
improves impaired object recognition memory in PDAPP mice. The discrepancy
between ours and others may be due to different behavioural paradigms and different
ages of animals tested. For example, only young TgCRND8 mice (from 2- to 6-
months) were tested by Janus et al (2000) in their Ap immunisation study. It can be
argued from the following two aspects for this study. First, no old Tg mice, which
develop large amount of plaques, were tested. Secondly, although young TgCRND8
mice show deficit in the acquisition of the watermaze reference memory task, they
display normal spatial memory in terms of the probe trials employed. It is still unclear
whether old TgCRND8 mice display spatial learning deficits and whether active AP
immunisation can produce similar rescue effects on old animals. Interestingly,
although Morgan et al (2000) reported the rescue effects of AP immunisation on
spatial learning of their Tg2576/PSl Tg mice, the same group recently reported that
short-term active Ap immunisation does not improve performance of old Tg mice
using the same task (Austin et al., 2003). One possible explanation for these two
studies is that early long-term Ap immunisation is effective in preventing impaired
learning, but late Ap immunisation is not effective in improving the impaired learning
in APP Tg mice.
Another explanation for the discrepancy between ours and Janus et al (2000) and
Morgan et al (2000) might be due to the sensibility of behavioural paradigms to Ap
levels. After reanalyzing my data for all vaccinated PDAPP mice from both the
prevention and treatment studies, we have found that, if we divided them in two
groups in terms of AP42 levels, one group displaying about 1000 ng/mg (low level)
and the other group showing about 5000 ng/mg of AP42 (high level), the group with
low Ap levels showed significantly better performance than the other group with high
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Ap levels (t=2.84, df=39, p<0.01). More interestingly, the low-AP group were not
different from non-Tgs in terms of behavioural performance. As Shenk et al (1999)
showed that very early Ap vaccination on PDAPP mice prior to 2 months can produce
more significant effects on Ap levels than the two paradigms used in this thesis, it
might be worth doing a very early Ap vaccination experiment using the trials to
criterion and learning capacity task in the future. By contrast, the performance on the
radial-arm watermaze task by PS 1/APP mice seems not sensitive to both Ap42 levels
and amyloid plaques, as 15-16 months mice display normal performance compared to
non-Tgs (Morgan et al., 2000).
Although active Ap immunotherapy is very effective in improving AD-like
pathology, it is ineffective in rescuing impaired spatial learning in PDAPP mice. Data
presented in Chapter 5 of this thesis seem not to be very supportive to the amyloid
cascade hypothesis, but they are not contradictory to it. Although Ap levels of PDAPP
mice in both the prevention and treatment studies have been significantly reduced by
9- or 5-month Ap vaccination, the post-treatment levels of Ap are still very high. This
might be the reason why I did not observe any rescue effects on spatial learning of
PDAPP mice. Indeed, as vaccinated PDAPP mice with low AP levels do show better
performance than these with high Ap levels, this suggests that, if the vaccination starts
earlier or more vaccines are given to PDAPP mice, we may be able to find a rescue
effect. Moreover, as the new version of the amyloid cascade hypothesis indeed
emphasizes the important role of soluble Ap (i.e. oligomers) in synaptic function and
learning and memory in AD (Selkoe 2002), it is not surprising to observe that the
vaccinated PDAPP mice with relatively high amount of AP levels display impaired
spatial learning and memory. Very interestingly, the finding of vaccinated PDAPP
mice with low AP levels displaying unimpaired behavioural performance might
suggest that there is an Ap Threshold Theory for AD, but more experiments need to
be designed to support this idea in the future.
8.3. PS1 and v-secretase inhibitors: potential novel treatment strategy for the
treatment ofAlzheimer's disease.
To investigate whether the inhibition of y-secretase has any effects on synaptic
transmission and spatial learning of APP Tg mice, two different studies (genetic and
pharmacological) were conducted in this thesis.
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In the genetic study, PSlcKO;APP mice, in which the PS1 gene is conditionally
inactivated in the forebrain 3 weeks after birth, were tested using several cognitive
tasks. Results from this study showed that, compared to age-matched non-Tg controls,
young PSlcKO;APP mice (3-4 months) display normal spatial learning in the visible
cuetask, trials to criterion and learning capacity task, suggesting a significant rescue
effect of PS1 inactivation on spatial learning at young age. However, this study also
showed that, while old PSlcKO;APP mice (15-17 months) display relatively
unimpaired performance on the trials to criterion task, they show significant
impairment in the cuetask and learning capacity task, suggesting only a limited partial
rescue effect of PS1 inactivation in old mice. Moreover, PS1 inactivation effectively
improves AD-like neuropathology such as amyloid plaques, microgliosis and
astrocytosis at both young and old age. It seems very likely that massive accumulation
of mutant APP CTFs causes deficits of spatial learning in old PSlcKO;APP mice.
Future work should further examine the mechanisms by which the build-up of APP
CTFs affects spatial learning.
Secondly, in the pharmacological study, a very potent functional y-secretase inhibitor,
ELN 44989 was administered to chronically treat PDAPP mice. I therefore have
investigated whether it is effective to improve AD-like neuropathology and rescue
impaired spatial learning. Firstly, this chronic in vivo study showed that ELN 44989
does not produce any significant effects on total A(3 levels in the cortex and
hippocampus. Secondly, it also showed that ELN 44989 has no effect on rescuing the
impaired learning in PDAPP mice. However, we observed that the chronic treatment
of ELN 44989 causes serious side effects, including high mortality, gastric problem
and color change, on the animals. By contrast, a y-secretase inhibitor LY411575,
similar to the ELN 44989, was reported to effectively inhibit A(3 accumulation (-80-
90% reduction) and plaque deposition in PDAPP mice after three-month treatment
(May et al., 2001). It is not clear what has caused the different observations between
us and May et al. As ELN 44989 is not effective to improve either AD-like pathology
or impaired learning of PDAPP mice, a more potent but less toxic y-secretase
inhibitor needs to be tested in the future.
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Interestingly, the genetic study on PSlcKO;APP mice indicated that conditional
inactivation of PS1 in the forebrain effectively improves both AD-like
neuropathology and cognitive impairment in young animals, and effectively improves
AD-like pathology but only partially rescues learning impairment in old ones. These
results suggest that inactivation of PS1 is useful to prevent cognitive decline for a
relatively short period, but not for the entire life. Moreover, compared to young APP
mice, young PSlcKO;APP mice show no accumulation of Ap, APP CTFs and other
AD-like pathology, but they display normal spatial learning and memory. Thus, they
are strong evidence to support the amyloid cascade hypothesis. On the other hand, old
PSlcKO;APP mice do not show accumulation of Ap and other AD-like pathology,
but they display age-dependent accumulation of APP CTFs. Although my behavioural
results on old PSlcKO;APP mice are not supportive to the amyloid cascade
hypothesis, in fact, they are not the evidence to be against it. The reason is that
accumulation of APP CTFs itself causes deleterious effects on learning and memory,
8.4. Sensibility of the trials to criterion and learning capacity task in determining age-
related learning deficit in APP Te mice.
In all studies of this thesis, the trials to criterion and learning capacity tasks in the
water maze were developed. In the trials to criterion task, the animals are required to
learn a series of 5 consecutive different platform locations to a strict performance
criterion. In the learning capacity task, the animals need to learn as many platform
locations as they can in a 10-day period. Both tasks require the animals not only to to
encode new spatial information as quickly as they can, but also to keep forgetting the
previously learned locations, or perhaps, the long-term memory traces stored in the
brain. Compared with the conventional reference memory task in the water maze,
these two tasks (collectively, the serial spatial learning task) are more episodic-
memory-like.
It has been shown that the serial spatial learning task is sensitive to detect both
plaque-independent and plaque-related learning deficits in APP Tg models of AD.
Previous studies showed that the standard reference memory task and the DMP task
reveal only age-independent spatial learning deficit in PDAPP mice (Justice and
Motter, 1997; Ramsay and Morris, 1998). One possibility is that these two water maze
tasks is less sensitive than the serial spatial learning task to detect plaque-related
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learning impairment in APP Tg mice. However, recent evidence suggests a second
possibility. By using two different sizes of water maze, Kelly et al (2003) observed
both age-dependent and age-independent learning impairment in APP23 Tg mice,
suggesting that the conventional reference memory task is still sensitive to detect age-
related learning deficit in APP mice.
It seems that the trials to criterion task is not very different from the learning capacity
task, as both tasks require the animal to encode new platform information (or to form
new memory traces in the brain) as fast as they can and to forget old platform
locations (or to erase memory traces for previously learned locations) as much as they
can. The difference between them is that, the former measures the encoding rate for
the individual spatial locations and the latter measures the encoding capacity of the
animals. Obviously, the faster the animals learn each individual platform location
(less trials to reach criterion), the more platform locations the animals will learn
(bigger learning capacity). Indeed, a correlation analysis for all data available for this
thesis indicated that there is a highly significant negative correlation between the trials
to criterion and learning capacity (r=-0.83, p<0.00001). This strongly suggests that the
two tasks are highly dependent. Overall, these two novel tasks in the water maze
should be continuously serving as sensitive ones to investigate age- and plaque-related
learning deficit in animal models of AD and aging brain.
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Relative Contribution of Endogenous Neurotrophins in
Hippocampal Long-Term Potentiation
Guiquan Chen, Roland Kolbeck, Yves-Alain Barde, Tobias Bonhoeffer, and Albrecht Kossel
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Recent evidence has shown that brain-derived neurotrophic
factor (BDNF) is involved in hippocampal long-term potentia¬
tion (LTP). Because the reagents used in acute experiments
react not only with BDNF but also with neurotrophin-4/5 (NT4/5)
and neurotrophin-3 (NT3), we examined the involvement of
these neurotrophins in LTP using two highly specific, function-
blocking monoclonal antibodies against BDNF and NT3, as well
as a TrkB-IgG fusion protein. Our results show that NT3 anti¬
bodies did not have any effects on LTP. However, both TrkB-IgG
fusion proteins and BDNF antibody similarly reduced LTP, sug¬
gesting that only BDNF but no other ligands of the TrkB-
receptor are likely to be involved in LTP induction. The reduc¬
tion in LTP depended on the inducing stimuli and was only
Neurotrophins are proteins that control the survival and differ¬
entiation of many types of neurons during development (Davies,
1994; Lewin and Barde, 1996). In addition, there is increasing
evidence indicating that neurotrophins are also involved in
activity-dependent neuronal plasticity in the developing CNS (for
review, see Lo, 1995; Thoenen, 1995; Berninger and Poo, 1996;
Bonhoeffer, 1996). Compared with NGF, brain-derived neurotro¬
phic factor (BDNF), and neurotrophin-3 (NT3), mRNAs are
highly expressed in the hippocampus and neocortex (Wetmore et
al., 1989; Ernfors et al., 1990; Hofer et al., 1990; Maisonpierre et
al., 1990), and the expression of BDNF is tightly regulated by
neuronal activity (Zafra et al., 1990, 1991; Castren et al., 1992;
Knipper et al., 1994; for review, see Lindholm et al., 1994).
Interestingly, tetanization, a stimulation paradigm used to induce
long-term potentiation (LTP) in the hippocampus, can induce
both BDNF and NT3 mRNA expression in different hippocampal
areas (Patterson et al., 1992; Dragunow et al., 1993). Also, the
release of neurotrophins is dependent on neuronal activity
(Blochl et al., 1995; Blochl and Thoenen, 1995; Griesbeck et al.,
1995). Using BDNF and NT3, Lohof et al. (1993) were the first
to show a direct influence of exogenous neurotrophins on synap¬
tic transmission in neuromuscular synapses in developing Xeno-
pus. Later, several reports demonstrated that acute application of
exogenous BDNF, neurotrophin-4/5 (NT4/5), or NT3 can alter or
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observed with theta-burst stimulation (TBS) but not with tetanic
stimulation. We further observed that LTP was only reduced if
BDNF was blocked before and during TBS stimulation, and
BDNF antibodies did not affect early or late stages of LTP if they
were applied 10, 30, or 60 min after TBS stimulation. These
results point toward a specific and unique role of endogenous
BDNF but not of other neurotrophins in the process of TBS-
induced hippocampal LTP. Additionally, they suggest that en¬
dogenous BDNF is required for a limited time period only
shortly before or around LTP induction but not during the whole
process of LTP.
Key words: BDNF; NT3; NT4/5; monoclonal antibodies; TrkB-
IgG fusion protein; UP
potentiate synaptic transmission in rat hippocampal cultures and
slices (Lessmann et al., 1994; Kang and Schuman, 1995; Levine et
al., 1995). Although these experiments indirectly suggested that
neurotrophins can participate in synaptic plasticity, work with
mice carrying a null mutation in the BDNF gene showed that the
lack of endogenous BDNF leads to drastically impaired LTP
(Korte et al., 1995; Patterson et al., 1996) and to a limited
capability of these animals to perform certain learning tasks
(Linnarsson et al., 1997). Importantly, it was also shown that
reexpression of the BDNF gene (Korte et al., 1996) or treatment
of slices with recombinant BDNF (Patterson et al., 1996) were
both able to restore LTP in slices of these mutant mice within
<14 hr, making unspecific developmental deficits unlikely as an
explanation for impaired LTP.
An additional approach to determine the involvement of en¬
dogenous neurotrophins in LTP is to block their function acutely
in slices from wild-type animals. Two recent studies used a
TrkB-IgG fusion protein (FP) and antibodies (Abs) against the
TrkB receptor to block the ligands or the function of the TrkB
receptor. This led to impaired LTP in slices from rat hippocam¬
pus (Figurov et al., 1996; Kang et al., 1997). Because both BDNF
and NT4/5 can interact with the TrkB receptor, these experi¬
ments still leave the issue unresolved as to which of the two
particular ligands actually contribute to LTP. The situation is
further complicated by the fact that TrkB FPs are not selective for
BDNF and NT4/5 but also bind NT3 (Shelton et al., 1995). The
availability of specific, function-blocking monoclonal antibodies
against BDNF and NT3 allowed us to acutely and selectively
interfere with these neurotrophins and to determine their func¬
tion in hippocampal LTP. We compared their effects on LTP with
those of TrkB-IgG FPs and assessed the time period relative to
the induction of LTP during which neurotrophins need to be
available.
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MATERIALS AND METHODS
Slice preparation. Hippocampal transversal slices (400-/xm-thick) were
prepared from male wild-type mice of SV129 strain (4—8 weeks old)
using conventional techniques (Korte et al., 1995) and maintained under
standard conditions [medium contained (in mM): 124 NaCl, 3 KC1, 1.25
KH2P04, 2 Mg2S04, 26 NaHC03, 2.5 CaCl2, and 10 glucose; at room
temperature) and gassed with 95% 02 and 5% C02. Slices were allowed
to recover in an incubation chamber for at least 1.5 hr at room temper¬
ature before they were transferred to the perfusion chamber and used for
the electrophysiological experiments.
Perfusion of slices with antibodies. The following antibodies were used
for LTP experiments: (1) a TrkB receptor body, which is a fusion protein
between the extracellular domain of the chick TrkB receptor and the Fc
part of a human IgG antibody (Dechant et al., 1993); (2) a mouse
monoclonal antibody (MAB) (clone #21, IgG2B) raised against BDNF,
characterized by its function blocking action with the same specificity as
MAB clone #9 described by Kolbeck et al. (1999); and (3) a mouse
monoclonal function-blocking NT3 antibody (IgGJ (Gaese et al., 1994).
Antibody solutions were freshly prepared in perfusate artificial CSF
(ACSF) from frozen antibody aliquots. The final concentration used for
TrkB-IgG fusion protein, anti-BDNF, or anti-NT3 antibody was 4 p.g/ml.
In the course of this study, we realized that it is of paramount importance
to counteract adhesion of the antibodies to surfaces of beakers, tubing,
etc. Therefore, tubing and beakers were siliconized for 1 hr and dried
afterward. Before the actual experiments, siliconized tubing was washed
extensively with fresh ACSF for 30 min. Additionally, BSA (0.1 mg/ml)
was added to the antibody, as well as to the control solutions. To test for
the presence and stability of the antibodies in the perfusion solution, the
level of antibodies was determined from probes taken at different time
points during perfusion using a specific enzyme immunoassay (ELISA).
All experiments were performed in a blind way; the experimenter per¬
forming the electrophysiological recordings did not know what type of
solution was added to the perfusion medium. A closed-loop perfusion
system was used for all experiments with a total volume of 30 ml of
perfusion medium. During preincubation of slices with either antibody
or control solution, perfusion rates were alternated between fast rate at
40 ml/min, which potentially facilitates diffusion of exogenously applied
substances into slices (Kang et al., 1996), and slow rate at 1 ml/min to
prevent possible damage to the slices. For electrophysiological record¬
ings, perfusion rate was kept constant at 1 ml/min during all experi¬
ments. After each recording, tubings and the recording chamber were
extensively washed with fresh ACSF for 5-10 min.
Electrophysiology. Recordings were performed at 32°C. Slices were
transferred from the incubation chamber to the recording chamber. In
the pretreatment LTP experiments, they were perfused for 1 hr in either
control or antibody-containing medium before electrophysiological re¬
cordings were started. In the other experiments in which antibody or
control aliquots were added at different time points after theta-burst
stimulation (TBS), the control or anti-BDNF antibody solutions were
washed into the recording chamber at 10, 30, or 60 min after TBS,
respectively. Control and antibody experiments were performed at the
same experimental day. Field EPSPs (fEPSPs) of CA1 apical dendrites
were recorded extracellularly with a glass electrode filled with 3 m NaCI
solution (resistance of 4-10 Mfi) at a depth of ~120 jam below the slice
surface. Two stimulating electrodes (monopolar, coated tungsten) were
placed on either side of the recording electrode (within 200- 400 /am).
Stimuli were delivered alternating between these two independent Schaf-
fer collateral-CAl pathways, one serving as test and the other as control
pathway, at a frequency of 0.1 Hz to each pathway. Stimulation in each
pathway was set to elicit a fEPSP with an amplitude of ~40-50%
of maximum. LTP was induced in the testing pathway by either tetanus
consisting of 3 x 30 pulses (100 Hz, 5 sec intertrain interval)
or theta-burst stimulation of three trains (10 sec intertrain interval),
each consisting of 15 [200 msec interstimulus interval (ISI)] x 4 pulses
(100 Hz).
Data analysis. Data were collected with a program written in LAB-
VIEW (National Instruments, Austin, TX) and stored onto computer.
The initial slope and amplitude of fEPSPs evoked by stimulation of the
Schaffer collateral afferents was observed online but later reanalyzed
off-line. Responses in each experiment were normalized to baseline,
which was defined as the mean value obtained in 100 responses before
tetanus or TBS, and shown as mean ± SEM. Experiments were excluded
from the experimental data set if (1) the baseline of testing pathway was
unstable (variability more than ±20%), or (2) the control pathway or the
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Figure 1. Basal synaptic transmission at the Schaffer collateral-CAl
pathway of hippocampal slices is not affected by treatment with TrkB-IgG
fusion protein or BDNF antibody. The slope of field EPSPs was plotted
against stimulus strength (in microamperes). A, TrkB-IgG fusion protein
(triangles, dotted line', n = 1 slices, 4 mice) and controls (diamonds, solid
line; n = 8 slices, 4 mice) (p > 0.2). B, BDNF antibody (triangles, dotted
line\ n = 8 slices, 4 mice) and controls (diamonds, solid line; n = 1 slices,
4 mice) (p > 0.3).
more than ±20%). The "identity" of all slices was not revealed to the
experimenter performing the electrophysiological recordings before the
analysis was completed. As statistical test, the unpaired one-tailed Stu¬
dent's t test was used. A one-tailed test was chosen because the effect of
the antibody and fusion protein treatments, if any, should be directional
i.e., with smaller LTP in the experimental group than the respective
controls. Significance levels are indicated in text, p > 0.05 were consid¬
ered as not significant.
RESULTS
Effects of TrkB-IgG fusion protein and BDNF
antibodies on basal synaptic transmission
We first tested whether the basal synaptic transmission at the
Schaffer collateral-CAl synapses was affected by pretreatment of
the slices with TrkB-IgG FP or anti-BDNF antibody. Basal syn¬
aptic transmission was assessed in two ways. First, we measured
the input-output curves of synaptic strength by plotting the slope
of the fEPSPs versus the stimulus strength in control and anti¬
body-fusion protein-treated slices. As shown in Figure IA, the
size of field EPSP slope in TrkB-IgG FP-treated slices was not
significantly lower than in the controls for all the stimuli used.
Also, incubation of slices with anti-BDNF monoclonal antibody
for 1 hr did not show any effect on the input-output curves (Fig.
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IB). We also compared the maximal response that we could elicit
in control and antibody treated slices. The maximal slope of field
EPSPs under treatments with both antibodies was also not signif¬
icantly reduced from control slices (data not shown). The data
above suggest that there is no deficit in basal synaptic transmis¬
sion after acutely blocking endogenous BDNF with BDNF anti¬
bodies or other TrkB ligands with a TrkB-IgG fusion protein in
hippocampal slices.
Effects of TrkB-IgG fusion proteins and BDNF
antibodies on short-term plasticity
We next examined the presynaptic function in antibody-treated
slices checking two forms of short-term synaptic plasticity in the
Schaffer collateral-CAl pathway of hippocampal slices: paired-
pulse facilitation (PPF) and post-tetanic potentiation (PTP).
First, we measured PPF in control and antibody-treated slices.
PPF is a form of presynaptic short-term plasticity in which the
response of a neuron to the second of two consecutive stimuli
with a given ISI to the first one is increased (Katz and Miledi,
1968; Zucker, 1989). One hour after perfusion of the slices with
control or antibody solutions, we tested PPF by using ISIs of 30,
40, 60, and 100 msec in control and antibody-treated slices. We
found that PPF was reduced in neither TrkB-IgG fusion protein-
treated slices compared with control slices (p >0.2 for all ISIs;
one-tailed t test) (Fig. 2A) nor in BDNF antibody-treated slices
(p > 0.2 for all ISIs; one-tailed t test) (Fig. 2B). No deficits in PPF
suggest that presynaptic forms of short-term plasticity stay normal
after blocking endogenous BDNF or other TrkB ligands in
antibody-treated slices. These results are consistent with our
earlier findings in BDNF mutant mice (Korte et al., 1995). We
also measured PTP, another form of short-term plasticity induced
by tetanic stimulation, by averaging the EPSPs during the first
minute after tetanic stimulation (average of six EPSPs) and cal¬
culating the ratio between this and the baseline value. We found
that the size of PTP immediately after tetanic stimulation was not
significantly reduced in TrkB receptor body-treated slices (TrkB-
IgG, 301 ± 43%; n = 6; control, 281 ± 20%; n = 6; p > 0.3;
one-tailed t test) (Fig. 3/4), as well as BDNF antibody-treated
slices compared with their controls (BDNF Ab, 324 ± 27%; n =
7; control, 264 ± 25%; n = l;p> 0.08; one-tailed t test) (Fig. 4A).
Together, the above results indicate that neither TrkB-IgG FP nor
BDNF antibody alter short-term plasticity in hippocampal slices,
thus suggesting that presynaptic neurotransmitter release is not
disturbed by blocking ligands of TrkB receptor.
TrkB-IgG fusion protein attenuates LTP induced by
TBS but not by tetanus
At present, two kinds of LTP-inducing stimuli, tetanus and TBS,
are widely used to induce LTP in hippocampal slices. Both
protocols were applied in our experiments in combination with
the blockade of neurotrophins. First, we checked the effect of
TrkB-IgG FP on LTP induced by tetanus. After the slice was
superfused by medium containing either 4 ^xg/ml FP or the
control solution for 1 hr, three trains of 100 Hz tetani were
delivered to the Schaffer collateral-CAl synapses to induce LTP.
We found that LTP measured 1 hr after tetanus was not reduced
by the TrkB-IgG FP compared with control slices (average slope
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Figure 2. Short-term plasticity measured by PPF remains normal and
unaffected at the Schaffer collateral-CAl pathway of hippocampal slices
after treatment with TrkB-IgG fusion protein or BDNF antibody. Plot
depicting the percent ratio of responses to the second pulse relative to the
first one. Pairs of pulses were delivered at interpulse intervals of 30, 40,
60, and 100 msec. A, TrkB-IgG fusion protein-treated slices (triangles,
dotted line; n = 7 slices, 4 mice) versus control slices (diamonds, solid line;
n = 8 slices, 4 mice). B, BDNF antibody-treated slices (triangles, dotted
line; n = 8 slices, 4 mice) versus control slices (diamonds, solid line; n =
7 slices, 4 mice).
24%; n = 6; control, 135 ± 10%; n = 6;p > 0.2; one-tailed t test)
(Fig. 14). TBS constitutes another important stimulus protocol to
induce LTP. Compared with tetanus, TBS is a weak stimulus, and
it is designed to mimic the theta rhythm in the hippocampus. We
therefore also used this stimulus paradigm to induce LTP. In
contrast to the tetanus-induced LTP, we found a significant re¬
duction in LTP 1 hr after TBS in TrkB-IgG fusion protein-
treated slices compared with their controls (average slope of
fEPSPs to baseline 55-60 min after TBS: TrkB-IgG, 132 ± 14%;
n = 7; control, 167 ± 12%; n = 5;p < 0.04; one-tailed t test) (Fig.
3B). Interestingly, PTP was also significantly lower in the treat¬
ment group, similar to the results of Figurov et al. (1996), who
used a similar stimulation paradigm to test the effects of TrkB-
IgG fusion proteins. Synaptic transmission in the control pathway
remained unaffected (average slope of fEPSPs to baseline in the
nontetanized pathway 1 hr after TBS: TrkB-IgG, 93 ± 5%; n =
7; control, 93 ± 3.0%; n = 5; p > 0.45; one-tailed t test). This
confirms previous reports (Figurov et al., 1996; Kang et al., 1997)











































-60 10 20 30 40
Time [mln]
50 60 70 80
Figure 3. Effects of blocking all endogenous TrkB ligands on LTP.
Pretreatment with TrkB-IgG fusion protein for 1 hr reduces LTP in a
stimulus-dependent manner; only LTP induced by TBS at the Schaffer
collateral-CAl synapses of hippocampal slices is affected but not LTP
induced by tetanic stimulation. Field EPSP slopes were plotted as percent
of baseline (mean ± SEM). Straight black line represents the presence of
TrkB-IgG fusion protein. First data point after LTP induction represents
FTP. A, Tetanus-induced LTP and the effects of TrkB-IgG fusion protein
(TrkB-IgG, n = 6 slices, 4 mice; control, n = 6 slices, 4 mice). B,
TBS-induced LTP and the effects of TrkB-IgG fusion protein (TrkB-IgG,
n = 7 slices, 4 mice; control, n = 5 slices, 4 mice).
suggesting that ligands of TrkB receptor might have direct effects
on TBS-induced LTP.
BDNF antibody reduces LTP induced by TBS but not
by tetanus
The experiments above showed that blocking ligands of TrkB
receptor reduced TBS-induced LTP. However, it still remains
unclear which of the endogenous ligands of the TrkB receptor
(BDNF, NT4/5, or both) participate in the process of LTP.
Therefore, in the following experiments, we also used a specific
monoclonal antibody against BDNF to determine whether block¬
ing endogenous BDNF alone will affect hippocampal LTP in the
same way. As before, we first checked the effect of BDNF anti¬
body on tetanus-induced LTP and found that, in the presence of
4 ju.g/ml BDNF antibody, LTP was again not significantly reduced
(average slope of fEPSPs to baseline 55-60 min after tetanus:
BDNF Ab, 138 ± 16%; n = 7; control, 151 ± 18%; n =l\p> 0.3;
one-tailed t test) (Fig. 4A). Slices pretreated with 4 p.g/ml BDNF
antibody for 1 hr and stimulated with TBS, however, showed
significant reduction in LTP (average slope of fEPSPs to baseline













-60 10 20 30 40
Time [min]













-60 10 20 30 40
Time [min]
50 60 70 80
Figure 4. Effect of selectively blocking endogenous BDNF on LTP.
Pretreatment with BDNF antibody for 1 hr significantly reduces LTP
induced by TBS but not by tetanic stimulation. A, Effects of BDNF
antibody on tetanus-induced LTP (BDNF Ab, n = 7 slices, 4 mice;
control, n = 1 slices, 4 mice). B, Effects of BDNF antibody on TBS-
induced LTP (BDNF Ab, n = 6 slices, 4 mice; control, n = 7 slices, 4
mice).
157 ± 12%; n =7;p < 0.018; one-tailed t test) (Fig. 47?), whereas
basal synaptic transmission in the control pathway remained
unaffected (average slope of fEPSPs to baseline in the nonteta-
nized pathway 55-60 min after TBS: BDNF Ab, 85 ± 1%; n = 4;
control, 90 ± 4%; n = A;p > 0.2; one-tailed t test). The difference
between the two groups became apparent immediately after TBS.
Thus, PTP after TBS stimulation was reduced by application of
BDNF antibodies in contrast to PTP after tetanic stimulation.
Together, these results show that hippocampal LTP is signifi¬
cantly reduced by the BDNF-antibody and to a comparable
degree as seen with TrkB-IgG FP.
Anti-NT3 antibody does not block LTP induced by
either tetanus or TBS
Previous studies that applied neurotrophins exogenously to the
medium have suggested a direct role for NT3 in the process of
LTP. We therefore asked the question whether blocking of en¬
dogenous NT3 by a specific function-blocking monoclonal anti¬
body alters the induction or expression of hippocampal LTP.
First, we checked the antibody effect on basal synaptic transmis¬
sion and short-term plasticity. We found that neither basal syn¬
aptic transmission nor short-term synaptic plasticity in hippocam¬
pal slices were affected (data not shown). Second, we pretreated
slices with antibodies for 1 hr and recorded LTP in control and
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Figure 5. Effect of blocking endogenous NT3 on LTP. NT3 antibody
does not affect LTP induced by either tetanus or TBS. Pretreatment time
for slices was again 1 hr before recordings were started. A, Effects of NT3
antibody on tetanus-induced LTP (NT3 Ab, n = 14 slices, 10 mice;
control, n = 15 slices, 9 mice). B, Effects of NT3 antibody on TBS-induced
LTP (NT3 Ab, n = 13 slices, 10 mice; control, n = 11 slices, 8 mice).
NT3 antibody-treated slices. We also did not find any significant
reduction effect in NT3 antibody-treated slices on either tetanus-
induced LTP (average slope of fEPSPs to baseline 55-60 min
after tetanus: NT3 Ab, 160 ± 12%; n = 14; control, 182 ± 10%;
n = 15; p > 0.09; one-tailed t test) (Fig. 5A) or TBS-induced LTP
(average slope of fEPSPs to baseline 55-60 min after TBS: NT3
Ab, 190 ± 11%; n = 13; control, 194 ± 16%; n — 11; p > 0.2;
one-tailed t test) (Fig. 5B). These results indicate that endogenous
NT3 seems not to be directly involved in hippocampal LTP.
BDNF antibody does not significantly reduce LTP when
applied after TBS
Because the data thus far indicate that endogenous BDNF but
not NT-4/5 or NT3 directly participates in TBS-induced LTP, we
were then interested in determining the time during which BDNF
needs to be present. Is endogenous BDNF required during a
longer time period before and after LTP induction, arguing for a
more permissive role, or might it be only required during the time
period of LTP induction, in line with an instructive role of the
protein? To address this question, we washed the BDNF antibody
into the recording chamber at different time points (10,30, and 60
min after delivery of TBS), and LTP was recorded for at least 1
hr after antibody infusion. In these experiments, we only used
slices with a strong initial PPF (>200% at 30 msec ISI), because



































10min alter 30min after 60min after
Time [mln]
Figure 6. Effect on LTP is dependent on the time when endogenous
BDNF is blocked by the antibodies. A, BDNF antibodies do not reduce
LTP significantly when applied 10 min after TBS. B, Applications 30 or
60 min after TBS also do not affect LTP and its maintenance. Field
EPSP slopes were plotted as percent of baseline. Bars indicate level of
LTP at the end of each recording averaged over a 5 min period. Late
phase LTP (3 hr after TBS) was measured for 30 and 60 min treatment
groups (10 min group: BDNF Ab, n = 9 slices, 7 mice; control, n = 8
slices, 7 mice; 30 min group: BDNF Ab, n = 6 slices, 6 mice; control,
n = 4 slices, 4 mice; 60 min group: BDNF Ab, n — 5 slices, 5 mice;
control, n = 5 slices, 5 mice).
LTP, important for long-term recordings. When the BDNF anti¬
body was applied 10 min after TBS, we found that early phase
LTP in BDNF antibody-treated slices was reduced; however, this
reduction was not significant (average slope of fEPSPs to baseline
90 min after TBS: BDNF Ab, 177 ± 23%; n — 9; control, 223 ±
24%; n = 8;p > 0.1; one-tailed t test; control pathway: BDNF Ab,
84 ± 5% n = 6; control, 97 ± 8%; n = 5; p > 0.1) (Fig. 6A).
Although the greater variability of the data in this experiment
require a cautious interpretation and conclusion about the ab¬
sence of a significant reduction effect, it is important to note that
wash-in of the antibodies does not cause any increase in the
difference between the two groups. Second, the smaller LTP
present in the antibody group already exists from the very begin¬
ning after TBS, that is, at a time before the antibodies were
washed in. Together, this experiment suggest that, after induc¬
tion, endogenous BDNF does not seem to be required anymore
for the maintenance of early phase LTP. We also tested whether
blocking of BDNF had effects on the later periods of LTP. For
this, antibodies were also applied 30 or 60 min after TBS, and
long-term recordings (>3 hr) were made. There was no significant
reduction of long-lasting LTP in antibody-treated slices (30 min
after treatment-average slope of fEPSPs to baseline 180 min
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after TBS: BDNF Ab, 164 ± 32%; n = 6; control, 167 ± 9%; n =
4\p> 0.5; one-tailed t test; 60 min after treatment-average slope
of fEPSPs to baseline 180 min after TBS: BDNF Ab, 179 ± 21%;
n = 5; control, 180 ± 38%; n = 5\p > 0.5; one-tailed t test) (Fig.
6B). These results strongly suggest that, after the delivery of TBS,
endogenous BDNF is not required, for neither early nor medium-
to-late phase LTP.
DISCUSSION
Although several recent studies have focused on the role of
BDNF in neurotransmission and LTP within the hippocampus,
data on the potential involvement of other neurotrophins are
sparse and mainly based on experiments using application of
exogenous neurotrophins. With regard to potentiation of synaptic
strength in CA1 (the area investigated in our study), BDNF and
NT3 seem to be equally effective (Kang and Schuman, 1995). In
this study, we specifically addressed the question as to what role
the endogenous neurotrophins BDNF, NT4/5, and NT3 play in
the process of LTP.
Specificity of neurotrophic action on LTP
Direct evidence for the involvement of endogenous BDNF on
LTP has been obtained by experiments using BDNF knock-out
mice that show greatly reduced enhancement (Korte et al., 1995).
Unlike NT3 -/— animals, BDNF null mutants survive long
enough for the kind of experiments to be performed in the
postnatal hippocampus. LTP can be "rescued" in BDNF -/- and
+/— animals by incubating these slices either in recombinant
BDNF (Patterson et al., 1996) or by reintroducing the BDNF
gene (Korte et al., 1996). Additionally, two recent studies dem¬
onstrate that blocking the endogenous ligands of the TrkB recep¬
tor in slices by TrkB-IgG FP also affects LTP (Figurov et al., 1996;
Kang et al., 1997). These studies left the question unresolved as to
whether the effect was obtained by blockade of endogenous
BDNF, by blockade of NT4/5, or both. Although the relative
abundance of BDNF could be taken as evidence for a significant
physiological role (Ernfors et al., 1990; Hofer et al., 1990; Mar¬
tinez et al., 1998), it is clear that NT4/5 is also expressed in the
hippocampus during all stages of development (Klein et al., 1992;
Timmusk et al., 1993). Experiments using a TrkB-IgG FP and a
BDNF-specific antibody enabled us to distinguish between the
roles of NT4/5 and BDNF in hippocampal LTP. Although TrkB
fusion protein bind equally to NT4/5 and BDNF and with slightly
lower affinity, even to NT3 (Shelton et al., 1995), the similar
reduction in LTP seen in response to the fusion protein and the
BDNF-specific antibody argues against a direct and necessary
involvement of NT-4/5 in hippocampal LTP.
So far, no clear evidence is available on the role of endogenous
NT3 in the process of hippocampal CA1 LTP. Although NT3 and
TrkC are strongly expressed early in development, the expression
of both is weaker but still present within the adult hippocampus
(Ernfors et al., 1990; Maisonpierre et al., 1990; Lamballe et al.,
1994; Martinez et al., 1998). Previous studies have shown that
exogenous NT3 added to the perfusion medium of slices leads to
a fast potentiation of synaptic strength in the CA1 region of
hippocampus, similar to the effects obtained with BDNF (Kang
and Schuman, 1995), suggesting that NT3 could be potentially as
important as BDNF for LTP. The experiments presented here
tested the role of endogenous NT3 in LTP by blocking its func¬
tion through a specific antibody. They show that blocking of NT3
affects neither TBS- nor tetanus-induced LTP. Given that both
the NT3 and the BDNF antibodies are IgG molecules, their
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diffusion properties should be very similar, and both should reach
the same sites. Therefore, our results strongly argue against a
direct role of endogenous NT3 in the induction of hippocampal
CA1 LTP. A similar conclusion was recently drawn by Kokaia et
al. (1998) for LTP in the lateral perforant path-granular cell
pathway. However, it was based on results using heterozygous
+/— NT3 knock-out mice, because of the nonviability of the
homozygous -/— mice. Several reports document the fact that
the presence of one NT3 allele has readily measurable functional
consequences, for example, on the number of sensory neurons or
on muscles spindles (Ernfors et al., 1994; Airaksinen and Meyer,
1996; Airaksinen et al., 1996).
Previous findings about NT3 and synaptic transmission may
then have been caused by fast, short-term effects of NT3 through
increase in ovoked EPSC amplitude or increase in miniature
EPSC frequency akin to the effects observed for BDNF of minis,
not directly related to LTP (Lohof et al., 1993; Lessman et al.,
1994; Levine et al., 1995; Li et al., 1998). Moreover, the increase
of synaptic transmission by exogenous NT3 may also have been
brought about by the secondary release of BDNF. Neurotrophins
can trigger the release of other neurotrophins in dissociated
cultures of hippocampal neurons (Canossa et al., 1997) and PC12
cells (Kruttgen et al., 1998). Neurotrophin-induced neurotrophin
release could therefore not only be an explanation of the NT3
results, but it could also constitute an important factor during
normal LTP induction. Still, the lack of any effects of NT3
blockade on LTP makes it highly unlikely that this neurotrophin
is directly involved in LTP or that BDNF-induced release of
other members of the neurotrophin family is involved in LTP
induction.
Stimulus dependency
Interestingly, blocking of BDNF by antibodies only impaired
LTP induced by theta-burst stimulation but not by tetanic stim¬
ulation, whereas in BDNF knock-out mice, tetanic stimulation-
induced LTP was strongly impaired (Korte et al., 1995, 1996;
Patterson et al., 1996). One possible explanation for the failure of
BDNF antibodies to block tetanus-induced LTP is that BDNF
levels after a tetanus might exceed the buffering capacities of the
antibody in the tissue at the critical time point. In fact, a number
of reports showing that BDNF is released in an activity-
dependent manner (Blochl and Thoenen 1995; Blochl et al., 1995;
Thoenen, 1995) would predict that BDNF concentrations are
considerably higher after a tetanus than after TBS, thereby pro¬
viding a straightforward explanation for this observation.
A second explanation is that tetanus and TBS activate different
signaling pathways that are necessary for LTP induction (Kang et
al., 1997). Small differences in stimulation paradigms are known
to trigger different signaling pathways leading to potentiation,
depotentiation, or depression of synapses (Staubli and Chun,
1996; Xu et al., 1998). Thus, unlike tetanic stimulation, TBS could
act through a pathway that involves immediate BDNF effects. In
particular, application of exogenous BDNF can occlude subse¬
quent potentiation induced by TBS but not by tetanus (Kang et
al., 1997). However, because tetanic stimulation-induced LTP was
so strongly diminished in BDNF knock-out mice, these additional
signaling pathway(s) would have to depend on the constitutive
presence of BDNF. BDNF could activate gene expression
through cAMP-response element binding protein, an important
component of LTP in hippocampus (Bourtchuladze et al., 1994;
Finkbeiner et al., 1997). Thus, these additional pathways in LTP
may be impaired and not be activated by tetanic stimulation in
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BDNF knock-out mice while they were active when endogenous
BNDF was blocked by antibodies only for a short period of time.
Time dependency of BDNF requirement
A major question concerning the role of BDNF in LTP is the
time period during which BDNF has to be present to exert its
effects. One hypothesis is that BDNF acts as a retrograde mes¬
senger that is released during LTP induction from the dendrites
of pyramidal neurons and subsequently induces the potentiation
of synaptic transmission. Direct evidence proving this hypothesis
is still missing. Using the BDNF antibody, we could acutely block
endogenous BDNF during different time periods relative to the
induction of LTP to determine when endogenous BDNF is
needed for induction or expression of LTP. Our results show that
the presence of BDNF antibodies in the superfusion solution for
80 min before LTP induction significantly reduced LTP induced
by TBS from the beginning, which suggests that BDNF is needed
during the induction process or before. Figurov et al. (1996) have
recently described for young animals that BDNF may influence
LTP by changing the effectiveness of tetanic stimulation or TBS
via facilitation of synaptic transmission. This effect also led to
enhanced paired-pulse facilitation at short interpulse intervals. In
our experiments, blockade of BDNF had no measurable effects
on basic synaptic transmission (Figs. 1, 2) or on synaptic depres¬
sion measured during TBS or tetanus stimulation. BDNF there¬
fore seems to affect LTP induction directly rather than by chang¬
ing the effectiveness of the LTP-inducing stimulus.
Infusion of the antibody starting at different time points after
TBS did not significantly reduce early (90 min after TBS) or late
(up to 3 hr after TBS) LTP. Although in the 10 min postappli-
cation experiment the larger variability of the data may have
obscured a potential significant reduction in LTP by the antibod¬
ies, later stages of LTP (up to 3 hr after TBS) clearly remained
unaffected when the antibodies were applied 30 or 60 min after
TBS. Endogenous BDNF therefore seems to be only required
within a short time period before (80 min) or around the time of
induction of TBS-induced LTP. Assuming similar short penetra¬
tion times of the BDNF antibody, these results seem to be in
contrast to the results obtained by Kang et al. (1997). Using
TrkB-IgG fusion proteins, they found that the application 30-60
min after LTP could still block late phase of LTP, whereas later
application had no effect. Because in these experiments a differ¬
ent tetanic stimulation protocol (1 sec at 100 Hz, three times, 5
min apart) was used to induce late phase LTP, this could indicate
that the pattern of stimulation might have relevant consequences
on the effect of BDNF on later stages of LTP. Another explana¬
tion for the different findings may be differences between the
onset of blocking in the two sets of experiments. A delayed onset
of blocking in the postapplication experiments with the antibody
could exceed a potential critical time window during which
BDNF is needed. Unfortunately, the question of when the onset
of the critical blocking concentration of the antibodies within
tissue is reached cannot conclusively be answered. Thus, postap¬
plication experiments in which the antibodies were applied after
LTP induction can only give a rough estimate of the temporal
requirements of BDNF for LTP.
In summary, our results provide clear evidence that endoge¬
nous BDNF plays a unique and specific role in LTP. We could
show that, under the same stimulus conditions and similar block¬
ing antibody concentrations, other neurotrophins are not involved
in CA1 LTP. Our study demonstrates that BDNF affects LTP
directly and not via secondary effects through induced release of
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other neurotrophins. Although the exact mechanism of the
BDNF action still remains unclear, our results further show that
the lack of BDNF for a relatively short period of time, before but
not after LTP-induction, is sufficient to block LTP. This seems to
point toward the possibility that BDNF is important during LTP
induction. However, the need for a constitutive activation of TrkB
receptors before LTP induction cannot be excluded and may be
very important for the activation of other LTP relevant pathways.
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Mice that overexpress the human mutant amyloid precursor
protein (hAPP) show learning deficits, but the apparent lack of
a relationship between these deficits and the progressive p-
amyloid plaque formation that the hAPP mice display is puzzling.
In the water maze1, hAPP mice are impaired before and after
amyloid plaque deposition2"7. Here we show, using a new water-
maze training protocol, that PDAPP mice8 also exhibit a separate
age-related deficit in learning a series of spatial locations. This
impairment correlates with P-amyloid plaque burden and is
shown in both cross-sectional and longitudinal experimental
designs. Cued navigation and object-recognition memory are
normal. These findings indicate that AP overexpression and/or
AP plaques are associated with disturbed cognitive function and,
importantly, suggest that some but not all forms of learning and
memory are suitable behavioural assays of the progressive cogni¬
tive deficits associated with Alzheimer's-disease-type pathologies.
We have developed a new water-maze protocol for mice in which,
after they learn to escape quickly and reliably onto the hidden
platform at one location, we move the platform to a new location.
Numerous locations are used successively, one at a time. In such a
procedure, earlier locations of the platform will be encoded in long-
term memory, potentially causing interference. Memory retrieval
must therefore be selective for the most recently encoded location,
an 'episodic-like' component of the task. The idea behind using
such a procedure, embedded within a larger test battery, derives
from lesion and single-unit recording studies in rodents that
implicate the hippocampal formation in only certain aspects of
spatial, working- or episodic-like memory9"13. Such a protocol is
worth exploring as, in the PDAPP mouse, the highest density of p-
amyloid plaques is first seen in the outer molecular layer of the
dentate gyrus and other regions of the hippocampus.
PDAPP and non-transgenic (non-Tg) littermate control mice









































Figure 1 Age-related and age-independent deficits in spatial learning in PDAPP mice.
Analysis of variance of 'trials to criterion' (3 successive trials with mean escape latency
< 20 s) for each platform location of the first place navigation task revealed a significant
groups x age effect (F= 5.27, d.f. 2/93, P < 0.01). This interaction justified separate
analyses of the two groups, a, PDAPP mice. Trials to criterion (inclusive) for each
successive platform location in the main series of five locations revealed a significant
age-related worsening of performance (F= 8.32, d.f. 2/46, P = 0.001) and a locations x
age interaction (F = 2.17, d.f. 6.59/151.7, P< 0.05; Greenhouse-Geisser correction),
b, Non-Tg mice also showed a modest decline with age (F = 7.24, d.f. 2/47, P< 0.005)
but no interaction, c, Platform location 1. A separate analysis of platform location 1
revealed poorer performance by the PDAPP mice which learned more slowly than non-Tgs
(f = 15.2, d.f. 1/93, P< 0.001) but there was no age-related effect or interaction,
d, Platform locations 4 and 5. There were significant main effects of group and age and,
critically, a group x age interaction (F= 8.30, d.f. 2/93, P< 0.001). This was because
the PDAPP mice got worse with age (F=12.56, d.f. 2/46, P< 0.0005) at a much faster
rate than non-Tgs (F=4.45, d.f. 2/47, P< 0.05). Results shown are mean ± 1 s.e.m.
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platform in the pool. Performance in the initial cued-navigation
task (see Methods) revealed no persistent sensorimotor or motiva¬
tional abnormalities. Escape latencies averaged less than 10 s in all
groups by the end of this pretraining.
Two key findings emerged in the new 'training-to-criterion' task,
which requires the learning of five successive platform locations.
The first of these (cross-sectional study) is a striking age-related
deficit in the number of trials required to reach the performance
criterion as the mice learned the series of individual platform
locations (Fig. la). Young PDAPP mice (6-9 months) improved
such that criterion was reached in fewer trials for later platform
locations, whereas middle-aged (13-15 months) and old PDAPP
animals (18-21 months) took longer to learn each new location.
The non-Tg control groups did not show this pattern (Fig. lb).
Second, the PDAPP groups of all ages took longer to learn the first
platform location of the series than the non-Tg groups (Fig. lc).
This second deficit was age-independent, in contrast to the age-
related learning deficit apparent for spatial locations 4 and 5 in the
PDAPP groups (Fig. Id).
Measured over the first three trials of training, swim speeds of
PDAPP and non-Tg mice declined in parallel as a function of age,
with PDAPP mice swimming only slightly more slowly (0.024 m s-1)
than non-Tgs (Fig. 2a, b). Fig 2c shows the swim-paths of repre¬
sentative animals for all trials of location 5 at each age. The young
PDAPP mouse reached the performance criterion (trials labelled CI
to C3) as quickly as its non-Tg control (top two rows). In contrast,
the middle-aged and old PDAPP mice displayed persistent deficits
(taking 13 and 19 trials, respectively, to learn, compared with 4 and
6 trials by non-Tgs). The paths taken by the older PDAPP animals
were noteworthy in two respects. First, path length showed great
variability from trial to trial until the criterion was reached,
suggestive of a retrieval deficit. Second, there was little indication
of thigmotaxis (that is, staying near the side walls) which is a pattern
ofbehaviour frequently displayed in the standard reference memory
task by mice that fail to learn well.
The test of 'learning capacity' provided a point of comparison
between the cross-sectional and longitudinal components of the
study. Both revealed a greater age-related decline in the PDAPP
groups (Fig. 3). This deficit was remarkably similar in both the
cross-sectional (Fig. 3a) and longitudinal (Fig. 3b) data.
The brains ofa subset ofPDAPP mice in the cross-sectional study
were analysed using the anti-AP monoclonal antibody 3D6 which
shows diffuse plaques. Very few plaques were visible in scattered
regions of the hippocampal formation at 9 months (Fig. 4a, young
mutant animal). By 16-17 months, plaque density was higher,
particularly in the termination zones of the axons of layers II and







Figure 3 An age-related decline in learning capacity in PDAPP mice.The y axes show
the number of successive spatial locations of a single hidden platform learned to criterion
in 10 d of training ('learning capacity'). Older PDAPP mice performed significantly more
poorly than older non-Tgs (interaction effect for cross-sectional: F = 4.05, d.f. 2/93,
P< 0.05; longitudinal: F = 6.83, d.f. 2/46, P< 0.005). a, Cross-sectional study. There
was a trend towards an age-related decline in learning capacity in non-Tgs (F = 2.94,
d.f. 2/47, 0.10 >P> 0.05), but the decline was highly significant in the PDAPP mice
(F = 8.84, d.f. 2/46, P< 0.005). b, Longitudinal study. Learning capacity declines in the
same age-related way in individual PDAPP mice retested throughout the lifespan.
Non-Tgs again showed no change in learning capacity as a function of age (F= 1.66,
d.f. 2/24, P> 0.2), whereas the PDAPP mice learned steadily fewer platform locations
[F = 18.30, d.f. 2/22, P< 0.001). Results shown are mean ± 1 s.e.m.
a Platform location 1
~ 0.4







































Figure 2 Swim speeds and swim paths, a, b, Mean (± s.e.m.) swim speeds over the first
three trials of training to the first, and the 4th and 5th platform locations. These trials were
chosen because, with the performance criterion being three trials with an escape
latency less than 20 s, the first three trials of training are only ones for which we have
data from all animals. Swim-speed declines with age (location 1: F = 27.46, d.f, 2/93,
P< 0.001; locations 4 and 5: F = 26.67, d.f. 2/93, P< 0.001). The small but
significant difference between PDAPPs and non-Tgs (overall: 0.024 m s"1; location 1:
0.10 > P> 0.05; locations 4 and 5: F —18.91, d.f. 1/93, P< 0.001) did not change as
a function of age (F< 1). c, Paths taken by representative animals (that is, close to the
group mean in terms of trials to criterion) in learning the 5th location at each of the three
ages. Note similar patterns in PDAPP and non-Tg mice at 6-9 months, but circuitous
paths taken by the PDAPP mice on some but not all trials at 13-15 and 18-21 months,
d, A PDAPP mouse on the hidden escape platform in the water maze.
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III entorhinal cells in the outer blade of the molecular layer of the
dentate gyrus and stratum moieculare lacunosum of area CA1
(Fig. 4b, middle-aged animal). Occasional plaques were seen in
cortex, particularly the cingulate cortex. By 21 -22 months, amyloid
plaques were apparent through many regions of the hippocampal
formation, the cingulate cortex, insular cortex dorsal to the rhinal
fissure and entorhinal cortex (Fig. 4c, old animal). A zone ofcortex
between these areas showed a lower density ofamyloid plaques but a
light background of diffuse staining. No amyloid plaques were
observed in control mice. (3-Amyloid plaque burden in the hippo¬
campus increased as a function of age as described previously
(Fig. 4d)8,14. Behavioural performance declined as a function of
plaque burden (Fig. 4e). A scatter plot of middle-aged and old mice
only revealed a significant negative correlation between learning
capacity and plaque burden (Fig. 4f).
In contrast to the learning of several spatial locations, object-
recognition memory was normal in PDAPP animals across their
lifespan. This was tested using a task requiring the spontaneous
recognition of a series of new and familiar objects15,16. We observed
(cross-sectional study) that both PDAPP and non-Tg mice prefer¬
entially explored each of five separate new objects to the same extent
(Fig. 5). The memory retention interval was varied to examine
forgetting rates. Forgetting occurred at the same rate in PDAPP and
non-Tg mice.
These findings indicate that the spatial learning impairment
displayed by PDAPP mice can be dissociated into age-related and
age-independent components. The age-related component became
apparent through the use ofa new task in which mice are required to
learn a series of successive spatial locations. This task is sensitive to
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Figure 4 The relationship between performance and (3-amyloid plaque deposition,
a-c, Diffuse amyloid plaque deposition revealed using the 3D6 antibody in PDAPP mice
of different ages. These sections are taken from the three mice whose paths are shown in
Fig. 2. Note prominent deposition of plaques in the outer molecular layer of the dentate
gyrus by age 16 months, d, Plot of plaque burden as a function of age measured in a
subset of mice. Quantitative analysis of plaque burden in the hippocampus confirmed an
age-related increase (F = 13.4, d.f. 2/24, P< 0.001). e, Two measures of performance
in learning a series of spatial locations as a function of plaque burden. Left-hand y axis,
trials to criterion on locations 4 and 5 (note axis is inverted); right-hand y axis, learning
capacity (number of platform locations learned to criterion in 10 d). The behavioural
scores are the means ± s.e.m. of all animals tested at each age. f, Scatter plot of learning
capacity scores in the subset of middle-aged and old animals for which plaque burden
measures are available. An overall analysis of all 27 PDAPP mice revealed significant
correlations between hippocampal plaque burden and both the number of trials to reach
criterion for platform locations 4 and 5, and the separate measure of learning capacity (r=
0.57 and r= -0.59, respectively; P< 0.01). However, these correlations may be
artificially inflated by the inclusion of young mice displaying few plaques. We also
examined the middle-aged and old animals as a single group (age range 16-22 months;
n = 21; these age groups did not differ significantly with respect to either plaque burden or
behavioural performance, P> 0.5 in all cases, Bonferroni post-hoc comparisons). The
correlation coefficients for these 21 animals were lower but were significant in both cases
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Figure 5 Normal object-recognition memory. Preference index for recognition of a
familiar object as a function of memory delay interval, group and age (mean ± s.e.m.).
Chance performance is 50% (dotted line). PDAPP and non-Tgs show equivalent above
chance performance reflecting their greater exploration of the new object. The memory
delay was varied across objects and familiarity observed to decay over time (F = 20.8,
d.f. 4/352, P< 0.001) at the same rate in PDAPP and non-Tg mice (F< 1). The mean
performance of both groups was significantly above chance at all time intervals (P< 0.05
or better; one-sample f-tests). Comparable results were obtained in the longitudinal study
(data not shown). Three young mice (1 PDAPP, 2 non-Tg) and one middle-aged PDAPP
mouse failed to explore the objects in the groups marked with an asterisk and these were
excluded from the data analysis Results shown are mean ± s.e.m.
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decline is substantially greater. The deficit in learning and recalling
separate platform locations learned successively was apparent both
when the PDAPP mice received their first training at the different
ages tested, and when initially young PDAPP mice were re-tested
through their lifespan. The use of a longitudinal design in the
behavioural testing ofhAPP mice is new, and reveals that individual
PDAPP mice have, relative to age-matched controls, a declining
capacity to learn and/or recall as they get older. This deficit in
working- or episodic-like memory in the PDAPP mouse is con¬
sistent with the age-related deficit in T-maze alternation exhibited
by APP695SWE mice17.
The age-independent learning deficit in PDAPP mice was
restricted to learning the first platform location, an impairment
analogous to that seen in previous water-maze reference memory
experiments2"7. In the single report claiming an age-related impair¬
ment in reference memory in APP695SWE mice18, there is reasonable
concern that an age-related change occurred in the control rather
than the transgenic animals. This age-independent deficit is unre¬
lated to progressive changes in (3-amyloid levels and plaque
deposition19, but may be associated with the smaller size of hippo¬
campus and glucose hypometabolism that occurs in V717F mice at a
young age20,21.
A general implication is that dissociations between age-related
and age-independent components of representational memory
need to be taken into account in animal models of progressive
neurodegenerative diseases if valid tests of the differential effects of
A(3 overexpression, (3-amyloid plaques and other neurodegenera¬
tive changes on cognitive function are to be made. We propose that
as (J-amyloid plaques are deposited, (3-amyloid levels rise and fast
synaptic transmission in the hippocampus and other brain areas
becomes less effective19,22, PDAPP mice are gradually less able to
rapidly encode changes in their memory representation of an
environment and/or to retrieve information selectively—a deficit
in 'episodic-like' memory12,23. These mice also show an early and
age-independent deficit in spatial learning24 but not in object-
recognition memory (but see ref. 25).
The decline in performance in this new water-maze task corre¬
lates with the age-related increase in 3-amyloid plaque deposition,
even when young animals with minimal deposits are excluded.
However, we do not yet know if this relationship to plaque
deposition is causal for our findings are also consistent with the
primary pathological trigger being elevated Ap levels rather than
frank plaque deposition26. It will be valuable to use this new test to
examine hAPP mice that have received exogenous treatments limit¬
ing the deposition of P-amyloid plaques27. □
Methods
Animals
In the cross-sectional study, there were 99 PDAPP and non-transgenic littermate
control mice (non-Tg) aged 6-9 months (young), 13-15 months (middle-aged) and
18-21 months (old). A subset of the young animals formed the longitudinal study, with
repeat testing at the two later ages, and a total of 25 mice completing the study at age
22 months (PDAPP = 12, non-Tg = 13). All animals were male, of common parentage, on
a Swiss Webster/DBA/C57BL6 background and fed freely on food and water.
Experimental protocol
Behavioural testing took place in a water maze and an exploratory arena. For cued
navigation, testing began with 5 d of cued training to a visible platform. For training to
criterion, place navigation to a single hidden platform was then tested, followed by
training to four successive new locations. Each animal was trained, for up to eight trials per
day, to a rigorous performance criterion of three successive trials with an escape latency of
less than 20 s before being transferred to the next location on the next day. For object-
recognition memory, testing took place in the arena over 5 d to examine rapidly acquired
memory for object familiarity. For learning capacity, place navigation consisting of
training to criterion of as many successive spatial locations as could be learned in a fixed
10-day training period. The only difference between the training-to-criterion and
learning-capacity tests was that the former measured the extent of training required to
learn five locations, and the latter measured the total number of platform locations that
could be acquired over a set number ofdays. The animals were killed when all behavioural
training was completed to measure the extent of P-amyloid plaque burden in the
hippocampus. The longitudinal component of the study involved only minor procedural
modifications. On re-testing the mice when they became middle-aged and old, they were
given 2 d of cued training, 3 d of object-recognition memory, and either 10 d or 5
successive platform locations (whichever took longer) of place-navigation training.
Water maze
Mice were trained in a 2-m diameter open-field water maze (opaque water at 25 ± 1 °C,
20-cm diameter platform, top surface 1.5 cm below water level, maximum trial duration
= 90 s, 30 s on platform at end of trials). They were placed into the water at and feeing the
side walls, being transported there by hand from a holding cage in an adjacent room. Swim
paths were monitored using an automated tracking system (Watermaze). The mice were
run in squads of six at a time by two experimenters who were 'blind' with respect to their
group assignment (three animals per squad were in each group). For cued training (four
trials per day over 5 d), the pool was surrounded by white curtains to occlude sight of
extra-maze cues. The platform was cued by means of a 15-cm high dark cylinder placed
onto it and placed pseudo-randomly in different locations across trials. For the training-
to-criterion and learning-capacity tests (eight trials per day), the curtains were pulled to
the side to reveal extra-maze cues and the platform was unmarked by any local cues within
the pool. For each mouse, the platform was moved between different locations, drawn
from a set of20 possible locations. The performance criterion for both tests was three trials
in a row with an average escape latency of less than 20 s (maximum trials = 40 for location
1, and 32 trials thereafter).
Object recognition
The animals were tested in an arena with sloping side-walls to prevent shadows from
overhead illumination (50 cm x 50 cm, 1 cm sawdust on floor). Habituation consisted of
daily 5-min periods in the empty arena over 5 d. The mice were then allowed to explore
two identical objects placed into the arena at fixed locations until they had accumulated
30 s oftotal inspection time (where this is defined as active exploration, sniffing, and so on,
of the objects) or for a maximum of 20 min. Five different sets of identical objects were
used on different days. After the initial period of inspection, the mice and the objects were
removed from the arena for the prescribed memory delay interval (10 s, 1 min, 10 min, 1 h
or 4 h spent in a transport cage in the laboratory). A third copy of the earlier identical
objects was then placed into the arena at one location and a new object at the other. The
mice were returned to the arena and allowed to explore until 30 s of inspection time had
again accumulated. The toy objects (for example, a model duck) measured about 10-
15 cm in height and were washed in alcohol between successive tests. Memory of the
familiar object is associated with increased exploration of the new object and a
performance index (PI) is calculated using the formula PI = 100 x (new object inspection
time)/30.
Immunocytochemistry
The brains of a subset of mice (« = 27; young, n = 6; middle-aged, n = 14; old, n = 7) were
removed and one hemisphere was drop-fixed in formalin. The tissue was mounted
coronally and 30-p.m sections collected using a cryostat. Every eighth section throughout
the extent of the brain was stored in antifreeze solution (30% glycerol/30% ethylene glycol
in 40 mM NaP04) at -20 °C before immunostaining. The sections were incubated with
3D6-biotinylated antibody overnight at 4 °C and then reacted with the horseradish
peroxidase-avidin-biotin complex (Vector Laboratories) and developed using 3,3'-
diaminobenzidine as the chromagen28. Amyloid deposition was quantified automatically
using a Leica Q-Win image analysis system. Video images of the brain were captured, the
area of the hippocampus outlined and a threshold optical density was obtained that
discriminated staining from background. The amyloid 'plaque burden' was defined as the
average percentage ofhippocampal area covered by amyloid depositions over six sections.
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Much evidence indicates that abnormal processing and extracel¬
lular deposition of amyloid-p peptide (Ap), a proteolytic deriva¬
tive of the p-amyloid precursor protein (PAPP), is central to the
pathogenesis of Alzheimer's disease (reviewed in ref. 1). In the
PDAPP transgenic mouse model of Alzheimer's disease, immuni¬
zation with Ap causes a marked reduction in burden of the brain
amyloid2,3. Evidence that Ap immunization also reduces cognitive
NATURE | VOL 408121/28 DECEMBER 2000 j www.nature.com
dysfunction in murine models of Alzheimer's disease would
support the hypothesis that abnormal AP processing is essential
to the pathogenesis of Alzheimer's disease, and would encourage
the development of other strategies directed at the 'amyloid
cascade'. Here we show that AP immunization reduces both
deposition of cerebral fibrillar Ap and cognitive dysfunction in
the TgCRND8 murine model of Alzheimer's disease without,
however, altering total levels of AP in the brain. This implies
that either a ~50% reduction in dense-cored AP plaques is
sufficient to affect cognition, or that vaccination may modulate
the activity/abundance of a small subpopulation of especially
toxic Ap species.
To explore the behavioural consequences of A3 immunization,
we used the TgCRND8 murine model of Alzheimer's disease that
expresses a mutant (K670N/M671L and V717F) human 3APP695
transgene under the regulation of the Syrian hamster prion pro¬
moter on a C3H/B6 strain background (M.A.C. et al., manuscript in
preparation). TgCRND8 mice have spatial learning deficits at
3 months of age that are accompanied by both increasing levels of
SDS-soluble A3 and increasing numbers ofA3-containing amyloid
plaques in the brain. Age- and sex-matched TgCRND8 mice and
non-Tg littermates in three cohorts were vaccinated at 6, 8, 12, 16
and 20 weeks with either A342 or islet-associated polypeptide
(IAPP), which has similar biophysical properties to A3 but is
associated with a non-central nervous system (CNS) amyloidosis.
Both immunogens were in 3-pleated-sheet conformation at the
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Figure 1 Ap and IAPP peptide immunogens were predominantly p-structured and
induced antibodies recognizing fibrillar Ap deposits, a, Circular dichroism spectra of Ap42
(dotted line) and IAPP (solid line) before immunization are predominantly p-structured.
mDegrees, millidegrees. b, Negative-stain electron microscopy (scale 150nm) of Ap42
peptide immunogen showed varying length fibres; c, IAPP peptide immunogen showed
short laterally aggregated fibres, d, f, Serum (1:1,000 dilution) from non-immunized
TgCRND8 mice (d) and from 23-week old lAPP-immunized mice (f) did not recognize the
Ap plaques in adjacent, non-formic-acid treated sections from a non-immunized
TgCRND8 mouse with abundant Ap-positive plaques, e, Sera from Ap42-immunized mice
strongly labelled dense-cored amyloid plaques but not diffuse Ap deposits (which are
profusely present in these animals and were labelled with other anti-Ap antibodies such
as 4G8; ref. 28).
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Abstract
Glial cell line-derived neurotrophic factor (GDNF) is best
known for its long-term survival effect on dopaminergic
neurons in the ventral midbrain. A recent study showed
that acute application of GDNF to these neurons sup¬
presses A-type potassium channels and potentiates neu¬
ronal excitability. Here we have characterized the acute
effects of GDNF on Ca2+ channels and synaptic transmis¬
sion. GDNF rapidly and reversibly potentiated the high
voltage-activated (HVA) Ca2+ channel currents in cul¬
tured dopaminergic neurons. Analyses of channel kinet¬
ics indicate that GDNF decreased the activation time con¬
stant, increased the inactivation and deactivation time
constants of HVA Ca2+ channel currents. Ca2+ imaging
experiments demonstrate that GDNF facilitated Ca2+ in¬
flux induced by membrane depolarization. To investi¬
gate the physiological consequences of the Ca2+ channel
modulation, we examined the acute effects of GDNF on
excitatory synaptic transmission at synapses made by
these dopaminergic neurons, which co-release the trans¬
mitter glutamate. Within 3 min of application, GDNF
increased the amplitude of spontaneous and evoked
excitatory autaptic- or multiple-postsynaptic currents.
The frequency as well as the amplitude of miniature ex¬
citatory postsynaptic currents was also increased. These
results reveal, for the first time, an acute effect of GDNF
on synaptic transmission and its potential mechanisms,
and suggest that an important function of GDNF for mid¬
brain dopaminergic neurons is the acute modulation of
transmission and ion channels.
_
Copyright© 2003 S. Karger AG, Basel
Introduction
GDNF is a potent neurotrophic factor capable of elic¬
iting diverse biological functions not only in the nervous
system but also in kidney and gastrointestinal system [ 1,
2]. It was originally identified as a potent survival factor
for cultured midbrain dopaminergic neurons [3], Subse¬
quent studies demonstrated that administration of
GDNF into the brain in vivo protects midbrain dopamin¬
ergic neurons from death induced by mechanical lesion of
medial forebrain bundle [4]. GDNF also prevents and
reverses the degeneration of midbrain dopaminergic neu¬
rons induced by chemical insults [5-7], Therefore, GDNF
is considered as a potential therapeutic agent for Parkin¬
son's disease [8], However, the physiological role of
GDNF in normal, healthy dopaminergic neurons is un-
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clear. Homozygous mice lacking GDNF gene do not
exhibit any loss in the number of midbrain dopaminergic
neurons [9-11, but see 12], Injection of GDNF into the
nigra or striatum of normal rats does not increase the
number of nigra dopaminergic neurons [13, 14], While
both could be attributed to compensation by or redundan¬
cy with the GDNF homologs (e.g. neuturin), it is also pos¬
sible that the major function of GDNF in normal mid¬
brain is not (or is in addition to) to regulate the long-term
survival of dopaminergic neurons.
Indeed, GDNF has been shown to elicit long-term
changes in the structure and function of synapses in a
number of systems. Transgenic mice overexpressing
GDNF in skeletal muscle cells exhibit hyperinnervation
of the neuromuscular junction (NMJ) [lb]. In the Xeno-
pus nerve-muscle co-culture, the probability of transmit¬
ter release is potentiated in the neuromuscular synapses
exposed to GDNF for 1-2 days [16]. This effect appears
to be mediated by an increase in the levels of frequenin, a
neuron-specific Ca2+-binding protein expressed in moto¬
neurons. GDNF/frequenin facilitates the activation of N-
type Ca2+ channels, leading to an enhancement of Ca2+
influx at the nerve terminals. Long-term treatment with
GDNF also elicits a marked increase in the number and
the size of synaptic vesicle clustering, as demonstrated by
synaptobrevin-GFP fluorescent imaging, and FM dye
staining [17], Unlike neurotrophins, however, acute ap¬
plication of GDNF to the NMJ does not elicit any effects
on the neuromuscular synapses [16, but see 18].
Long-term treatment with GDNF also modulates syn¬
apses made by the midbrain dopaminergic neurons. Am-
perometric recording demonstrates that treatment with
GDNF enhanced quantal synaptic transmission in cul¬
tured dopaminergic neurons [19]. The quantal size re¬
corded from GDNF-treated varicosities is dramatically
increased. These dopaminergic neurons also co-release
glutamate [20], Both the frequency of spontaneous and
the amplitude of evoked synaptic currents are increased
in autapses of isolated dopaminergic neurons in GDNF-
treated cultures [21], In addition to these long-term
effects, we have recently reported an unexpected acute
modulation of ion channels by GDNF [22]. Application
of GDNF to dopaminergic neurons in culture or slices
elicits a rapid and reversible enhancement of neuronal
excitability. This effect appears to be mediated by a sup¬
pression ofA-type K+ channels through a mechanism that
involves activation of MAP kinase. GDNF also elicits a
potentiating effect on Ca2+ channels. Changes in neuronal
excitability and ion channels are expected to result in
functional consequences on synaptic transmission. The
present study is designed to investigate whether synaptic
transmission is indeed regulated by acute application of
GDNF. We characterized in detail the acute modulation
of Ca2+ channels by GDNF in the dopaminergic neurons.
We also investigated the effect of GDNF on excitatory
transmission at synapses made by the midbrain dopamin¬
ergic neurons. These experiments demonstrated GDNF
not only rapidly potentiates presynaptic transmitter re¬
lease, but also enhances postsynaptic responses. Our
study has revealed, for the first time, an acute modulation
of synaptic transmission by GDNF. These results may
help understand the normal function of GDNF in the
midbrain dopaminergic neurons in vivo.
Materials and Methods
Cell Culture
Neuronal cultures were prepared from ventral midbrain as de¬
scribed [22]. Briefly, embryos at gestation day 14 (E14) were
removed from anaesthetized pregnant rats. Ventral midbrains were
dissected, cut into pieces, and digested with 0.125% trypsin in D-
Hanks' solution at 37 °C for 30-45 min. The pieces then were tritu¬
rated gently in DMEM/F 12(1:1, plus 100 U/ml penicillin, 0.1 mg/ml
streptomycin), and were centrifuged for 3 min at 1,200 rpm. The
pellets were resuspended by gentle trituration in DMEM/F12 con¬
taining 10% fetal bovine serum (FBS), and plated at 0.3 million cells
per 35 mm culture dish coated with poly-D-lysine (0.1 mg/ml). Cul¬
tures were maintained at 37 °C, 5% CO2 and 95% humidity, first in
10% FBS/DMEM, and switched 8 h later to the serum-free medium
(DMEM/F12 plus Neurobasal B27, 1:50 and glutamine, 0.5 mM).
All culture media and reagents were obtained from Life Technolo¬
gies. GDNF was purchased from Promega. Unless indicated other¬
wise, all chemicals were from Sigma or RBI. The cultures were grown
for 10-14 days and media were changed twice a week.
Calcium Imaging
Neurons were loaded with the membrane-permeable fluorescence
dye fluo-3/AM (10 \iM, Molecular Probes) in darkness at 37 °C for
45 min [23]. After dye loading, cells were washed with DMEM to
remove any remaining dye, and kept in darkness for 0.5-1 h [24], A
coverslip of cells was transferred to a glass-bottomed chamber on the
stage of a confocal microscope, and continuously superfused with
standard extracellular solution (SES, in mM, NaCl 158, KC1 3, CaCh
2, D-glucose 10, Na pyruvate 1, HEPES 10, pH 7.3) at a rate of
1 ml/min. Depolarization was evoked by high potassium solution
(HKS, same as SES except 50 mM Na+ was replaced by 50 mM K+).
Fluorescence measurements were performed at room temperature
using a Bio-Rad MRC 1000 scanning confocal microscope coupled to
an imaging system. Optical excitation was accomplished using the
488-nm line of a krypton/argon laser. The emitted fluorescence
passed through a 515-nm primary barrier filter before it reached a
CCD camera. The laser intensity was minimized to prevent dye
bleaching. The fluorescence images were acquired in real-time mode
(1 frame/2 s), and the data were stored for off-line analysis.
GDNF Potentiates Synaptic Transmission Neurosignals 2003;12:78-88 79
Electrophysiological Recording
The cultured midbrain dopaminergic neurons were perfused with
SES, using an MSC-200 fast solution changer system. Spontaneous
and evoked synaptic currents were recorded using whole-cell, volt¬
age-clamp recording techniques as described [22], The recording
electrodes were filled with intracellular pipette solution (in mM, KC1
140, MgCl2 1, CaCl2 0.5, EGTA 5, ATP 3, HEPES 10, GTP 0.2, pH
7.3), with a typical resistance of2-4 when measured in SES. For
recording of HVA Ca2+ channel currents, extracellular solution con¬
tained (in mM): NaCl 102, BaCl2, D-glucose 10, Na pyruvate 1, TEA
30,4-AP 5, CsCl 5, TTX 0.001 and HEPES 10, pH 7.3. Ionic current
or voltage was measured using Axopatch 200A amplifier, digitized at
20 kHz using pClamp 6.04 or Axotape 2.1 software, and stored on a
computer and monitored on storage oscilloscope. Miniature synaptic
currents were identified automatically by the SCAN software (gift
from Dr. J. Dempster, University of Strathclyde, Glasgow). All
events were included if their peak amplitudes were greater than
15 pA. All data are shown as mean ± SEM. Capacitance was com¬
pensated and leak currents were subtracted by P/4 protocol. All
recordings were made at room temperature (20-24 °C). Series resis¬
tance was measured and partially compensated (typically 60-75%).
A small percentage of cells with any one of the following criteria were
considered as unhealthy and not included for analysis: a resting
membrane potential less than -50 mV; action potential overshoot
less than 15 mV; gradual changes in membrane potential, input resis¬
tance, or action potential amplitudes.
Results
Modulation of Voltage-Gated Calcium Channels by
GDNF
Whole-cell, current- or voltage-clamp recordings were
performed on ventral midbrain neurons cultured for 10-
14 days. In general, the GDNF-responsive dopaminergic
neurons were large, multipolar neurons that extend two to
five thick and rather straight primary processes, with rela¬
tively large varicosities found mainly in the distal segment
of the processes. In contrast, nondopaminergic neurons
possessed highly branched thick and thin primary pro¬
cesses with intensive arborization and numerous varicosi¬
ties [20, 25], The dopaminergic neurons were tyrosine
hydroxylase (TH) immunoreactive [22], The identity of
dopaminergic neurons was further confirmed by their dis¬
tinctive electrophysiological properties [26-29], When
step depolarization currents were applied to the cell body
under the current-clamp mode, these neurons fired an
action potential with much broader duration (fig. 1A).
They also exhibited a typical 'anomalous rectification', or
'sag' potential when stimulated with a strong hyperpolar-
izing current injection (fig. IB). Only cells with apparent
sag potential or action potential half duration (APD5o)
greater than 2.0 ms were chosen for further investigation.
Previous studies showed that GDNF acutely regulates
high voltage-activated (HVA), but not low voltage-acti¬
vated Ca2+ channels in midbrain dopaminergic neurons
[22], To determine the mechanisms as well as the poten¬
tial physiological significance of such regulation, we re¬
corded HVA Ca2+ currents in cultured midbrain dopa¬
minergic neurons. SES was modified to include tetrodo-
toxin (TTX, 1 jxM) to block Na+ channels, 4-aminopyri-
dine (4-AP, 5 mM), CsCl (5 mM), and tetraethylammo-
nium (TEA, 30 mM) to block K+ channels. Extracellular
Ba2+ (5 mM) was used as the charge carrier to avoid Ca2+-
induced inactivation of Ca2+ channels. A step depolariza¬
tion (from -60 to 0 mV, 200 ms) activated HVA Ca2+
channels, which slowly inactivated and exhibited a typical
tail current when membrane potential was repolarized to
0 mV (fig. 1C). It was reported that GDNF induced the
maximal responses on Ret autophosphorylation [30] and
the inhibition of K+ channels [22] at a concentration of
20-50 ng/ml. To elicit the maximal effect, we used 25 ng/
ml GDNF in this and all other experiments unless indi¬
cated otherwise. It markedly increased the Ba2+ currents
(fig. 1C). The GDNF-induced potentiation of Ba2+ cur¬
rent was rapid; within 40 s after GDNF was perfused into
the cultures, the peak Ba2+ currents began to increase,
reaching maximal levels in less than 200 s (fig. ID). The
effect of GDNF was also transient and reversible. Within
4 min after GDNF withdrawal, the peak current returned
to control levels (fig. ID).
The voltage-clamp result was supported by calcium
imaging experiments. Cells were loaded with the mem¬
brane-permeable indicator fluo-3/AM (10 \iM), and
changes in intracellular calcium concentration ([Ca2+];)
were monitored using a confocal microscope. As shown in
figure IE, application of GDNF alone did not change the
basal levels of [Ca2+]j. Perfusion of the depolarizing agent
high potassium solution (HKS, 50 mM KC1) rapidly
increased [Ca2+];. This increase was blocked when HKS
was perfused in the presence of a general Ca2+ channel
blocker Cd2+ (200 \iM), suggesting Ca2+ influx via voltage-
gated calcium channels. Application of HKS together
with GDNF increased HKS-induced Ca2+ fluorescence
(fig. IE). On average, treatment with GDNF increased
Ca2+ influx by 32.9 ± 18.3% (p < 0.01, n = 7, t test).
Effects ofGDNF on the Kinetics ofHVA Channels
To understand how GDNF modulates HVA channels,
we analyzed the kinetics of channel activation. HVA cur¬
rent was evoked by a step depolarization from -60 to
0 mV for 200 ms before and after GDNF application. The
rise phase of the HVA Ba2+ currents was fitted with single
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Fig. 1. Acute effect of GDNF on HVA Ca2+
channels. A Superimposed waveforms of ac¬
tion potentials recorded from dopaminergic
and non-dopaminergic neurons. The half-
width of the action potential (APD50) of the
dopaminergic neuron (Nl) was greater than
that of non-dopaminergic neuron (N2).
B Characteristic response of a dopaminergic
neuron to a strong hyperpolarization. Cur¬
rents were injected into a dopaminergic neu¬
rons with various amplitudes (-0.09 to
0.03 nA, in 0.03-nA increments). At mem¬
brane potentials below -90 mV there was a
typical delayed relaxation of the voltage re¬
sponse to hyperpolarizing current known as
'sag' potential. C Enhancement of HVA Ca2+
channels by GDNF. HVA Ba2+ currents, in¬
duced by step depolarization from -60 to
0 mV (protocol shown on top), were com¬
pared before, 3 min after GDNF applica¬
tion, and 10 min after washout of GDNF.
D Time course of GDNF regulation of HVA
Ba2+ currents. GDNF (n = 21), 25 ng/ml for
3 min, control (n = 12). E Effect ofGDNF on
high K+ solution (HKS)-evoked Ca2+ influx.
GDNF itself did not induce any change in
Ca2+ influx. HKS evoked Ca2+ influx via
voltage-gated Ca2+ channels since the influx
could be blocked by CdCb (200 \iM).
GDNF reversibly potentiated the response
induced by HKS. This experiment was re¬
peated 7 times and similar results were ob¬
tained.
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exponential curve, and the time constant of HVA channel
activation (xact) was obtained (fig. 2A). Application of
GDNF elicited a small but significant decrease in tact
(control: 2.97 ± 0.10 ms; GDNF-treated: 2.17 ± 0.10 ms;
p < 0.01, n = 14, t test). The decay phase of the HVA Ba2+
currents was fitted by a single exponential function
(fig. 2B). The amplitude of the peak current in control was
scaled up to match that after GDNF application (fig. 2B).
On average, treatment with GDNF increased the inacti-
vation time constant (iinact) from 41.6 ± 3.5 ms to 54.0 ±
2.2 (p < 0.05, n = 5, t test).
We next analyzed deactivation kinetics. After a 50-ms
depolarization to 0 mV, the dopaminergic neurons were
repolarized to -40 mV to activate the tail current. The
decay phase of tail current, which can be fitted with single
exponential curve, reflects the channel deactivation time
course during closing. The decay time constant (xdeact)
increased from 5.7 ± 0.2 to 8.0 ± 0.3 ms (p < 0.01, n =
14, t test) after GDNF application (fig. 2C). These results
suggest that GDNF attenuates the deactivation of HVA
Ca2+ channel and increases the ratio of opened channels.
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Fig. 2. Kinetic analyses of HVA Ca2+ channel currents. A Effect of
GDNF on activation of HVA Ba2+ currents. HVA Ba2+ current was
evoked by a step depolarization from -60 to 0 mV for 200 ms before
and after GDNF application. The rising phase of the currents were
fitted by a single exponential function. B Effect of GDNF on inacti-
vation of HVA currents. The amplitude of the peak current in control
was scaled up to match that after GDNF application. The decay
phase of the currents was fitted by a single exponential function.
Note that the inactivation was much slower after GDNF application.
C Effect of GDNF on deactivation of HVA currents. The neurons
were held at -60 mV and then depolarized to 0 mV for 50 ms. Tail
currents were induced by stepping membrane potential from 0 to
-40 mV, before and after GDNF application. The amplitude ofpeak
currents after GDNF application was scaled to that before GDNF
application. The current traces were fitted with a single exponential.
Note that application ofGDNF resulted in a slower deactivation dur¬
ing the repolarization phase. D Effect of GDNF on steady-state acti¬
vation of HVA Ca2+ channel current. The depolarization protocol is
shown on top. Steady-state activation curves were derived from tail
current amplitudes, which were measured at 0.5 ms after repolariza¬
tion to -40 mV from voltage steps ranging from -60 to +30 mV for
100 ms. Holding potentials were -60 mV. Normalized tail current
amplitude (///max) was plotted as a function of membrane potentials,
and the data were fitted with a single Boltzmann function I/Imax =
1/(1 +exp[-(V -V!/2)/K]|, where V|/2 is half-activation potential. Kis
the slope factor. GDNF had no significant effect on the steady-state
activation (p > 0.05, n = 14, covariance test).
We also constructed steady-state activation curves
based on tail currents [31]. Cells were repolarized to
-40 mV, after a depolarization from -60 mV to a series of
test potentials (from -60 to +30 mV). Tail currents were
measured at 0.5 ms after the repolarization. The maximal
currents (Imax) were obtained when cells were repolarized
from + 30 mV. The steady-state activation of tail currents
was obtained by plotting normalized peak tail current
I/Imax against various depolarizing potentials. The data
were fitted with a Boltzmann function: I/Imax = 1 /{1 +
exp[-(V - Vi/2)/K]}, where V is membrane potential, V1/2
is the membrane potential at which the current amplitude
is half-maximum, and K is slope factor. As shown in fig¬
ure 2D, treatment with GDNF did not produce a signifi¬
cant effect on the steady-state activation curve (V1/2 is
-22.8 ± 1.3 mV for GDNF and-20.7 ± 0.9 mV for con¬
trol, p > 0.05%, covariance analysis).
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Fig. 3. GDNF potentiates glutamate-me-
diated sEPSCs and eEPSCs. A GDNF-in-
duced increase in the amplitude and fre¬
quency of sEPSCs. A neuron was voltage
clamped at -70 mV and was stimulated by
depolarizing steps (0 mV, 2 ms) at every 6 s.
The large downward currents are evoked
EPSCs (eEPSCs) induced by inward Na+
spikes. The currents in between eEPSCs are
sEPSCs, which can be blocked by TTX. Per¬
fusion of GDNF (50 ng/mi) dramatically
and reversibly increased the frequency and
the average amplitude of sEPSCs. This ex¬
periment was repeated 8 times and similar
results were obtained. B Inhibition of
eEPSCs by glutamate receptor antagonists.
Depolarization step (2 ms to 0 mV from
holding potential of -70 mV) elicited three
EPSCs at the latencies of 3.5, 8.5 and
17.0 ms. All the currents were blocked by
APV (100 vM) + CNQX (10 pM) and not by
bicuculline (10 \iM), suggesting that they
were all glutamatergic. C Time course of the
change in the peak amplitude of eEPSCs.
Peak amplitude of eEPSCs was normalized
to the control response right before GDNF
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Potentiation ofSynaptic Transmission by GDNF
An increase in the neuronal excitability induced by
GDNF, as a consequence of the enhancement of Ia and
HVA Ca2+ currents, could lead to a potentiation of synap¬
tic transmission. To test this possibility, we recorded
evoked synaptic currents under the whole-cell voltage-
clamp mode. It has been shown that these midbrain dopa¬
minergic neurons also secrete the excitatory neurotrans¬
mitter glutamate [20], To avoid the interference of inhibi¬
tory transmission, we blocked GABAa receptor mediated
currents by including bicuculline (10 \xM) in the perfu¬
sion. Under the voltage-clamp conditions, a single depo¬
larizing step (from the holding potential of -70 to
0 mV, 2 ms) initiated an action potential in the un¬
damped axonal processes, leading to autaptic or feedback
polysynaptic currents that can be recorded at the soma
(fig. 3B). Figure 3A shows an example of evoked excitato¬
ry postsynaptic currents (eEPSCs, the regularly spaced
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Fig. 4. Effect of GDNF on eEPSCs ofautap-
tic and polysynaptic feedback connections.
A Schematic diagram of possible neuronal
network. B Changes in eEPSCs amplitudes
after twice GDNF applications with a corre¬
sponding time course shown in C. A step
depolarization applied to the cell under re¬
cording induced three eEPSCs (PI, P2, P3)
with fixed latencies, possibly due to autaptic
(from neuron 1) and polysynaptic feedback
connections (from neurons 2 and 3). The
eEPSCs before, during, after the first GDNF
application, and during and after the second
GDNF application were indicated by 0.5, 5,
10, 15 and 18 min, respectively. Application
ofGDNF resulted in a gradual increase ofall
three peaks (PI, P2, P3). C Time course of
GDNF-induced increase in eEPSC ampli¬
tudes. GDNF repeatedly and reversibly in¬
creased the amplitudes of all three eEPSCs.
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large downward currents), which are superimposed with
inward Na+ currents, and spontaneous synaptic currents
(sEPSCs, smaller downward currents randomly occurring
between eEPSCs). We observed eEPSCs in 34 of 78 neu¬
rons recorded. Both eEPSCs and sEPSCs were mediated
by glutamate receptors because they could be completely
blocked by the NMDA receptor antagonist DL-2-amino-
5-phosphonovaleric acid (APV, 100 \iM) plus the non-
NMDA receptor antagonist cyano-7-nitroquinoxaline-
2,3-dione (CNQX, 10 \xM) (fig. 3B). Application of
GDNF reliably increased the frequency of sEPSCs as well
as the amplitude of eEPSCs (fig. 3A). The peak amplitude
of eEPSCs increased shortly after GDNF was perfused
into the culture medium, reaching the maximum in less
than 3 min (fig. 3C). No desensitization was observed
during 3-min application of GDNF. The eEPSCs re¬
turned to control values 3-5 min after GDNF washing out
(fig. 3C).
In these cultures, the axons of midbrain neurons could
innervate themselves through monosynaptic (autaptic) as
well as polysynaptic feedback connections (fig. 4A). Occa¬
sionally, multiple peaks of eEPSCs were observed, with
relatively constant intervals (fig. 4B), suggesting a poly¬
synaptic feedback connection as outlined in figure 4A
(diagram). Interestingly, GDNF appeared to increase the
amplitudes of eEPSPs in at least some, if not all, of the
connections (fig. 4C). Moreover, repeated applications of
GDNF seemed to elicit comparable effects on eEPSC
amplitudes.
To determine whether GDNF acts presynaptically or
postsynaptically, we investigated the effect of GDNF on
miniature EPSCs (mEPSCs). TTX (1 \iM) was included
in the perfusion solution to block all Na+ channels me¬
diated action potentials. Bicuculline (10 \iM) was also
included in the medium to block GABAa receptors. Ap¬
plication of APV (100 |iM) plus CNQX (10 \iM) com¬
pletely blocked the currents (data not shown), indicating
that the mEPSCs were mediated by excitatory synaptic
currents. An example recording is shown in figure 5A. We
observed that application of GDNF elicited a rapid
increase in the frequency of mEPSCs (p < 0.01, n = 14, Q
test). On average, mEPSCs frequencies increased 2.3-fold,
and reached maximum 2 min after application of GDNF
(fig. 5B). In 14 of 32 neurons recorded, we observed an
acute effect of GDNF on mEPSCs. Interestingly, GDNF
increased not only the frequency but also the amplitude of
mEPSCs. There was a significant right shift of the cumu¬
lative frequency plot of mEPSCs amplitude (fig. 5C, p <
0.01, n = 14, Kolmogorov-Smirnov test). These results
suggest that GDNF could modulate postsynaptic gluta¬
mate receptors, in addition to potentiate presynaptic
transmitter release.
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Fig. 5. Increase in the frequency and ampli¬
tude of mEPSCs by GDNF. A Consecutive
recording traces of miniature EPSCs ob¬
tained before (control), during, and after
(wash) GDNF (50 ng/ml) application under
voltage-clamp (Vh = -70 mV). Note that
GDNF increased the frequency and ampli¬
tude of mEPSCs. B Time course of GDNF-
induced increase in mean mEPSCs frequen¬
cy (over 30-second intervals). GDNF was
perfused (indicated by the bar) at time 0.
Data were normalized to the mean mEPSCs
frequency of the same cell prior to the addi¬
tion ofGDNF. * Significantly different from
control values (n = 14, p < 0.05, Q test).
C Cumulative plot of mEPSCs amplitude
distribution. The difference between GDNF
and control groups, and that between GDNF
and wash groups, are significant (p < 0.001,
Kolmogorov-Smirnov test). The distribution
curve for GDNF-treated synapses was
shifted to the right, indicating that GDNF
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Discussion
Ever since the discovery of GDNF, a dogmatic view
holds that GDNF is a long-term survival factor for the
midbrain dopaminergic neurons. Careful examination of
the literature, however, indicates that most, if not all, of
the studies of survival promoting effects of GDNF were
done on damaged dopaminergic neurons. In these studies,
an elevation of GDNF levels in the brain, either by infu¬
sion of the protein or by transplantation of GDNF-
expressing cells, protects and even reverses the death of
the midbrain dopaminergic neurons induced by mechani¬
cal or chemical insults [4-7, 32-34], In the adult ventral
midbrain, the receptors for GDNF, c-Ret and GFR-al,
are highly expressed in adult dopaminergic neurons [35-
37], Moderate levels of GDNF have also been detected in
striatum, the target of the midbrain dopaminergic neu¬
rons [37], A critical question is then: What is the function
of GDNF in the normal, undamaged dopaminergic neu¬
rons in adult midbrain? It has been shown that injection
of GDNF into the nigra or striatum of normal adult rats
does not increase the number of nigra dopaminergic neu¬
rons [13, 14], Interestingly, a single injection of GDNF to
nigra of normal rats elicits a dose-dependent increase in
dopamine release in the striatum, as well as an enhance¬
ment of locomotor activity [38, 39]. Thus, GDNF may
regulate the function, rather than survival, of the dopa¬
minergic neurons in normal midbrain. Recently, we
showed that GDNF acutely suppresses the A-type potas¬
sium channels and potentiates the excitability of the
dopaminergic neurons in culture and in brain slices [22].
The present study further demonstrates that GDNF
acutely potentiates high-voltage activated Ca2+ channels,
and enhances excitatory synaptic transmission in these
dopaminergic neurons. Taken together, these data rein¬
force the notion that the main function of GDNF in the
dopaminergic neurons in normal midbrain is the acute
modulation of synaptic transmission and ion channels,
rather than (or in addition to) the long-term regulation of
survival. The new results also imply that GDNF may
acutely potentiate the release of dopamine at the termi¬
nals of the midbrain neurons. Direct recording with am-
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perometric method will be necessary to demonstrate
whether GDNF acutely potentiates dopamine release.
A number of recent studies have demonstrated the
long-term, nonsurvival effects of GDNF on the midbrain
dopaminergic neurons. For example, in the cultured do¬
paminergic neurons treated with GDNF for a number of
days, glutamatergic transmission at autapses is signifi¬
cantly enhanced [21]. Long-term treatment with GDNF
has been shown to increase the quantal size recorded from
nerve terminals of dopaminergic neurons [19]. Using
Xenopus nerve-muscle co-culture, the mechanisms un¬
derlying the long-term synaptic effects of GDNF have
been studied in some detail [16]. Electrophysiological
recording and FM dye imaging demonstrate that GDNF
facilitates synaptic transmission at the neuromuscular
synapses. These effects are very similar to the synaptic
potentiation elicited by presynaptic expression of freque-
nin, a neuron-specific Ca2+-binding protein. GDNF en¬
hances the expression of frequenin in Xenopus motoneu¬
rons. Inhibition of frequenin expression or activity pre¬
vents the synaptic action of GDNF. Ca2+ imaging experi¬
ments show that GDNF also facilitates Ca2+ influx at the
nerve terminals during evoked synaptic transmission by
enhancing Ca2+ currents. The effect of GDNF on Ca2+
currents is blocked by inhibition of frequenin expression,
occluded by overexpression of frequenin, and is selective
to N-type Ca2+ channels. Thus, the long-term effects of
GDNF on transmission and Ca2+ channels at the neuro¬
muscular synapses are mediated by the Ca2+-binding pro¬
tein frequenin. In the present study, we show that GDNF
acutely potentiates synaptic transmission and non-L-type
HVA calcium channels in cultured midbrain dopaminer¬
gic neurons. This effect also appears to be mediated, at
least in part, by potentiating Ca2+ channels. Through
accelerating activation and inhibiting inactivation during
depolarization, GDNF may keep Ca2+ channels open for a
longer time resulting in a larger amount of Ca2+ influx.
This is supported by the finding that GDNF enhances
HKS-induced Ca2+ influx through voltage-gated Ca2+
channels. Also, the fast deactivation of the presynaptic
Ca2+ channels during repolarization may be important for
the termination of exocytosis. The rapid Ca2+ signaling
will be a critical determinant of the precise timing of
transmitter release [40]. In addition to presynaptic Ca2+
channels, GDNF might regulate postsynaptic glutamate
receptors to potentiate synaptic transmission, suggested
by GDNF increasing the amplitude of mEPSCs. This is
unlike its acute effect on isolated nerve-muscle prepara¬
tions [18], which shows that GDNF increased the fre¬
quency, but not the amplitude of mEPSCs. GDNF lack of
effect on acetylcholine receptor at neuromuscular synapse
might be the reason. In either presynaptic or postsynaptic
mechanism, modulation occurs within a few minutes
after GDNF application, and it seems unlikely that these
acute effects are mediated by an upregulation of freque¬
nin expression. While the precise molecular mechanisms
remain to be established, it is plausible that the acute
effects ofGDNF are mediated by a cascade ofphosphory¬
lation events triggered by c-Ret tyrosine kinase.
To reveal the acute effects of GDNF on synaptic trans¬
mission, we studied autapses and feedback synapses on
the midbrain dopaminergic neurons in culture. These
neurons have been shown to release glutamate as a co-
transmitter in response to electric stimulation [20], Dopa¬
mine is known to be packaged in large dense-core vesicles
(LDCV). It is unclear whether glutamate is packaged in
the same LDCV or classic small clear vesicles in these
dopaminergic neurons. In situ hybridization and immu-
nocytochemistry experiments demonstrate that the mid¬
brain dopaminergic neurons express AMPA and NMDA
receptors [41, 42], Iontophoretic application of specific
ligands for glutamate receptors reveal that functional
AMPA and NMDA receptors are present on the surface of
the dopaminergic neurons [43]. In the case of polysynap¬
tic feedback connections, the secondary and tertiary neu¬
rons do not have to be dopaminergic. The increase in the
amplitudes of all three eEPSCs after GDNF application
(fig. 4) could be achieved by either a global enhancement
of AMPA/NMDA responses in the primary neurons, or
an enhancement of glutamate release at the synapses
made by the secondary and tertiary neurons.
Another interesting question is why regulation of both
Ca2+ channels (14 of 32, 43.75%) and synaptic transmis¬
sion (34 of 78, 43.58%) occurred only on a subgroup of
dopaminergic neurons? Recent morphological studies
demonstrated that not all midbrain dopaminergic neu¬
rons express GFRal, GDNF preferred receptor [44], Dif¬
ferent sub-regions, i.e. substantia nigra compacta, reticu¬
late, lateralis and ventral tegmental area, have different
percentages ofdopaminergic neurons expressing GFRa-1,
ranging from 36 to 90%. It is unlikely that GDNF would
act through GFRas other than GFRal in the midbrain.
While GFRal, 2 and 4 mRNAs are expressed there [35,
45,46], GDNF only binds GFRa2 at low affinity, but not
GFRa4 [46].
In summary, our study has provided the first demon¬
stration that GDNF rapidly potentiates synaptic trans¬
mission in midbrain dopaminergic neurons. Our results
also suggest that such potentiation is mediated, at least in
part, by modulating the activation and inactivation kinet-
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ics of the high voltage-activated Ca2+ channels. These
results may have help understand the normal function of
GDNF in the midbrain dopaminergic neurons in vivo,
and therefore may have implications in the use of GDNF
to treat Parkinson's disease.
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